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Advances in life expectancy without commensurate improvement in healthy life expectancy 
has resulted in increased demand for healthcare services, particularly among older adults. 
Consequently, healthcare services must adapt to accommodate this increased demand. 
Influences on healthcare service usage are multidimensional, including demographic, social 
and health need factors; those which are modifiable serve as potential targets for intervention 
to improve capacity and service delivery. Novel models of pharmaceutical care for older adults 
have been developed within intermediate care and care homes in Northern Ireland, providing 
an opportunity to explore individual variation in healthcare usage by older adults. Older adults 
are more sensitive to medications and often receive inappropriate prescribing. Thus, improving 
prescribing appropriateness, via pharmacist intervention, may serve as a modifiable target 
with respect to health service usage by older adults. Secondary data analysis of data from the 
Northern and Western Health and Social Care Trusts was conducted to evaluate the 
effectiveness of pharmacist case management in intermediate care (N=532) and care home 
(n=1095) settings. A significant reduction in inappropriate prescribing was achieved in both 
settings, with pharmacist intervention types found to influence subsequent healthcare 
resource usage.  Previous healthcare utilisations were consistently predictive of post-
intervention healthcare usage. Longitudinal patterns of healthcare utilisation were explored in 
a complementary cohort.  A latent transition analysis of The Irish Longitudinal Study of Ageing 
(TILDA) (N=8175) identified heterogeneity in healthcare utilisation by community dwelling 
older adults. Three latent statuses of usage were identified across three data collection waves: 
‘effective referral’, ‘multiple utilisation’ and ‘primary care only utilisation’. Variation in 
longitudinal healthcare utilisation was influenced by a range of factors including the number of 
medications, frailty, falls and depression.  This thesis serves to extend theory regarding 
healthcare utilisation specific to older adults, advocating for an integrated approach to 
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1.1 Changing healthcare landscape 
Worldwide, life expectancy at birth has risen considerably from 1990 to 2013 (Murray 
et al., 2015). Improvements in public health and social systems globally has meant that there 
has been considerable progress in reducing age-standardised rates for a wide range of causes 
of death (Murray et al., 2015). However, healthy life expectancy is increasing more slowly than 
life expectancy, resulting in more years spent living with illness and disability, as evidenced by 
the lack of decline in age-standardised years living with disability (YLD) rates (Murray et al., 
2015). In fact, the number of disability adjusted life years (DALYs) for non-communicable 
diseases (NCDs) has increased steadily during the same 23-year period, likely owed to a 
growing, ageing population (Murray et al., 2015). Increases in DALYs have been shown for 
NCDs such as ischaemic heart disease, diabetes, chronic obstructive pulmonary disease, 
depression, and stroke (Murray et al., 2015). Thus, the disparity between our extended life 
expectancy and our healthy life expectancy has placed an additional demand on healthcare 
services across the world.  
An increase in the number of older adults living with more than one chronic condition 
(multimorbidity) exerts further demand upon global health systems. The management of 
chronic conditions has been estimated to account for three quarters of healthcare 
expenditure, accounting for 80% of general practitioner (GP) consultations and 60% of hospital 
bed days (Department of Health and Children: DOHC, 2008). Multimorbidity is associated with 
increased healthcare usage across many points within the healthcare system, including 
increased physician visits, the prescribing of multiple medications, an increased risk of 
hospitalisation and longer hospital admissions (Cassell et al., 2018; Glynn et al., 2011; 
Marengoni et al., 2011; Palladino, Lee, Ashworth, Triassi & Millett, 2016). The greater the 
degree of multimorbidity, the greater the costs incurred. It has been estimated that healthcare 
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spending for one chronic condition is three times of that for someone with no chronic illness 
(Anderson, 2010). Multimorbidity has been suggested to be associated with a 33% increase in 
costs for each additional condition and that the healthcare spend for those with ≥5 long term 
conditions is 17 times greater than that for those with no chronic illnesses (Anderson, 2010; 
Båhler, Huber, Brungger & Reich, 2015).   
The future impact of multimorbidity on healthcare systems is likely to prove even 
more challenging when one considers future projections for multimorbidity prevalence. 
Kingston, Robinson, Booth, Knapp, and Jagger (2018) conducted a simulation study to 
determine the future prevalence of multimorbidity among the older population in England by 
2035 using a base sample of individuals aged ≥35 years. Between the years 2015 and 2035 the 
simulation estimated that the proportion of individuals ≥65 years living with four or more 
conditions would increase from 10% to 17% (Kingston et al., 2018). Furthermore, 
approximately one third of those living with four or more morbidities are expected to have 
mental ill-health such as depression, dementia, or cognitive impairment. The simulation 
further predicted that approximately half of those aged 65 years and over would report two or 
more chronic diseases, with a greater proportion of increase occurring in the 85+ year 
category. Accordingly, an increased burden will be placed on primary and secondary 
healthcare usage in order to cope with this increased demand.  
Thus, one of the largest challenges facing governments globally is the need to ensure 
there are adequate provisions made for an ageing population. Older people are an increasingly 
important cohort of individuals admitted to hospitals (Abrahamsen, Hauglan, Nilsen and 
Ranhoff, 2014). Hospital admissions and readmissions have risen sharply among this cohort, 
with acute hospital admissions reported to rise by 16% from the period of 2006/07 to 2012/13 
(Smith, McKeon, Blunt & Edwards, 2014). It has been suggested that 30-60% of healthcare 
costs are consumed by older people (Hasan, Thiruchelvam, Kow, Ghori & Babar, 2017). 
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Woodford and George (2010) argue that the rise in demand has not been met with a 
commensurate increase in bed capacity, resulting in a reduction in hospital length of stay. This 
has been evidenced in the findings of Godden, McCoy, and Pollock (2009) who found a trend 
of reduced numbers of NHS beds in England for the period of 1987/88 to 2006/07. Godden et 
al., (2009) further report that from 1998/99 to 2006/07 the number of annual hospital 
admissions continued to rise, whilst mean length of stay reduced. Furthermore, during the 
same period, a rise in emergency readmissions within 28 days was found for both adults aged 
16-74 years and for those aged 75 years and older.  
In England, since 1979, there has been a 65% reduction in the number of beds used for 
geriatric care, in contrast to the 35% reduction in acute care beds observed during the same 
period (Appleby, 2013). Reductions in overall numbers of beds are not restricted to the United 
Kingdom (UK) context, with almost all Organisation for Economic Cooperation (OECD) 
countries showing a reduction in acute care beds during the period from 1995 to 2010, save 
for Korea, Turkey, and Greece (Appleby, 2013). With a growing population with increased 
levels of comorbidity to treat but fewer beds available, the resultant effect is a trend towards a 
shorter length of hospital stay as reported by Godden and colleagues (2009). From 1979 to 
2011 it has been estimated that the average length of hospital stay for an acute case in 
England has decreased from 9.4 days to approximately 3 days (Appleby, 2013). Bakken, 
Ranhoff, Engeland & Ruths (2012) argue that the combination of highly specialised hospital 
departments and short durations of stay may not be suitable for older people who may require 
longer rehabilitation and a more comprehensive multidisciplinary approach. Consequently, 
healthcare systems need to adapt in order to accommodate the increased demand created by 
a growing number and proportion of older persons within the population.  
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1.2 Older adults as a cohort 
The United Nations, Department of Economic and Social Affairs, Population Division 
(UNDESA; 2015) predict that between 2015 and 2030, the number of persons aged 60 years or 
over globally, will rise by 56%, reaching 1.4 billion, and that by 2050 this figure will approach 
2.1 billion. The UN further predicts that the proportion of those aged 80 years or over will 
grow even faster, with 2050 projections estimating a three-fold increase on 2015 figures.  In 
fact, globally, the number of older persons is growing at a faster rate than any other age group 
(UNDESA, 2015).  
It must also be remembered that there is considerable variability in the risks of 
morbidity and mortality across individuals of the same age, attributed to individual differences 
in biological, social, and environmental factors (UNDESA, 2015). The complex interplay of 
factors such as genetic polymorphisms, educational attainment, location, and service uptake 
creates a context that is unique to the individual. Within older people this context may also 
include the amalgamation of many factors over a considerable period of time. In addition, 
individual variability in health risk behaviours such as alcohol and tobacco consumption 
introduce considerable heterogeneity in morbidity patterns in a given cohort, and as such must 
be considered with respect to medical care (UNDESA, 2015). Consequently, older persons 
should not be seen as a relatively homogenous group for which morbidity and associated 
treatment remain consistent across all members of the cohort. Rather, there exists 
considerable variability in their experiences of health and illness, owed to these individual 
differences. Therefore, health and social care provision must be appreciated at an individual 
level. 
1.3 Healthcare utilisation by older adults 
Among older people, the reasons for hospital admissions are multifactorial.  Andersen 
and Newman (1973) propose that the decision to access healthcare services is influenced by 
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several factors, predisposing factors (e.g. age), enabling factors (e.g. education level) and need 
factors (e.g. chronic disease). Each of these factors have shown differential but significant 
associations with health services use (Babitsch, Gohl & von Lengerke, 2012). Thus, chronic 
disease and comorbidity are important aspects to consider when examining healthcare 
resource utilisation by older people. Chronic conditions are associated with high health service 
utilisation (Hutt, Rosen & McCauley, 2004; Lehnert et al., 2011) and account for a third of 
emergency admissions to NHS hospital beds among those aged 65 years and older (Hutt et al., 
2004). Those with four or more chronic conditions are more than 90 times more likely to 
experience a hospital admission that could have been prevented with appropriate primary 
care as those without chronic conditions (Wolff, Starfield & Anderson, 2002).  
Whilst a hospital admission may be welcome with respect to resolving acute illness 
through medical intervention, acute hospitalisation has been shown to be related to a decline 
in functional status among older adults (Hirsch, Sommers, Olsen, Mullen & Winograd, 1990). 
Functional status is the person’s ability to perform basic and instrumental activities of daily 
living (ADLs). Basic ADLs include feeding, dressing, personal hygiene, and walking (Katz, Ford, 
Moskowitz, Jackson & Jaffe, 1963). Instrumental activities (IADLs) are those which facilitate the 
person to remain living independently within their own community. Examples include the 
ability to prepare meals, manage their own finances and take their medications (Lawton & 
Brody, 1969). Functional status on discharge from acute care has been shown to be poorer 
when compared with functional status on admission (Covinsky et al., 2003). Recovery from this 
decline in functional status occurs at a much slower rate than recovery from the acute illness 
itself (Hirsch et al., 1990). The very old (> 90 years’ age) have been found to be at particularly 
high risk of poor outcomes, as they have been shown to be less likely to recover function lost 
before admission and more likely to develop new functional deficits whilst in acute care 
(Covinsky et al. 2003).  
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Declining functional status among older people serves to reduce their ability to live 
independently at home. Abrahamsen and colleagues (2014) argue that a high proportion of 
those discharged from acute care are at risk for increased dependency and institutionalisation 
if appropriate treatment and opportunity for rehabilitation is not delivered. Providing 
opportunities to recover functional deficits may facilitate a return to home for older adults 
who may otherwise transition into a long-term care setting.  Intermediate models of care have 
been developed with the aim of supporting the individual back to wellness, and to regain the 
ability to live as independently as possible. Bridging the gap between acute hospital discharge 
and return to home, intermediate care serves to facilitate the recovery of functional status lost 
during acute hospitalisation, and delay institutionalisation of older people.  
In recent years attention has also been drawn to healthcare utilisation by care home 
residents, in particular their presentation to hospital emergency departments (ED). A 
systematic review, comprised of 77 studies, found that 4-55% of transfers from the nursing 
home to ED were classified as inappropriate (Lemoyne et al., 2019). However, the varied 
operationalisation of what constitutes an inappropriate ED transfer limits the comparisons that 
can be made between studies. The commonly identified reasons for ED transfer included 
trauma, altered mental status, infection, fever, respiratory, gastrointestinal, and cardiovascular 
symptoms (Lemoyne et al., 2019). Numerous factors are believed to interact to increase the 
likelihood of transfer from residential care to ED, including inadequate numbers or skill mix 
among care home staff; access to GPs, particularly out of hours; the absence of end of life 
advanced care planning; pressure from family members to seek active treatment (Arendts, 
Riebel, Codde & Frankel, 2010). Interventions that have sought to increase attendance of 
clinicians within residential care facilities have been shown to reduce ED presentations and 
hospital admissions (Lemoyne et al., 2019). A ‘hospital in the nursing home’ intervention 
involving ED-based nurses working in partnership with nursing home staff to manage care of 
residents who would otherwise require an ED presentation or hospital admission resulted in a 
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reduction in ED attendances by 17% and hospital admissions by 47% (Fan et al., 2016). The use 
of telemedicine has also shown positive results with reductions in hospitalisation and ED visits 
observed (Mierdel & Owen, 2015; Shah et al., 2015).  
1.4 Prescribing for older adults 
The ageing population present numerous challenges to the funding and operation of 
healthcare services globally. If we are spending a greater number of years living with illness, it 
follows that we are spending a greater number of years consuming treatments to eradicate or 
minimise the impact of disease on quality of life. Medicines are the most common medical 
intervention worldwide (Mair, Kinnear, Hurding, Michael & Wilson, 2017), owed largely to the 
pervasiveness of the biomedical model in how we conceptualise illness. The biomedical model 
supports the view that drug prescribing is a fundamental aspect of treatment solutions. 
Prescribed medication, and associated drug monitoring costs, serve as a significant stressor on 
health budgets. It is estimated that, at any one time, 70% of the population consume a 
prescribed or over the counter medicine to treat or prevent illness (Scott & Fleming, 2017). 
Furthermore, it has been projected that global expenditure on medicines will reach nearly $1.5 
trillion by 2021 (QuintilesIMS Institute, 2016). At a time when global health systems are under 
increasing financial pressure, drug therapies are being increasingly interrogated in terms of 
their benefits relative to economic cost. Given their relative high consumption of medication, 
and the aforementioned considerable heterogeneity within the cohort, prescribing for older 
people requires an additional degree of specialism to ensure that they receive the most 
benefit from their prescribed therapies.  
Despite considerable global expenditure on medications it is highly probable that 
healthcare funders may not be receiving the best return on their investment. The World 
Health Organisation (2018) estimates that more than half of all medicines are supplied 
inappropriately, and that half of all patients fail to take them correctly. They further argue that 
30 
 
the overuse, underuse, or misuse of medicines not only poses a serious health hazard, but also 
generates considerable wastage of scarce resources. At present, annual expenditure on 
medicines in Northern Ireland (NI) is estimated to be in the region of £550 million, which is 
higher than other regions of the UK, in terms of both cost and volume (Scott & Fleming, 2017). 
Of this expenditure, it is estimated that £18 million is wasted on medicines annually in 
Northern Ireland (Health and Social Care Board Northern Ireland: HSCBNI, 2015). 
Prescribing for older persons requires an acknowledgement of the physiological 
changes that occur in older age, in particular the reduced ability to maintain homeostasis 
under conditions of physiological stress (Mangoni & Jackson, 2004). This loss of functional 
reserve underpins the vulnerability associated with older age. In terms of major metabolic 
organ systems, there is a decline in renal and liver blood flow with age (Mangoni & Jackson, 
2004). There is also a change in overall body composition with advancing age, such that there 
is a reduction in total body water and lean body mass (Mangoni & Jackson, 2004). Age-
dependent changes in body composition and function can thus alter both the 
pharmacodynamics and pharmacokinetic responses to medication.  
Pharmacokinetics are concerned with how the organism processes a drug including 
aspects such as drug absorption, metabolism, and clearance. Medications that undergo 
extensive first-pass metabolism in the liver are consequently impacted by age-related declines 
in liver function, leading to higher bioavailability (Mangoni & Jackson, 2004). Conversely, pro-
drugs, which depend on the liver for activation, are also impacted resulting in lower activation. 
Changes in body composition, in terms of total body water and lipid quantities results in 
altered serum drug levels owed to differences in volumes of distribution for hydrophilic and 
lipophilic drugs (Mangoni & Jackson, 2014). Reduction in renal function in older people alters 
the clearance of many drugs, which can be of particular concern for those drugs with a narrow 
therapeutic index. It has been suggested that decreased excretion via the kidney is of more 
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relevance than decreases in hepatic drug metabolism (ElDesoky, 2007). Pharmacokinetic 
changes are further compounded by the impact of chronic diseases on organ systems, such as 
nephropathy secondary to diabetes.  
Pharmacodynamics, on the other hand, represents the physiological response to 
drugs, in other words how the drug affects an organism. Pharmacodynamic changes are 
frequent among older people and are often related to alterations in sensitivity to drugs 
(ElDesoky, 2007), including anticoagulants, cardiovascular and psychotropic drugs (Mangoni & 
Jackson, 2004).  Advancing age is associated with an increased sensitivity to the sedating 
properties of benzodiazepines, of which the exact mechanism remains unclear (Mangoni & 
Jackson, 2004).  
Despite an awareness of altered physiological responses to medications, older people 
are often excluded from clinical trials. Therefore, our understanding of medication safety 
among older people often only emerges in the post-marketing surveillance period following 
the launch of a medicinal product onto the market. What has been elucidated is that older 
people are more vulnerable to drug-related problems (DRPs), owed due to the combination of 
age-related and disease-related metabolic changes, multimorbidity, increased numbers of 
prescribers and higher medication burden (Lehnert et al., 2011; Merle, Laroche, Dantoine & 
Charmes, 2005; Shelton, Fritsch & Scott, 2000; Somers, Mallet, van der Carmen, Robays & 
Petrovic, 2012). Interactions between two medications, referred to as drug-drug interactions, 
are a common source of adverse drug events (ADEs), and are found to occur more frequently 
in older compared with younger patients (Shelton et al., 2000). An ADE is an injury resulting 
from medical intervention related to a drug (National Coordinating Council for Medication 
Error Reporting and Prevention, 2015) and can be considered to occur at any dose, whether a 
standard therapeutic dose or not. 
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Whilst in many cases hospitalisations are necessary to appropriately treat an emergent 
acute illness, it must be recognised that a proportion of these admittances are avoidable. 
Adverse drug event related hospitalisations are more prevalent among older people; 
approximately 11% of hospitalisations in this cohort believed to be related to ADEs (Alhawassi, 
Krass, Bajorek & Pont, 2014; Kongkaew, Noyce & Ashcroft, 2008). In contrast, it is estimated 
that 5.3-6.5% of hospitalisations amongst the general population are due to ADEs (Kongkaew 
et al., 2008; Pirmohamed et al., 2004). Fatal ADEs account for approximately 3% of deaths in 
the general population (Wester, Jönsson, Spigset, Druid & Hӓgg, 2008), and are estimated to 
be the sixth leading cause of death in the United States (US) (Lazarou, Pomeranz & Corey, 
1998). However, ADEs represent a preventable source of hospital admission with almost three 
quarters (72%) of ADE-related hospital admissions considered to be preventable (Pirmohamed 
et al., 2004).  
Furthermore, ADEs contribute a considerable cost burden to health systems, 
estimated to cost the NHS £446 million annually (Pirmohamed et al., 2004). In conjunction 
with associations with unplanned hospital admissions, ADEs are also associated with greater 
numbers of ED visits, longer hospital stays, greater outpatient health service usage and overall 
higher healthcare costs (Bond & Raehl, 2006; Hohl et al., 2011; Wu, Bell & Wodchis, 2012). 
Given that many ADEs are considered preventable, healthcare attendances could be reduced 
through a rational and cautious approach to prescribing for older people. 
1.5 Inappropriate prescribing 
Inappropriate prescribing is considered to be the use of medications where the risk of 
an ADE outweighs the clinical benefit to the patient, especially when safer alternatives are 
available (Beers et al., 1991; Gallagher, O’Connor & O’Mahony, 2011; Spinewine, Schmader, et 
al., 2007). Inappropriate prescribing also includes the omission of clinically indicated 
medications in the absence of a clear contraindication (Gallagher, et al., 2011; Spinewine, 
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Schmader, et al., 2007). There has been a move within the literature to refer to inappropriate 
prescribing in terms of potential and not absolute risk. As such, many papers refer to 
potentially inappropriate prescribing in clear recognition that such prescribing is not always 
inappropriate. For the purposes of the present discussion the terms inappropriate prescribing 
and potentially inappropriate prescribing are considered to be interchangeable. Potentially 
inappropriate prescribing (PIP) is not merely the presence of at risk medications, or the 
absence of clinically indicated medications, but also encompasses a range of misprescribing 
practices such as inappropriate durations of therapy and unsuitable formulations for the 
patient (Hanlon et al., 1992; Samsa et al., 1994; Simonson & Feinberg, 2005).  
Inappropriate prescribing is common among older patients, and is associated with 
poorer outcomes (Cahir, Bennett, Teljeur & Fahey, 2014; Cahir, Moriarty, Teljeur, Fahey & 
Bennett, 2014). Prevalence estimates of PIP among older persons have been reported to range 
from 19.8 to 52.7% (Moriarty, Bennett, Fahey, Kenny & Cahir, 2015), 28-42% (Cahir, Moriarty, 
et al., 2014), and even as high as 63% (Hudhra et al., 2016) and 71.2% (Recoche et al., 2017). 
Furthermore, prevalence of PIP has also been found to increase longitudinally among older 
adults (Moriarty, Bennett, Fahey, et al., 2015; Moriarty, Hardy, Bennett, Smith & Fahey, 2015).  
Inappropriate prescribing is a driver for ADEs in older people (Hamilton, Gallagher, 
Ryan, Byrne & O’Mahony, 2011). Inappropriate prescribing for older Irish adults has been 
shown to be associated with ADEs, hospitalisation and inefficiencies in the healthcare system. 
Within the Irish context, patients with more than two inappropriate medications were twice as 
likely to have experienced an adverse drug event and to be at a nearly two-fold risk of an ED 
visit (Cahir, Bennet, et al., 2014). Similarly, Cahir, Moriarty, et al., (2014) found inappropriate 
prescribing to be associated with a one third increase in hospital attendance in those who had 
at least two potentially inappropriate medications, even after adjusting for covariates. 
Furthermore, Moriarty, Cahir, Fahey & Bennett, (2014) also found that PIP was independently 
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associated with increased healthcare utilisation. It was found that the incidence rate ratio for 
hospitalisation was 1.24 for each additional inappropriate medication consumed. PIP has also 
been shown to be associated with increased numbers of ED and GP visits (Moriarty, Bennett, 
Cahir, Kenny & Fahey, 2016). Thus, within the Irish context inappropriate prescribing is 
associated with increased healthcare utilisation.  
However, the international evidence is more equivocal. Jano and Aparasu (2007) 
conducted a systematic review to examine the associations between inappropriate 
prescribing, when assessed using the Beer’s criteria, and healthcare outcomes. Three out of 
four studies which examined the association with hospitalisation among community dwelling 
older people found an association between inappropriate medication and time to 
hospitalisation (Fillenbaum et al., 2004), acute hospitalisation (Klarin, Wimo & Fastbom, 2005) 
and the number of inpatient visits (Fick, Mion, Beers & Waller, 2008). No association was 
found with other healthcare services within the community, and studies examining healthcare 
resource usage by nursing home residents exposed to inappropriate prescribing were 
inconclusive (Jano & Aparasu, 2007). A more recent systematic review, examining the 
relationship between PIP and healthcare costs reported evidence of a significant relationship 
between PIP and hospitalisation (Hyttinen, Jyrkka & Valtonen, 2016). Twenty-two out of 39 
studies examined reported a significant association between PIP and hospitalisation (Hyttinen 
et al., 2016). However, five studies reported no significant association (Hyttinen et al., 2016), 
suggesting the relationship may not be as clearly delineated as previously thought. Therefore, 
chronic disease management within this cohort becomes a delicate balance of symptom 
control and adverse event avoidance. Such a balance is even more difficult to strike when one 




Polypharmacy as a term has evolved over the years. Originally conceptualised as a 
means of describing issues related to multiple medication consumption, including excessive 
drug use, it has come to mean different things to different people. A cursory glance at the 
literature would lead one to consider polypharmacy in terms of a numerical threshold of 
medications, above which the patient would be considered to be experiencing polypharmacy. 
Nonetheless, one would quickly find that there is considerable variance in the numbers 
proposed as a threshold figure. A total of 138 definitions for polypharmacy have been 
identified within the literature (Masnoon, Shakib, Kalisch-Ellett & Caughey, 2017). This lack of 
consensus on a definition has made interpreting studies purported to investigate the 
phenomenon a difficult terrain to navigate.  
More recently, there has been a call to move away from a ‘many drugs’ approach to 
that of a ‘too many drugs’ approach, with an emphasis placed on the appropriateness of the 
medication regimen (Cadogan, Ryan & Hughes, 2016). The multimorbid patient will likely 
consume a considerable number of medications, all of which might be highly appropriate for 
meeting the patient’s therapeutic goals. The conversation thus requires reframing such that 
we are less concerned with the total number of prescription medicines being consumed by the 
patient, but rather the suitability of each individual medication, not just in isolation, but also in 
combination with the entirety of the regimen. The rationale should therefore become one of 
quality of prescribing and not volume of prescribing (Stuijt, Franssen, Egberts & Hudson, 2008).  
Cadogan et al., (2016) argue that when viewed negatively, polypharmacy could be a 
driving force behind underprescribing, which in itself is an inappropriate prescribing practice. 
Solely focusing on the number of medications would therefore fail to address inappropriate 
prescribing in its entirety by not addressing the underprescribing element. Rather, Cadogan 
and colleagues prudently argue that the number of clinical conditions a patient has needs to 
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be considered when evaluating drug therapy. This is of particular importance when one 
considers that many clinical guidelines are predicated on a single disease state rather than 
focusing on multimorbid patients. The mismatch between prescribing guidelines for specific 
conditions and the range of complexity that exists in the patient with multiple morbidities can 
result in polypharmacy, which can be both appropriate and inappropriate (Mair, Fernandez-
Llimos & SIMPATHY Consortium, 2017). Accordingly, Cadogan et al., (2016) advocate for a 
move towards qualifying the clinical appropriateness of a medication and away from 
quantifying the number of medications.  
However, we should not completely disregard the value of knowing the number of 
medications a patient is consuming, as the number of repeat medications has been 
consistently shown to be an independent predictor of inappropriate prescribing (Bradley et al., 
2012; Bradley et al., 2014; Hudhra et al., 2016; McMahon, Cahir, Kenny & Bennett, 2014). 
Among the Northern Irish population aged ≥70 years, those who received seven or more 
medications were five times more likely to receive PIP, compared with those who consumed 
between zero and three medications (Bradley et al., 2012). When defined as ≥4 medications, 
Bradley et al., (2014) found that polypharmacy resulted in an 18-fold increase in the risk of PIP 
among the UK population ≥70. Older Irish fallers (≥70 years) presenting to ED on ≥4 
medications were four times more likely to be in receipt of inappropriate prescribing 
(McMahon et al., 2014). Jiron et al., (2016) found that the number of medications taken by 
participants increased their risk of PIP 7.5-fold. Thus, polypharmacy may still serve as a useful 
guide in highlighting patients that would benefit from optimisation of their medication 
regimen.  
Polypharmacy is also related to health outcomes. Cahir, Bennett, et al., (2014) found 
that the number of repeat drug classes to be significantly associated with ADEs and an 
increased risk of ED visits. Polypharmacy has been shown to be related to frailty status among 
37 
 
older adults (Palmer et al., 2019; Saum et al., 2017), with those frail older adults who receive 
polypharmacy shown to have longer hospital admissions, more discharges to residential care 
and are more likely to experience a hospital readmission (Rosted, Schultz & Sanders, 2016).  
Polypharmacy can occur as the result of many different processes. It can arise as a 
consequence of stringent application of clinical guidelines, aimed at standardising practice. 
However, guidelines should be seen as exactly that, and not an attempt to replace the 
judgement of the clinician.  Stefanacci & Khan (2017) argue that such application of clinical 
guidelines is often required by value-based payment models. Thus, attempts to rationalise the 
medication budget within a health system may lead to over-application of clinical guidelines to 
the detriment of the actual patient.  Multiple prescribers, in particular those who are not 
experienced in geriatric medicine, as well as multiple transitions of care can also result in 
polypharmacy. Similarly, the treatment of an adverse drug reaction caused by one medication, 
with another medication can quickly result in a prescribing cascade (Figure 1-1) and increase 
the patient’s number of medications in a dramatic fashion (Rochon & Gurwitz, 1995, 1997, 
2017).  
 











Blozik, Rapold, von Overbeck and Reich (2013) argue that polypharmacy and 
inappropriate prescribing are closely related but remain distinct. To simply look at it as a 
numbers issue is to risk missing the point about appropriateness completely. Whilst the 
number of repeat medications has been shown to be a consistent predictor of inappropriate 
prescribing, it is the number of inappropriate medications that poses a greater risk to the 
patient than just the number of medications per se. When the number of clinical conditions is 
accounted for, the association between number of drugs and unplanned hospital admissions 
has been shown to reduce (Payne, Abel, Avery, Mercer & Roland, 2014). Morath et al., (2017) 
further argue that a patient’s number of medications is a modifiable risk factor associated with 
unplanned hospital admittance and suggest that the pharmacist is clinically placed to provide 
an appropriate intervention.  
Given their inherent vulnerability to drug-related problems any review of 
pharmacotherapy in older people should consider appropriateness as a key focus (Somers et 
al., 2012). However, the lack of a standardised assessment of PIP has made it difficult to 
determine the true prevalence of PIP (Bregnhøj, Thirstup, Kristensen & Sonne, 2005), with 
estimates shown to vary depending on the screening tool used (Cahir, Moriarty, et al., 2014; 
Moriarty, Bennett, et al., 2015; Morin, Fastbom, Laroche, & Johnell, 2015).  
1.7 Detecting inappropriate prescribing 
Several instruments have been developed over the years aimed at detecting 
inappropriate prescribing. These can be broadly characterised as either explicit or implicit 
measures. Explicit tools provide lists of medications to be avoided, and/ or scenarios (disease 
states) whereby a medication is considered inappropriate. In contrast, implicit tools involve a 
judgement-based approach on the part of the clinician, by taking the patient’s clinical state 
into consideration.  
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Early attempts to provide guidance with respect to prescribing appropriateness 
resulted in the development of explicit lists of medications not suitable for use in older adults. 
Examples include the American Beers’ Criteria (Beers et al., 1991), which has been revised and 
updated in 2015 (American Geriatrics Society, 2015), and the Screening Tool of Older People’s 
Potentially Inappropriate Prescriptions (STOPP; Gallagher, Ryan, Byrne, Kennedy & O’Mahony, 
2008), which is better suited to the European context. Furthermore, the Screening Tool to 
Alert Doctors to Right Treatments (START; Gallagher et al., 2008) can be used to identify 
prescribing omissions, which themselves are considered to be an inappropriate prescribing 
practice. Used together, STOPP/START address different aspects of inappropriate prescribing 
practices, commission, and omission, and thus provide a comprehensive resource to refer to. 
Both STOPP/START have been applied and validated within the literature (Gallagher et al., 
2008; Gallagher et al., 2009).  
Prescribing guidelines are not restricted to Beers and STOPP/START. Kaufmann, Tremp, 
Hersberger and Lampert (2014) suggests that there are 36 tools to assess PIP among older 
adults in existence. Indeed, there are a great many country specific guidelines and explicit lists, 
including the Scottish Polypharmacy Guidance, the French Laroche list, the German PRISCUS 
list, and the Norwegian NORGEP listing. The sheer volume of prescribing assessment tools in 
operation precludes any direct comparisons being made between studies in the wider 
literature on inappropriate prescribing.  
Regardless of their nature, both explicit and implicit tools have a number of limitations 
(Table 1-1). Explicit measures fail to consider the entirety of the medication regimen, focusing 
on each medication in isolation. In such instances explicit tools can underestimate the 
potential for drug-drug interactions. Such inadequacies prevent a comprehensive, patient-
centred assessment (Shelton et al., 2000), thereby obstructing true medicines optimisation. 
Whilst implicit measures, which incorporate room for clinician decision making, provide more 
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scope for patient-centred care, those that lack structure run the risk of not being reliable 
(Shelton et al., 2000).  
Explicit measures provide a means for standardisation of patient care, albeit at the 
expense of a patient-centred approach. However, systematising the autonomous judgements 
of a clinician may not always be in the best interests of the patient. Certainly, equity of access, 
and a consistently high standard of care for all patients is a motivating factor for most 
clinicians. Nevertheless, failing to consider the patient holistically, which explicit measures are 
oft to do, is reductionist, and perhaps ethically wrong. For example, Shelton et al., (2000) 
argue that medication should not be withheld simply because a patient is an older adult. 
Furthermore, the application of explicit criteria in a rigid manner somewhat suggests that 
there is no added value provided by clinical pharmacists, which rather demeans their training 
and experience. It has been argued that there is sufficient evidence to suggest that the 
combination of a structured approach to review prescribing, in tandem with clinical judgement 
is the optimum method of assessing prescribing appropriateness (Somers et al., 2012; Shelton 
et al., 2000). A combination approach allows for a comprehensive assessment that can be 




Table 1-1: Comparison of explicit and implicit tools to assess appropriateness of prescribing  
 Explicit Implicit 
Conceptual Origin Developed from literature Developed from expertise 
   
Pros Allow standardisation of care Patient centred 
 Low cost Considers entire regimen 
   
Cons Does not consider 
comorbidities 
Time consuming 
 Requires constant revision Can be unreliable if 
unstructured 
 Poor generalisability  
 
Several studies, including those in older Irish adults, have found prevalence estimates 
of inappropriate prescribing to vary depending on the screening tool used (Cahir, Moriarty, et 
al., 2014; Moriarty, Bennett, et al., 2015; Hudhra et al., 2016). Moriarty, Bennett, et al., (2015) 
conducted a retrospective assessment of inappropriate prescribing among community-
dwelling older Irish adults and identified a prevalence of 52.7% when the STOPP criteria were 
used, in comparison with a much lower estimate of 30.5% when the Beers’ list was used. 
Similarly, Cahir, Moriarty, et al., (2014) found Beers to detect PIP in 28% community-dwelling 
older Irish adults compared with STOPP, which identified PIP in 42% participants. 
Consequently, Cadogan et al., (2016) argue that the predictive validity of prescribing 
assessment tools has not been adequately determined.  
More recently, Hudhra et al., (2016) found that the version of the explicit tool that is 
used must also be considered. A comparison of different versions of STOPP within the same 
sample revealed a prevalence of 34.5% for the 2008 criteria, compared with 63% when the 
2014 criteria were used. Whilst it is intuitive that revised criteria, containing more indicators 
42 
 
would identify a higher prevalence of PIP, it highlights the need for a screening tool that 
remains adaptable to advances in clinical knowledge.  
A limitation of many studies of inappropriate prescribing, including many conducted 
within Irish samples, is that many have involved the application of explicit measures such as 
STOPP/START in a retrospective manner, through the analysis of prescribing databases. Such 
an approach limits the use of the screening tool to only those indicators which do not require 
the concomitant examination of the individual’s medical notes. The variance in the number of 
indicators applied within the literature limits the comparisons that can be drawn between 
studies. For example, Bradley et al., (2014) found that, in a retrospective cohort study of those 
UK adults aged 70 years or over, PIP prevalence using only 28 STOPP indicators to be 14.9%, 
compared with 29% when 52 out of the 65 indicators were used. Similarly, Galvin et al., (2014) 
found a prevalence of PIP of only 14% when using 26 indicators of STOPP in a sample of 
community-dwelling adults aged ≥65 years. Thus, the use of a restricted number of STOPP 
indicators may underestimate the true prevalence of inappropriate prescribing within a 
sample.  
Retrospective database studies fail to account for pertinent information that may 
provide insight into the prescribing culture for a particular individual. Information regarding 
other treatments trialled as a first-line option may not be apparent. Furthermore, information 
regarding contraindications may not be included. Such databases may also provide misleading 
information regarding duplication of therapy, a recognised aspect of inappropriate prescribing. 
In some cases, the patient’s record may indicate a duplicated drug class, however this may not 
be reflective of what was actually dispensed to the patient, nor what was consumed by the 
patient. Consequently, database reviews fail to provide true estimates of PIP prevalence given 
the lack of information contained within them. In essence, such reviews cannot account for 
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occasions where seemingly inappropriate medications have been determined to be 
appropriate for the specific patient in question.  
1.8 Quantifying inappropriate prescribing: The Medication Appropriateness 
Index 
The Medication Appropriateness Index (MAI) is a ten-item weighted questionnaire that 
provides a quantitative assessment of the appropriateness of a medication for a given patient 
(Hanlon et al., 1992).  It has been successfully applied in a number of different patient settings 
including hospitals, long term care facilities and community settings (Hanlon & Schmader, 
2013). Shelton et al., (2000) considers it to be a combination prescribing tool that allows for an 
explicitly structured review process whilst retaining implicit judgements.  
Each of the ten items of the MAI assesses a different aspect of the medication which, if 
unaddressed, has the possibility of resulting in inappropriate therapy. These aspects include 
clinical indication, effectiveness, correct dosage, correct directions, practical directions, drug-
drug interactions, drug-disease interactions, duplication, duration, and expense (refer to 
Chapter 2). It formalises a clinical pharmacist review and provides a standardised score for 
each medication, ranging from 0 to 18. Higher scores reflect less appropriate prescribing. Each 
of the ten items is weighted to reflect the relative importance of the item, a clear recognition 
that certain aspects, such as effectiveness, are more important than others, such as cost 
considerations.   
The particular advantage of the MAI is that it allows for quantification of 
appropriateness, through the reduction of considerable data into a standardised metric. In 
doing so, one can compare findings between studies and visualise trends in prescribing 
appropriateness, in an efficient manner. By incorporating a structured approach with implicit 
judgements, as suggested by Shelton et al, (2000) as the ideal prescribing assessment tool, the 
MAI may bridge the gap between explicit and implicit tools. In addition, instead of considering 
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the implicit nature of the measure to be solely comprised of the pharmacist’s clinical 
knowledge, one must accept that explicit measures often form this implied knowledge. As a 
consequence, where explicit lists have failed, the MAI may remain robust to advances in 
clinical knowledge by not requiring constant revision.  
The predictive validity of the MAI has been shown in early studies examining the 
relationship between MAI score and health outcomes. Schmader et al., (1997) found higher 
MAI scores to be significantly associated with unscheduled ED visits and inadequate blood 
pressure control. However, Schmader and colleagues (1997) found no significant association 
between higher MAI and hospital admissions. In contrast, Gillespie et al., (2013) found higher 
MAI scores to be significantly associated with drug-related hospital admissions, suggesting that 
the relationship between MAI score and hospital admission is predicated on the experience of 
an adverse drug event. Notably, Lund, Carnahan, Egge, Chrischilles & Kaboli (2010) found that 
higher MAI scores using a modified MAI significantly predicted adverse drug reactions.  
Like any instrument, MAI is not without its limitations. Stuijt, Franssen, Egberts & 
Hudson, (2009) caution that the MAI score should only be calculated by experienced clinicians 
who have full access to the patient’s clinical information. The MAI does not provide a means of 
assessing adverse drug events (ADEs), an important consideration associated with drug 
therapy. However, Shelton et al., (2000) justly argue that there are several other tools which 
serve this function, and as such MAI need not concern itself with this objective. For the 
practitioner, this may necessitate the use of multiple assessment tools, and may unnecessarily 
extend the review process.  An additional criticism levelled at MAI is that it has been argued it 
does not detect underprescribing, and indeed its structure does not include a specific indicator 
to this end. However, one would be dismissing the clinical knowledge of the experienced 
clinician if one did not concede that this may already form part of their implicit thought 
processes. Just because there is not an indicator to alert to underprescribing does not mean 
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the pharmacist would not consider this. Shelton and colleagues (2000) suggested that, at the 
time of writing, it was the closest to a reliable and comprehensive instrument to assess 
prescribing appropriateness. Hanlon & Schmader (2013) argue that in the absence of a gold 
standard for identifying inappropriate prescribing, it remains a valuable research tool by 
providing a structured process for medication review, in tandem with a quantitative measure.  
1.9 Medication use in older adults 
Numerous medication classifications have been identified as particularly risky for use 
in older people. Specific concerns have been raised as far back as 1987, when federal oversight 
regulations regarding the use of antipsychotics in nursing homes were introduced in the US 
(Kales et. al., 2011). Antipsychotic medications are often used to treat behaviour and 
psychological symptoms of dementia (BPSD), however they are associated with an increased 
risk of cerebrovascular events and sudden death (Ray, Chung, Murray, Hall & Stein, 2009; Wu, 
Tsai & Tsai, 2015). In 2009 they were estimated to cause 1800 deaths and 1620 
cerebrovascular accidents in the United Kingdom (Banerjee, 2009), despite an earlier 
regulatory warning in 2004 by the Medicines and Healthcare Products Regulatory Agency 
(MHRA) regarding the risk of stroke with risperidone and olanzapine (MHRA; 2004). This 
warning was further extended to include all antipsychotics in 2009 (MHRA, 2009).  
However, adverse drug events for older people are not reserved to cerebrovascular 
accidents with antipsychotics. Several drug classes have been identified as increasing the risk 
of falls including antihypertensives, diuretics, sedatives, antipsychotics, antidepressants, 
benzodiazepines, and nonsteroidal anti-inflammatories (Woolcott et al., 2009). Falls resulting 
in fractures can lead to prolonged complicated sequelae for older people. Thus, it is vital that 
any assessment of inappropriate prescribing does not solely focus on the quantitative severity 
of the issue but also retains a qualitative element regarding the medication classifications that 
are contributing to objectionable pharmacotherapy for older adults.  
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The nature of inappropriate prescribing of psychoactive medications among older 
adults is particularly concerning, especially among nursing home residents (Barry, Parsons, 
Passmore & Hughes, 2015; Patterson, Hughes & Lapane, 2007) and people with dementia 
(Renom-Giuteras et al., 2018). The high prevalence of psychoactive prescribing among care 
home residents warrants attention given concerns that such medications are being used as a 
form of chemical restraint. A high proportion of older patients (73.9%) receive at least one 
psychoactive medication; more than half of these are considered to be prescribed 
inappropriately (Arnold et al., 2017). Psychotropic medication use has been found to be higher 
among nursing home residents compared with those residing in the community, and to 
increase sharply following admission to such facilities (Maguire, Hughes, Cardwell & O’Reilly, 
2013). Given the increased susceptibility to the pharmacodynamic effects of many 
medications, the use of psychoactive medication in older people can result in harmful 
outcomes. For example, the use of benzodiazepines, to which older people are more sensitive 
(ElDesoky, 2007) is associated with an increased risk of falls (Díaz-Gutiérrez, et al., 2017), and 
can thus be a contributing factor in the return of a care home resident to an acute care setting 
if a fracture is experienced. The higher levels of psychoactive prescribing observed in care 
homes point to a clear need for pharmacist input to ensure that medicine use is optimised and 
that the risk of medication related harm is eliminated. 
1.10 Pharmaceutical care needs of older adults 
A central tenet to which pharmacists adhere is to optimise pharmacotherapy for 
patients whilst at all times ensuring they receive safe and efficacious treatments. 
Pharmaceutical care can be considered as the processes by which a pharmacist liaises with 
patients and/or other healthcare professionals to optimise pharmacotherapy, through the 
implementation and monitoring of goals that will produce specific therapeutic outcomes for 
patients (Spinewine, Fialova & Byrne, 2012).  
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Older adults may require pharmaceutical care more than most, increasing the 
potential for mediation related harm, and thus, associated healthcare utilisation. 
Polypharmacy, multimorbidity, inappropriate prescribing and age-related physiological 
changes creates a perfect storm for an adverse drug event to occur. Social factors such as 
residence in a care home, premature discharge from hospital due to an increased demand for 
beds may further the need for pharmaceutical care. Furthermore, irrespective of whether 
medication-related or not, a hospital admission can have deleterious effects on the functional 
and cognitive status of older adults. Thereby increasing the potential for future healthcare 
utilisation. Addressing those modifiable aspects of risk of hospital admission, such as 
medication-related factors may serve to limit the harm to older adults and the impact upon 
health services.  
Pharmaceutical care services have undergone somewhat of an evolution over the last 
twenty years. The Fleetwood Model, when launched in 1995 in the US was considered an 
innovative approach to delivering pharmaceutical care to nursing home residents (Spinewine 
et al., 2012). The Fleetwood Model advocated for the identification of potential drug related 
problems and subsequent liaison with the prescriber to resolve these problems (Spinewine et 
al., 2012). In doing so, the Fleetwood Model set the foundation for the development of a 
‘consultant pharmacist’ role, which commonly involved a medication review and management 
of the patient’s regimen (Hughes & Lapane, 2011).  Alldred et al., (2007) consider a medication 
review to be multidimensional. Accordingly, a medication review can be considered as ‘a 
review performed by a healthcare professional, taking into consideration a patient’s health 
status and medications, with access to full medical and care records, in conjunction with a 
consultation with the patient and their carer’ (Hughes & Lapane, 2011, p. 107).  
The Fleetwood Model was considered a successful approach, resulting in an estimated 
$3.6 million reduction in healthcare costs, owed to consultant pharmacist input into drug-
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related problems in nursing homes (Bootman, Harrison & Cox, 1997). It has also been argued 
that this new consultant pharmacist role allowed for better integration of the pharmacist into 
the multidisciplinary team (Spinewine et al., 2012). The model also highlighted the challenges 
with respect to inappropriate prescribing within care homes. An evaluation of the Fleetwood 
Model in 12 nursing homes in the US identified 40% of residents were at high risk of drug-
related problems, and 27% were in receipt of a potentially inappropriate medicine (Lapane & 
Hughes, 2006).  
However, despite the clear advantages of pharmacist-led medication review, more 
often it is the case that hospital pharmacists are preoccupied with medication reconciliation, 
aimed at identifying the correct up to date list of a patient’s medication. The occurrence of 
medication errors during patient transitions, for example from home to hospital admission, 
has dictated that need for medication reconciliation (Aronson, 2017). Whilst such an exercise is 
a prerequisite for a patient safety and a high standard of care, it is nevertheless time 
consuming, and may not be the best use of a clinical pharmacist’s time.   
Dalton & Byrne (2017) argue that traditional medicines reconciliation services are 
insufficient in reducing post-discharge clinical outcomes, and that the exercise needs to 
incorporate a medication review in order to be impactful. Similarly, Shelton et al., (2000) argue 
that good pharmaceutical care involves sufficient monitoring of therapy in terms of both 
beneficial and detrimental outcomes. Therefore, it is now generally accepted that a core 
element of the pharmacist’s role is to systematically review each individual’s 
pharmacotherapy, with a view to medicines optimisation (Christensen & Lundh, 2016). The 
inherent value of clinical pharmacist input can be appreciated in the considerable evidence 
available to support the acceptance of pharmacist suggestions by the wider prescribing team 
(Viktil & Blix, 2008). 
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Dalton & Byrne (2017) propose that pharmacists can contribute considerable savings 
to healthcare systems via immediate cost savings and future cost avoidance. For example, the 
clinical outcomes directly influenced by the clinical pharmacist’s intervention can be 
calculated. In addition, future cost avoidance of drug related problems that have been 
resolved may also be quantified. This is particularly relevant when one considers that many 
drug related problems are considered preventable (Pirmohamed et al., 2004).  
1.11 Consultant pharmacist roles 
The US consultant pharmacist role is distinctive from the consultant pharmacist role in 
the UK. The publication of ‘A Vision for Pharmacy in the New NHS’ sought to develop 
consultant pharmacist positions to recognise the clinical excellence and leadership of 
experienced pharmacists (Department of Health; DOH, 2003). The primary aim of these 
consultant pharmacist posts was to provide patients with access to expertise from a 
practitioner who was not only leading the profession through practice but was also involved in 
research and teaching within their specialist area (Specialist Pharmacy Service Medicines Use 
and Safety Team, 2017).  
Consultant pharmacists in the UK are required to have the necessary skills and 
experience to work across four key areas: clinical practice, professional leadership, education 
and mentoring of practice, and to conduct evaluative and service development research 
(Consultant Pharmacist Short Life Working Group, 2020; DOH, 2005; Specialist Pharmacy 
Service Medicines Use and Safety Team, 2017). These consultant pharmacist roles were 
created as distinctive posts that pharmacists could be appointed to, provided the necessary 
competency requirements were met. This advanced role sought to “provide a dynamic link 
between clinical practice and service development to support new models for delivering 
patient care” (DOH, 2005, p4.). Thus, this UK consultant pharmacist role is quite different from 
that in the US, where the purpose of the role is to identify and resolve medication related 
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problems, particularly for those who are resident in nursing homes (Spinewine et al., 2012). 
Consultant pharmacist posts have been established across the UK in diverse areas such as 
cardiology, antimicrobials, anticoagulation, paediatrics and older people’s care (Specialist 
Pharmacy Service Medicines Use and Safety Team, 2017, 2020).  
1.12 Pharmaceutical care interventions for older adults 
With respect to medicines optimisation interventions targeted towards older adults, 
pharmacists have been active participants, and in many instances, have led the agenda when 
developing initiatives (Spinewine et al., 2012). Despite this involvement, an examination of the 
evidence surrounding the effectiveness of pharmacist interventions raises some contradictory 
findings (Christensen & Lundh, 2016; Verrue, Petrovic, Mehuys, Remon & Stichele, 2009). 
An integrated medicine management (IMM) service, incorporating increased 
pharmacist input throughout the hospital patient journey, has been shown to significantly 
reduce hospital length of stay by two days, decrease the rate of readmission and significantly 
increase the time to readmission (Scullin, Scott, Hogg & McElnay, 2007). The IMM service has 
also been shown to be reproducible as part of routine clinical practice with significant 
reductions in hospital length of stay observed (Scullin, Hogg, Luo, Scott & McElnay, 2011). In 
contrast, a recent Cochrane review examining medication reviews as an intervention for 
hospitalised patients showed a decrease in emergency department admissions but no 
decrease in hospitalisations or all-cause mortality (Christensen & Lundh, 2016).  
In the nursing home context, pharmacist-led medication reviews have been shown to 
result in a non-significant reduction in the number of medications prescribed and 
consequently in associated drug costs (Furniss et al., 2000). However, no effect on subsequent 
morbidity or mortality was observed. Roberts et al., (2001), on the other hand, found that 
when pharmacist-led medication reviews were combined with a focus on professional 
relationship building and nurse education, a significant decrease in number of medications was 
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observed.  When considering health outcomes, Zermansky et al., (2006) found that a 
pharmacist-led medication review resulted in a significant number of drug changes, and a 
significant reduction in falls, compared with a control. However, no significant difference was 
observed between the intervention and control groups for GP consultations, hospitalisation, 
deaths, or number and/or cost of drugs per patient.  
The inclusion of the pharmacist into a multidisciplinary case conference approach to 
nursing home care has shown more success, with a significant improvement in 
appropriateness of prescribing (Crotty, Halbert, et al., 2004) and a reduction in prescribing of 
antipsychotics, benzodiazepines, and antidepressants (Schmidt, Claesson, Westerholm, Nilsson 
& Svarstad, 1998). In contrast, a pharmacist-led education intervention reported no significant 
differences in psychotropic prescribing, when compared with a control group (Crotty, 
Whitehead, et al., 2004). When acting as a coordinator at the transition of care between 
hospital and nursing home, intervention by the pharmacist has been shown to prevent 
worsening in level of prescribing appropriateness compared with a usual care control group 
(Crotty, Rowett, Spurling, Giles & Philips, 2004).  
More recently, Huiskes et al., (2017) set out to assess the effectiveness of medication 
review as an isolated short-term intervention, irrespective of patient population. In their 
systematic review, 31 randomised controlled trials (RCTs) with a duration of less than three 
months were reviewed. Best evidence synthesis was conducted for 22 outcome measures. No 
effect on clinical outcomes, save for a decrease in falls was found. Similarly, no effect on 
quality of life or economic outcomes was observed. However, an effect was found for drug-
related problems. Their conclusion was that despite showing effects for most drug-related 
outcomes, no conclusion could be drawn on the effect of the interventions on clinical and 
economical outcome measures. On the balance of such evidence, Huiskes and colleagues 
advocate for a cessation of widespread medication reviews as an aspect of standard care and 
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consider examining high-risk individuals instead. Such a conclusion underscores the need to 
clearly identify who these high-risk individuals are.   
In their review of 107 studies, Faria, Barbieri, Light, Elliot and Sculpher (2014) found 
that most studies evaluated were predicated on the measurement of intermediate outcomes. 
Intermediate outcomes, such as blood pressure and error rates, may impact on final outcomes, 
such as health resource usage and mortality. However, as Faria and colleagues (2014) notably 
argue, none of the studies included in the review attempted to link the intermediate outcomes 
with final outcomes, undermining the inherent presumption in the utility of intermediate 
outcomes. They further argue that any association between intermediate outcomes and final 
outcomes may vary as a function of the disease in question. Furthermore, the absence of a 
standardised measurement approach prevents comparisons of multiple study findings.  
Whilst the evidence regarding effectiveness of clinical pharmacist interventions 
provides conflicting results, it must be recognised that many studies are not comparable based 
on the differing outcomes assessed. Such heterogeneity in study design and limitations in 
terms of the outcomes measured precludes a true assessment of medicines optimisation 
interventions (Faria et al., 2014). Furthermore, when considering healthcare utilisation as an 
outcome of any intervention for older adults, one must appreciate the myriad of factors which 
influence healthcare utilisation generally speaking, but also those factors which are particularly 
relevant in older cohorts. 
1.13 Healthcare utilisation by older adults: myriad of antecedents and 
consequences 
The risk for hospital admission increases for those older adults who experience 
cognitive impairment (Toot, Devine, Akporobaro & Orrell, 2013). Once hospitalised, those with 
cognitive impairment are likely to experience a longer admission and are also more likely to be 
readmitted within 28 days of discharge, compared with those without cognitive impairment 
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(Tropea, LoGiudice, Liew, Gorelik & Brand, 2018). The experience of a hospital admission can 
also result in altered cognition and delirium among older adults (Inouye, Westendorp & 
Saczynski, 2014).  
Variation in cognitive function and functional status of older adults has been shown to 
be related to depression (Song, Meade, Akobundu & Sahyoun, 2014) and may exhibit a 
bidirectional relationship, with poorer functional and cognitive status related to greater 
depressive symptomology in older adults (Vankova, Holmerova, Andel, Veleta & Janeckova, 
2008). Furthermore, depression may intensify the relationship between chronic illness and 
healthcare usage (Dickens et al., 2012). For example, the coexistence of depression or anxiety 
among those with chronic obstructive pulmonary disease (COPD) has been shown to be 
related to greater levels of healthcare usage and increased costs (Laurin et al., 2009; Maurer et 
al., 2008; Gudmundsson et al., 2005; Xu et al., 2008).  
Frailty is a multidimensional syndrome described as the inability to maintain 
homeostasis in the presence of stressors due to an age-related decline in physiological reserve 
(Rockwood et al., 2005; Xue et al., 2011). The presence of frailty increases the risk of falls, 
increased level of disability, hospitalisation, transfer to long term care and death (Ensrud et al., 
2008; Fried et al., 2001; Rockwood et al., 2004). Frailty has also been shown to increase the 
numbers of consultations with GPs and practice nurses and to be associated with longer 
hospital admissions (Han, Clegg, Doran & Fraser, 2019).  
Chronic disease management is associated with higher levels of healthcare utilisation 
(Cassell et al., 2018; Glynn et al., 2011; Hutt et al., 2004; Lehnert et al., 2011; Marengoni et al., 
2011; Palladino et al., 2016) and is found to be more prevalent among older adults (Barnett et 
al., 2012; Britt, Harrison, Miller & Knox, 2008; Cassell et al., 2018; Violan et al., 2013; Zulman et 
al., 2015). Multimorbidity and frailty both increase the risk of polypharmacy among older 
adults (Palmer et al., 2019; Saum et al., 2017), thereby increasing the risk for additional 
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healthcare utilisation. Furthermore, those with both frailty and polypharmacy have been 
shown to have longer hospital admissions, more nursing home transfers and have a higher risk 
of hospital readmission (Rosted et al., 2016). As previously discussed, polypharmacy increases 
the risk of inappropriate prescribing.  
There are numerous mechanisms by which medications can increase the need for 
healthcare utilisation among older adults, with falls a particular conduit. An increased 
sensitivity to the pharmacodynamic effects of sedative medications such as benzodiazepines 
(ElDesoky, 2007) can increase the risk of falls in older adults (Bloch et al., 2011; Díaz-Guitérrez, 
et al., 2017; Hill & Wee, 2012; Landi et al., 2005). As a consequence, an escalation of care may 
be required, particularly if a fracture is experienced. Falls and associated fractures are often a 
contributing factor in the transfer of a care home resident to an acute care setting (Carey & 
Laffoy, 2005; NHS Scotland, 2016; Quinn, 2011; Smith, Sherlaw-Johnson, Ariti & Bardsley, 
2015). Orthostatic or postural hypotension as a consequence of antihypertensive medications 
can also result in falls among older adults (Tinetti et al., 2014). The adverse effects of 
anticholinergic medications, including postural hypotension, blurred vision, and confusion, 
further increase the risk of falls and subsequent negative outcomes such as fractures or 
traumatic brain injuries (Carey & Laffoy, 2005).  
 




Given the intimate associations between medication use and negative outcomes 
resulting in increased healthcare utilisation, it can be argued that pharmacist intervention may 
serve as a leverage point from which an improved experience of aging can be achieved. Thus, 
perhaps the words of Spinewine and colleagues (2012) remain valid such that “opportunities 
exist for multi-centre, European-based, pharmacist-intervention trials in all settings, to 
determine the effectiveness and economic benefit of pharmacist involvement in the 
optimisation of pharmacotherapy in older persons’” (p. 508).  
1.14 Health service provision in Northern Ireland (NI) 
Since 1999, responsibility for health services has been a function of the devolved 
government of Northern Ireland. Consequently, public health decisions, including policies and 
expenditure, are made locally in Northern Ireland. Unlike the remainder of the United 
Kingdom, Northern Ireland has a single organisation that purchases services for the whole 
population (National Audit Office; NAO, 2012). The Health and Social Care Services (HSC) in 
Northern Ireland coordinates the provision of integrated services to the population, across six 
health trusts. These are Belfast HSC Trust, South Eastern HSC Trust, Western HSC Trust, 
Southern HSC Trust and Northern HSC Trust. The sixth trust is the Northern Ireland Ambulance 
Service, which operates a single service across the territory. HSC Trusts manage and administer 
hospitals, health centres, residential homes, day centres and other health and social care 
facilities, whilst also providing a wide range of services throughout the community (Health and 
Social Care Northern Ireland, 2018). In addition to patient facing organisations, the HSC in 
Northern Ireland also coordinates a number of additional agencies and programmes 
concerned with a wide range of activities including public health, clinical trials, health 
screening, research and development and education.  
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Northern Ireland has been adjudged to have the highest average health need per 
person, compared to the rest of the United Kingdom (NAO, 2012), based upon indicators such 
as population age, levels of disability and wealth etc. Funding for public services in Northern 
Ireland comes from the Treasury, the amount of which is calculated primarily based upon 
historical levels (NAO, 2012).  Despite the autonomy to determine how to fund health and 
social care services, NI has had the most variability in health spending from one year to the 
next. Simultaneously, NI also has devoted the lowest proportion of public spending to health 
when compared with other parts of the UK.  
1.15 Demand for healthcare services for older adults in NI 
The demand for health services in Northern Ireland will increase substantially when 
one considers the disproportionate rate of population growth among the older generation. 
There has been a consistent increase in the number and proportion of older people living in 
Northern Ireland. In the period from 2004 to 2014, the number of adults aged 65 years and 
over increased by 23.1%, which was more than three times higher than the total population 
growth rate (7.4%) over the same period (Office of the First Minister and Deputy First Minister, 
2015). During the same period, the proportion of the population aged 85 years and older 
increased by 41% (Office of the First Minister and Deputy First Minister, 2015). It is estimated 
that by 2024, those aged over 65 years will increase by 25.8% in Northern Ireland (Northern 
Ireland Statistics and Research Agency; NISRA, 2018). This is juxtaposed with the marginal 
projected growth of 0.8% predicted to occur among those of working age (NISRA, 2018). By 
mid-2039 it is estimated that almost one quarter (24.7%) of the population will be aged 65 
years and over, with 4.4% of the population projected to be 85 years and over (Office of the 
First Minister and Deputy First Minister, 2015). It is therefore imperative that future health 
service provision is suitably organised and sufficiently resourced in order to cater to the unique 
demands of this patient profile.  
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Previous studies of inappropriate prescribing among the older people in NI have 
estimated the prevalence to be approx. 34%, representing approximately 5% of the health 
budget (Bradley et al., 2012). Similar prevalence estimates were observed in the Republic of 
Ireland (ROI), with 36% of participants of a database review found to have at least one 
inappropriate medication (Cahir et al., 2010). When examined in greater detail, inappropriate 
prescribing among older adults in Northern Ireland was found to be associated with 
polypharmacy and female gender (Bradley et al., 2012). However, these associations are based 
upon retrospective database review of those aged 70 years and older, using only 28 STOPP 
indicators (Bradley et al., 2012). As previously argued, database reviews may underestimate 
the prevalence of PIP owed to a limited number of inappropriate prescribing indicators being 
available to analyse, such as the case of Bradley and colleagues’ (2012) findings. Similarly, 
whilst Bradley and colleagues identified inappropriate prescribing in NI to be associated with 
polypharmacy and female gender, the relationship between PIP and healthcare resource 
utilisation was not explored.  
1.16 Pharmaceutical care for older adults in NI 
Northern Ireland has enshrined a patient-centred approach with respect to 
pharmaceutical care within its Medicines Optimisation Quality Framework (Department of 
Health, Social Services and Public Safety Northern Ireland; DHSSPSNI, 2016). This framework 
seeks to support better health outcomes for the Northern Irish population by improving the 
way that medicines are used.  Among its key recommendations the framework called for the 
introduction of a Regional Model for Medicines Optimisation to engage health and social care 
professionals in the delivery of best practices across the region (DHSSPSNI, 2016). This regional 
model was designed to be delivered by a multidisciplinary medicines optimisation workforce, 
with pharmacists involved in all settings (DHSSPSNI, 2016). Furthermore, the framework called 
for the development, testing and scale up of services and for best practices to be co-designed 
with patients (DHSSPSNI, 2016).  
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In recognition of the innovation and outcomes demonstrated in medicines 
management, Northern Ireland was selected as a reference site with the European Innovation 
Partnership for Active and Healthy Ageing and was awarded ‘3 star’ status in 2013 (Scott & 
Fleming, 2017). This recognised Northern Ireland as a leading region in addressing the health 
and social care needs of the older population (Scott & Fleming, 2017). It would then go on to 
become one of seven regions in Europe to be awarded ‘4 star’ status in 2016 (Scott & Fleming, 
2017). Northern Ireland serves as a partner country in the ‘Stimulating Innovation 
Management of Polypharmacy and Adherence in the Elderly’ (SIMPATHY) project which 
comprises of 10 organisations representing eight EU countries (Scullin, Fleming, Scott & 
Harrison, 2016).   
Accordingly, the Medicines Optimisation and Innovation Centre (MOIC) was 
established with a mandate to deliver the best outcomes for the patient through facilitating 
best practice with respect to medicine use, in a consistent way (MOIC, 2016). Such has been 
the success of their activities that Northern Ireland is considered as a leading region in Europe 
for medicine optimisation for older people (Scott & Fleming, 2017). The development of MOIC 
in NI can be considered as a prudent response to the increased demand on health and social 
care services owed to a growing, ageing population with chronic comorbidities (MOIC, 2016). 
The MOIC platform provides space for regional development of innovative solutions aimed at 
safer, more rational use of medications.  
Recent advances within the region include the development of a new model of 
consultant pharmacist-led pharmaceutical care and case management for older people within 
intermediate care (Miller, Darcy, Friel, Scott & Toner, 2016). Within this care model the 
implementation of individualised pharmaceutical care plans by consultant pharmacists was 
found to significantly improve prescribing appropriateness from admission to discharge (Miller 
et al., 2016). Given that intermediate care as a setting has been developed to ease the burden 
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on acute care, and to prevent early admission into care homes, it may provide an ideal point at 
which to intervene with respect to drug related problems. Pharmacotherapy interventions to 
reduce inappropriate prescribing in intermediate care have not received as much research 
attention when compared with other settings (Millar, 2016). In particular, how the reduction in 
inappropriate prescribing relates to later healthcare resource usage has also not been fully 
elucidated.  If such an intervention were to improve the outcomes of the individual patient 
post-discharge from intermediate care, this could result in greater numbers of older people 
returning to their own homes and ward off transfer into a longer-term care home setting.  
Additionally, a consultant pharmacist-led outreach clinic to nursing homes showed 
similar successful outcomes, with a significant improvement in prescribing appropriateness 
achieved (McKee, Miller, Cuthbertson, Scullin & Scott, 2016). This model of care addresses a 
particular ethical issue with respect to respecting the autonomy of older people in addressing 
any concerns that they may have regarding their pharmacotherapy. Care home residents often 
do not receive direct access to a pharmacist, with medication being supplied via the care home 
staff. The older person living well within the community may have more opportunity to engage 
with pharmacy services, have their medications reviewed, discuss any apparent issues with the 
pharmacist and thus exhibit greater autonomy over their medication. Traditionally such access 
has not been available to care home residents.  
1.17 Need for further investigation 
Against a backdrop of an ageing population who are living for longer with more 
chronic conditions, an increased level of scrutiny is being placed on the ability of health 
services to address the unique health needs of older adults. The projected growth among older 
people in Northern Ireland, coupled with the increased level of prescribing within the region, 
points to an increased need for pharmaceutical care services that ensure older adults obtain 
the greatest benefit from their medicines, with minimal harm. To date, several studies have 
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indicated that inappropriate prescribing is prevalent among those older adults living in the 
community (Bradley et al., 2012), intermediate care (Millar, 2016; Miller et al., 2016) and in 
care homes (Maguire et al., 2013; McKee et al., 2016) within Northern Ireland.  
This need is not unique to the Northern Irish context but rather is increasingly 
becoming a global priority. Indeed ‘Medication without harm’ has become the third WHO 
Global Patient Safety Challenge, with high-risk situations such as prescribing for older adults, 
polypharmacy and transitions of care identified as priority areas (WHO, 2017). Given the 
impact of factors such as frailty, polypharmacy, inappropriate prescribing, and falls on 
healthcare utilisation by older adults, it is not surprising that increasing attention is being paid 
to the need to develop integrated care strategies to support older adults to age well 
(DHSSPSNI, 2011a; Health Service Executive: HSE, 2017).  
The Department of Health (DOH) published a National Service Framework (NSF) for 
Older People in 2001, advocating for a person-centred care approach, whereby older people 
would be enabled to be active participants in choices regarding their own care (DOH, 2001). As 
part of this NSF a new layer of care, intermediate care, was proposed. Interfacing between 
primary care and specialist services, this new point of care was designed to promote 
independence via enhanced services from the NHS and prevent unnecessary hospital 
admissions, enable early discharge from hospital and prevent early or unnecessary admission 
to long-term residential care (DOH, 2001). Accordingly, intermediate care has emerged as a 
key location for the care of older adults following discharge from acute care. Acting as a 
‘bridge’ between hospital and home, intermediate care provides an opportunity to address 
those modifiable factors that can support the older person to remain independent within their 
own homes for longer. 
Thus, intermediate care may serve as an ideal location for medicines optimisation for 
older adults.  Given that many medication-related hospitalisations of older people are 
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avoidable, and that increased clinician input in residential care results in reduced healthcare 
usage, it stands to reason that an intervention to address inappropriate prescribing may also 
result in reduced healthcare usage by care home residents. Thus, there is a need to 
understand the implications of pharmacist intervention to improve prescribing 
appropriateness in terms of additional secondary outcomes such as healthcare utilisation. An 
examination of healthcare usage at both primary and secondary care level will provide an 
insight into the escalation of care within this context. Concerns have been raised within the 
literature regarding the appropriateness of transfers of care home residents to hospital 
emergency departments (Lemoyne et al., 2019).   
The literature also points to an increasing concern regarding the use of psychoactive 
medication among older adults, and in particular those living within residential care. There is 
evidence to suggest that such prescribing is prevalent in Northern Irish care homes (Maguire et 
al., 2013). However, to focus solely on inappropriate prescribing of one classification of 
medications does little to inform of the broader prescribing culture within such care settings. 
Thus, as the Medicines Optimisation in Older People (MOOP) care services continue to develop 
throughout the region there is a greater need to understand the effectiveness of both care 
models at a deeper level.  
Both of these pharmaceutical care models have shown significant improvements in 
prescribing appropriateness and also considerable drug cost savings. Such outcomes suggest 
that there are considerable advantages to pharmacist-led medicines optimisation services that 
are not reflected within the findings of previous systematic reviews. A greater understanding 
of what drives the improvement in prescribing appropriateness observed in both models can 
be used to inform the future directions of the service.  
Whilst there has been a wealth of research examining the prevalence of and risk 
factors for inappropriate prescribing globally, there is a dearth of research examining the 
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relationship between improvements in prescribing appropriateness and subsequent 
healthcare utilisation. As such, there is no clear consensus as to the characteristics of patients 
who are at risk of poorer health outcomes associated with inappropriate prescribing. A better 
understanding of how addressing the medicines optimisation needs of older adults is related 
to subsequent use of healthcare services may serve to support the further development and 
refinement of services.  
However, it must be appreciated that hospital readmissions are a complex 
phenomenon and are influenced by sociocultural factors in as much as by health need 
(Cooksley et al., 2016; Hubbard et al., 2017). Thus, it is not surprising that many risk prediction 
models for hospital admission perform poorly (Kansagara et al., 2011). This is despite theorists 
alerting us to the multidimensional factors that influence healthcare access as far back as 1968 
(Andersen, 1968). Moving away from the reductionist nature of the biomedical model, 
theorists such as Bronfenbrenner (1979) and Engel (1980) proposed that clinicians and 
theorists adopt a broader ecological systems perspective. Nevertheless, many studies which 
have sought to examine healthcare utilisation in a multifactorial manner, using the Andersen 
Behavioural Model (Andersen, 1995; Andersen & Newman, 1973), have failed to adopt 
multivariate approaches in order to accommodate the complexity of factors involved (Babitsch 
et al., 2012).  
The evaluation of healthcare interventions, such as pharmaceutical care models can be 
further augmented by a complementary examination of healthcare utilisation over a 
considerable period of time. Longitudinal data sources provide an opportunity to examine 
more data points and develop a more nuanced view of what influences healthcare usage in a 
representative sample, thus providing a broader context within which to examine intervention 
studies. Furthermore, the examination of healthcare usage in an isolated manner limits our 
understanding of the multifactorial nature of healthcare utilisation as particularly with respect 
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to older adults who, as a cohort, which exhibit considerable complexity. Andersen (1995) 
recommended that studies consider healthcare usage patterns longitudinally, as healthcare 
usage in itself may predict future healthcare usage. Longitudinal cohort studies that collect 
information on demographic and socioeconomic factors, as well as clinical information provide 
an opportunity to address such a question. 
1.18 Aims and objectives of the thesis 
There is a clear need to identify the true prevalence and characteristics of 
inappropriate prescribing among older people in Northern Ireland, and further to examine 
associated healthcare outcomes. The present thesis seeks to address this by examining data 
collated by the MOOP pharmacists appointed to deliver inappropriate prescribing 
interventions within intermediate care and care home settings. These interventions were 
conducted in the Western and Northern HSC Trusts using the Medication Appropriateness 
Index as a review tool and metric. Patient MAI scores were calculated by the MOOP 
pharmacist at baseline and on discharge from intermediate care or upon completion of the 
intervention in the care homes.  
This thesis seeks to address two principal aims. The first is to examine whether a 
relationship exists between improvements in prescribing appropriateness and subsequent 
healthcare resource usage, in those patients who receive a specialist pharmacist case 
management service. Furthermore, the study aims to identify those individuals who receive 
the most benefit from the case management interventions and those who are most at risk of 
poorer health outcomes, operationalised as subsequent healthcare resource usage. In doing 
so, future interventions may be targeted more effectively in order to reduce inappropriate 
prescribing in Northern Ireland, with potential scope for more universal application. At a time 
when health resources are under significant strain, risk stratification with respect to 
inappropriate prescribing will serve to increase efficiencies within the health and social care 
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services in Northern Ireland. Similarly, the present study seeks to examine those classes of 
medicines, identified as inappropriate at baseline, that are found to be associated with 
increased healthcare resource usage. The identification of novel classes of high-risk 
medications may then be used to inform future prescribing guidelines.  
Secondly, this thesis seeks to examine the broader contextual factors that influence 
healthcare service usage by older adults, using complementary analyses in a longitudinal 
cohort study of older people. The multifactorial nature of healthcare usage by older people 
makes it particularly challenging to appreciate the impact of interventions on subsequent 
healthcare resources. Thus, the thesis seeks to provide more detail of the context within which 
interventions to support older people should be interpreted. The present study sets out to 
achieve these aims by means of the following objectives: 
i. Calculation of the change in total MAI from baseline to intervention completion for 
patients reviewed by case management pharmacists in intermediate care and care 
homes in the Northern and Western HSC Trusts.  
ii. Identification of the proportion of variability in healthcare resource usage over 30- and 
90-days’ post intervention completion that is explained by the change in MAI. 
iii. Identification of which patients have reduced healthcare resource usage in association 
with a reduced MAI score and those which show no decrease or even increased 
healthcare resource usage, despite a reduction in MAI score.  
iv. Identification of classifications of medications that are frequently prescribed 
inappropriately at baseline for both care home and intermediate care patients.  
v. Establish whether improvements in prescribing appropriateness of these classifications 
leads to a change in healthcare resource usage 30- and 90-days’ post intervention.  
vi. Identify latent longitudinal trajectories of healthcare utilisation by older people using a 
comparable cohort study.  
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vii. Summarise longitudinal change in a range of covariates with a known or theoretical 
association with healthcare utilisation by older people. 
viii. Identify those contributory factors that explain variation in longitudinal healthcare 
utilisation patterns by older adults.  
1.19 Overview of thesis structure 
In order to deliver the thesis objectives, the remainder of the thesis is presented as follows: 
• Chapter 2 forms the foundation for the method sections of subsequent empirical 
chapters, thereby serving as a landmark for the reader. It introduces the methodology 
applied in the thesis by providing information on the data sources, measures and 
sample characteristics, before providing an overview of the analytic plan for the thesis.  
• Chapter 3 examines variability in healthcare utilisation by older adults following the 
receipt of a novel pharmaceutical care intervention within intermediate care settings 
in Northern Ireland. Prior to examining the impact of this intervention on healthcare 
utilisation, preliminary exploration of the prevalence of inappropriate prescribing and 
an examination of variability in MAI score improvement is conducted.  
• Chapter 4 examines the same objectives as those explored in Chapter 3 in relation to 
care homes settings in Northern Ireland.  
• Chapter 5 augments the findings of Chapters 3 and 4 with respect of the prescribing 
culture in intermediate care and care home contexts in Northern Ireland. The 
medication classifications most frequently prescribed inappropriately in both care 
contexts are identified. Furthermore, an examination is conducted of the 
appropriateness of prescribing of psychoactive medications. Healthcare utilisation 




• Within Chapter 6, longitudinal variation in healthcare utilisation is examined using the 
Irish Longitudinal Study of Ageing, a nationally representative study of community 
dwelling older adults in the Republic of Ireland. Heterogeneity in healthcare utilisation 
over time is investigated through the application of latent variable modelling in the 
form of latent class and latent transition analyses.  
• Chapter 7 serves as a foundational chapter for subsequent empirical findings 
presented in Chapter 8. Within Chapter 7, potential covariates which may explain 
differences in healthcare utilisation patterns identified in Chapter 6 are 
operationalised for inclusion in the analyses presented in Chapter 8. Latent growth 
curve models are used as a means of data reduction, capturing longitudinal change in 
several pertinent variables identified from the literature.  
• Chapter 8 integrates the findings of Chapters 6 and 7 through further analysis. 
Covariates operationalised in Chapter 7 are explored as predictors of healthcare 
utilisation patterns identified in Chapter 6 using logistic regression analyses. 
• The concluding chapter, Chapter 9, integrates the findings from the medicines 
optimisation intervention evaluation and the findings obtained from the longitudinal 
cohort study, providing a discussion of the implications of overall thesis findings for 






2.1 Chapter overview 
This chapter outlines the methodology adopted in the present thesis with a particular focus on 
data sources, data collection, measures, and sample characteristics. The purpose of this 
chapter is to serve as a reference landmark to the methods sections of subsequent empirical 
chapters.  
2.2 Introduction 
Conducting research on older adults highlights several key points that must be 
considered. Older people are often excluded from clinical trials on medications, largely due to 
variation in physiological changes in key metabolic systems. As such our understanding of the 
relative safety of medicinal products in older cohorts tends to only surface in the post-
marketing surveillance period. Not only does this result in a dearth of research into how 
medication affects older people specifically, but it also enshrines the view that older people 
are inherently vulnerable, and that research poses a greater risk to them that the wider 
population. This is somewhat of a contentious issue, ethically speaking, as it removes the 
active participation of older people in research topics that are directly relevant to them. Whilst 
there is an obvious need to protect any individual from succumbing to research-related harm it 
is overly simplistic to deduce that all older people are vulnerable. Instead it reinforces an 
ageist approach that is pervasive in many research fields.  
The ‘gold-standard’ approach to research is that of randomised studies that control for 
possible confounders. Doing so provides the best possible means for gathering a robust 
evidence base from which conclusions may be drawn. However, within the context of 
healthcare, and in particular healthcare for older people, randomisation to a control or ‘usual 
care’ group introduces the possibility of denial of efficacious treatments in the pursuit greater 
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academic rigour. This in itself raises additional ethical concerns, particularly when considering 
research conducted in end-of-life scenarios.  
Attrition within studies due to age-related declines in health and death makes research 
within older cohorts particularly challenging with respect to maintaining statistical power. One 
must counterbalance the need for a sufficiently large sample size at the outset with the 
possibility of a large control group receiving no benefit from the intervention under 
examination. Craig et al., (2008) argue that a balance must be struck between the importance 
of the intervention and the value of evidence that can be gathered within the research design. 
Furthermore, there may be ethical objections to the use of experimental methods, despite 
their superiority as a research design (Craig et al., 2008). The time taken to design, pilot, and 
conduct a randomised controlled trial (RCT) can add considerable delay to the evaluation of an 
intervention. Whilst such a design may be required to adequately examine secondary 
outcomes, such as healthcare utilisation following clinical intervention, an RCT design may be 
excessive to examine a primary outcome such as improvements in prescribing from pre- to 
post-intervention. Thus, it may be difficult to justify the time required to conduct an RCT to 
those future service users who experience a delay in receiving the benefits of the intervention.  
Rather, the best available methods should be employed as despite lacking internal 
validity they may still yield useful results (Craig et al., 2008). Craig and colleagues (2008) 
caution that researchers must be cognisant of the limitations of non-experimental methods 
when interpreting study findings and argue that the use of complementary evidence sources 
may offset the potential weakness of non-experimental methods. Craig and colleagues (2008) 
further argue that a key consideration when evaluating interventions is whether the 
intervention is effective in everyday practice.  
There are additional challenges when examining outcomes in frail older adults, who 
may be approaching end of life. Their exclusion from trials raises some ethical concerns 
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regarding the suitability of the study to be generalisable to their needs. Higginson et al., (2013) 
argue that it is more ethical to offer patients and their families the opportunity of 
participation, especially when they are willing to engage with research. Thus, a study design 
that is time intensive (e.g. ethical approval, randomisation procedures with intention to treat 
analyses) may not serve the needs of the population under examination.  
 Those who participated in the Methods of Researching End of life Care (MORECare) 
consultation reported the need for timely research results in order to influence service 
developments (Higginson et al., 2013) and that RCTs are not the limit for robust evaluation 
data. Higginson and colleagues (2013) argue that secondary data analysis can be particularly 
beneficial, especially in the context of high-quality data, including that which is gathered in 
routine clinical practice. Furthermore, randomisation may not be possible if the policy decision 
regarding the intervention has already been made (Craig et al., 2008). The additional costs of 
an experimental design must be counterbalanced with the reliability of the information (Craig 
et al., 2008). Should an observational study provide high quality information at a reduced cost, 
then more expensive randomised study may not be justifiable.  
Furthermore, the current digital age means that there are already a multitude of 
readily available data sources which provide an opportunity for novel research designs.  It is 
imperative that we interrogate the data already available to us before needlessly gathering 
more. Thus, a natural tension exists within healthcare between that which is service evaluation 
and that which is research.  
Many healthcare professionals may not view their roles as that of researchers and yet 
their desire to innovate and to improve service delivery to meet the changing demands of the 
populations they serve suggests otherwise.  Many new service models undergo small scale 
pilot work whereby innovations to practice are evaluated on an economic basis.  Those which 
show a positive return on investment are rewarded with scaled up implementation. Such a 
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process can be viewed with academic disdain given the inherent limitations that such an 
approach confers. Yet the ends justify the means as service evaluation pieces can be 
conducted in a shorter timeframe and can result in alterations to practice that the entire 
population can readily benefit from.  
 An alternative approach is to examine existing data, such as service evaluation data, 
which may provide additional insights beyond that of which was intended during the initial 
data collection period. By doing so we can also remove a duplication of effort; rather than 
seeking to reinvent the wheel we can concern ourselves with the characteristics that inform its 
optimal performance.  
 The use of established data sources is becoming an increasingly popular means of 
research within the social sciences (Vartanian, 2011), given the inherent advantage that it is 
less resource intensive. Furthermore, many existing secondary data sources contain a large 
sample size (Vartanian, 2011), that is often gathered in a stratified manner to ensure that it is 
representative of the population (Boslagh, 2007). Thus, secondary data often overcomes the 
challenges posed by smaller studies which make use of smaller convenience samples that have 
limited generalisability (Boslaugh, 2007).  
 Secondary data analysis is not without its challenges given that the data was not 
collected with a view to the specifics of the researcher’s question (Boslaugh, 2007). As such, 
the researcher may be faced with examining variables that are not direct indicators of the 
phenomenon in question but rather serve as a proxy for them. Furthermore, the analysis that 
can be conducted is limited by the extent to which the collected data has been recorded. 
Notwithstanding these limitations secondary data analysis provides an opportunity to cross-
pollinate research in a manner that has perhaps not been considered previously. A researcher 
from one discipline examining data gathered in another will approach this data from a 
different perspective, offering the possibility of alternative data manipulations and 
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interpretations. For example, information relating to product sales can inform of both the 
economic position and behavioural habits of a sample population.  
 Secondary data analysis is also an efficient means of examining longitudinal data, a 
labour intensive yet rich source of data. Longitudinal studies, where data is collected form the 
same participants on more than one occasion, allows for the investigation of temporal 
relationships within the data. Such studies allow for the identification of within-individual 
differences as well as those between-individual differences, providing a more nuanced view of 
a phenomenon that would otherwise be considered as static by a cross-sectional study.   
As such, longitudinal study allows for the examination of potential antecedents and 
consequence of the phenomenon under investigation. Thus, the examination of change within 
a phenomenon can be better facilitated by more than one data capture. Longitudinal study is 
not without its limitations. In particular, it is particularly vulnerable to the effects of attrition 
which needs to be accounted for during study design, often resulting in the recruitment of a 
large sample at phase one. This increased level of recruitment increases the costs associated 
with data collection, which is already considered to be a costlier type of research design 
(Brannon, Feist & Updegraff, 2013). Notwithstanding these limitations, there is merit in 
conducting secondary data analysis using both service evaluation and longitudinal data. The 
use of more than one data source will allow for complementary analyses that may not have 
been possible using both sources.  
2.3 Medicines Optimisation in Older People data 
2.3.1 Data source 
The analyses reported in Chapters 3-5 involved the use of data sets obtained from the 
Medicines Optimisation in Older People (MOOP) team, which operates under the guidance of 
the Medicines Optimisation and Innovation Centre (MOIC). The implementation and 
evaluation of these service models has generated a rich source of clinical data, beyond that 
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found in many database studies examining prescribing appropriateness. Thus, it may fulfil the 
recommendations of Higginson and colleagues (2013), particularly when examined with 
complementary sources of evidence.  
Development of the MOOP models: historical context 
The 2001 publication of the NSF for Older People called for a person-centred approach to 
care, whereby older people would be active participants in their own care choices (DOH, 
2001). Shortly afterwards, the DOH (2003) published ‘A Vision for Pharmacy in the New NHS’. 
This position paper sought to enshrine convenient ease of access to medicines and 
pharmaceutical advice for patients. It recognised that the environment within which patients 
accessed health services was changing, and that the profession needed to adapt to this, whilst 
maintaining high levels of professional standards. It advocated for increased medicines 
management services, including medication reviews, and in particular highlighted the NSF for 
Older People as a key cohort where a clinical need for review existed. It also called for 
innovation with respect to delivering pharmacy services across the primary and secondary care 
interface.  
At a time when there was a shortage of pharmacists, the position paper called for 
focusing the pharmacist’s time on where value could be added and identify tasks that could be 
carried out by others. Within the hospital pharmacy sector, it was proposed that consultant 
pharmacist positions would be developed, recognising the clinical excellence and leadership of 
experienced pharmacists. It was envisaged that these consultant pharmacists could also be 
supplementary or independent prescribers or provide other specialist clinical services. Their 
role would thus focus on medicines management services within hospitals but would also 
influence the use of medicines in the local community.  
Thereafter, in 2005, the DOH published guidance for the development of consultant 
pharmacist posts. A further update has recently been published in 2020 (Consultant 
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Pharmacists Short Life Working Group, 2020). These guidance documents outline the four key 
functions of the role: expert practice; research, evaluation and service development; 
education and mentoring of practice; and professional leadership (Royal Pharmaceutical 
Society of Great Britain, 2020). Through this role patients could receive access to high level 
expertise from practitioners leading the profession, through practice, research and training, in 
their specialist area (Specialist Pharmacy Service Medicines Use and Safety Team, 2017).  
Recognising the needs of the ageing population within Northern Ireland, a policy shift 
occurred that was largely driven by the 2011 publication of Compton Review: ‘Transforming 
Your Care’ (TYC) (DHSSSPS, 2011a; Miller, 2018). This position led to a move from focusing on 
provision of health services within the secondary hospital setting to developing services within 
primary care that also encompassed a social care element. The refocus on delivery in primary 
care ‘closer to home’ was supported by the redistribution of £83 million from hospital services 
to primary care services (DHSSPSNI, 2011a).  In conjunction with a move towards more 
patient-centred integrated care services, there was also a recognition that workforce 
development should also become a priority. At around the same time it was apparent that 
consultant pharmacist posts had been developed in England, but such posts did not exist 
within Northern Ireland. 
In response to the call to action that was TYC, the Western and Northern Health and Social 
Care Trusts (WHSCT and NHSCT respectively) set out to address the needs of the older 
population by establishing consultant pharmacist posts and introducing novel innovative 
models of care that were led by these consultant pharmacists. In the WHSCT region the focus 
was on delivery of a service for intermediate care settings, whilst in the NHSCT an outreach 
service to care home residents was developed (McKee, Miller, Cuthbertson, Scullin & Scott, 
2016; Miller et al., 2016). The development of these novel pathways was facilitated by the 
engagement of stakeholders across primary and secondary care (Miller, 2018). 
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Both of these models followed a case management approach. Case management is 
considered to involve planning, coordination, management, and review of the care of an 
individual to improve the quality of life through an integration of services around individual 
need (Hutt et al., 2004; Ross, Curry & Goodwin, 2011). Rather than comprising a single 
intervention, case management refers to a package of care that can vary widely in its delivery 
(Hutt et al., 2004; Ross et al., 2011). In principle, case management involves an assessment of 
the individual’s needs, the development of a personalised plan to address these needs, the 
arrangement of suitable care and the continual communication with patients, their families 
and other professionals within the health and social care team (Ross et al., 2011). Since 
medicines management issues are commonly experienced in case management models 
(Challis et al., 2010; Sargent, Pickard, Sheaff & Boadten, 2007), pharmacists would appear to 
be ideally placed to deliver such a model of care. Ross and colleagues (2011) consider 
prescribing qualifications to be a key skill for effective case managers, highlighting the 
expanded role that exists for those pharmacists who are qualified as independent prescribers.  
The MOOP case management models both commence with an initial patient assessment, 
where all prescribed medications are reviewed by the case management pharmacist. The MAI 
was applied to assess prescribing appropriateness. Following this assessment, a person-
centred pharmaceutical care plan (PCP) to resolve identified medication related issues is 
developed. Necessary clinical interventions are enacted and liaison with other members of the 
healthcare team occurs, when required. Following the implementation of necessary 
interventions, the case management pharmacists recalculates the MAI scores for each 
medication and proceeds to monitor the individual, intervening further if deemed necessary.  
2.3.2 Intermediate Care Model of Care 
Within the intermediate care (IC) pathway, the initial assessment occurs on entry into 
IC (Figure 2-1). MAI scores are recalculated at the point of discharge from IC, after which case 
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management continues for a period of approximately 30 days. This duration of this case 
management period varies dependent upon individual patient needs and during this time the 
case management pharmacist conducts follow-up telephone calls and home visits, where 
necessary, to monitor patient progress. Additional interventions may be required during this 
monitoring period. Healthcare usage in the form of unplanned hospital readmissions and ED 
visits not leading to a readmission are monitored for 90 days following discharge from IC. 
  
Figure 2-1: Consultant pharmacist-led pharmacy team case management of older people in intermediate care 




This novel pharmaceutical care model within IC has moved the pharmacy service 
beyond that of a ‘supply only’ service to one focused on patient outcomes. The initial 
development of the IC pathway occurred in the Western HSCT, where a significant 
improvement in MAI scores was observed, and estimated annual drug cost savings of £68,000 
were made (Miller et al., 2016). The model was successfully reproduced in the Northern HSCT 
in 2016 where again significant reduction in MAI scores was observed and considerable drug 
cost savings made (Miller et al., 2017a; Miller, 2018).  
2.3.3 Care Home Model of Care 
The care home (CH) MOOP model is broadly similar to the IC model but also includes a 
care home specific aspect for care home selection (Figure 2-1). In the development of the CH 
model selection of care homes was based upon high rates of presentation to ED. Within the CH 
model there is an initial baseline assessment (t0) where demographic information is collated, 
and an initial assessment of prescribing appropriateness is conducted using MAI. An 
individualised PCP is developed, and clinical interventions are implemented where necessary. 
Within the CH model, the number of weekly visits conducted by the case management 
pharmacist are specific to the needs of the individual older person, resulting in a patient 
specific component. As a consequence, each older person receives a number of visits that is 
unique to their clinical need (tx). Following completion of the pharmaceutical care plan (tx) 




Figure 2-2: Consultant pharmacist-led pharmacy team case management of older people in care homes (courtesy of 
the Medicines Optimisation in Older People Team) 
The CH model was developed in the NHSCT and also reported similar improvements in 
prescribing appropriateness and annual drug cost savings as those delivered by the 
intermediate care model. Furthermore, a reduction in inappropriate attendances to ED were 
also noted (McKee et al., 2016).  
In the original development of the CH model outreach visits to care homes were 
conducted in conjunction with a consultant geriatrician. The model was found to be equally 
effective when delivered by pharmacists alone in comparison with the more human resource 
heavy collaboration with a consultant geriatrician (Miller, 2018). As a consequence, the service 
evolved to one that was led by the pharmacist but included a facility for referral to a 
geriatrician when it was deemed medically necessary.  
The further development of both MOOP models was facilitated by the Change Fund in 
2015, where funding to examine the reproducibility of both models in a different geographical 
region was accessed. Thus, the IC model was tested within the NHSCT and the CH model 
replicated in the WHSCT. The replication of the CH model within the WHSCT allowed for the 
opportunity to examine alternative models of communication with GPs. The original model 
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developed in the NHSCT communicated clinical interventions and recommendations to GPs via 
letter. In addition to these letters of recommendation, the case management pharmacists 
within the WHSCT care home service used teleconferencing and direct access to the GP’s 
computer system.  
Both patient centred MOOP models have been shown to be reproducible and have 
now been rolled out across Northern Ireland as a fully funded service (Miller, 2018).  As the 
pharmacist case management models embed across Northern Ireland there is a need to 
develop a greater understanding of the nature and extent of inappropriate prescribing among 
older people in intermediate care and in care homes. As previously stated, our understanding 
of the prevalence of inappropriate prescribing in intermediate care has been limited by the 
sheer lack of studies conducted in this setting. Similarly, whilst there is an increasing concern 
regarding the use of psychotropic medications in care homes and there is evidence to suggest 
that this is prevalent in Northern Ireland (Maguire et al., 2013), less is known about the nature 
of inappropriate prescribing of other medication classifications. Furthermore, as the service 
continues to develop throughout the region there is a greater need to understand the 
effectiveness of both models at a deeper level. A greater understanding of what drives the 
improvement in prescribing appropriateness observed in both models can be used to inform 
the future directions of the service.  
2.3.4 Participants 
Data was collected by the MOOP team in the WHSCT and NHSCT between 2015 and 
2016. During this period both care models were being delivered by Band 8a case management 
pharmacists, all of whom were independent prescribers, whilst being led and mentored by 
consultant pharmacists. The study population involves all individuals ≥ 65 years of age who 
were assessed by case management pharmacists in the intermediate care and care home 
settings. The models of care were delivered to all inpatients and residents in both settings, 
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irrespective of age, as it was deemed that it would have been unethical to not deliver the same 
standard of care to all inpatients/residents. For the purposes of this thesis data pertaining to 
those aged <65 years were excluded.  
The IC sample comprised of 532 participants and the CH sample comprised of 1095 
individuals. Participants in the IC sample ranged in age from 65 to 99 years (M = 82, SD = 7.6 
years). Participants in the CH sample were slightly older (M = 84, SD = 7.5, range = 65 to 102 
years). In the IC sample, data was collected from three sites across both HSCTs. In the CH 
sample, data was collected from 32 homes across both HSCTs. The sample characteristics can 
be observed in Table 2-1.  
Table 2-1: Descriptive statistics for participants in intermediate care (N = 532) and care homes (N = 1095) datasets 




Age    
65-69 years 34 (6.4) 39 (3.6) 
70-74 years 62 (11.7) 95 (8.7) 
75-79 years 100 (18.8) 153 (14.0) 
80-84 years 115 (21.6) 212 (19.4) 
85+ years 221 (41.5) 596 (54.4) 
Sex     
Female 353 (66.4) 773 (70.6) 
Male 179 (33.6) 322 (29.4) 
Marital status    
Married/cohabiting 181 (34.1) † - 
Single (never married)  68 (12.8) † - 
Divorced/separated 13 (2.4) † - 
Widowed 178 (33.5) † - 
HSC Trust   
Northern  322 (60.5) 530 (48.4) 
Western 210 (39.5) 565 (51.6) 




2.3.5.1 Medication information 
Prescribed medicines were recorded in the initial data collection according to their 
British National Formulary (BNF) 70th Edition chapter subclassification (Joint Formulary 
Committee, 2015). The BNF classifies medications into chapters according to the physiological 
system within which they are licensed to treat (Figure 2-3). These physiological categories are 
further subdivided in terms of mechanism of action of medication. Two additional 
subclassifications in addition to the BNF sub-categories were used to capture information 
relating to clinical trial medications and unlicensed medications which would not feature 














Figure 2-3: British National Formulary (BNF) 70th Edition chapter classifications  
 
Participants in the CH cohort were prescribed greater numbers of medications for the 
nervous and gastrointestinal systems, even when the larger sample size is considered (Figure 
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3. Respiratory system 
4. Nervous system 
5. Infection 
6. Endocrine system 
7. Genito-urinary system 
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2-4). Similarly, the CH cohort were prescribed considerably greater numbers of medications 
from the skin chapter of the BNF1. 
 
Figure 2-4: Counts for medications by BNF chapter in IC (N = 532) and CH (N = 1095) cohorts 
The number of medications prescribed by polypharmacy category can be observed in 
Table 2-2. A greater proportion of CH participants were prescribed more than 15 medications 
in comparison to the IC cohort. A greater proportion of IC participants were prescribed 0-5 
medications in comparison with the CH cohort. 
Table 2-2: Frequencies for each polypharmacy category in IC (N = 532) and CH (N = 1094) samples 




0-5 medicines 50 (9.4) 67 (6.1) 
6-10 medicines  223 (41.9) 354 (32.3) 
11-15 medicines 191 (35.9) 443 (40.5) 
16-20 medicines 61 (11.5) 179 (16.3) 
>20 medicines 7 (1.3) 51 (4.7) 
Note. Information regarding the number of medications at baseline was missing for one CH participant 
 
1 Three CH participants were prescribed one clinical trial medication and one CH participant was 
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2.3.5.2 Medication Appropriateness Index 
All individual medications prescribed to participants in both IC and CH datasets were 
scored by the case management pharmacist according to the Medication Appropriateness 
Index (MAI: Hanlon et al., 1992). The MAI is a ten-item weighted questionnaire (Table 2-3), 
with each item rated as either 0 ‘appropriate’ or 1 ‘marginally appropriate or inappropriate’. 
Each item has a differential weighting to reflect the relative importance of that item. A total 
score is computed for each medication by summating the scores for items 1-10. Thus, the 
possible score for each medication ranges from 0 to 18.  
Table 2-3: Medication Appropriateness Index (Hanlon et al., 1992) 
 Question Score 
1 Is there an indication for the drug? 3 
2 Is the medication effective for the condition? 3 
3 Is the dosage correct? 2 
4 Are the directions correct? 2 
5 Are the directions practical? 2 
6 Are there clinically significant drug-drug interactions? 2 
7 Are there clinically significant drug-disease interactions? 1 
8 Is there unnecessary duplication with other drug(s)? 1 
9 Is the duration of therapy acceptable? 1 
10 Is this drug the least expensive alternative compared with others of equal 
utility? 
1 
 Maximum score of inappropriateness 18 
 
Scores for each medication were computed and total MAI scores were computed for 
each participant by summating the individual drug MAI scores. MAI scores were recalculated 
for each participant upon discharge from IC or following completion of the pharmaceutical 
care plan for CH participants. A MAI score change variable was calculated by subtracting the 
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total MAI score on completion of case management (post-score) from the baseline total MAI 
score (pre-score).  
Good reproducibility of MAI scores has been shown irrespective if the ratings were 
conducted by two pharmacists, a pharmacist and a physician or two physicians, with kappa 
statistics ≥ 0.59 (Hanlon et al., 1992; Gallagher et al., 2011; Kassam, Martin & Ferris, 2003; 
Samsa et al., 1994; Spinewine, Dumont, Mallet & Swine, 2006). Intra-rater reliability has also 
been shown in a number of studies (Bregnhøj et al., 2005; Hanlon et al., 1992; Stuijt et al., 
2009). It has been argued that the MAI is sufficiently sensitive to detect even small departures 
from best prescribing practice. Samsa and colleagues (1994), on developing the weighting 
system for each of the ten items, found that whilst only 16% of medications were deemed to 
be inappropriate based on the indication or effectiveness indicators, the MAI was able to 
detect some element of suboptimal prescribing practice in approx. 75% patients.  
2.3.5.3 Interventions  
Information pertaining to the type of intervention completed by the case management 
pharmacists were also recorded. Interventions types included medication discontinuation, 
medication initiation, dose changes, blood testing, addressing Kardex issues, referral to other 
HCPs and patient education. Less commonly delivered interventions were recorded as ‘other’. 
These include interventions such as liaison with community pharmacists to coordinate 
prescription dispensing cycles. Patient education was not offered as a possible intervention in 
the CH model due to challenges with respect to patient communication.  
2.3.5.4 Eadon  
The clinical significance of each clinical intervention enacted by the case management 
pharmacists was assessed using the Eadon (1992) grading system (Table 2-4). Interventions 
were self-rated by the case management pharmacists on a six-point scale, with higher ratings 
indicating more clinically significant interventions.  
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Table 2-4: Eadon grading of clinical pharmacist interventions used in the MOOP datasets (Eadon, 1992) 
Score Clinical significance 
1 Intervention which is detrimental to a patient’s well-being 
2 Intervention is of no significance to patient care 
3 Intervention is significant but does not lead to improvement in patient care 
4 Intervention is significant and results in improvement in the standards of care 
5 Intervention is very significant and prevents major organ failure or adverse reaction 
of similar importance 
6 Intervention is potentially lifesaving 
Participant follow up for those in IC was conducted using both telephone calls and 
home visits, where required. For both cohorts if additional medication-related issues were 
identified in during follow-up, additional interventions were conducted and scored using the 
Eadon criteria.  
2.3.5.5 Healthcare utilisation 
Data pertaining to healthcare utilisation was collated for both 30- and 90-days 
following pharmacist intervention. Information was collated regarding hospital admission for 
both cohorts. In the case of CH participants, data was also collected regarding ED visits, GP 
visits and out of hours (OOH) GP visits. Baseline levels of healthcare utilisation were collected 
in both cohorts. For both cohorts, the number of hospital admissions in the 12 months prior to 
pharmacist intervention was recorded. For CH participants counts of ED visits, GP visits and 
OOH GP visits in the 30 and 90 days before pharmacist intervention was also collected.  
2.3.5.6 Clinical history 
Participants in both cohorts experienced a diverse range of previous medical histories. 
The top 20 most frequently endorsed diagnoses, as classified by the 10th revision of the 
International Statistical Classification of Diseases and Related Health Problems (ICD-10: WHO, 
1992), for participants in IC and CH can be observed in Figure 2-5 and Figure 2-6, respectively. 




Figure 2-5: The top 20 most frequently endorsed medical histories by ICD-10 coding in the IC sample (N = 532) 
 
Cardiovascular diagnoses of ‘atrial fibrillation and flutter’, ‘chronic ischemic heart 
disease’, ‘hypercholesterolaemia’ and ‘heart failure’ were also common in both datasets. In 
the CH dataset, the diagnosis of ‘unspecified dementia’ was the most prevalent with 379 
instances recorded for CH residents. Additional cognitive impairments were common among 
CH residents including ‘Alzheimer’s disease’ and ‘vascular dementia’. Such cognitive 
impairment diagnoses were not a common feature in the IC sample. Similar counts of 
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Figure 2-6: Top 20 most frequently endorsed medical histories by ICD-10 coding in the CH sample (N = 1095) 
 
2.3.5.7 Pharmacist intervention  
In both datasets, the most frequent clinical intervention completed by the case 
management pharmacists was medication discontinuation; a total of 948 instances of 
discontinued medicines were counted within the IC sample and 2003 instances recorded in the 
CH sample (Figure 2-7). Information regarding the classification of intervention type was 
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Figure 2-7: Counts for each intervention type in both IC (N = 532) and CH (N = 1095) at baseline  
 
Table 2-5 outlines the frequency of participants who endorsed a minimum count of 
one for each clinical intervention type. A greater proportion of IC participants had a 
medication initiated or a medication dose changed in comparison with CH participants. The 
percentage of participants who had at least one medication discontinued was similar in both 
cohorts.  
Table 2-5: Frequency of participants who experienced at least one count for each intervention type at baseline 
Intervention type Intermediate Care (N = 532) 
n (%) 
Care Homes (N = 1095) 
n (%) 
Medication stopped 411 (77.3) 821 (75.0) 
Medication started 267 (50.2) 103 (9.4) 
Blood tests 62 (11.7) 132 (12.1) 
Medicines information 11 (2.1) 66 (6.0) 
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Referral to another HCP 69 (13.0) 61 (5.6) 
Kardex issue addressed 197 (37.0) 62 (5.7) 
Education 53 (10.0) - 
Other 44 (8.3) 18 (1.6) 
Note. Education was not a possible intervention in the CH dataset. Some CH participants received 
additional clinical interventions-details reported below.  
 
The clinical significance of each intervention was assessed by the case management 
pharmacists using the Eadon classification system, with higher numerical grades indicating the 
more clinically significant the intervention. Frequency counts for each grade can be observed 
in Figure 2-8. The most frequently recorded grade was for Eadon 4 ‘significant and improves 
the standard of care’. No interventions were graded as ‘not significant to patient care’ (Eadon 
2).  
 
Figure 2-8: Counts for each baseline intervention by Eadon grading in IC (N = 532) and CH (N = 1095) datasets 
 
The majority of intermediate care (89.1%) and care homes (84.6%) participants 
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care’. Except for one individual who received a clinical intervention graded as ‘detrimental to 
patient well-being’ all participants in both datasets received clinical interventions rated as at 
least clinically significant (≥ Eadon 3). Clinical interventions rated as Eadon 5 and 6 were more 
prevalent for IC participants (Table 2-6).  
Table 2-6: Frequencies of participants who endorsed at least one count for each Eadon grade in IC (N = 532) and CH 
(N = 1095) datasets 
Eadon Grade Intermediate Care  
n (%) 
Care Homes  
n (%) 
1 1 (0.2) 0 (0) 
2 0 (0) 0 (0) 
3 27 (5) 182 (16.6) 
4 474 (89.1) 926 (84.6) 
5 212 (39.9) 50 (4.6) 
6 5 (0.9) 1 (0.1) 
 
The model of case management in care homes allows for a patient-specific number of 
visits by the case management pharmacist to the care home on a weekly basis. Thus, 
information regarding interventions conducted during these discrete visits was also available 
for examination in addition to information relating to interventions conducted at baseline. A 
total of 106 participants received additional pharmacist interventions with 76 participants 
receiving only one additional intervention, 25 receiving two interventions and 5 receiving three 
interventions. In total 141 additional clinical interventions were completed during these 
additional patient-specific visits to the care homes (M= 0.28, SD = 0.70, range 0-9). Counts for 
each clinical intervention type can be observed in Figure 2-9. In total, from beginning to 
completion of the intervention the number of clinical interventions for CH participants ranged 




Figure 2-9: Counts for additional clinical interventions completed for CH participants during the monitoring period (N 
= 106)  
 
The majority (84%) of additional clinical interventions implemented for CH participants 
were graded as ‘intervention is significant and results in an improvement in standard of care’ 
(Eadon 4). None of the additional interventions completed were graded as ‘detrimental to the 
patient’s wellbeing’ (Eadon 1) or as ‘potentially life-saving’ (Eadon 6). Information on the 
Eadon grading was missing for one intervention (Figure 2-10).  
 


































2.3.6 Ethical approval 
Ethical approval for the study was granted by Office for Research Ethics Committees 
Northern Ireland (ORECNI) under protocol number 17/NI/0052 (Appendix A). This initial 
approval was subsequently amended to allow the study to become the subject of the present 
thesis. A substantial amendment was submitted to ORECNI and was subsequently approved 
for implementation on 9th March 2018 (Appendix B). This amendment included the author as a 
PhD student on the project, conducting analysis of the data, and also facilitated the addition of 
Ulster University School of Psychology staff members as supervisors on the project. Access to 
the data was received following the approval of this substantial amendment. A further non-
substantial amendment was submitted to include the use of Mplus statistical software to 
support data analysis in the event of data non-normality. This non-substantial amendment was 
approved for implementation from 31st May 2019 (Appendix C).  
2.3.7 Funding 
The further development of both MOOP models was facilitated by the Change Fund in 
2015, where funding to examine the reproducibility of both models in a different geographical 
region was accessed. Thus, the IC model was tested within the NHSCT and the CH model 
replicated in the WHSCT. 
2.4 Selection of a comparable longitudinal cohort 
Several longitudinal cohort studies of older people are currently in progress 
internationally, including in the United Kingdom and Ireland. In England, the English 
Longitudinal Study of Ageing (ELSA) began in 2002 and has been collecting data from people 
aged 50 years and older on a two-yearly basis. Similarly, the Irish Longitudinal Study on Ageing 
(TILDA) has been collecting data since 2010 on a two-yearly basis in the Republic of Ireland. 
Both ELSA and TILDA form part of the Gateway to Global Aging Data initiative to facilitate data 
harmonisation and international cross-country research. The Northern Ireland Longitudinal 
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Study of Ageing (NICOLA) commenced in 2014 and was designed to be compatible with the 
approaches taken by ELSA and TILDA, whilst also including questions specific to the Northern 
Irish context. At the time of conducting the research presented in the present thesis the 
NICOLA study did not have sufficient data collection time points to facilitate a thorough 
longitudinal examination of healthcare utilisation. Thus, longitudinal analysis was conducted 
using the TILDA cohort.  
2.5 The Irish Longitudinal Study on Ageing (TILDA) 
2.5.1 History/background to study 
The Irish Longitudinal Study on Ageing (TILDA) is a nationally representative study of 
people living in Ireland aged 50 years and older. Its conception was designed to increase our 
understanding of the health, social and financial circumstances of the people in Ireland as they 
age (TILDA, 2020). TILDA is modelled on the Health and Retirement Study (HRS) design. The 
study was designed to be representative of members of the Irish community aged 50 years and 
over who were living within the community.  As such it does not represent individuals residing 
in long term care (TILDA, 2020).  
2.5.2 Sampling/recruitment 
The sampling strategy commenced with all postal addresses in Ireland being assigned 
to one of 3155 geographic clusters, from which a sample of 640 clusters were selected, 
stratified by socio-economic group and geography in order to create a sample representative 
of the population (TILDA, 2020). Clusters were selected with a probability proportional to the 
number of participants within each cluster aged 50 years and older (TILDA, 2020). As it had 
been estimated that 25,600 addresses would be required in order to achieve a sample size of 
8000, 40 households were selected from each cluster (TILDA, 2020). Each of these addresses 
was visited by an interviewer with all individuals aged 50 years and over and their partners 
were invited to take part in the study (TILDA, 2020). In short, a response rate of 62% was 
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achieved (TILDA, 2020). Further details on data collection have previously been widely 
published (Donoghue et al., 2018; Kenny et al., 2010; Whelan & Savva, 2013).  
2.5.3 Design 
Each participant completed a home interview conducted by a trained interviewer 
(TILDA, 2020). At the time of the home interview each participant was given a self-report 
questionnaire for completion and return by post. This questionnaire contained more sensitive 
questions regarding aspects such as relationship quality, emotional wellbeing, and health 
behaviours (TILDA, 2020). Participants were also asked to undertake a health assessment at 
Waves 1 and 3, which were conducted in a dedicated health assessment centre or in their own 
home if travel to the centre was not possible (TILDA, 2020).  
Within each household all those household members eligible for the study were 
invited to take part (TILDA, 2020). The participants completed a Computer Aided Personal 
Interview (CAPI) in their own home, which contained questions on health, wellbeing, family, 
and finances (TILDA, 2020). At the first wave of data collection participants were invited to 
complete a health assessment at a dedicated centre in Dublin or Cork or to complete a 
modified reduced assessment in their home were travel to such a centre was not possible 
(TILDA, 2020). The health assessment was repeated at wave three.  
Each participant was assigned a unique identifier (ID) in addition to a household 
identifier (household ID) and geographic cluster identified (cluster) (TILDA, 2020). All 
respondents within the same household had the same household ID. The individual identifier 
for each participant comprised of this household ID with an additional number appended to 
distinguish them from other participants within the same household (TILDA, 2020).  
2.5.3.1 Complex survey design 
In order to ensure that the sample remained representative of the Irish population 
survey weights were applied to correct for selection bias (TILDA, 2020). These weights were 
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calculated such that the participant’s weight was equal to the number of individuals in the 
population represented in the study by that participant (TILDA, 2020). Those participants who 
came from groups less likely to participate were thus assigned a higher weight (TILDA, 2020). 
Four sets of weights were applied within the dataset. The CAPI weight is applied when the 
whole sample is analysed (TILDA, 2020). This weight is equal to the number of individuals in 
the population (determined from the 2010 Quarterly National Household Survey) represented 
by each of the 8175 participants who completed the CAPI interview (TILDA, 2020).  
Additional weights were calculated for the self-completion questionnaire (SCQ) and 
the health assessment, for application in analyses using only the SCQ or health assessment 
sample, respectively (TILDA, 2020). These weights also incorporate the CAPI weight whilst also 
accounting for some subgroups to be more likely to complete the SCQ or the health 
assessment than others (TILDA, 2020). Further details on the generation of the weights can be 
reviewed in Donoghue et al., (2018), TILDA (2020) and Whelan and Savva (2013).  
Two cluster variables are available in the dataset to indicate the geographic cluster 
(cluster) and the household (household ID) to which the participant belongs (TILDA, 2020). 
Geographic clusters were stratified (stratum) so that equal numbers of clusters were selected 
from each of the three socio-economic groups (TILDA, 2020).  
2.5.4 Data collection 
The study commenced data collection between October 2009 and July 2011. At the 
first wave of data collection a total of 8175 participants aged 50 years and over completed the 
study (TILDA, 2020). Additional data was collected from 329 interviews with younger 
spouses/partners of participants but are not included in the analysis presented here (TILDA, 
2020). The second wave of data collection took place between February 2012 and March 2013. 
A total of 6917 of the original 8175 sample submitted data at Wave 2 (TILDA, 2020). The third 
wave of data collection was conducted between March 2014 and October 2015, with 6128 
95 
 
participants reporting data (TILDA, 2020). The fourth wave of the study was undertaken in 
2016. A total of 5457 participants submitted data at Wave 4 (TILDA, 2020).  
The analyses presented in this thesis utilised the anonymised publicly available data. 
This data has been anonymised by the research team so that no directly identifiable 
information such as names or addresses were released (TILDA, 2020). As a consequence, some 
variables available in the publicly available data have been recoded to ensure this anonymity is 
maintained (TILDA, 2020). Other potentially identifiable data was either top-coded, grouped or 
dropped for any data which on its own, or in combination with other publicly available data 
could result in identification of a participant (TILDA, 2020). Top and bottom coding was 
performed on those variables with extreme values occurring at either end of the scale. Any 
respondents who answered over or below the threshold value were grouped together to form 
a new category (TILDA, 2020).  
2.5.4.1 Sample demographics 
 At Wave 1 the TILDA sample comprised of 8175 participants ranging in age from 50 to 
80 years2. Approximately 85% of participants at Wave 1 reported at least one diagnosed 
morbidity. Further details regarding the sample characteristics can be observed in Table 2-7.  
Table 2-7: Sample characteristics for TILDA cohort at Wave 1 
Characteristic n (%) 
Age, years (M, SD) 63.53 (9.16) 
Sex  
Male 3744 (45.8) 
Female 4431 (54.2) 
Marital status  
Married 5638 (69) 
Never married 791 (9.7) 
Separated/divorced 551 (6.7) 
 
2 As per data anonymisation techniques those individuals aged 80 years and over were banded together 
and reported as aged 80 years. 
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Widowed  1195 (14.6) 
Education level  
No education/primary level 2504 (30.6) 
Secondary level 3263 (39.9) 
Third/higher level 2404 (29.4) 
Household location  
Dublin city/county 1936 (23.7) 
Another town/city 2311 (28.3) 
Rural area 3916 (47.9) 
Employment status  
Employed 2934 (35.9) 
Retired 3046 (37.3) 
Other 2195 (26.9) 
Comorbidity level  
None 1210 (14.8) 
1 1720 (21.0) 
2 1699 (20.8) 




Measures included in the analysis of the TILDA dataset included the creation of an adapted 
Frailty Index (Appendix D) based upon the index utilised previously by Roe, Norman, Wren, 
Browne and O’Halloran (2017) in the TILDA cohort. Depression, anxiety, and cognition were 
measured using the Center for Epidemiologic Studies Depression (CESD-8: Radloff, 1977), 
Hospital Anxiety and Depression Scale- Anxiety (HADS-A: Zigmond & Snaith, 1983) and Mini 
Mental State Examination (MMSE; Folstein, Folstein & McHugh, 1975) questionnaires, 
respectively. Further details on the measures are outlined in Chapter 7.  
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2.5.5 Ethical approval 
Ethical approval for data collection was granted by the Trinity College Research Ethics 
Committee (TILDA, 2020). TILDA is funded by the Department of Health and Children, Irish Life 
and The Atlantic Philanthropies (TILDA, 2020). Ethical approval for the secondary data analysis 
of TILDA data was included in the original overall ethical approval of TILDA. Ethical approval for 
secondary data analysis conducted in this thesis was granted by the School of Psychology Filter 
Committee (Appendix E).  
2.5.6 Data access 
Data access was granted following an application to the Irish Social Science Data Archive 
(ISSDA) for the publicly available data. Four data files representing each wave of data 
collection were obtained and merged to form one dataset. The following file versions were 
used for the present thesis: 
• Wave 1 version 1.9 (TILDA, 2019) 
• Wave 2 version 2.4 (TILDA, 2019) 
• Wave 3 version 3.3 (TILDA, 2019) 
• Wave 4 version 4.1 (TILDA, 2019) 
2.5.7 Attrition 
Attrition is a challenge in all longitudinal assessments, be it temporary or permanent. 
However, attrition within studies of older people is even more challenging due to the 
increased likelihood that older adults have in experiencing health and functional problems, 
thus impacting upon data collection (Hardy, Allore & Studenski, 2009). Longitudinal studies of 
older adults can be impacted by loss to follow-up or dropout due to the increased likelihood of 
illness, disability, cognitive impairment, and institutionalisation (Di Bari, Williamson & Pahor, 
1999). Hardy et al., (2009) argue that plans should be developed to minimise the possibility of 
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missing data at each phase of the research and also suggest that data collection can be 
adapted to meet the needs of the respondent.  
Several cohort maintenance strategies were adopted in order to limit the degree of 
attrition that occurred in as much as was possible. Questionnaires were designed such that 
information from previous waves was fed forward into subsequent waves, limiting the to need 
repeat the same questions at each wave (Donoghue, Foley & Kenny, 2017). Accordingly, 
participants were asked to clarify any change in circumstances since the last wave (Donoghue 
et al., 2017). Proxy interviews were conducted if a participant was unable to complete the 
interview due to impairment and had consented to proxy-interviews in the preceding wave 
(Donoghue et al., 2017). End of life interviews were conducted where participants had died 
(Donoghue et al., 2017). Modified home-based health assessments were conducted if 
participants were unable or unwilling to travel to the health assessment centre (Donoghue et 
al., 2017). The large sample size recruited at Wave 1 has meant that a sample of considerable 
size remains by Wave 4. Thus, it could be argued that every effort has been made by the TILDA 
research team to ensure that the recommendations of Hardy and colleagues (2009) were 
implemented in as much as possible.  
2.6 Overview of analytic strategy 
This thesis aims to examine healthcare utilisation by older adults more broadly and 
also to determine if pharmacist intervention to improve prescribing appropriateness influences 
healthcare resource usage and outcomes. Sample characteristics of the IC and CH datasets 
have been compared thus far, however, analysis of the MOOP datasets is conducted 
separately to reflect the qualitative difference in the populations and in the MOOP models 
delivered.  
Chapter 3 examines a cohort of older adults who were admitted to IC and who 
received the pharmacist case management model in operation in this care setting. This chapter 
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seeks to examine healthcare resource usage following improvements in prescribing 
appropriateness achieved by the case management model. Multivariate linear regression, 
logistic regression, Poisson regression and Kaplan-Meier survival analysis techniques will be 
reported. Chapter 4 will examine similar objectives within a CH context. Chapter 5 seeks to 
explore the associations between improvements in MAI score for medication classifications 
frequently prescribed inappropriately and subsequent healthcare utilisation. Descriptive 
statistics and chi-square tests for differences are primarily used within Chapter 5. 
Chapter 6 seeks to examine trends in healthcare utilisation more broadly by adopting 
latent variable modelling techniques to identify heterogeneity in healthcare utilisation. Latent 
class analysis (LCA) is first conducted cross-sectionally using the first three waves of the TILDA 
study. A latent transition analysis (LTA) is then conducted to serve as a foundation for further 
analysis in Chapter 8, where covariates are incorporated into the analysis to examine variation 
in healthcare utilisation. Relevant covariates for inclusion in this analysis are examined in 
further detail in Chapter 7, where change over time in these covariates are also explored.  
2.7 Conclusion 
The present chapter has served to provide a foundation for subsequent empirical 
chapters by providing a description of the data samples, evaluated models of care and 
measures that are used in the thesis. Subsequent chapters will only provide a brief description 
of the relevant data set used and will rather focus on the specific analytical approaches that 
were taken. The reader will be referred back to this chapter or other relevant sources (e.g. 
Donoghue et al., 2018; Kenny et al., 2010; McKee et al., 2016; Miller et al., 2017a; Miller et al., 
2017b, Miller et al., 2016; Miller, 2018; Whelan & Savva, 2013), where appropriate. Specific 
variables that are manipulated within the analyses will be detailed in subsequent chapters. 
Additionally, the specific analyses undertaken will be described in greater depth in the relevant 
empirical chapters.  
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3 Healthcare utilisation following pharmacist case management 
of older adults in Intermediate Care in Northern Ireland  
 
3.1 Chapter overview 
This chapter begins by examining the literature surrounding inappropriate prescribing 
in older people within intermediate care. Following this, the chapter examines the baseline 
prevalence of inappropriate prescribing within this care context in NI and characterises the 
nature of interventions conducted by the MOOP pharmacists before evaluating the success of 
pharmacist involvement in IC in modifying this inappropriate prescribing. Variation in the 
degree of change in MAI score from admission to discharge will be elucidated before variability 
in healthcare resource usage is examined as a function of MAI score change.  
3.2 Introduction 
3.2.1 Intermediate care 
Intermediate care (IC) can be defined as “healthcare occurring somewhere between 
traditional primary (community) and secondary (hospital) care settings” (Woodford & George, 
2010, p. 119). It has been suggested that 25% of older people have additional care needs in the 
post-acute period (Young, Forster & Green, 2002). Smith and colleagues (2014) specifically cite 
the development of intermediate care services as a vital component of coping with the 
demands placed upon the hospital sector of the NHS. Melis, Parker and van Eijken (2004) 
argue that intermediate care in the United Kingdom developed as a result of a shift in policy as 
opposed to scientific evidence regarding its effectiveness. Accordingly, it has been argued that 
intermediate care has developed as “policy before evidence” (Lee et al., 2014, p. 267; Vetter, 
2005). The increased demand for inpatient beds, an ageing population and workforce changes 
have all contributed to the development of IC (Steiner, 2001). Posited to sit in the ‘space 
between’ hospital and home, intermediate care was proposed as a means of freeing up 
hospital bed capacity, encouraging independence of older people and preventing unwanted 
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hospital admissions (Melis et al., 2004). In England, the development of intermediate care 
services has been largely at the discretion of local commissioners, and thus has been largely 
influenced by local history and the availability of care homes (Williams et al., 2018). 
Furthermore, there was limited evidence regarding intermediate care to help guide 
commissioners with decisions regarding IC development within their area (Woodford & 
George, 2010). As a result, intermediate care developed at the behest of local policymakers 
resulting in markedly different models of intermediate care.  
Despite a call to action from the National Service Framework for Older People (DOH, 
2001), and a series of objectives to be achieved, no clear definition of what the ideal model of 
intermediate care should be was put forward at the time (Melis et al.,2004). As such it is 
imperative that we are explicit in what we mean when we refer to intermediate care. Even as 
far back as 20 years ago numerous definitions for intermediate care existed within the 
literature (Steiner, 2001). This lack of consensus on a definition of intermediate care has 
limited our understanding of how effective a care model it is (Melis et al., 2004). Rather than 
being clearly defined intermediate care has come to mean care that is ‘in between’ and 
without a clear definition its potential may not truly be recognised. In general, IC occupies the 
space between acute and community care, facilitating rehabilitation following discharge from 
acute care, as well as step-up care to prevent an acute care admission. 
3.2.1.1 The potential within intermediate care 
Increasing demands for acute care beds, in conjunction with specialisation of hospital 
departments has resulted in a reduction in acute care length of stay, something which is not 
always suitable for older people who may require a more comprehensive period of 
rehabilitation (Bakken et al., 2012). Among older people, acute hospitalisation is associated 
with a decline in functional status, the recovery of which has been found to occur at a much 
slower rate than recovery from the acute illness itself (Hirsch et al., 1990).  The very old, those 
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aged 90 years and older, are less likely to regain function lost before admission to acute care 
and are more likely to develop new functional deficits whilst in acute care (Covinsky et al., 
2003). A high proportion of those older people discharged from acute care are at risk for 
increased dependency and institutionalisation if insufficient opportunity for rehabilitation is 
available (Abrahamsen et al., 2014). By optimising the ‘space between’ hospital and home that 
is intermediate care, better outcomes for older people may be achieved.  
Intermediate care is distinguished from long-term residential care with respect to the 
duration that the person is engaged with the service. Intermediate care is a time-limited 
rehabilitative service with the primary aim of facilitating the person to successfully transition 
to independence at home. There will of course be some instances whereby an individual may 
not safely return to their own home and thus may transition into longer-term residential care. 
So, whilst there is a clear distinction between the two contexts there is a trajectory that may 
exist for some individuals comprised of a transfer from hospital to intermediate care and then 
finally into residential care. 
3.2.1.2 Intermediate care provision in Northern Ireland 
In 2005, the DHSSPSNI set out a high-level definition of intermediate care as “a range 
of integrated services to prevent unnecessary hospital admission, promote faster recovery 
from illness, support timely discharge and maximise independent living” (DHSSPSNI, 2005, p. 
3). Thus, within Northern Ireland, intermediate care developed with the aim of creating a 
responsive, integrated primary and community care network to promote independent living 
among older people and reduce dependency on acute hospitals (DHSSPSNI, 2005). It was 
further aimed that the service would provide a person-centred approach with the 
development of an individualised care plan delivered using a multidisciplinary team approach.  
At the outset, it was deemed that such services should be targeted towards those who were at 
risk of inappropriate admission to acute care, long-term residential care, and unnecessarily 
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prolonged hospital admissions. Based upon such prioritisation criteria it is highly evident that 
intermediate care in Northern Ireland would become a key setting for delivery of care to older 
people.  
Provision of intermediate care across Northern Ireland varies somewhat across the five 
geographical Health and Social Care Trusts (HSCTs). Care is provided in non-acute community 
hospitals, in the person’s own home or in some cases via a short-term care home admission. 
Within these types of settings, the care is provided via nursing staff and allied health 
professionals such as occupational therapists and physiotherapists. In the case of non-acute 
community hospitals medical input is provided by visiting clinicians, usually general 
practitioners, and not via an on-site medical team.  
3.2.2 Inappropriate prescribing 
Inappropriate prescribing is the use of an unsuitable medication, where the risk 
outweighs the clinical benefits for the patient, particularly when safer alternatives exist (Beers 
et al., 1991; Gallagher et al., 2011; Spinewine, Schmader, et al., 2007). It encompasses a broad 
range of poor prescribing processes including overprescribing, underprescribing and 
misprescribing. Overprescribing is considered to be the use of medication in the absence of a 
clinical indication. Underprescribing occurs when the individual does not receive necessary 
pharmacotherapy when clinically indicated and can be considered to be a failure to adequately 
manage the underlying condition. Misprescribing is an umbrella term to describe a range of 
suboptimal practices including the use of an incorrect dosage, or duration of therapy, or the 
use of medication when drug-drug interactions are likely. Assessment of inappropriate 
prescribing has largely focused on older age groups due to the high levels of medication 
consumption in those aged 65 years and older. Inappropriate prescribing has been shown to 
be highly prevalent among older people with estimates ranging from 20% up to as much as 
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71% (Cahir, Moriarty, et al., 2014; Hudhra et al., 2016; Moriarty, Bennett, et al., 2015; Recoche 
et al., 2017).  
3.2.2.1 Assessing inappropriate prescribing 
As previously discussed in Chapter 1, several instruments have been developed aimed 
at detecting inappropriate prescribing which, broadly speaking, may be dichotomised into 
explicit and implicit tools. Explicit tools consist of lists of medications and/or clinical scenarios 
where their use is considered inappropriate. Generally developed by expert consensus there 
has been an explosion in the number of explicit tools in operation, with many reflective of the 
specific availability of medicines in a particular country (Kaufmann et al., 2014). Implicit tools 
on the other hand provide some flexibility by encouraging the clinician to apply some 
experience-based judgement thus providing more scope for patient-centred care (Shelton et 
al., 2000).  
The application of different explicit screening tools within the same population has 
been shown to result in varying estimates of inappropriate prescribing (Cahir, Moriarty, et al., 
2014; Hudhra et al., 2016; Moriarty, Bennett, et al., 2015). A particular limitation of explicit 
tools is that they require continual revision in order to incorporate advances in clinical 
knowledge. The 2014 version of STOPP (O’Mahony et al., 2015) was found to detect 
inappropriate prescribing in 63% of individuals in comparison with 35% detected with the 2008 
(Gallagher et al., 2008) version (Hudra et al., 2016). The greater number of indicators included 
in the revised version of STOPP has highlighted the need for screening tools that are 
sufficiently robust to advances in clinical knowledge.  
The MAI (Hanlon et al., 1992), which quantifies prescribing appropriateness through its 
ten-item questionnaire structure, is superior to explicit lists as it is not subject to continual 
revision. In fact, MAI can be used in conjunction with explicit lists to quantify the severity of 
inappropriate prescribing in a given individual. An overall patient score can be calculated by 
105 
 
summating individual drug MAI scores. In doing so it provides a more holistic sense of the 
problem for the individual. 
As our clinical knowledge base grows the focus of our attention may shift, thus it is 
imperative that we utilise a tool that is flexible and still retains utility for use in the field. 
Furthermore, if we are to truly understand inappropriate prescribing in older people, and to 
develop suitable interventions we need to understand not just how prevalent the problem is 
but also its severity. Only then can we make real inroads in reducing medication related harm 
for older people. 
3.2.2.2 Inappropriate prescribing within the wider context of healthcare provision 
Inappropriate prescribing is particularly challenging for both the patient and the 
healthcare system as it is associated with several negative outcomes. For the patient, there is 
an increased risk of experiencing an adverse drug event (Cahir, Bennett, et al., 2014) and an 
increased risk of hospitalisation (Hyttinen et al., 2016; Moriarty et al., 2014). Every point of 
contact that a patient has with the health service provides an opportunity for intervention, 
including better rationalisation of drug therapies. Medicines optimisation has been defined as 
“a person-centred approach to safe and effective medicine use to ensure that people obtain 
the best possible outcomes from their medicines” (National Institute for Health and Care 
Excellence, 2015, p. 7). Within the acute care setting an opportunity exists for hospital 
pharmacists to review patients’ medications and make recommendations to the medical team 
as to how these medications may be optimised.  
However, the health system landscape has changed considerably over the last number 
of years. The number of adults aged 75 years and older being admitted into acute hospitals in 
the UK continues to rise and is largely attributed to the rise in the number of people living with 
long-term conditions (Wilson, Buck & Ham, 2005). Approximately one third of emergency 
admissions to NHS hospital beds among those aged 65 years and older are associated with 
106 
 
chronic conditions (Hutt et al., 2004). Furthermore, those with multiple chronic conditions (≥ 4 
conditions) are 99 times more likely to be hospitalised for adverse events compared with those 
without chronic conditions (Wolff et al., 2002). Woodford and George (2010) argue that this 
rise in demand has not been met with a commensurate increase in bed capacity, thereby 
resulting in a reduction in hospital length of stay.  
There is a concern that patients are now discharged earlier from acute care with 
evidence showing that mean length of hospital stay has reduced, and the number of 
readmissions has increased (Godden et al., 2009). A reduction in length of hospital stay may 
also pose several challenges for medicines optimisation. It is often the case that an accurate 
list of the patient’s medications may not have been collated in that time, a process known as 
medication reconciliation. As such, potential drug related problems may not have been 
identified and thus not rectified prior to discharge. Furthermore, in the absence of medicines 
reconciliation having taken place, acute care setting prescribers may prescribe additional 
medications for the patient that are incompatible with their existing regimen, creating the 
potential for adverse events post-discharge that may result in a readmission to acute care. The 
demand for earlier discharge from acute care services has largely driven the development of 
newer, complementary models of care, including intermediate care. 
Acute hospitalisation can itself be a driver for inappropriate prescribing. Within the 
Irish context it has been shown that hospital admission increases the likelihood of receiving at 
least one potentially inappropriate medication by 49% (Peréz et al., 2018). Furthermore, those 
who were admitted to hospital were found to have a 72% increased risk of having at least one 
potentially inappropriate medication at discharge, compared with before admission. In 
Australia, estimates of prevalence of inappropriate prescribing follow hospital discharge have 
been shown to vary from 12-42% (Chang, Kowalksi, Sorich & Alderman, 2017; Runganga, Peel 
& Hubbard, 2014). Furthermore, very few inappropriate medications are likely to be 
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discontinued within hospital (Scott et al., 2018), supporting the need for appropriate 
medication reviews in the post-discharge period. Edey et al., (2018) argue that many barriers 
to deprescribing exist within the hospital setting, including the clinician’s preoccupation with 
the acute illness, a lack of time for follow up, and lack of interdisciplinary communication. 
Often, the factors directly contributing to the admission diagnosis are addressed whereas 
medication related issues are left for primary care physicians to respond to (Edey et al., 2018).  
3.2.2.3 Inappropriate prescribing in intermediate care 
Our understanding of inappropriate prescribing in intermediate care is limited by the 
paucity of research conducted in this setting. One prevalence study, conducted in an 
intermediate care nursing unit in Norway, identified inappropriate prescribing in 26% of 
patients at admission and this increased to 33% of patients at discharge (Bakken et al., 2012). 
More recently a small study conducted in intermediate care in Northern Ireland (NI) (N = 74) 
reported that inappropriate prescribing was highly prevalent (Millar, 2016). Using the 
STOPP/START criteria it was found that approximately 72% of patients were prescribed at least 
one inappropriate medication on admission into intermediate care and that 73% of patients 
had at least one inappropriate medication at discharge (Millar, 2016). Medications for the 
central nervous system were reported to be the classification of medication most frequently 
prescribed inappropriately. Similarly, potential prescribing omissions were identified in 61% of 
patients at admission and 50% of patients at discharge.  
High prevalence of inappropriate prescribing in intermediate care is not surprising 
given the historical delivery of pharmacy services within this context. Traditionally, there has 
been an absence of clinical pharmacy services to intermediate care facilities in NI. Rather, a 
‘supply only’ function would have been served. In response to a call for better integration of 
primary and secondary care services for older people in NI, as outlined in the ‘Transforming 
Your Care’ Compton Review (DHSSPSNI, 2011a), clinical pharmacy services began to be 
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introduced into intermediate care in Northern Ireland. A novel care pathway providing 
pharmacy services within intermediate care was piloted in the Western Health and Social Care 
Trust (WHSCT) in 2012-2013 with 12-month follow-up (Miller et al., 2016).  
3.2.3 Pharmacy services across the primary-secondary care interface 
Community pharmacies are responsible for pharmacy service provision directly to 
individuals residing within the community. Furthermore, many community pharmacies may be 
responsible for the supply of medication to residential care settings. However, in this instance 
the service is largely one of supply only, as decisions regarding pharmacotherapy for the 
individual predominately lies with that of the GP, although non-medical prescribers also 
contribute to care.    
Within secondary care, clinical pharmacy services have developed to such an extent 
that specialist pharmacy roles have been developed across a diverse range of specialties 
including antimicrobial, renal, paediatrics, oncology, geriatrics etc. The role of the pharmacist 
in these specialist areas allows for greater opportunity for multidisciplinary work with other 
members of the healthcare team. As a consequence of these expanded roles pharmacists in 
secondary care are often involved in making recommendations for treatment optimisation to 
the multidisciplinary team. 
A critical aspect in the pharmaceutical care of patients in secondary care is the 
collation of an accurate list on prescribed medications upon admission, often referred to as 
medication reconciliation. It is a fundamental aspect of ensuring appropriate pharmacotherapy 
and avoidance of medication related harm. In the absence of medicines reconciliation 
inappropriate decisions regarding patient care can occur and may result in medication related 
harm. Similarly, at the point of discharge from secondary care a further potential for harm 
exists in relation to the communication of any medication related changes to those responsible 
for the care of the patient in primary care. 
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Transitions of care have thus been recognised as a key point within the healthcare 
system during which medication related harm can occur, necessitating the need for some 
element of service provision to ‘mind the gap’. In particular, discharge from hospital poses 
challenges for communication of medication related changes. Healthcare professionals report 
that communication of information between care settings is often sub-optimal (Sargent et al., 
2007), increasing the risk for ADEs. It has been estimated that only one-fifth of changes to 
medication made during a hospital admission are explained in discharge summaries (Belleli, 
Naccarella & PiIrotta, 2013). Furthermore, the practice of handwritten communication 
persists, with illegible writing and the omission of medication related information a common 
occurrence (Belleli et al., 2013). It has been found that three in five hospital discharge 
summaries prepared without pharmacist involvement contain at least one medication error 
(Tong et al., 2017).   
Integrated Medicines Management (IMM) is a collaborative programme that seeks to 
address medicines management issues across the primary-secondary care interface in 
Northern Ireland. It is initiated in secondary care and begins with the collation of an accurate 
drug history from available sources (Scullin et al., 2007). During this hospital admission the 
patient is monitored by the pharmacist and appropriate patient education is provided, where 
necessary. In preparation for discharge the IMM pharmacist prepares a discharge prescription 
and communicates the details of any changes with the patient's GP and community 
pharmacist. The focus of this service is to ensure that patient safety is not compromised during 
transitions of care. 
However, whilst IMM has been shown to be a valuable service, resulting in a reduction 
in hospital length of stay and readmissions (Scullin et al., 2007; Scullin et al., 2011), a possibility 
remains for medication related issues to persist beyond hospital discharge. A reduced length 
of stay in secondary care may result in a patient transitioning into intermediate care or a care 
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home that may have still have some unmet pharmaceutical care needs. Furthermore, IMM is 
not universal across all hospital wards, with only approximately 50% of wards providing IMM 
services. As such, there are gaps within the acute care setting in Northern Ireland where 
pharmacy have no input other than to supply medications. Case management proffers an 
opportunity to improve such communication through coordination of care. 
3.2.4 Pharmacist case management in intermediate care 
Despite the important role that intermediate care plays in responding to the needs of 
the older population, and their vulnerability to medication related harm, pharmacy services 
have not routinely been integrated into this care setting. Traditionally pharmaceutical care 
services within intermediate care have predominately been limited to medication supply and 
reconciliation services, with very little clinical pharmacy services having been developed 
(Millar, 2016). Therefore, it is not surprising that inappropriate prescribing has been found to 
be highly prevalent among intermediate care patients (Millar, 2016).  
The MOOP case management models in intermediate care (refer to Chapter 2) begins 
with an initial patient assessment on admission into IC. Medications are reviewed by the 
MOOP pharmacists using MAI, with scoring of each medication influencing the interventions 
conducted to redress this inappropriate prescribing. MAI scores are recalculated on discharge 
and case management continues for approximately 30 days. Healthcare usage in the form of 
unplanned hospital readmissions and ED visits not leading to a readmission are monitored for 
90 days following IC discharge. 
The development of this care model has expanded the pharmacy service within IC 
beyond that of a ‘supply only’ model to one focused on improving patient outcomes. In 
addition to significant improvements in prescribing appropriateness, the model was found to 
make an estimated annual drug cost saving of £68,000 (Miller et al., 2016). Pharmacotherapy 
interventions to reduce inappropriate prescribing in intermediate care have not received as 
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much research attention when compared with other settings (Millar, 2016). In particular, how 
the reduction in inappropriate prescribing relates to later healthcare resource usage has also 
not been fully elucidated. If such an intervention were to improve the outcomes of the 
individual patient following discharge, this could result in greater numbers of older people 
returning to their own homes and ward off transfer into a longer-term care home setting.  
3.3 Objectives  
• Describe the prevalence of inappropriate prescribing in Intermediate Care settings in 
Northern Ireland, as assessed using MAI  
• Calculate the change in total MAI score from admission into and discharge from IC 
following pharmacist intervention 
• Characterise the nature of interventions conducted by the MOOP pharmacists in this 
care setting 
• Establish the proportion of variability in MAI score change that is explained by a 
number of demographic and medication related factors 
• Examine variability in healthcare resource usage and outcomes that is explained by 
changes in total MAI score, as well as examining the patient level covariates associated 
with this variability 
3.4 Method 
3.4.1 Study population 
This study involved secondary data analysis of cross-sectional data collected by the 
MOOP team in IC, between 2015 and 2016. Further detail on the sample characteristics and 
data collection can be observed in Chapter 2. The IC sample comprised of 532 participants who 
ranged in age from 65 to 99 years (M = 82, SD = 7.6 years).  
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3.4.2 Design and variables 
The study involved secondary data analysis of data previously collected by the MOOP 
pharmacists in NHSCT and WHSCT. As described in Chapter 2 this data collection adopted a 
prospective design, with data captured by the MOOP pharmacists upon admission into IC 
(baseline) and at discharge. Further details regarding data collection can be found in Chapter 2. 
Demographic information such as age, sex and residential status were examined in the present 
study. In addition, the following variables reflecting the clinical status of IC participants were 
also considered: 
▪ Independence: this related to how independent participants were with respect to 
medicines management. Four dummy variables were created such that indp1 were 
those who were completely independent; indp2 were those who received some 
assistance or prompting for medicines management; indp3 were those who received 
informal assistance from a relative/carer/friend; indp4 were those who received a 
formal assistance package. 
▪ Acute inpatient: this binary variable was created using information from the ‘origin’ 
variable. The ‘origin’ variable outlined all sources of admissions into intermediate care. 
All those who were categorised as being admitted into intermediate care from acute 
care were coded as ‘yes’. Those who were admitted into intermediate care following a 
GP step up request, via the WHSCT Older Persons Assessment and Liaison (OPAL) and 
Rapid Response teams were coded as ‘no’.  
▪ Number of acute admissions in previous 12 months: this continuous variable 
indicated the number of acute care admissions experienced by participants in the 12-
month period prior to the index admission into intermediate care. This variable was 




▪ Origin: this binary variable was recoded from the original ‘type of residence’ variable 
such that 0 was ‘private nursing home, residential home, supported living 
accommodation, or other’ and 1 was ‘own home’.  
3.4.2.1 Clinical history information 
Details for up to ten previous medical history diagnoses were captured within the 
dataset. This information was coded according to ICD-10 criteria (WHO, 1992). Frequency 
counts for each previous medical history endorsed were completed using IBM SPSS Statistics 
for Windows 24 (IBM Corp., 2016) and consolidated using Microsoft Excel. Binary variables 
were computed for the most frequently endorsed medical histories. These binary variables 
were then aggregated into higher order groups of similar diagnosis codes to ensure that no 
variable contained <5% of the sample population. The higher-order diagnoses examined within 
intermediate care can be observed in Table 3-1.  
Table 3-1: Aggregated previous medical histories examined in the IC sample 
Higher order variable Diagnosis subtypes 
Fracture Fractured neck of femur 
 Fracture 
 Fractured pubic ramus 
 Fractured humerus 
 Fractured arm 
 Multiple fractures 
 Fractured hip 
 Fractured lumbar vertebrae 
Anaemia Iron deficiency anaemia 
Stroke Cerebrovascular accident 
 Cerebral infarct 
 Transient ischaemic attack 
 Stroke non-specified 
Acute myocardial infarction Acute myocardial infarction 
Cognitive impairment Cognitive impairment 
 Acute on chronic with Alzheimer’s background 
 Unspecified dementia 




 Unspecified falls 
 Increased frequency of falls 
 Other fall from one level to another  
Urinary tract infection Urinary tract infection 
Heart failure Heart failure 
Chronic obstructive pulmonary disease (COPD) Other COPD 
Pneumonia Bacterial pneumonia not elsewhere specified 
 Pneumonia, organism unspecified 
 Hospital acquired pneumonia 
Essential primary hypertension  Essential primary hypertension 
Lower respiratory tract infection (LRTI) Bacterial LRTI 
 Unspecified acute LRTI 
Osteoarthritis Osteoarthritis 
Renal failure Acute renal failure 
 Chronic renal failure 
Atrial fibrillation and flutter Atrial fibrillation and flutter 
Type II diabetes Type II diabetes 
 Non-insulin dependent diabetes 
Hip replacement Hip replacement 
Chronic ischemic heart disease Chronic ischemic heart disease 
Diverticular disease of the intestine Diverticular disease of the intestine 
Malignancy Malignant neoplasm of bone 
 Malignant neoplasm of brain 
 Malignant neoplasm of rectosigmoid junction 
 Malignant neoplasm of stomach 
 Multiple myeloma and malignant plasma cell neoplasms 
 Other skin 
 Malignant neoplasm of colon 
 Malignant neoplasm of gallbladder 
 Malignant neoplasm of bronchus/lung 
 Malignant neoplasm of breast 
 Malignant neoplasm of kidney except renal pelvis 
 Other and unspecified types of non-Hodgkin’s lymphoma 
 Basal cell carcinoma 
 Follicular lymphoma 
 Follicular nodular non-Hodgkin’s lymphoma 
 Hodgkin’s disease 
 Lung cancer with bony metastases 
Osteoporosis Osteoporosis with fracture 
 Osteoporosis without fracture 
Hypothyroidism Hypothyroidism 
Depression with or without anxiety Depression with anxiety 
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 Depressive episode 
Chronic kidney disease Chronic kidney disease 
Gout Gout 
Hypercholesterolaemia  Hypercholesterolaemia 
 
3.4.2.2 Healthcare utilisation outcome variables  
Several binary variables relating unplanned hospital readmissions were available within 
the intermediate care dataset. These included ‘unplanned readmission within 30 days’, 
‘unplanned readmission within 31-90 days’ and ‘unplanned readmission within 90 days’. 
Several continuous variables were also available including ‘number of readmissions within 30 
days’, ‘number of readmissions within 31-90 days’, ‘total number of readmissions within 90 
days’, ‘length of stay on first unplanned readmission’ and ‘time to readmission’.  
These outcome variables were recoded to address data entry errors and to ensure that 
participants who died during their intermediate care admission were captured as ‘non-
applicable’ on outcome variables. An examination of the ‘total number of readmissions within 
90 days’ variable revealed data entry errors for five cases (8272, 8263, 8159, 8257, 8017). 
Thus, a new variable ‘recoded total number of readmissions within 90 days’ was computed by 
summating the values from ‘number of readmissions within 30 days’ and the values ‘number of 
readmissions within 31-90 days’ variables. Details regarding recoding of information to address 
data entry errors are as follows: 
▪ r_read30: binary variable (Y=1, N=0) recoded from the original binary ‘unplanned 
readmission within 30 days of intermediate care discharge’ variable such that those 
who died during the index IC admission were recoded as 8888 (non-applicable).  
▪ r_read90: binary variable (Y=1, N=0) recoded from the original binary ‘unplanned 
readmission within 31-90 days of intermediate care discharge’ variable such that those 
who died during the index IC admission were recoded as 8888 (non-applicable).  
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▪ r_adm90: binary variable (Y=1, N=0), representing readmission between 0 and 90 days 
of IC discharge, was computed using information from ‘r_read30’ and ‘r_read90’. If 
‘r_read30’ OR ‘r_read90’ were labelled as ‘yes’ then r_adm90 was coded as 1. Those 
who died during IC admission were labelled as 8888 (non-applicable).  
▪ r_admboth: binary variable (Y=1, N=0) computed using information from ‘r_read30’ 
and ‘r_read90’, such that if ‘r_read30’ AND ‘r_read90’ were both labelled as ‘yes’ then 
r_admboth was coded as 1. Those who died during IC admission were labelled as 8888 
(non-applicable). 
▪ r_LOSread: this continuous variable was recoded from the original ‘length of stay on 
first readmission’ such that those who died during IC admission were labelled as 8888 
(non-applicable). All other missing values were labelled as 9999. 
▪ r_TTread: this continuous variable was recoded from the original ‘time to first 
unplanned readmission’ variable such that those who died during IC admission were 
labelled as 8888 (non-applicable). All other missing values were labelled as 9999.  
▪ r_Died90: Information on death during the intervention was captured on either the 
‘died during intermediate care admission’ or ‘died within 90 days of intermediate care 
discharge’ variables. It was noted that two participants (8001 and 8062) who died 
during the intermediate care admission were also listed on the 90-day variable. These 
two cases were considered as deaths during intermediate care admission as all 
subsequent variable information had been captured as non-applicable for these 
participants. Thus, the ‘died90’ variable was recoded to r_Died90 such that if ‘died 
within 90 days of intermediate care discharge’ was ‘yes’ then r_Died90 was coded as 1; 
‘no’ was coded as 0. If ‘died during intermediate care admission’ was ‘yes’ then 
r_Died90 was coded as 8888 (non-applicable).  
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3.4.3 Data analyses 
Demographic and clinical characteristics of participants are expressed in terms of 
counts, mean (with standard deviation), median and proportions, as appropriate. Descriptive 
statistics were completed using IBM SPSS Statistics for Windows 24 (IBM Corp., 2016).  
Frequencies of endorsement for previous medical histories and frequency of prescribing in 
each BNF chapter subclassification were consolidated using Microsoft Excel for efficiency in 
tabulation.  
Prevalence of inappropriate prescribing at baseline was examined using participant 
Total MAI score. Kolmogorov-Smirnov and Shapiro- Wilks tests were conducted to examine the 
distribution of Total MAI score at baseline and following case management completion. Tests 
of normality indicated that participant Total MAI score at both time points were non-normally 
distributed.  Differences in mean Total MAI score at baseline were examined using Wilcoxon-
Signed rank tests for continuous variables and Chi-square tests of independence for categorical 
variables. Total MAI score at baseline was categorised according to the following: 0; 1-18; 19-
36; 37-54; 55-72; >72 categories to examine the proportion of participants who had an 
increasing severity of inappropriate prescribing. Chi-square tests of independence were 
conducted to examine differences between categorical demographic variables and MAI 
baseline category. The change in Total MAI score between both time points was examined 
using Wilcoxon-Signed Rank test.  
Linear regression analyses were used to determine the association between 
demographic and clinical variables and MAI total score change during the intervention. 
Multivariate regression analyses were conducted using Mplus 8.1 (Muthén & Muthén, 1998-
2018), using the maximum likelihood robust estimator (MLR) to account for multivariate non-
normality. This estimator provides a robust estimation of standard errors whilst accounting for 
non-normality of outcomes and non-independence of observations. These robust standard 
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errors are computed using a sandwich estimator (Muthén & Muthén, 1998-2016). Preliminary 
regression analyses in SPSS indicated that the data violated the assumption of 
homoscedasticity, necessitating the requirement for more robust estimation methods. Several 
demographic and clinical variables were entered into the predictive model. The regression 
coefficients, associated significance values and R2 were examined for each predictive model.  
Binary healthcare utilisation outcome variables were examined using multivariate 
logistic regression analyses completed with Mplus 8.1 (Muthén & Muthén, 1998-2018), using 
the maximum likelihood robust (MLR) estimator to account for multivariate non-normality. 
Poisson regression analyses were completed for count outcome variables using the robust 
estimator of the Generalized function within IBM SPSS Statistics for Windows 24 (IMB Corp., 
2016). Survival analyses were conducted for ‘time to readmission’ outcome variables using the 
Kaplan Meier function within IBM SPSS Statistics for Windows 24 (IMB Corp., 2016). 
Multivariate linear regression analyses were conducted for ‘length of stay on first unplanned 
readmission’ variables using Mplus 8.1 (Muthén & Muthén, 1998-2018), using the MLR 
estimator. Regression coefficients, odds ratios and associated confidence intervals, significance 
values and model fit statistics are reported for each predictive model.  
3.5 Results 
3.5.1 Clinical history and care context 
The majority of IC participants entered intermediate care via an acute care hospital (n 
= 462). Additional admittances from acute care were made within WHSCT via specialist teams, 
including the Rapid Access team (n = 1) and the OPAL team in the ED (n = 7).  A small number 
of participants who entered IC were recorded as entering via an ‘other’ acute care location, for 
example an acute care hospital outside of the relevant HSCT (n = 5). A total of 57 participants 
were admitted to IC following a GP step up request.  
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Prior to entering IC, the majority of participants resided in their own home (n = 484). 
Twenty-two resided in supported living accommodation, 14 resided in a private nursing home 
and 11 resided in a residential home. Two-thirds of the IC sample had an intermediate care 
length of stay of more than two weeks but less than two months. A small proportion of 
participants had an intermediate care length of stay in excess of three months. Further detail 
on intermediate care length of stay can be observed in Table 3-2.  
Table 3-2: Frequencies for category of length of stay in IC (N = 498) 
Length of stay in intermediate care n (%) 
0-7 days 16 (3.0) 
8-14 days 58 (10.9) 
15-28 days 177 (33.3) 
29-56 days 174 (32.7) 
57-84 days 50 (9.4) 
>84 days 23 (4.3) 
Note. Information regarding intermediate care length of stay missing for 34 participants.  
Of the participants who transitioned into intermediate care from an acute care setting, 
almost three-quarters (71.2%) experienced an acute care length of stay of up to three weeks. 
The most frequently endorsed length of stay in acute care was between eight and 14 days. Just 
over one-tenth of those who transitioned into intermediate care from acute care had 
experienced an acute care length of stay greater than one month (Table 3-3).  
Table 3-3: Frequencies for category of acute care length of stay for those IC participants admitted from acute care (N 
= 475) 
Length of stay in acute care n (%) 
0-7 days 134 (25.2) 
8-14 days 171 (32.1) 
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15-21 days 74 (13.9) 
22-28 days 37 (7.0) 
>28 days 59 (11.1) 
 
3.5.2 Medicines management 
The majority of IC participants were completely independent with respect to managing 
their medicines at home (n = 286). A total of 166 participants received some form of assistance 
with managing their medicines from an informal carer, relative or friend. Fifty-seven 
participants received a formal assistance package. Eleven participants required some 
assistance with managing their medicines at home, whilst a further seven required some 
prompting. Two-fifths of the sample (n = 213) used a compliance aid to assist with medicines 
management, with the majority of these being filled by their community pharmacist (n = 180). 
Family carers filled the compliance aid for 26 participants, whilst seven took personal 
responsibility for filling their compliance aid. A further 29 IC participants used another 
unspecified compliance solution that was not a monitored dosage system.  
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An examination of BNF chapter subclassifications revealed that ‘non-opioid analgesics 
and compound analgesic preparations’ was the most frequently endorsed subclassification for 
IC participants (Figure 3-1). 
3.5.3 Prescribing appropriateness at baseline 
A large proportion of IC participants (89.5%) had some degree of inappropriate 
prescribing upon admission into IC. Total MAI scores at admission ranged from 0 to 63 (M = 
15.51, SD = 11.88). Baseline total MAI score categories can be observed in Table 3-4.  
Table 3-4: Frequencies for category of total MAI score at baseline (N = 532)  
Baseline total MAI category n (%) 
0 56 (10.5) 
1-18 293 (55.1) 
19-36 155 (29.1) 
37-54 25 (4.7) 
55-72 3 (0.6) 
The Mann-Whitney test of differences indicated that the mean ranks for baseline total 
MAI score was significantly higher for participants who were in the NHSCT (Mdn = 16) than for 
participants in the WHSCT (Mdn = 13), U = 29092.0, p =.006, r = .12.  No significant difference 
was observed in the mean ranks of baseline MAI total scores for males (Mdn = 13) and females 
(Mdn = 15, U = 28648.5, p = .078). Similarly, no significant difference was observed in the mean 
ranks of baseline MAI total scores between those who had previously been an acute inpatient 
(Mdn = 14) and those that were not (Mdn = 16, U = 13383, p = .155). Furthermore, there was 
no difference in baseline total MAI scores for those who were ordinarily resident in their own 
home (Mdn = 14) compared with those who were not (Mdn = 10.5, U = 10747, p = .392).  
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A chi-square test of independence was conducted to examine the relationship 
between HSCT trust and MAI total score category at baseline. A statistically significant weak 
association was observed, X2(4, N = 532) = 12.75, p = .013, Cramer’s V = .16. Chi-square tests of 
independence to examine the association between baseline MAI total score category and 
intermediate care length of stay; polypharmacy category; and age category could not be 
conducted as an assumption underlying the application of this test, that <20% of cells have an 
expected count less than 5, was violated in all instances. Results of a Spearman correlation 
indicated that there was a significant positive association between the number of prescribed 
medications at baseline and baseline total MAI score rs = .419, p < .001. 
3.5.4 Case management intervention 
 
In the IC sample the number of clinical interventions conducted by the case 
management pharmacists ranged from 0 to 12 (M = 4.48, SD = 2.56).  Details for a total of 2377 
interventions recorded within the IC dataset can be observed in Figure 2-7 (Chapter 2). 
Information regarding the classification of intervention type was missing for four interventions 
in the IC dataset. The most prevalent interventions were medication stopped (77.3%), dosage 
change (54.9%) and medication started (50.2%) (refer to Chapter 2, Table 2-5). A total of 948 
medication cessations, 432 medication initiations and 435 dosage changes were recorded for 
the cohort (refer to Chapter 2, Figure 2-7). 
3.5.5 Prescribing appropriateness following case management pharmacist 
intervention  
The majority of IC participants (83.6%) experienced a change in total MAI score from 
baseline (N = 497). On average, participant total MAI score reduced by 15.41 points (SD = 
11.76, range 0-63). Upon discharge participants were found to be prescribed an average of 
9.68 medications (SD = 4.02, range = 0-23, N = 493). A significant weak Spearman’s rho 
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correlation was observed between number of prescribed medications and total MAI score at 
discharge (rs = .091, p = .043).  
Table 3-5: Means and standard deviations for number of medications and total MAI score at both time points in IC 
 Time 1: Admission  Time 2: Discharge 
 N M (SD)  N M (SD) 
Number of medications 532 10.68 (4.14)  493 9.68 (4.02) 
MAI total score 532 15.51 (11.88)  497 0.41 (1.84) 
Note. MAI total score missing for 35 IC participants at Time 2 
 
A Wilcoxon sign-rank test showed that pharmacist intervention significantly reduced 
MAI total scores from admission (Mdn = 14) to discharge from intermediate care (Mdn = 0) (Z = 
-18.28, p < .001). Furthermore, the number of medications prescribed for intermediate care 
participants was also significantly reduced (Z = -8.30, p < .001). Median numbers of 
medications changed from 10 to 9 following pharmacist intervention.  
3.5.6 Explaining variability in MAI score change  
Linear regression was conducted to predict MAI score change in intermediate care 
with demographic, clinical history, and pharmacist intervention variables as independent 
variables. The model explained 44.2% of the variance in MAI score change. Age, sex, and 
ordinary residence status were not significant predictors of MAI score change. Participant’s 
health and social care trust (HSCT) was a significant predictor of variability in MAI score change 
(ß = .191, p < .001). Participants in the Northern HSCT experienced a greater reduction in MAI 
score compared with their counterparts in WHSCT. These participants were found to have 
higher MAI total scores at baseline.  Length of stay in IC was a statistically significant weak 
predictor of MAI score change (ß = .087, p = .029). 
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Several interventions conducted by the case management pharmacists explained 
variance in MAI score change. The change in the number of prescribed medications from 
baseline to completion of the intervention was the strongest predictor (ß = .584, p < .001). 
Having the dose of at least one medication changed also explained variability in MAI score 
change (ß = .206, p < .01). Providing a medicines information intervention was a significant 
negative predictor of MAI score change (ß = -.080, p =.001) with those participants who 
experienced a medicines information intervention experiencing a smaller MAI score change. 
Addressing Kardex issues was also as significant weak predictor of MAI score change in 
intermediate care.  






Demographics    
Age -.007 -.004 .905 
Sex 1.601 .064 .059 
HSC Trust 4.451 .191 <.001** 
Original residence (ref other): own home 1.303 .032 .317 
Clinical history    
Number of hospital admissions in previous 12 months  .257 .031 .320 
Length of stay in acute care .023 .028 .491 
Length of stay in intermediate care .043 .087 .029* 
Pharmacist intervention    
Change in number of prescribed medications 2.805 .584 <.001** 
Blood tests completed -.038 -.001 .981 
Medicines information -5.948 -.080 .001* 
Medication dosage change 4.813 .206 <.001** 
Referral to another healthcare professional .051 .002 .969 
Kardex issue addressed 1.916 .079 .032* 
Education 1.237 .033 .347 
Other .885 .020 .488 
Note. * p < .05; ** p < .001  
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3.5.7 Explaining variability in healthcare resource utilisation 
Baseline healthcare resource utilisation  
The number of unplanned hospital admissions in the 12 months prior to the index IC 
admission ranged from 0 to 11 (M = 0.90, SD = 1.49). Just over half of IC participants (55.8%) 
did not experience an unplanned hospital admission in the 12 months prior to the index IC 
admission. Approximately one fifth (22.4%) of the sample experienced just one unplanned 
hospital admission, 11.7% experienced two unplanned hospital admissions and 4.7% 
experienced three unplanned hospital admissions in the preceding 12 months. The remainder 
(5.5%) experienced between four and 11 unplanned hospital admissions. No significant 
correlation was observed between MAI total score at baseline and the number of unplanned 
hospital admissions experienced by IC participants in the preceding 12 months (r = .043, p = 
.328).  
Post-intervention healthcare utilisation 
A total of 115 IC participants experienced an unplanned hospital readmission within 90 
days of discharge from intermediate care, with a greater number of participants experiencing 
this readmission between 31 and 90 days of discharge from intermediate care.  
Table 3-7: Counts for hospital readmission for IC participants (N = 532) 
 < 30 days 31-90 days Both time periods 0-90 days 
No 448 430 482 396 
Yes 63 81 29 115 
N/a 21 21 21 21 
Note. N/a = non-applicable; participants who died prior to discharge from intermediate care 
The duration of these unplanned readmissions by IC participants ranged between 1 
and 76 days (M = 13.85, SD = 15.30, n = 101), with time to readmission found to range 
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between 1 and 89 days (M = 33.56, SD = 25.71, n = 113). On average IC participants 
experienced 0.34 readmissions (SD = 0.67, range 0-5, n = 432) within 90 days of IC discharge.  
Predicting unplanned hospital admission 
The degree of MAI total score change was not significantly associated with likelihood 
of experiencing a hospital readmission for IC participants, in either the 30-day or 31-90-day 
period (Table 3-8). Patient education was the only intervention type found to be associated 
with a reduced likelihood of hospital readmission within 30 days (OR = 0.15, 95% CI 0.03, 0.71, 
p < .001). None of the clinical intervention types were significantly associated with likelihood 
of unplanned readmission within 31-90 days of IC discharge.  
Table 3-8: Multivariate logistic regression of likelihood of hospital readmission <30 days and 31- 90 days for IC 
participants (N = 483) 
 < 30 days 31-90 days 
Variables OR (95% CI) p OR (95% CI) p 
MAI score difference 1.01 (0.98, 1.04) .470 1.01 (0.98, 1.04) .432 
Age 0.96 (0.91, 1.01) .082 1.01 (0.97, 1.05) .652 
Sex (reference: male)     
Female  2.37 (1.04, 5.39) .040 0.98 (0.53, 1.82) .939 
Medicines management (reference: 
formal assistance) 
    
Completely independent 9.21 (1.33, 63.79) .025 1.63 (0.52, 5.07) .401 
Some assistance/prompting 11.41 (1.04, 125.61) .047 2.18 (0.40, 12.01) .370 
Informal assistance from 
relative/friend/carer 
5.07 (0.72, 35.87) .104 1.00 (0.31, 3.30) .999 
IC length of stay (days) 0.99 (0.98, 1.01) .332 1.00 (0.99, 1.01) .835 
HSC trust (reference: W HSCT)     
Northern HSCT 0.95 (0.36, 2.53) .922 0.79 (0.36, 1.73) .553 
Acute care inpatient (ref: no) 0.33 (0.12, 0.94) .038 1.12 (0.47, 2.71) .798 
Number of acute admissions in the 
previous 12 months  
1.37 (1.12, 1.68) .002 1.37 (1.14, 1.65) .001 
Original residence (ref: other)     
Own home 0.99 (0.19, 5.07) .988 0.60 (0.20, 1.74) .344 
Medication stopped 0.96 (0.40, 2.29) .929 0.65 (0.32, 1.32) .238 
Medication initiated 1.80 (0.85, 3.84) .126 1.14 (0.63, 2.07) .671 
Blood tests requested 0.64 (0.20, 2.09) .643 2.78 (1.27, 6.07) .010 
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Medicines information service 33.34 (5.67, 195.85) <.001 1.07 (0.20, 5.78) .942 
Dose changed 1.04 (0.51, 2.14) .915 0.61 (0.34, 1.09) .093 
Referred to another HCP 0.66 (0.24, 1.81) .418 0.82 (0.35, 1.90) .645 
Kardex issue addressed 0.99 (0.47, 2.08) .968 1.07 (0.59, 1.95) .823 
Education 0.15 (0.03, 0.71) .016 1.15 (0.46, 2.88) .769 
Other intervention 4.32 (1.60, 11.68) .004 1.22 (0.49, 3.04) .676 
Fracture  0.72 (0.34, 1.54) .397 0.34 (0.18, 0.64) .001 
Anaemia 2.38 (0.57, 9.99) .236 0.46 (0.12, 1.79) .261 
Acute myocardial infarction 1.50 (0.49, 4.60) .480 1.25 (0.49, 3.22) .641 
Stroke 0.61(0.24, 1.56) .305 0.54 (0.26, 1.14) .108 
Cognitive impairment 2.52 (0.87, 7.28) .087 1.29 (0.51, 3.28) .590 
Falls 0.71 (0.27, 1.86) .484 0.85 (0.41, 1.79) .675 
Urinary tract infection 4.12 (1.51, 11.24) .006 1.40 (0.55, 3.58) .481 
Heart failure 1.54 (0.56, 4.28) .406 0.64 (0.26, 1.53) .314 
COPD 0.73 (0.28, 1.94) .530 1.00 (0.46, 2.18) .997 
Pneumonia 2.75 (0.96, 7.89) .061 1.08 (0.45, 2.62) .862 
Hypertension  0.58 (0.28, 1.23) .154 1.01 (0.56, 1.84) .970 
LRTI 3.64 (1.05, 12.55) .041 1.45 (0.47, 4.52) .520 
Osteoarthritis 0.93 (0.33, 2.65) .888 0.80 (0.35, 1.82) .591 
Renal failure 0.78 (0.28, 2.16) .635 1.70 (0.80, 3.65) .170 
Atrial fibrillation and flutter 1.52 (0.68, 3.39) .306 1.31 (0.68, 2.54) .426 
Type 2 diabetes mellitus 1.32 (0.57, 3.05) .522 1.52 (0.79, 2.94) .211 
Hip replacement 0.94 (0.24, 3.72) .932 0.95 (0.34, 2.62) .914 
Ischaemic heart disease 0.50 (0.18, 1.43) .198 0.92 (0.42, 2.01) .824 
Diverticular disease 0.42 (0.07, 2.35) .321 0.54 (0.17, 1.77) .311 
Malignancy  0.36 (0.07, 1.87)  .226 1.32 (0.45, 3.83) .611 
Osteoporosis  0.82 (0.28, 2.40) .717 1.30 (0.55, 3.06) .548 
Hypothyroidism 0.82 (0.31, 2.19) .687 0.41 (0.16, 1.09) .074 
Depression  1.41 (0.38, 5.14) .607 1.01 (0.35, 2.95) .986 
Chronic kidney disease 3.16 (0.89, 11.15) .074 1.25 (0.42, 3.71) .687 
Hypercholesterolaemia 0.86 (0.28, 2.57) .780 1.31 (0.55, 3.14) .541 
Note. HCP = healthcare professional; LRTI: lower respiratory tract infection 
Those who had previously been an acute care inpatient were significantly less likely to 
have experienced a readmission within 30 days of discharge from intermediate care, compared 
with those who entered IC following a GP step up request. The greatest significant predictor of 
likelihood of readmission in both monitoring periods was the number of acute care admissions 
in the preceding 12-month period; each additional acute care admission in the preceding 12 
months increased the risk for readmission 1.37-fold. Those with a previous medical history of a 
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fracture were significantly less likely to experience an unplanned hospital readmission 
between 31- and 90-days following IC discharge.  
When readmissions were aggregated (0 to 90 days following IC discharge) the number 
of hospital admissions in the 12 months prior to the index admission remained a significant 
predictor of increased likelihood for readmission (Table 3-9). Each additional admission in the 
preceding 12 months increased the risk for readmission 1.44-fold (95% CI 1.18, 1.74).  Neither 
the degree of total MAI score change, nor the clinical intervention types were associated with 
risk of hospital readmission in the 90 days following IC discharge.  
Table 3-9: Multivariate logistic regression of predictors of hospital readmission within 90 days for IC participants (N = 
483) 
Variables OR (95% CI) p 
MAI score difference 1.01 (0.99, 1.04) .340 
Age 0.97 (0.94, 1.01) .150 
Sex  1.51 (0.84, 2.72) .166 
Medicines management (ref: formal assistance package)    
Completely independent 1.87 (0.66, 5.32) .240 
Some assistance or prompting 2.37 (0.50, 11.20) .277 
Informal assistance from relative/friend/carer 1.23 (0.42, 3.63) .707 
Intermediate care length of stay (days) 1.00 (0.99, 1.01) .654 
HSC trust (ref: Western HSCT) 0.68 (0.34, 1.38)   .285 
Acute inpatient (ref: no) 0.65 (0.30, 1.43) .284 
Number of hospital admissions in previous 12 months  1.44 (1.18, 1.74) <.001 
Original residence (ref: other) 0.57 (0.21, 1.56) .277 
Medication stopped 0.83 (0.44, 1.60) .586 
Medication initiated 1.35 (0.78, 2.34) .280 
Blood tests requested 1.68 (0.77, 3.66) .194 
Medicines information service 4.15 (0.90, 19.07) .068 
Dose changed 0.71 (0.42, 1.21) .207 
Referred to another HCP 0.69 (0.32, 1.49) .350 
Kardex issue addressed 1.06 (0.62, 1.82) .835 
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Education 0.60 (0.25, 1.46) .256 
Other intervention 2.01 (0.90, 4.50) .090 
Fracture  0.39 (0.22, 0.68)   .001 
Anaemia 0.74 (0.23, 2.40) .619 
Acute myocardial infarction 1.18 (0.49, 2.83) .719 
Stroke 0.51 (0.26, 1.01) .053 
Cognitive impairment 1.19 (0.52, 2.73) .684 
Falls 0.68 (0.34, 1.33) .258 
Urinary tract infection 2.41 (1.06, 5.46) .035 
Heart failure 0.98 (0.45, 2.16) .962 
COPD 0.88 (0.43, 1.81) .737 
Pneumonia 1.21 (0.52, 2.81) .661 
Hypertension  0.79 (0.46, 1.34) .376 
Lower respiratory tract infection 2.74 (0.99, 7.52) .051 
Osteoarthritis 0.83 (0.39, 1.75) .620 
Renal failure 1.17 (0.57, 2.40) .670 
Atrial fibrillation and flutter 1.50 (0.82, 2.74) .188 
Type 2 diabetes mellitus 1.50 (0.82, 2.74) .188 
Hip replacement 0.73 (0.27, 1.97) .733 
Ischaemic heart disease 0.72 (0.34, 1.51) .717 
Diverticular disease 0.46 (0.15, 1.35) .156 
Malignancy  0.93 (0.34, 2.53) .880 
Osteoporosis  1.36 (0.64, 2.90) .428 
Hypothyroidism 0.51 (0.22, 1.14) .101 
Depression  1.80 (0.70, 4.62) .219 
Chronic kidney disease 1.48 (0.56, 3.94) .433 
Hypercholesterolaemia 1.09 (0.49, 2.40) .836 
 
Participants who had previously had a fracture were significantly less likely to be 
readmitted within 90 days of IC discharge compared with those participants who did not have 
a previous fracture. A previous medical history of at least one urinary tract infection was 
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associated with a significantly increased likelihood of readmission within 90 days of IC 
discharge.   
No significant predictive relationship was observed between MAI score change and the 
number of unplanned hospital admissions within 30 days of IC discharge (Table 3-10). Females 
were found to have almost twice the number of unplanned hospital admissions (OR = 1.83, 
95% CI 1.03, 3.26) compared with males. Each additional hospital admission in the 12 months 
preceding the index admission resulted in 1.2 times more readmissions within 30 days of IC 
discharge (95% CI 1.04, 1.40).  
Table 3-10: Poisson regression of number of readmissions within 30 days of discharge from IC (N = 424).  
Variables Estimate  SE OR (95% CI) p 
MAI difference .003 .013 1.00 (0.98, 1.03) .801 
Age -.020 .018 0.98 (0.95, 1.02) .257 
Sex (ref: male)     
Female  .604 .295 1.83 (1.03, 3.26) .041 
Medicines management (ref: independent)     
Some assistance or prompting .455 .703 1.58 (0.40, 6.25) .517 
Informal assistance from relative/friend/carer -.363 .306 0.70 (0.38, 1.27) .235 
Formal assistance package -1.56 .668 0.21 (0.06, 0.78) .019 
Intermediate care length of stay (days) -.006 .007 0.99 (0.98, 1.01) .375 
Trust (ref: WHSCT)     
NHSCT .383 .443 1.47 (0.62, 3.49) .388 
Acute inpatient (ref: no) -.648 .354 0.52 (0.26, 1.05) .067 
Number of hospital admissions in previous 12 
months 
.189 .075 1.21 (1.04, 1.40) .012 
Original residence (ref: other)     
Own home -.110 .535 0.90 (0.31, 2.56) .837 
Medication stopped .000 .278 1.00 (0.58, 1.72) .999 
Medication initiated .336 .279 1.40 (0.81, 2.42) .229 
Blood tests requested -.286 .434 0.75 (0.32, 1.76) .511 
Medicines information  1.938 .523 6.95 (2.49, 19.35) <.001 
Dose changed .076 .298 1.08 (0.60, 1.94) .567 
Referred to another HCP -.194 .339 0.82 (0.42, 1.60) .567 
Kardex issue addressed -.042 .274 0.96 (0.56, 1.64) .878 
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Education  -1.372 .511 0.25 (0.09, 0.69) .007 
Other intervention .856 .325 2.35 (1.25, 4.45) .008 
Fracture  -.312 .309 0.73 (0.40, 1.34) .312 
Anaemia .348 .550 1.42 (0.48, 4.16) .527 
Acute myocardial infarction .357 .449 1.43 (0.59, 3.45) .427 
Stroke -.358 .373 0.70 (0.34, 1.45) .337 
Cognitive impairment .818 .342 2.27 (1.16, 4.43) .017 
Falls -.288 .380 0.75 (0.36, 1.58) .488 
Urinary tract infection .885 .350 2.42 (1.22, 4.81) .012 
Heart failure .648 .482 1.91 (0.74, 4.92) .179 
COPD -.278 .359 0.76 (0.38, 1.53) .438 
Pneumonia .712 .373 2.04 (0.98, 4.23) .056 
Hypertension  -.350 .273 0.70 (0.41, 1.20) .198 
Lower respiratory tract infection .832 .407 2.30 (1.04, 5.10) .041 
Osteoarthritis .203 .486 1.23 (0.47, 3.18) .174 
Renal failure -.444 .375 0.64 (0.31, 1.34) .236 
Atrial fibrillation and flutter .342 .306 1.41 (0.77, 2.57) .264 
Type 2 diabetes mellitus .204 .297 1.23 (0.69, 2.19) .493 
Hip replacement -.037 .626 0.96 (0.28, 3.29) .953 
Ischaemic heart disease -.505 .355 0.60 (0.30, 1.21) .155 
Diverticular disease -.751 .603 0.47 (0.15, 1.54) .213 
Malignancy  -.785 .620 0.46 (0.14, 1.54) .205 
Osteoporosis  -.144 .366 0.87 (0.42, 1.77) .694 
Hypothyroidism -.161 .413 0.85 (0.38, 1.91) .697 
Depression  .166 .479 1.18 (0.46, 3.02) .730 
Chronic kidney disease .557 .503 1.75 (0.65, 4.68) .268 
Hypercholesterolaemia .316 .505 1.37 (0.51, 3.69) .532 
 
A formal assistance package for medicines management was found to result in 
significantly fewer unplanned readmissions within 30 days of IC discharge compared with 
those who were completely independent with respect to medicines management. Patient 
education resulted in significantly fewer unplanned readmissions (OR = 0.25, 95% CI 0.09, 0.69, 
p = .007). A medicines information intervention resulted in almost seven times more 
readmissions (OR = 6.95, 95% CI, 2.49, 0.69, p < .001) within 30 days of IC discharge. Those 
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who received at least one intervention categorised as ‘other’ experienced twice the number of 
unplanned admissions within 30 days of IC discharge than those who did not receive this 
intervention type (OR = 2.35, 95% CI 1.25, 4.45, p = .008). 
Several previous medical history variables exhibited significant associations with the 
number of unplanned hospital admissions within 30 days of IC discharge. Those with cognitive 
impairment experienced over twice the number of readmissions compared with those with no 
diagnosis of cognitive impairment (OR = 2.27, 95% CI 1.16, 4.43, p = .017). Those IC 
participants with a previous medical history of experiencing a urinary tract infection (UTI) were 
also found to have twice the number of unplanned hospital readmissions. Similarly, those who 
had previously been diagnosed with a lower respiratory tract infection (LRTI) also experienced 
over twice the number of unplanned hospital admissions within 30 days of IC discharge in 
comparison with those with no previous medical history of a LRTI. 
No significant association was observed between the degree of MAI score change and 
the number of unplanned readmissions within 31-90 days of discharge from intermediate care 
(Table 3-11). However, having had at least one medication dose changed was found to 
significantly reduce the number of readmissions (OR = 0.60, 95% CI 0.36, 0.98, p = .042). Each 
additional hospital admission in the 12-month period prior to the index admission increased 
the number of unplanned hospital admissions in the 31 to 90-day post-IC discharge period 
1.31-fold (95% CI 1.17, 1.48).  
Table 3-11: Poisson regression of count of number of readmissions within 31-90 days of IC discharge (N = 414) 
Variables Estimate  SE OR (95% CI) p 
MAI difference -.001 .015 1.00 (0.97, 1.03) .966 
Age .015 .016 1.02 (0.98, 1.05) .366 
Sex (ref: male)     
Female  -.055 .262 0.95 (0.57, 1.58) .835 
Medicines management (ref: independent)     
Some assistance or prompting .453 .690 1.57 (0.41, 6.08) .512 
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Informal assistance from relative/friend/carer -.079 .273 0.92 (0.54, 1.58) .771 
Formal assistance package -.529 .520 0.60 (0.21, 1.63) .309 
Intermediate care length of stay (days) .006 .005 1.01 (0.99, 1.02) .215 
HSC Trust (ref: WHSCT)     
NHSCT .074 .353 1.08 (0.54, 2.15) .834 
Acute inpatient (ref: no) .071 .354 1.07 (0.54, 2.15) .841 
Number of hospital admissions in previous 12 
months 
.273 .060 1.31 (1.17, 1.48) <.001 
Original residence (ref: other)     
Own home -.418 .481 0.66 (0.26, 1.69) .386 
Medication stopped .050 .311 1.05 (0.57, 1.93) .871 
Medication initiated .388 .258 1.47 (0.89, 2.45) .133 
Blood tests requested .494 .299 1.64 (0.91, 2.95) .099 
Medicines information  -.989 .993 0.37 (0.05, 2.61) .319 
Dose changed -.520 .255 0.60 (0.36, 0.98) .042 
Referred to another HCP -.133 .432 0.88 (0.38, 2.04) .758 
Kardex issue addressed .341 .284 1.41 (0.81, 2.45) .229 
Education  .351 .446 1.42 (0.59, 3.40) .431 
Other intervention .049 .441 1.05 (0.44, 2.49) .911 
Fracture  -1.08 .297 0.34 (0.19, 0.61) <.001 
Anaemia -1.11 .749 0.33 (0.08, 1.43) .138 
Acute myocardial infarction .411 .388 1.51 (0.71, 3.23) .290 
Stroke -.632 .279 0.53 (0.31, 0.92) .024 
Cognitive impairment .491 .416 1.63 (0.72, 3.69) .239 
Falls -.173 .317 0.84 (0.45, 1.57) .584 
Urinary tract infection -.024 .426 0.98 (0.42, 2.25) .995 
Heart failure .104 .367 1.11 (0.54, 2.28) .777 
COPD -.086 .326 0.92 (0.49, 1.74) .792 
Pneumonia -.377 .403 0.69 (0.31, 1.51) .349 
Hypertension  .331 .240 1.39 (0.87, 2.23) .168 
Lower respiratory tract infection -.059 .432 0.94 (0.40, 2.20) .891 
Osteoarthritis -.283 .348 0.75 (0.38, 1.49) .416 
Renal failure .643 .318 1.90 (1.02, 3.55) .043 
Atrial fibrillation and flutter .281 .270 1.33 (0.78, 2.25) .298 
Type 2 diabetes mellitus .172 .316 1.19 (0.64, 2.21) .587 
Hip replacement -.056 .488 0.95 (0.36, 2.46) .908 
Ischaemic heart disease -.187 .295 0.83 (0.47, 1.48) .526 
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Diverticular disease -.358 .438 0.70 (0.30, 1.65) .414 
Malignancy  .322 .419 1.38 (0.61, 3.14) .442 
Osteoporosis  .504 .371 1.66 (0.80, 3.42) .174 
Hypothyroidism -1.00 .428 0.37 (0.16, 0.85) .019 
Depression  -.449 .458 0.64 (0.26, 1.57) .327 
Chronic kidney disease -.105 .441 0.90 (0.38, 2.14) .813 
Hypercholesterolaemia .707 .395 2.03 (0.94, 4.40) .074 
 
A previous medical history of a fracture resulted in significantly fewer unplanned 
readmissions in the 31 to 90-day period (OR = 0.34, 95% CI 0.19, 0.61, p < .001). Those who 
had a stroke or had been previously diagnosed with hypothyroidism were also found to have 
significantly fewer readmissions during this time period. Renal failure increased the number of 
readmissions within 31-90 days of IC discharge 1.9-fold.  
Magnitude of MAI total score change was not significantly associated with the number 
of unplanned readmissions within 90 days of IC discharge (Table 3-12).  When readmissions in 
both time periods were aggregated none of the clinical intervention types predicted the 
number of unplanned admissions in the three months following IC discharge. Baseline levels of 
hospitalisation were again found to positively predict the number of unplanned readmissions 
in the monitoring period. Each additional previous admission increased the number of 
unplanned readmissions 1.24-fold (95% CI 1.13, 1.37). When readmissions information was 
aggregated only a previous medical history of fracture or hypothyroidism significantly 
predicted number of unplanned readmissions. No significant association was observed for 
stroke or cognitive impairment.  
Table 3-12: Poisson regression of count of number of readmissions within 90 days of IC discharge (N = 424) 
Variables Estimat
e  
SE OR (95% CI) P 
MAI score difference .001 .011 1.00 (0.98, 1.02) .896 
Age -.001 .013 1.00 (0.98, 1.02) .949 
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Sex (ref: male)     
Female  .228 .196 1.26 (0.86, 1.85) .245 
Medicines management (ref: independent)     
Some assistance or prompting .259 .466 1.30 (0.52, 3.23) .578 
Informal assistance from relative/friend/carer -.175 .214 0.84 (0.55, 1.28) .411 
Formal assistance package -.792 .404 0.45 (0.21, 1.00) .050 
Intermediate care length of stay (days) .002 .004 1.00 (0.99, 1.01) .664 
Trust (ref: WHSCT)     
NHSCT .127 .292 1.14 (0.64, 2.01) .664 
Acute inpatient (ref: no) -.194 .275 0.82 (0.48, 1.41) .479 
Number of hospital admissions in previous 12 months .215 .049 1.24 (1.13, 1.37) < .001 
Original residence (ref: other)     
Own home -.186 .368 0.83 (0.40, 1.71) .613 
Medication stopped .051 .218 1.05 (0.69, 1.61) .816 
Medication initiated .345 .203 1.41 (0.95, 2.10) .088 
Blood tests requested .197 .265 1.22 (0.73, 2.05) .456 
Medicines information  .457 .504 1.58 (0.59, 4.24) .364 
Dose changed -.237 .202 0.79 (0.53, 1.17) .239 
Referred to another HCP -.172 .302 0.84 (0.47, 1.52) .568 
Kardex issue addressed .179 .217 1.20 (0.78, 1.83) .409 
Education  -.358 .358 0.70 (0.35, 1.41) .317 
Other intervention .427 .291 1.53 (0.87, 2.71) .142 
Fracture  -.779 .233 0.46 (0.29, 0.73) .001 
Anaemia -.282 .379 0.76 (0.36, 1.59) .457 
Acute myocardial infarction .439 .313 1.55 (0.84, 2.87) .161 
Stroke -.496 .254 0.61 (0.37, 1.00) .051 
Cognitive impairment .565 .320 1.76 (0.94, 3.30) .077 
Falls -.176 .255 0.84 (0.51, 1.38) .489 
Urinary tract information .418 .254 1.52 (0.92, 2.50) .099 
Heart failure .308 .343 1.36 (0.70, 2.66) .369 
COPD -.163 .247 0.85 (0.52, 1.38) .509 
Pneumonia .003 .257 1.00 (0.61, 1.66) .990 
Hypertension  .112 .191 1.12 (0.77, 1.63) .557 
Lower respiratory tract infection .305 .327 1.36 (0.72, 2.58) .351 
Osteoarthritis -.093 .328 0.91 (0.48, 1.73) .776 
Renal failure .235 .281 1.27 (0.73, 2.19) .402 
Atrial fibrillation and flutter .288 .225 1.33 (0.86, 2.08) .202 
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Type 2 diabetes mellitus .204 .234 1.23 (0.78, 1.94) .383 
Hip replacement -.079 .428 0.92 (0.40, 2.14) .854 
Ischaemic heart disease -.245 .244 0.78 (0.49, 1.26) .316 
Diverticular disease -.387 .422 0.68 (0.30, 1.55) .359 
Malignancy  -.008 .368 0.99 (0.48, 2.04) .983 
Osteoporosis  .320 .309 1.38 (0.75, 2.52) .300 
Hypothyroidism -.685 .329 0.50 (0.26, 0.96) .038 
Depression  -.145 .337 0.87 (0.45, 1.67) .666 
Chronic kidney disease .139 .364 1.15 (0.56, 2.34) .702 
Hypercholesterolaemia .487 .365 1.63 (0.80, 3.32) .182 
 
The survival distributions for time to first readmission (days) for IC participants can be 
observed in Figure 3-2. A log-rank test of differences indicated that the survival distributions 
for those who had experienced a change in total MAI score (Mdn = 25) and those who did not 
(Mdn = 28) were not statistically significantly different, Χ2 (1) = .468, p = .494.  
 
Figure 3-2: Kaplan-Meier survival plot for time to readmission for intermediate care participants (N = 113) 
 
The degree of change in total MAI score was not a significant predictor of length of 
stay during the first unplanned hospital admission for IC participants (Table 3-13). A dosage 
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adjustment for at least one medication was associated with a reduced length of stay on 
readmission (ß = -.181, p = .015). A diagnosis of heart failure or previous medical history of an 
acute myocardial infarction was associated with a longer duration of admission. Previous 
medical history of pneumonia or a lower respiratory tract infection was associated with a 
shorter admission.  








MAI score difference .059 .050 .096 .603 
Age .078 .040 .106 .705 
Sex (ref: male)     
Female  4.454 .143 .122 .242 
Medicines management (ref: formal 
assistance package) 
    
Completely independent -6.099 -.205 .298 .492 
Some assistance or prompting -7.812 -.106 .112 .346 
Informal assistance from 
relative/friend/carer 
-2.199 -.069 .270 .800 
Intermediate care length of stay (days)  -.001 .070 .986 
HSC trust (ref: Western HSCT)     
Northern HSCT -4.379 -.149 .128 .243 
Acute care inpatient (ref: no) -1.430 -.033 .105 .751 
Number of acute admissions in the previous 
12 months  
-.174 -.025 .084 .761 
Original residence (ref: other)     
Own home -14.033 -.290 .155 .060 
Had a medication stopped -1.409 -.039 .096 .681 
Had a medication initiated 2.778 .094 .116 .417 
Blood tests requested -1.237 -.029 .098 .769 
Medicines information service 7.372 .121 .068 .075 
Dose changed -5.334 -.181 .075 .015 
Referred to another HCP 2.913 .072 .090 .424 
Kardex issue addressed -.074 -.002 .086 .978 
Education -6.143 -.121 .083 .143 
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Other intervention 1.130 .024 .087 .779 
Fracture  -6.091 -.184 .109 .093 
Anaemia -3.734 -.056 .073 .444 
Acute myocardial infarction 14.205 .318 .120 .008 
Stroke -.262 -.006 .088 .943 
Cognitive impairment -2.563 -.051 .118 .669 
Falls 1.506 .037 .107 .728 
Urinary tract infection 2.668 .067 .109 .536 
Heart failure 11.807 .312 .130 .017 
COPD 5.557 .156 .094 .097 
Pneumonia -6.620 -.137 .066 .037 
Hypertension  -1.621 -.055 .125 .661 
Lower respiratory tract infection -9.623 -.180 .083 .031 
Osteoarthritis 6.569 .136 .085 .109 
Renal failure 8.494 .229 .122 .059 
Atrial fibrillation and flutter -1.757 -.052 .104 .616 
Type 2 diabetes mellitus -5.996 -.183 .122 .133 
Hip replacement -1.083 -.016 .073 .824 
Ischaemic heart disease -1.989 -.049 .121 .686 
Diverticular disease -12.777 -.192 .099 .051 
Malignancy  2.845 .047 .090 .603 
Osteoporosis  5.161 .123 .076 .104 
Hypothyroidism 3.086 .064 .091 .484 
Depression  -4.721 -.093 .110 .396 
Chronic kidney disease 4.002 .093 .117 .428 




A total of 40 IC participants died during data collection. Twenty-one participants died 
during the index admission in intermediate care. Nineteen participants died during the 90-day 
monitoring period, six of whom died during an unplanned hospital readmission. No significant 




The present study sought to examine inappropriate prescribing within intermediate care 
in Northern Ireland, as well as to determine the effectiveness of a pharmacist case 
management model developed within the NHSCT and WHSCT at reducing this inappropriate 
prescribing. Previous studies have indicated that inappropriate prescribing is prevalent within 
this type of care setting (Bakken et al., 2012; Millar, 2016; Miller et al., 2016). 
The majority of IC participants (89.5%) experienced some degree of inappropriate 
prescribing, lending support to the need for pharmaceutical care services within intermediate 
care settings beyond the traditional ‘supply only’ function. Millar (2016) previously examined 
inappropriate prescribing among IC facilities in Northern Ireland using the STOPP/START 
criteria. It was found that 72% of patients had at least one inappropriate medication on 
admission, with 74% prescribed at least one inappropriate medication on discharge. 
Prescribing omissions were also highly prevalent, with 61% of patients having at least one 
potential prescribing omission on admission and 50% having at least one prescribing omission 
on discharge from intermediate care. Such findings highlight the requirement for clinical 
pharmacy services within intermediate care. The present study found that not only was 
inappropriate prescribing still highly prevalent in intermediate care facilities in Northern 
Ireland, but that the inclusion of a clinical pharmacist conducting person-centred medication 
reviews, aimed at addressed such poor prescribing practices, resulted in a significant reduction 
in suboptimal prescribing.  
Few studies that have examined inappropriate prescribing using MAI have provided any 
insight into the patient and environmental factors that are associated with high MAI scores. In 
the present study, no age or sex differences were observed in severity of inappropriate 
prescribing at baseline, for intermediate care participants. International evidence would 
suggest that inappropriate prescribing is more prevalent among females.  
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Jiron and colleagues (2016) previously found that females in the US had a 12% increased 
risk of being prescribed an inappropriate medicine when using the 2012 Beers’ Criteria as a 
screening tool. Using the same screening tool, Morgan, and colleagues (2016) found that 
Canadian females aged ≥ 65 years had 23% increased risk for receiving at least one potentially 
inappropriate medicine. An increased prevalence of inappropriate prescribing among Swedish 
females aged ≥ 60 years was also reported by Sköldunger, Fastbomm Wimo, Fraiglioni and 
Johnell (2015). Similarly, Morin et al., (2015) found in large sample of 1.3 million Swedish 
people aged ≥ 65 years that females were more likely to be exposed to inappropriate 
prescribing, irrespective of what screening tool was used to detect this suboptimal prescribing.  
Within the Northern Irish context, Bradley, and colleagues (2012) found that 
inappropriate prescribing, assessed using 28 STOPP indicators, was more likely to occur in 
females (OR 1.26, 95% CI 1.23-1.29), after adjusting for age and polypharmacy. In contrast, a 
study in the UK context, using 52 STOPP indicators, found that exposure to an inappropriate 
medication was less likely for females (OR 0.9, 95% CI 0.9-0.9) (Bradley et al., 2014). It has 
been suggested that prescribing omissions, the absence of a clinically indicated medication, 
may be more prevalent in males (Galvin et al., 2014),   
It is not surprising that a significant moderate positive correlation was observed 
between the number of prescribed medications and baseline MAI total score in intermediate 
care. A significant association between the number of prescribed medications and the 
likelihood of exposure to inappropriate prescribing has also been reported internationally 
using a variety of inappropriate prescribing screening tools (Hudhra et al., 2016; Jiron et al., 
2016; Morin et al., 2015). This association has been reported in a number of patient contexts 
including at hospital discharge (Hudhra et al., 2016), among community dwelling individuals 
(Galvin et al., 2014), and among those older people presenting to hospital following a fall 
(McMahon et al., 2014).  
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In the UK, Bradley et al., (2014) examined a cohort of over 1 million participants aged ≥ 
70 years in the UK Clinical Practice Research Datalink and found those who were prescribed ≥ 4 
medications were 18 times more likely to be exposed to an inappropriate medication 
compared with those prescribed 0-3 medications, when adjusted for age, gender and 
morbidity.  This study was conducted using 52 out of 65 STOPP criteria. When assessed in 
Northern Ireland using a smaller subset of STOPP (28 indicators), a significant association 
between polypharmacy (operationalised as ≥ 4 medications) and inappropriate prescribing was 
found. A linear trend between increasing levels of polypharmacy and likelihood of 
inappropriate prescribing was observed, with those who received seven medications five times 
more likely to be exposed to inappropriate prescribing compared with those who received 0-3 
medications.  
Pharmacist case management services to intermediate care settings was shown to result 
in significant improvement in prescribing appropriateness, with a large proportion of 
participants (>80%) showing a reduction in total MAI score of at least one point. Participant 
MAI total score reduced by an average of 15 points for IC participants, resulting in an almost 
negligible score of 0.41 at discharge from IC.   
A number of pharmacist intervention studies have examined inappropriate prescribing 
using the MAI. Hanlon et al., (1996) have previously shown that pharmaceutical care for older 
patients (≥ 65 years) in primary care significantly reduces MAI scores, and that this reduction is 
sustainable at 12 months. The inclusion of a specialist clinical pharmacist to an inpatient 
geriatric evaluation unit, to provide pharmaceutical care from the point of admission to 
discharge, also resulted in an increased likelihood for MAI score reduction (OR = 9.1, 95% CI 
4.2-21.6) compared with control (Spinewine, Swine, et al., 2007). Chiu et al., (2018) reported 
that pharmacist intervention in a geriatric unit of Hong Kong hospital resulted in a significant 
reduction in MAI scores for the intervention group compared with normal care. The present 
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findings extend those of previous studies by reporting evidence that pharmacist case 
management also results in a significant reduction in MAI scores in additional care settings 
such as intermediate care.  
Gillespie and colleagues (2013) conducted an RCT to examine the influence of an 
enhanced pharmacy service through the addition of a clinical pharmacist to the care team, in 
comparison with a control group where no pharmacist was involved in patient care. The 
intervention comprised of initial medication reconciliation, medication review, communication 
of drug-related problems to the physician, patient education, communication of the treatment 
plan to primary care and follow-up phone calls to the patient following discharge. As such their 
intervention bore some resemblance to that delivered by the case management pharmacists in 
the present study. The intervention reported by Gillespie et al., (2013) was standardised, but 
the medication review component did not involve the consistent use of any particular 
instrument. Retrospective assessments of prescribing appropriateness were made using 
STOPP, START and MAI. Between admission and discharge, MAI scores were found to improve 
in 60% of intervention participants compared with 11% of control group participants.  
In the present study, higher rates of improvement were reported in IC (approx. 80%) 
and may be as a consequence of the medication review component being structured around 
MAI. The MAI considers appropriateness of prescribing across 10 domains and its structured 
format can be used to guide subsequent pharmaceutical care plans. Within the Northern Irish 
context, Burnett and colleagues (2009) also found that incorporating assessments of 
prescribing appropriateness using MAI within the framework of Integrated Medicines 
Management led to a significant reduction in inappropriate prescribing when compared with 
standard pharmaceutical care.  
By examining the intervention types enacted by the case management pharmacists in 
the present study we have a clearer understanding of what may be a driver of MAI score 
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reduction, namely medication cessation, dosage changes and the alteration of Kardex related 
issues. There is evidence to suggest that providing medicines information to the clinical team is 
a somewhat passive strategy that limits the degree of MAI score change that may occur with 
other intervention types.  
We must also move beyond assuming that existing therapy has already been optimised 
in earlier care settings. A high proportion of those in intermediate care required some 
adjustment to their pharmacotherapy, which is notable given that for the most part this cohort 
had recently experienced an acute care admission. Kardex issues were frequently addressed in 
the IC sample which may point towards the persistence of medication-related problems 
following discharge from acute care. It has been reported that over 90% of patients have at 
least one medication-related problem following discharge from acute care (Basger, Moles & 
Chen, 2015; Ellitt, Engblom, Aslani, Westerlund & Chen, 2010). Integrated Medicines 
Management as an initiative to improve communication across the primary-secondary care 
interface has been shown to result in improved prescribing appropriateness (Burnett et al., 
2009). 
Most of the clinical interventions conducted by the case management pharmacists in 
the present study were self-rated to be clinically significant and resulted in an improvement in 
the care of the patient. Eadon (1992) in proposing the rating criteria used in the present study 
found that ratings of clinical significance did not differ between the pharmacist’s scores and 
those of three physicians. Vo et al., (2016) conducted a systematic review of tools used to 
assess potential significance of pharmacist interventions. All 133 tools identified were assessed 
for quality by the review authors based upon a framework that included setting, sampling, 
quality, and number of raters, rating method, reliability, and risk of bias. As part of their 
assessment Vo and colleagues concluded that the Eadon criteria were of high quality.  A 
previous study conducted examining pharmacist case management in intermediate care in 
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Northern Ireland found that 84% of interventions were self-graded as Eadon 4 and above 
(Miller et al., 2016). In this study a sample of ten of these gradings were independently 
reviewed by four consultant geriatricians for consistency. Reliability analysis indicated an 
excellent level of consistency between the ratings (Cronbach’s alpha coefficient 0.909), 
indicating that pharmacist self-ratings were congruent with that of consultant geriatricians.  
When considering the proportion of variability in MAI score change explained by a 
number of demographic and intervention variables, the change in the number of prescribed 
medications was the strongest predictor of MAI score change for IC participants. The greater 
the reduction in the number of medications prescribed at discharge, compared with at 
admission, the greater the difference in MAI score between both time points. For each 
discontinued medication, a MAI score reduction of 0.584 points was observed.  
A change in medication dosage was also a significant predictor of MAI score change for 
IC participants, indicating that inappropriate dosages contributed to MAI score calculation at 
baseline and highlighting the requirement for prescribers to be cognisant of the need for 
reduced medication doses for some older people. The location of the intermediate care site 
was also a significant predictor of MAI score change within intermediate care with those in the 
Northern HSCT experiencing a greater change in total MAI score. This finding is not surprising 
considering baseline total MAI scores for were higher for NHSCT intermediate care participants 
compared with WHSCT participants.  
A longer duration of stay in intermediate care also facilitated a greater reduction in 
MAI score change. Within Northern Ireland the goal of intermediate care is to prevent 
unnecessary hospital admission, promote recovery and support independent living. There is 
considerable debate as to the effectiveness of intermediate care as a model, owed largely to 
the varied conceptualisations of intermediate care in existence (Steiner, 2001; Melis et al., 
2004). These varied models have prevented firm conclusions from being drawn regarding the 
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effectiveness of intermediate care from preventing unnecessary hospital admission. 
Nevertheless, the present study indicates that improvements in prescribing appropriateness 
can be achieved for each additional day spent in intermediate care and given the relationship 
between inappropriate prescribing and adverse events, this is not a trivial finding.  
Additional clinical interventions explained variability in MAI score change, with having 
experienced at least one medication dosage change the second most significant predictor. 
Furthermore, having at least one Kardex issue addressed by the case management pharmacist 
was also a significant weak predictor of MAI score reduction. In contrast, merely providing a 
medicines information service to the clinical team was a significant negative predictor of MAI 
score change, indicating that the provision of clinical information was insufficient to improve 
medication appropriateness, and highlighting the importance of active interventions on the 
part of the pharmacist.  
Medication dosage and Kardex instructions may not have been contributing to 
baseline MAI scores in the first instance to the same level that the mere presence of a 
particular medication may have been. The MAI is a weighted questionnaire whereby the 
greatest weighting of 3 points is given to the use of a medication in the absence of a clinical 
indication. In terms of score calculation, a lack of indication would provide the same MAI score 
for a medication (3) as would the combination of an incorrect dosage (2) and inappropriate 
duration (1). In the development of the MAI weighting system Samsa and colleagues (1994) 
acknowledge that interpretation of MAI scores must also be considered in light of the 
individual item weightings.  
Overall, the magnitude of total MAI score improvement did not reduce healthcare 
resource utilisation. Despite a significant reduction in MAI total score, the magnitude of MAI 
score change did not predict the likelihood of experiencing a hospital readmission for IC 
participants. Furthermore, MAI score change was not predictive of time to readmission, with 
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no significant difference observed between those who experienced a change in total MAI score 
and those who did not.  
Similar findings have previously been reported by Chiu et al., (2018) following a 
prospective controlled study within a geriatric hospital unit setting. Two hundred and twelve 
participants were randomly allocated to receive usual care or pharmacist intervention. The 
intervention comprised of medication reconciliation, a medication review guided by MAI, and 
patient counselling. A significant reduction in MAI score was observed in the intervention 
group when compared with control. However, this reduction was not predictive of duration of 
inpatient stay or of inpatient mortality. Furthermore, no significant differences were observed 
in the number of ED attendances or mortality within one or three months of hospital 
discharge. In contrast, a previous systematic review and meta-analysis has suggested that 
pharmacist-led medication reconciliation services were associated with significant reductions 
in hospital readmissions (19%), ED visits (28%) and ADE-related hospitalisations (67%) 
(Mekonnen, McLachlan & Brien, 2016).  
In contrast to the present study, Chiu, and colleagues (2018) noted a significant 
reduction in the number of unplanned hospital admissions within one month, but not within 
three months of discharge following the index admission. It is not apparent whether the 
participants examined by Chiu and colleagues received any formal post-discharge care such as 
intermediate care. It is possible that differences in outcomes between the present study and 
the findings of Chiu and colleagues relates to the rehabilitative function of intermediate care, 
which may have served to reduce the likelihood for readmission for all participants irrespective 
of the degree of MAI score change observed.  
There is some evidence to suggest that intermediate care may be functioning 
effectively as a post-discharge care setting within NI. It was observed that those who entered 
IC from acute care were less likely to be readmitted to hospital within 30 days compared with 
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those who entered IC via another pathway, such as following a GP step-up request. Such a 
finding underscores the importance of intermediate care to encourage more clinical stability 
for older people. The high prevalence of inappropriate prescribing observed here and in the 
findings of Millar (2016) further emphasises the need for clinical pharmacist input in this care 
setting.  
Whilst the significant reduction in MAI score was not associated with a reduction in 
readmission potential for IC participants, pharmacist intervention showed some significant 
relationships with healthcare outcomes in this cohort. Those IC participants who received at 
least one education intervention had a reduced likelihood of hospital readmission, and a 
reduced number of hospital readmissions within 30 days of IC discharge, compared with those 
who did not receive this intervention type.  
Studies examining the impact of patient education by pharmacists on readmissions 
rates show mixed results. Bach, Peasah and Barber (2018) conducted a systematic review to 
examine the effectiveness of several pharmacist interventions on reducing hospital 
readmissions. Many of the studies reviewed focused on post-discharge patient education, 
either alone or in combination with medication reconciliation before discharge. Five of the 
education intervention studies included in the review were conducted among older 
populations, with two showing a reduction in readmissions (Al-Rashed, Wright, Roebuck, 
Sunter & Chrystyn, 2002; Briggs et al., 2015), two showing no impact (Krska et al., 2001; 
Nazareth et al., 2001) and one reported evidence of an increase in readmissions (Holland et al., 
2005). In the present study, patient education was an important factor, over and above 
improvements in prescribing appropriateness, highlighting that pharmacist interventions 
should not solely focus on a metric, such as MAI, but also on the qualitative nature of the 
intervention type.  
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Those IC participants who experienced at least one medication dosage change were 
found to spend five fewer days in acute care on readmission compared with those who did not 
have any medication dosage changes. Such a finding highlights the need to consider more than 
merely stopping existing medicines or starting new medicines, as advocated by explicit criteria 
such as STOPP and START. Optimising existing therapy whilst offsetting potential harm can be 
achieved through dosage reduction and MAI provides a metric within which this can be 
captured.  
Several pharmacist interventions within IC were found to be associated with increases 
in readmissions within the 30-day post-discharge period. Those IC participants who received a 
‘medicines information’ or ‘other’ intervention had significantly greater numbers of 
readmissions during this period. It could be argued that such intervention types may be too 
passive to have a real clinical impact for the patient. For example, providing a medicines 
information service to the prescriber may perhaps infer the continuation of a medication that 
may have not been entirely appropriate and thus may suggest the maintenance of a status quo 
for the patient.  
There is some evidence that targeted post-discharge follow up can be associated with 
increases in healthcare utilisation, and that this may indicate better chronic disease 
management. Rosstad et al., (2017) examined a new generic care pathway in Norway in 
comparison to a normal care control. The novel care pathway comprised of pre-discharge 
planning and coordination of care between the general hospital and primary care, with GP 
visits to support where required. During the 12-month follow up period it was found that those 
in the intervention group had more GP visits, with the authors hypothesising that GPs were 
taking an active role in the management of patients following acute care discharge. In the 
present study utilisation of primary care services by IC participants was not available, and the 
primary outcome recorded for this cohort was unplanned hospital readmission. Increases in 
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the number of readmissions within 30 days of IC discharge could not be seen to be a marker of 
increased primary care physician engagement but rather some element of clinical 
deterioration that required an acute care admission.  
Throughout the analyses presented here it was observed that previous levels of 
healthcare resource utilisation were a significant predictor in a large proportion of the 
analyses. The number of hospital admissions in the 12-month period prior to the index 
intermediate care admission was a consistent predictor of likelihood for readmission in all 
periods, and of numbers of readmissions and thus may serve as a marker of the relative clinical 
instability of some IC participants.  
It has been argued that intermediate care has been developed as a policy initiative, to 
ease pressures within other structures of the health service. Notwithstanding these arguments 
of its empirical origins and the challenges posed by various definitions of what intermediate 
care is, a universal theme is that this care setting should provide an opportunity for recovery 
and re-enablement of the patient with prolonged care needs following an acute care 
admission. This recovery should facilitate the patient to return to their preferred destination 
and in an effective intermediate care model they should not experience an avoidable hospital 
readmission.  
Within the present study those IC participants who had a previous medical history of a 
fracture exhibited a lower likelihood of readmission and fewer admissions within 90 days. 
Those with a clinical history of a stroke had fewer numbers of readmissions within the 31-90-
day period. These findings must be interpreted cautiously, as no information regarding the 
recency of diagnoses was available. Similarly, the primary diagnosis on admission to 
intermediate care was also not available. That said, common reasons for admission into 
intermediate care include fracture and stroke rehabilitation. Thus, if such were the case for 
intermediate care participants in the present study, this would suggest that intermediate care 
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is performing effectively within Northern Ireland, as reduced risk for readmission was 
observed with these diagnoses.  
Notably, those IC participants who had previously been diagnosed with cognitive 
impairment had significantly greater numbers of readmissions < 30 days, compared with those 
with no such diagnosis. Such a finding supports the existing literature that those older people 
living with dementia are at greater risk of an acute care admission. A systematic review by 
Toot et al., (2013) concluded that people with dementia had an increased risk of hospital 
admission compared with people without dementia. In particular, the likelihood for admission 
due to orthopaedic (Nourhashemi et al., 2001; Natalwala et al., 2008; Malone et al., 2009; 
Tuppin et al., 2009), respiratory (Carter & Porell, 2005; Natalwala et al., 2008; Sampson et al., 
2009; Tuppin et al., 2009) and urological (Carter & Porell, 2005; Natalwala et al., 2008; 
Sampson et al., 2009; Tuppin et al., 2009) crises was greater among people with dementia 
compared with those without.  
Several methodological limitations must be considered when interpreting the present 
study’s findings. Information pertaining to previous medical history did not indicate whether 
the various diagnoses were currently clinically relevant. The recency of diagnoses such as falls, 
fractures, or infective episodes could not be ascertained, limiting the inferences that may be 
drawn regarding the influence of morbidity on healthcare utilisation and outcomes. The 
absence of a matched control group prevents an assessment of the effectiveness of 
pharmacist case management in comparison with usual care. This is further compounded by 
the high proportion of participants who experienced a change in total MAI score. Maintaining 
adequate statistical power to examine outcomes such as healthcare resource usage in the 
post-intervention period is a challenge when most participants have experienced some degree 
of MAI score change.  
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Several limitations also relate to the use of the MAI. The implicit nature of the MAI 
means that the impact of clinical experience on the calculation of MAI scores cannot be 
eliminated. The possibility remains that regional differences in baseline MAI score may occur 
because of inter-individual differences among the case management pharmacists. Future 
research should seek to examine the impact of pharmacist experience, as well as investigating 
regional differences using multi-level modelling. The scoring process of the MAI is somewhat 
time consuming to apply. It has been estimated that it can take up to ten minutes to calculate 
the MAI score for one medication alone (Hanlon et al., 1992). Thus, within the context of the 
considerable polypharmacy evident within the present sample it could take up to 100 minutes 
to determine MAI scores for the patient who is prescribed ten medications. Luo, Scullin, 
Mullan, Scott and McElnay (2011) previously conducted a comparison of several tools to assess 
inappropriate prescribing and concluded that while the MAI was in their experience the most 
comprehensive tool to apply it also was the most time consuming. Furthermore, the weighting 
of MAI indictors was developed based on clinical relevance and does not account for what the 
patient may place importance upon.  
 
3.7 Conclusion 
In the present study it has been shown that inappropriate prescribing is highly prevalent 
among those aged ≥ 65 years who are cared for within IC in NI. No differences in baseline 
severity of MAI score was observed for age or sex.  Regional differences in baseline severity of 
prescribing inappropriateness was observed, which may warrant further examination in future 
studies.  
The majority of interventions delivered by the case management pharmacist were self-
rated to be clinically significant and resulting in improvements in the standard of care, with the 
most common interventions including medication discontinuation and dosage adjustment. 
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Pharmacist intervention was found to significantly improve appropriateness of 
pharmacotherapy, lending support to earlier pilot work and highlighting the need for 
continued involvement of clinical pharmacists in these contexts. Furthermore, the successful 
delivery of the care model was maintained when delivered by case management pharmacists 
who are supported and mentored by a consultant pharmacist.  
The present study also extends work conducted previously within IC in NI by examining 
the relationship between improved prescribing appropriateness and subsequent healthcare 
resource usage. The present study has shown that improvement in prescribing 
appropriateness, as indicated by the degree of change in total MAI score, was not significantly 
associated with a reduction in healthcare resource usage. Individual pharmacist intervention 
types such as patient education and medication dosage adjustments did show significant 
benefits in terms of reduced resource usage.  Several medical diagnoses showed significant 
relationships with increased healthcare resource usage including cognitive impairment, urinary 
tract infections, renal failure, and heart failure. Associations between reduced healthcare 
utilisation and previous medical history of stroke and fracture provide some tentative evidence 
that intermediate care is performing as an effective rehabilitative space in Northern Ireland.  
Furthermore, previous healthcare resource usage was a dominant predictor of 
healthcare utilisation which underscores the high level of clinical need among those patients 
who access IC in NI. Despite clear evidence that significant improvements in prescribing were 
achieved via case management approaches, multivariate analyses indicated that several 
patient level factors contribute to increased healthcare resource usage. The natural clinical 
course of some of these patient level factors is not always directly modifiable by the clinical 
pharmacist.  
Hospital admissions and healthcare resource usage is multifactorial. The multimorbid 
patient provides a level of complexity that is further augmented with older age, increased 
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levels of dependency and the impact that transitions of care have upon the older person. It 
could be argued that for the comorbid older person with a history of previous healthcare 
resource usage the goal of intervention may be to achieve a ‘steady state’ as opposed to 
absolute reductions in healthcare usage. With hospital readmission associated with 
considerable functional deficits a pharmacist case management intervention that is not related 






4 Healthcare utilisation following pharmacist case management 
of older adults in Care Homes in Northern Ireland 
 
4.1 Chapter overview 
This chapter begins by building on the literature discussed in the previous chapter (Chapter 3) 
through a discussion of inappropriate prescribing specifically within the context of care homes. 
The reader is reminded of the case management model developed for care homes in Northern 
Ireland (previously introduced in Chapter 2: Methodology). The effectiveness of this case 
management model is then examined in two ways. First, the degree of change in inappropriate 
prescribing, as assessed using MAI, from baseline to post-intervention is examined. Secondly, 
the proportion of variability in healthcare resource usage that is explained by changes in 
patient total MAI score is examined.  
4.2 Introduction 
Discharge from secondary care may result in admission into long term residential care 
for some older people.  Inappropriate prescribing is also a particular concern in this care 
setting. Estimates of inappropriate prescribing in care home settings are wide ranging from 27-
88% (Anrys et al., 2018; Cool et al., 2014; Elseviers, Vander Stichele & Van Bortel, 2014; 
Heppenstall et al., 2016; Lau, Kasper, Potter & Lyles, 2004; Ryan et al., 2013).  The variance in 
prevalence estimates may be related to the use of different screening tools or may relate to 
differences in healthcare contexts in different jurisdictions, for example in medication 
reimbursement and availability. Morin, Laroche, Texier and Johnell (2016), in their systematic 
review, found that pooled prevalence estimates for European studies was higher at 49% in 
comparison with 26.8% in the US. Thus, drawing inferences from the international literature 
may do little to inform of the incidence of the problem within the Northern Irish setting.  
Northern Ireland has a long history of integrated health and social care since the HPSS 
(NI) Order in 1973, which originally provided for the establishment of four Health and Social 
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Services Boards responsible for the provision of services (Bengoa, Stout, Scott, McAlinden & 
Taylor, 2016). In 2007, five new integrated Trusts, five Local Commissioning Groups, a smaller 
Health and Social Care Board and the Public Health Agency were established, with the Health 
and Social Care Board responsible for the commissioning of services (Bengoa et al., 2016). 
However, it has been reported that funding for social care has not been commensurate with 
health care funding and has not adapted in line with the increasing demand for services due to 
an ageing demographic (Dowds, McParland, Devine & Gray, 2012). Northern Ireland has the 
fastest growing ageing population within the United Kingdom (DHSSPSNI, 2011a). The Appleby 
Report (2011) identified that Northern Ireland has an additional 9% need in comparison to 
England and that a potential £1 billion gap in funding would have to be addressed. It is 
estimated that 62% of total spending on adult social care services in Northern Ireland is spent 
on older people’s care (Bengoa et al., 2016). In fact, 42% of HSC finances are spent on those 
aged over 65 years despite only occupying 14% of the population (Bengoa et al., 2016).  
The availability of healthcare services in Northern Ireland is limited by its ability to 
meet the demand placed upon services. Approximately two-thirds of acute hospital beds are 
occupied by those aged over 65 years (Bengoa et al., 2016) and approximately 9670 people 
aged over 65 years live in residential care or nursing homes (Bengoa et al., 2016).  An increase 
in demand creates additional pressures at both admission and discharge points. Between 
2010/11 and 2013/14 the number of hospital admissions increased by 48,000 and the number 
of outpatient appointments increased by 121,000 (DHSSPSNI, 2011a). Furthermore, based 
upon population projections it is estimated that by 2037 an additional 20,101 care packages 
will be required compared to 2016, which is an increase of 68% (Bengoa et al., 2016). 
The TYC report (DHSSPSNI, 2011a) sought to reset the balance of care within Northern 
Ireland to provide more community and home care services for those living with comorbidity, 
reducing the need for hospital-based interventions. The Commissioner for Older People 
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Northern Ireland (COPNI; 2017) argue that categorising long-term care as social care and not 
health care is a move towards shifting responsibility for cost of such services and an attempt to 
encourage people to make provisions for their own long-term care.  Entry into a care home 
environment usually occurs at the point where the individual cannot safely live at home due to 
increased functional dependency. In many instances this transition occurs at a point of crisis 
and as such the choice of care is often limited by the availability of places (COPNI, 2017).  
There are 483 registered care homes in Northern Ireland comprised of 248 nursing 
homes and 235 residential care homes (Health and Social Care Board Northern Ireland: 
HSCBNI, 2020a). The majority of these are independently owned with only five statutory 
nursing homes and 43 statutory residential homes on the register (HSCBNI, 2020a). A 
distinction is drawn between residential care and nursing home care. Residential care is 
comprised of residential accommodation with board and personal care provided for those in 
need of personal care. Nursing homes provide additional nursing care and some homes are 
registered to provide both residential and nursing care (HSCBNI, 2020a). Each HSCT has a 
capped amount for which it pays for residential care and if the selected care home charges 
more than this capped amount, the difference is paid for by the individual or their family 
(COPNI, 2017).   
The Care Standards for Nursing Homes sets out the criteria for registration and 
inspection of nursing homes as per the Nursing Homes Regulations (Northern Ireland) 2005 
(DHSSPS, 2015). These standards set the benchmark for care provision within the region with 
the aim of ensuring consistency of care irrespective of whether care is provided within the 
voluntary, independent, or statutory sector. There are 48 care standards in total and are 
categorised in relation to a number of key areas: before admission, quality of life, quality of 
care, quality of management, quality of the physical environment (DHSSPSNI, 2015). Whilst 
four of the 48 standards relate to medicines, they do not consider the wider aspects of 
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pharmaceutical care. Rather the standards only consider more logistical aspects such as 
medicines management, records, storage, and controlled drugs (DHSSPS, 2015).  Thus, there is 
an argument that there is room for improvement with respect to medicines optimisation 
within this care context.  
In addition to TYC (DHSSPSNI, 2011a), the 2016 publication of ‘Systems not structures: 
changing health and social care’ Expert Panel Report chaired by Prof. Bengoa made additional 
recommendations for service provision within NI (Bengoa et al., 2016). The Bengoa Report set 
out several key aims with respect to transformation of health and social care in NI. It 
advocated a move towards a proactive model, based on the needs of chronic patients, and 
that worked to ‘cure, care, and prevent illness’ (Bengoa et al., 2016, p. 39). It also encouraged 
a move towards active patient participation in self-management and the development of 
continuity of care that provided services in the right place for patients (Bengoa et al., 2016). In 
order to achieve this a move towards a multidisciplinary approach to primary care provision 
and away from a GP-led model of care was proposed. Thus, these two seminal reports set out 
a clear mandate for health and social care provision in Northern Ireland to adapt in order to 
fulfil the needs of the population it served.  
Further adaptation is required going into the future. As the Northern Irish population 
ages dementia will become a larger public health consideration, with numbers set to rise to 
60,000 by 2051 (DHSSPSNI, 2011b). This will demand a health and social care system that is 
responsive to the complex needs of older people who are likely to also be living with 
considerable multimorbidity. Safe, effective, person-centred care has been identified as a core 
value in the Dementia Strategy (DHSSPSNI, 2011b) and is an aspect that must be considered 
with respect to pharmaceutical care needs of the person living with dementia in a care home. 
Traditionally, access to pharmaceutical care is limited within care homes, as care home 
residents often do not have direct access to a pharmacist. Thus, it can be argued that residents 
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do not have the same opportunity as their community-dwelling counterparts to raise any 
concerns that they may be having with their medications.  
Chapter 1 and 2 outlined the challenges with prescribing for older people, the 
particular problem of inappropriate prescribing and the higher prevalence of inappropriate 
prescribing in care homes. Those care home residents with polypharmacy, history of falls and a 
neuropsychiatric disorder are more likely to receive inappropriate prescribing (Anrys et al., 
2018). High rates of inappropriate prescribing have been reported for people with dementia 
(PWD) (Hukins, Macleod & Boland, 2019; Parsons et al., 2012). Concerns have been raised 
regarding the use of psychotropic medications to control the behavioural and psychological 
symptoms of dementia (BPSD) in care home settings (Barry et al., 2015; Patterson et al., 2007; 
Renom-Giuteras et al., 2018). Psychotropic medications are those which can alter the mind, 
emotions, and behaviour and thus their use in BPSD may be considered a form of chemical 
restraint.  
In NI, the prevalence of psychotropic medication is higher among care home residents 
compared with community dwelling individuals (Maguire et al., 2013). An examination of 
administrative claims information found that the longitudinal increase in prescribing of 
psychotropic medication for those moving into a care home was greater than that seen in 
community-dwelling individuals over the same time period (Maguire et al., 2013). In fact, 
psychotropic prescribing increased sharply following admission into a care home (Maguire et 
al., 2013).  However, such a practice may not be as insidious as it sounds. Maguire and 
colleagues (2013) make the compelling argument that much of the inappropriate prescribing in 
care homes may be a continuation of the prescribing culture within primary care prior to 
admission, given that the patients’ GP remains the main prescriber to the individual whilst they 
are in a care home. There is evidence to suggest that suboptimal management of repeat 
prescriptions exists in Northern Ireland (McGavock, Wilson-Davis & Connolly, 1999).  
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Transition into long-term care is associated with a change in prescribing practices 
(Maguire, et al., 2013), and in many cases inappropriate pharmacotherapy is initiated, often in 
response to BPSD (Cornegé-Blokland, Kleijer, Hertogh & var Marum, 2012). The initiation of 
inappropriate medications in this care context may increase the risk for medication related 
harm, and thus subsequent interaction with healthcare services. There is also a concern that 
older care home residents may be presenting to Emergency Departments unnecessarily, with 
lack of access to primary care services cited as a contributory factor (Lemoyne et al., 2019).  
Clinical pharmacy services have shown positive impacts on healthcare outcomes 
within hospital and care home settings. Pharmacist-led interventions and medication reviews 
conducted in the general hospital inpatient population have shown reductions in emergency 
department visits and hospital readmissions (Christensen & Lundh, 2016; Ravn-Nielson et al., 
2018). For older people specifically, pharmacist-led interventions within the hospital context 
have been shown to reduce the hospital length of stay (Scullin et al., 2007; Scullin et al., 2011), 
emergency department visits and drug-related readmissions (Gillespie et al., 2013). Within the 
care home setting pharmacist intervention has been shown to result in a reduction in falls 
(Zermansky et al., 2006) and in the prescribing of psychoactive medications (Schmidt et al., 
1998). 
The MOOP care home model (refer to Chapter 2, Figure 2-2) was developed in the 
NHSCT and also reported similar improvements in prescribing appropriateness and annual 
drug cost savings as those delivered by the intermediate care model (McKee et al., 2016). 
Furthermore, a reduction in inappropriate attendances to ED were also noted. In the original 
development of the care home model outreach visits to care homes were conducted in 
conjunction with a consultant geriatrician. The model was found to be equally effective when 
delivered by pharmacists alone in comparison with the more human resource heavy 
collaboration with a consultant geriatrician (McKee et al., 2016; Miller, 2018). As a 
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consequence, the service evolved to one that was led by the pharmacist but included a facility 
for referral to a geriatrician when it was deemed medically necessary.  
The replication of the care home model within the WHSCT allowed for the opportunity 
to examine alternative models of communication with GPs. The original model developed in 
the NHSCT communicated clinical interventions and recommendations to GPs via letter. In 
addition to these letters of recommendation, the case management pharmacists within the 
WHSCT used teleconferencing and had direct access to the GP’s computer system to 
communicate clinical interventions. As the pharmacist case management models embed 
across Northern Ireland there is a need to develop a greater understanding of the nature and 
extent of inappropriate prescribing among older people in care homes.  
As previously outlined in Chapter 3, pharmacist case management significantly 
improved prescribing appropriateness in intermediate care, where pharmacist interventions 
were associated with a reduced likelihood of hospital readmission. The continual development 
of clinical pharmacy services for older people is warranted in light of the high prevalence of 
inappropriate prescribing identified. Given that inappropriate prescribing is known to be highly 
prevalent in care homes internationally, there is a clear need to understand the extent of the 
problem within the Northern Irish care home context. Furthermore, the associations between 
suboptimal prescribing and increased healthcare resource utilisation highlight the opportunity 
to identify if improvements in prescribing relate to reduced healthcare resource usage by care 
home residents. A reduction in hospital admissions and readmissions will provide for better 
capacity within the health service whilst avoiding the potential for decrements in physical 





• Describe the prevalence of inappropriate prescribing in Care Home settings in 
Northern Ireland, as assessed using MAI scores. 
• Calculate the change in total MAI scores from baseline to completion of pharmacist 
case management. 
• Establish the proportion of variability in MAI score change that is explained by a 
number of demographic and medication related factors. 
• Examine the proportion of variability in healthcare resource usage that is explained by 
total MAI score change and examine the patient-level covariates that are associated 
with this 
4.4 Methods 
4.4.1 Study population 
This study involved secondary data analysis of cross-sectional data collected by the 
MOOP pharmacists from 32 care homes in the Northern and Western HSCTs, between 2015 
and 2016. The CH sample comprised of 1095 individuals ranging in age from 65 to 102 years 
(M = 84, SD = 7.5). The sample characteristics can be observed in Table 2-1 in Chapter 2.  
4.4.2 Design and variables 
Similar to the design previously reported in Chapter 3, the present study involved 
secondary data analysis of data collected by the MOOP pharmacists in NHSCT and WHSCT. 
Initial data collection adopted a prospective design, with data captured by the clinical 
pharmacists at baseline and throughout the case management intervention. The prospective 
nature of data collection facilitated the determination of prevalence of inappropriate 
prescribing at baselines, as well as an assessment of how this prescribing changed during the 
course of the intervention. Data collection in the Care Homes (CH) sample was collected at the 
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point of first contact with the participant (baseline) and at the completion of the patient-
specific pharmaceutical care plan. Data were collected from 32 homes across both HSCTs. The 
breakdown of homes for each HSCT is as follows: WHSCT Southern Sector: nine homes; WHSCT 
Northern Sector: 10 homes; NHSCT: 13 homes. Further details regarding data collection can be 
found in Chapter 2.  
Demographic characteristics such as age, sex, bed type, and care home length of stay 
were examined in the present study. Additional demographic variables were also included to 
allow for a greater depth of patient-level analysis. The following variables were also 
considered: 
▪ Baseline origin: this binary variable outlined the source of admission into the 
care home. Those who were admitted into the care home from their own 
home were coded as ‘0’. Those who were admitted into CH from acute care 
were coded ‘1’. 
▪ Direct access to GP’s computer system: this binary variable was created using 
information from the ‘approach’ variable, which provided information on the 
communication method used to relay changes to the participant’s medications 
by the CH MOOP pharmacist. In the WHSCT a novel method of communication 
was being trialled where the CH MOOP pharmacist had direct real time access 
to the GP’s computer system and could directly enact changes to the 
medication record. This modification was done so that comparisons could be 
made with the previous communication methods conducted in NHSCT 
including a letter to the GP (with/without telephone follow up) or 
teleconference with GP. Where direct access was available this was coded as 
‘yes=1’ and where it was not available this was coded ‘no=0’.  
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▪ Received ACP: this binary variable (Y=1, N=0) reflected whether the 
participant had received advanced care planning.  
▪ Previously received IMM: this binary variable (Y=1, N=0) reflected whether 
the participant had received Integrated Medicines Management during their 
last inpatient admission to acute care. 
Clinical history information 
Details for up to ten previous medical diagnoses, coded according to ICD-10 criteria 
(WHO, 1992), were captured within the original dataset. Frequency counts for each of the ten 
medical history variables were completed using IBM SPSS Statistics for Windows 24 (IBM 
Corp., 2016) and consolidated using Microsoft Excel, for efficiency in tabulation. Binary 
variables (yes/no) were computed for the most frequently endorsed medical histories. These 
binary variables were then aggregated into higher order groups of similar diagnosis codes to 
ensure that no variable contained <5% of the sample population. The higher-order diagnoses 
examined Table 4-1.  
Table 4-1: Aggregated previous medical histories examined in the CH sample 
Higher order variable Diagnosis subtypes 
Fracture Fractured neck of femur 
 Fracture 
 Fractured pubic ramus 
 Fractured humerus 
 Fractured arm 
 Multiple fractures 
 Fractured hip 
 Fractured lumbar vertebrae 
 Fractured ribs 
Angina pectoris Angina pectoris 
Parkinson’s disease Parkinson’s disease 
Senile cataract Senile cataract 
Anaemia Iron deficiency anaemia 
 Vitamin b12 deficiency anaemia 
 Other anaemias 
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 Megaloblastic anaemia 
 Normochromic anaemia 
 Deficiency of another b group vitamin 
 Normocytic anaemia 
Stroke Cerebrovascular accident 
 Cerebral infarct 
 Subarachnoid haemorrhage 
 Intracerebral haemorrhage 
 Other cerebrovascular diseases 
 Cerebral aneurysm 
 Transient ischaemic attack and related syndromes 
 Stroke non-specified 
Acute myocardial infarction Acute myocardial infarction 
Cognitive impairment Cognitive impairment 
 Acute on chronic with Alzheimer’s background 
 Unspecified dementia 
 Vascular dementia 
 Memory loss 
 Alzheimer’s disease 
 Acute confusion 
 Age related memory loss 
Falls Falls 
 Fall involving other furniture 
 Increased frequency of falls 
Urinary tract infection Urinary tract infection?? 
 Recurrent urinary tract infection 
Heart failure Heart failure 
Chronic obstructive pulmonary disease (COPD) Other COPD 
Gastric Duodenal ulcer 
 GORD 
 Gastric ulcer 
 Gastritis and duodenitis 
 Peptic ulcer unspecified site 
Essential primary hypertension  Essential primary hypertension 
Osteoarthritis Osteoarthritis 
Renal failure Acute renal failure 
 Chronic renal failure 
Atrial fibrillation and flutter Atrial fibrillation and flutter 
Diabetes Type II diabetes 
 Non-insulin dependent diabetes 
 Type I diabetes 
 Insulin dependent diabetes 
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Chronic ischemic heart disease Chronic ischemic heart disease 
Diverticular disease of the intestine Diverticular disease of the intestine 
Malignancy Malignant neoplasm of stomach 
 Multiple myeloma and malignant plasma cell 
neoplasms 
 Malignant neoplasm of colon 
 Malignant neoplasm of bronchus and lung 
 Malignant neoplasm of breast 
 Malignant neoplasm of kidney except renal pelvis  
 Basal cell carcinoma 
 Lung cancer with bony metastases 
 Myeloid leukaemia 
 Myelodysplastic disorders 
 Malignant meninges uncertain 
 Malignant uncertain oral cavity 
 Malignant neoplasm of thyroid 
 Malignant neoplasm of spinal cord 
 Malignant neoplasm of ovary 
 Malignant neoplasm of oesophagus 
 Malignant neoplasm of the lip 
 Malignant neoplasms immunoproliferative 
disorders 
 Metastatic breast cancer 
 Malignant neoplasm of prostate 
 Malignant neoplasm of bladder 
 Basal cell carcinoma 
 Squamous cell papilloma 
 Malignant neoplasm of pancreas 
 Carcinoma in situ of skin 
 Diffuse non-Hodgkin’s 
 Malignant neoplasm of skin 
 Malignant neoplasm of cervix 
 Malignant neoplasm of vagina 
 Other and unspecified types of non-Hodgkin’s  
 Carcinoma in situ in oral cavity  
Osteoporosis Osteoporosis with fracture 
 Osteoporosis without fracture 
Hypothyroidism  
Depression  Depression with anxiety 
 Recurrent depressive episode 
 Depressive episode 
 Bipolar affective disorder 
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 Other mood disorder 
 Unspecified mood/affective disorder 
Chronic kidney disease  
Hypertensive heart disease  
Hypercholesterolaemia   
 
Healthcare utilisation outcome variables 
A total of fifteen outcome variables available within the care homes data were examined 
in the present study. Count variables included: 
▪ Number of GP call outs within 30 days 
▪ Number of GP call outs within 90 days 
▪ Number of OOH GP visits within 30 days 
▪ Number of OOH GP visits within 90 days 
▪ Number of ED visits not leading to an admission within 30 days 
▪ Number of ED visits not leading to an admission within 90 days 
▪ Number of unplanned hospital admissions within 90 days 
Binary variables were as follows: 
▪ Died within 30 days (No = 0, Yes = 1) 
▪ Died within 90 days (No = 0, Yes = 1) 
▪ Died between 31 and 90 days (No = 0, Yes = 1) 
▪ Unplanned hospital admission within 30 days (No = 0, Yes = 1) 
▪ Unplanned hospital admission between 31 and 90 days (No = 0, Yes = 1) 
▪ Unplanned hospital admission within 90 days (No = 0, Yes = 1) 
Continuous outcome variables included: 
▪ Length of stay on first unplanned hospital readmission (days) 
▪ Time to first unplanned readmission (days) 
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4.4.3 Data analyses 
Demographic and clinical characteristics are expressed in terms of mean (with 
standard deviation), median and proportions, as appropriate. Descriptive statistics were 
completed using IBM SPSS Statistics for Windows 24 (IBM Corp., 2016).  Frequencies of 
endorsement for prescribing in each BNF chapter subclassification and endorsement of 
previous medical history diagnoses were consolidated using Microsoft Excel for efficiency in 
tabulation.  
Prevalence of inappropriate prescribing at baseline was examined using participant 
Total MAI score. Kolmogorov-Smirnov and Shapiro- Wilks tests were conducted to examine the 
distribution of Total MAI score at baseline and following case management completion. Tests 
of normality indicated that participant Total MAI score at both time points were non-normally 
distributed.  Differences in mean Total MAI score at baseline were examined using Wilcoxon-
Signed rank tests for continuous variables and Chi square tests of independence for categorical 
variables. Total MAI score at baseline was categorised according to the following: 0; 1-18; 19-
36; 37-54; 55-72; >72 categories to examine the proportion of participants who had an 
increasing severity of inappropriate prescribing. Chi square tests of independence were 
conducted to examine differences between categorical demographic variables and MAI 
baseline category. The change in Total MAI score between both time points was examined 
using Wilcoxon-Signed Rank test.  
Linear regression analyses were used to determine the association between 
demographic and clinical variables and MAI total score change during the intervention. 
Multivariate regression analyses were conducted using Mplus 8.1 (Muthén & Muthén, 1998-
2018), using the maximum likelihood robust estimator (MLR) to account for multivariate non-
normality. This estimator provides a robust estimation of standard errors whilst accounting for 
non-normality of outcomes and non-independence of observations. These robust standard 
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errors are computed using a sandwich estimator (Muthén & Muthén, 1998-2017). Preliminary 
regression analyses in SPSS indicated that the data violated the assumption of 
homoscedasticity, necessitating the requirement for more robust estimation methods. Several 
demographic and clinical variables were entered into the predictive model. The regression 
coefficients, associated significance values and R2 were examined for each predictive model.  
Multivariate logistic regression analyses were completed for binary healthcare 
utilisation outcome variables using Mplus 8.1 (Muthén & Muthén, 1998-2018), using the 
maximum likelihood robust (MLR) estimator to account for multivariate non-normality. 
Poisson regression analyses were completed for count outcome variables using the robust 
estimator of the Generalized function within IBM SPSS Statistics for Windows 24 (IMB Corp., 
2016). Survival analyses were conducted for ‘time to readmission’ outcome variables using the 
Kaplan Meier function within IBM SPSS Statistics for Windows 24 (IMB Corp., 2016). 
Multivariate linear regression analyses were conducted for ‘length of stay on first unplanned 
readmission’ variables using Mplus 8.1 (Muthén & Muthén, 1998-2018), using the MLR 
estimator. Regression coefficients, odds ratios and associated confidence intervals, significance 
values and model fit statistics are reported for each predictive model.  
4.5 Results 
4.5.1 Care context 
The majority of CH participants occupied a ‘general nursing’ bed (n = 695). 
Approximately one quarter of the sample occupied an ‘elderly mentally impaired (EMI) bed’ (n 
= 283), with the remainder occupying a ‘residential’ bed (n = 117). Over half of CH participants 
(60.5%) entered the care home setting from their own home, with the remainder transitioning 
into their care home following hospital discharge. Almost half of care home participants had 
been resident in their care home for over two years when assessed by the case management 
pharmacists at baseline. Frequencies for length of residence categories for CH participants can 
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be observed in Table 4-2. Almost all CH participants (98.3%) were permanent residents within 
their care home. The remainder (1.7%) were resident on a short-stay or respite basis.   
Table 4-2: Frequencies for category of residence duration for CH participants (N = 1095) 
Length of residence n (%) 
<4 weeks 16 (1.5) 
4-12 weeks 58 (5.3) 
3-6 months 88 (8.0) 
6-12 months 159 (14.5%) 
1-2 years 247 (22.6) 
>2 years 527 (48.1) 
 
4.5.2 Medicines management 
A total of 3936 nervous system medications were prescribed for CH participants, with 
1067 participants prescribed at least one medication for the nervous system. The most 
frequently endorsed BNF chapter classification was for medications for the nervous system 
(refer to Chapter 2, Figure 2-4). The most frequently endorsed BNF chapter subclassification 
was ‘osmotic laxatives’ (Figure 4-1).  
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Higher mean numbers of medications were prescribed for participants in the CH 
sample (M = 12.08, SD = 4.75, range 1-32) compared with the IC sample (refer to Chapter 3: M 
= 10.68, SD = 4.14, range 1-24). Frequency of polypharmacy in CH can be observed in Table 2-2 
(refer to Chapter 2). The most frequently endorsed polypharmacy category for CH participants 
was 11-15 medicines.  
A total of 348 CH participants had previously received Integrated Medicines 
Management services whilst in acute care. A total of 235 CH participants had received some 
form of advanced care planning. At baseline, a total of 31 CH participants had been identified 
as high risk and referred to a consultant geriatrician for medical input. Fifty-nine participants 
were identified as requiring consultant pharmacist input by the case management pharmacist. 
For the CH participants the method of communication of medication related changes adopted 
by the case management pharmacists included a letter to the GP (n = 578), telephone 
conference with the GP (n = 3), a letter and follow up telephone call (n = 92) and real time 
access to the GP’s computer system (n = 422).  
4.5.3 Prescribing appropriateness at baseline 
 
The mean total MAI score at baseline was 14.87 (SD = 13.11), with 84.1% of CH 
participants reporting some degree of inappropriate prescribing at baseline. Frequencies of 
endorsement for total MAI score ranges can be observed in Table 4-1.  
Table 4-3: Frequencies for category of total MAI score at baseline for CH (N = 1088) 
Baseline total MAI category n (%) 
0 174 (15.9) 
1-18 575 (52.5) 
19-36 257 (23.5) 
37-54 69 (6.3) 
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55-72 12 (1.1) 
>72 1 (0.1) 
 
The Mann-Whitney test of differences indicated that the mean rank of baseline MAI 
total scores was significantly higher for WHCST (Mdn = 14) participants compared with the 
NHSCT participants (Mdn = 9), U = 114020, p < .001, r = .20.  The mean rank of baseline MAI 
total scores was also significantly higher for those participants for whom the case management 
pharmacist had direct access to the GP’s computer system (Mdn = 16) compared with those 
where such access was not available (Mdn = 9), U = 93208.5, p < .001, r = .28. No significant 
difference was observed in the mean ranks of baseline MAI total scores for males (Mdn = 12) 
and females (Mdn = 13), U = 116902.5, p = .204.  
A statistically significant weak association was observed between HSCT trust and MAI 
total score category at baseline, X2(5, N = 1088) = 44.07, p < .001, Cramer’s V = .20. A MAI 
baseline total score of 0 was more frequently observed for NHSCT participants. A MAI total 
score category of 37-54 was more frequently observed for WHSCT participants. A chi-square 
test of independence also revealed a significant weak to moderate association between direct 
access to the patient’s GP’s computer system and category of MAI total score at baseline, X2(5, 
N = 1088) = 92.04, p < .001, Cramer’s V = .28. A MAI total score of 0 at baseline was more 
frequently observed for those where no direct access was available. MAI total score categories 
of 19-36, 37-54 and 55-72 were more frequently observed for those participants where direct 
access was available.  
A significant weak association was observed between care home length of stay 
category and baseline MAI total score category, X2(15, N = 1088) = 42.26, p < .001, Cramer’s V 
= .11. Participants who had resided in a care home for less than six months were more 
frequently found to have a baseline category of 0. Those who had resided in a care home for 
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more than two years were more frequently found to have a baseline MAI total score in the 
range of 37 to 54. No significant association was observed for bed type and baseline MAI total 
score category, X2(10, N = 1088) = 14.10, p = .173. Similarly, no significant association was 
observed between age category and baseline MAI total score category, X2(20, N = 1088) 
=18.59, p = .549.  
A significant weak to moderate association was observed between polypharmacy 
category and baseline MAI total score category, X2(20, N = 1088) = 362.04, p < .001, Cramer’s V 
= .29. A baseline MAI score of 0 was more frequently observed for those prescribed between 0 
and 5 medications. Those who were prescribed 6-10 medications were more frequently 
observed to have MAI total scores of both 0 and 1-18 categories. Baseline total MAI scores of 
19-36 were more frequently observed for those prescribed between 11 and 15 medications. 
Those who were prescribed 16-20 medications were more frequently found to have baseline 
MAI total scores in the range of 19-36 and 37-54. Those who were prescribed more than 20 
medications at baseline were more frequently found to have a MAI total score category of 55-
72. Results of a Spearman correlation indicated that there was a significant positive association 
between the number of prescribed medications at baseline and baseline total MAI score rs = 
.538, p < .001.  
4.5.4 Case management intervention 
In the CH sample the number of clinical interventions recorded at baseline ranged 
from 0 to 12 (M = 2.68, SD = 1.99) with details relating to 2903 clinical interventions recorded 
at baseline. The frequency of participants who endorsed a minimum count of one for each 
clinical intervention type can be observed in Table 2-5 (refer to Chapter 2). The most 
frequently endorsed intervention was medication cessation (refer to Figure 2-7, Chapter 2), 
with 75% CH participants having had at least one medication stopped.  
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4.5.5 Prescribing appropriateness following pharmacist case management 
The majority of CH participants (82%) experienced a change in total MAI score from 
baseline (N = 1088). On average, CH participant total MAI score reduced by 14.17 points (SD = 
12.50, range 0-71) following pharmacist intervention. A Wilcoxon sign-rank test showed that 
CH participants experienced a statistically significant reduction in MAI total scores from the 
initial baseline assessment to the completion of the pharmaceutical care plan (Z= -25.97, p < 
.001).  
Table 4-4: Means and standard deviations for total MAI score at both time points for CH sample (N = 1088)  
 Time 1 
Baseline 
 Time 2 
Case management 
completion 
MAI total score 1088 14.87 (13.11)  1088 0.70 (2.04) 
Note. MAI total score missing for 7 CH participants at Time 2 
 
4.5.6 Explaining variability in MAI score change 
Linear regression was conducted to predict MAI score change in the care home setting 
with demographic, clinical history, and pharmacist intervention variables as independent 
variables. The model explained 51% of the variance in MAI score change. Age, sex, and 
baseline origin were not significant predictors of MAI score change in the care homes sample. 
As the WHSCT was investigating the impact of a novel method of communicating suggested 
interventions to care home resident’s prescriber, namely direct access to the GP’s computer 
system, it was not possible to examine both ‘HSCT’ and ‘GP direct access’ in the same 
predictive model. The inclusion of ‘GP direct access’ resulted in a significant contribution to 
explaining variability in MAI score change (ß = .187, p < .001).  
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Those who occupied a residential bed experienced a smaller MAI score change 
compared with those who occupied an EMI bed. No effect was observed for those occupying a 
general nursing bed. Those who were residing in their care home < 6 months and 6-12 months 
experienced a smaller MAI score change compared with the reference category, which was 
care home residence >2 years. No difference was observed for those CH participants who were 
resident between 1 and 2 years. Having received IMM during the previous acute care 
admission was associated with a smaller MAI score change. The number of prescribed 
medications at baseline was the strongest predictor of MAI score change (ß = .400, p < .001). 
Of the clinical interventions conducted by the case management pharmacists only medication 
discontinuation was a significant predictor of MAI score change (ß = .358, p < .001).  






Demographics    
Age .028 .017 .446 
Sex -.987 -.036 .090 
Baseline origin -.630 -.025 .267 
Direct access to GP’s computer system 4.819 .187 <.001** 
Bed type: elderly mentally impaired 
(reference) 
 - - 
General nursing .647 .025 .311 
Residential -2.373 -.059 .007* 
Clinical history    
Care home length of stay: >2 years 
(reference) 
 - - 
 Care home length of stay: <6 months  -1.679 -.047 .036* 
6 months – 1 year -1.698 -.048 .027* 
1-2 years -1.197 -.040 .077 
No. of acute care admissions in previous 
12 months 
.037 .003 .903 
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Received ACP .184 .006 .831 
Previously received IMM -2.449 -.091 .001** 
Baseline number of medications 1.059 .400 <.001** 
Pharmacist intervention    
Medication stopped 10.518 .358 <.001** 
Medication started .527 .013 .571 
Blood tests completed .701 .019 .423 
Medicines information -1.469 -.034 .051 
Medication dosage change .851 .032 .199 
Referral to another healthcare 
professional 
1.058 .020 .430 
Kardex issue addressed 1.567 .031 .154 
Other -.722 -.008 .708 
Note. *= p < .05; ** p < .001; ACP = advanced care planning; IMM= integrated medicines 
management  
 
4.5.7 Explaining variation in healthcare resources usage 
Baseline (pre-intervention) healthcare resource utilisation  
The number of unplanned hospital admissions in the 12 months prior to pharmacist 
intervention ranged from 0 to 11 (M = 0.66, SD = 1.12). Almost two-thirds of CH participants 
(62.3%) did not experience an unplanned hospital admission in the previous 12 months. 
Almost one-quarter (23.2%) experienced one unplanned hospital admission, 8.2% experienced 
two unplanned admissions and 3.9% experienced three unplanned hospital admissions in the 
preceding 12 months. The remainder of CH participants (2.4%) experienced between four and 
11 hospital admissions. No significant correlation was observed between MAI total score at 
baseline and the number of unplanned hospital admissions in the preceding 12 months (r = -
.045, p = .136). The average length of time since the last unplanned hospital admission was 
21.54 weeks (SD = 15.48, range 0-52, n = 445). Additional healthcare utilisation information at 
baseline was available for CH participants (Table 4-6).  
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Table.4-6: Descriptive statistics for pre-intervention healthcare resource utilisation by CH participants (N = 1089-
1095)  
 n M (SD) Range 
GP call outs previous 30 days 1091 0.27 (0.58) 0-4 
GP call outs previous 90 days 1089 0.66 (1.18) 0-12 
Out of hours GP call outs previous 30 days 1095 0.15 (0.45) 0-5 
Out of hours GP call outs previous 90 days 1095 0.42 (0.86) 0-7 
ED presentation previous 30 days 1091 0.07 (0.32) 0-6 
ED presentation previous 90 days 1091 0.18 (0.54) 0-6 
Unplanned hospital admissions previous 30 days 1095 0.08 (0.30) 0-2 
Unplanned hospital admissions previous 90 days 1094 0.18 (0.48) 0-4 
 
Hospital admission post-intervention 
A total of 110 CH participants experienced an unplanned hospital readmission within 
90 days of case management pharmacist review (Table 4-7). The duration of the first 
unplanned hospital readmission ranged between 1 and 95 days (M = 8.79, SD = 11.68, n = 110), 
with time to readmission found to range from 0 and 89 days (M = 42, SD = 25.22, n = 109). The 
number of unplanned hospital readmissions within 90 days ranged from 0 and 3 (M = 0.13, SD 
= 0.39, n = 1004).  
Table 4-7: Counts for hospital readmission for care home participants (N = 1095) 
 < 30 days 31-90 days Both time periods 0-90 days 
No 999 941 1079 894 
Yes 45 81 16 110 
Non-applicable 34 57 - 51 
Missing  17 16 - 40 
Note. Twenty-two CH participants died prior to completion of pharmacist review 
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Likelihood of unplanned hospital readmission for CH participants can be observed in 
Table 4-8. In order to obtain model identification for likelihood of readmission within the 30-
day period a reduced model was specified. The number of admissions to acute care in the 
preceding 12 months was the only significant predictor of likelihood of an unplanned 
admission within 30 days of pharmacist intervention. Each additional previous admission 
increased the likelihood of an unplanned admission by 38%. Likelihood of admission in each 
time period was significantly predicted by previous patterns of hospital admissions. 
 A care home length of stay of 1-2 years was significantly associated with a reduced 
likelihood of unplanned hospital admission in the 31-90 day when compared to a care home 
length of stay of <6 months. Those who occupied an EMI bed had increased odds of an 
unplanned admission within the 31-90-day period, compared with those who occupied a 
general nursing bed. Males had a significantly increased odds of readmission in the 0-90-day 
period post-intervention (OR = 1.75, 95% CI 1.07, 2.88, p = .027). Those CH participants with a 
previous medical history of diabetes were also an increased risk of an unplanned hospital 
admission in the three-month period following pharmacist intervention.   
Table 4-8: Multivariate logistic regression for predictors of unplanned hospital readmission for CH participants 
 N = 999 N = 974 N = 957 
 < 30 days 31-90 days < 90 days 
Variables Odds ratio (95% 
CI) 
p Odds ratio (95% 
CI) 
p Odds ratio (95% 
CI) 
p 
MAI difference 1.02 (0.99, 1.05) .285 0.99 (.96, 1.02) .378 1.00 (0.98, 1.03) .776 
Age 1.01 (0.97, 1.05) .734 1.04 (1.00, 1.08) .052 1.02 (0.99, 1.06) .183 
Sex (ref: female)       
Male  1.43 (0.74, 2.76) .291 1.64 (0.93, 2.89) .091 1.75 (1.07, 2.88) .027 
Bed type (ref: general)       
Residential bed 2.17 (0.95, 4.93) .065 1.35 (0.62, 2.92) .446 1.53 (0.79, 2.97) .211 
EMI bed 0.80 (0.35, 1.85) .608 2.11 (1.12, 3.94) .020 1.51 (0.87, 2.64) .146 
Care home length of 
stay (ref: < 6mths) 
      
6-12 months - - 1.07 (0.48, 2.39) .879 0.98 (0.47, 2.07) .983 
1-2 years - - 0.30 (0.18, 0.76) .011 0.46 (0.22, 1.01) .054 
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>2 years - - 0.61 (0.29, 1.29) .195 0.72 (0.37, 1.41) .336 
Baseline origin (ref: 
home) 
      
Hospital - - 1.18 (0.68, 2.04) .563 1.07 (0.67, 1.73) .774 
Received ACP  - - 0.51 (0.24, 1.08) .079 0.66 (0.35, 1.26) .204 
Received IMM  - - 0.83 (0.45, 1.53) .549 1.23 (0.72, 2.09) .445 
Access to GP computer  - - 1.29 (0.64, 2.60) .483 1.27 (0.67, 2.40) .461 
Number of admissions 
in 12 months  
1.38 (1.14, 1.67) .001 1.30 (1.07, 1.59) .009 1.27 (1.06, 1.53) .011 
Medication stopped 0.67 (0.27, 1.65) .385 1.05 (0.50, 2.24) .894 0.69 (0.36, 1.32) .266 
Medication initiated 2.20 (0.98, 4.97) .058 2.04 (0.99, 4.19) .052 2.28 (1.24, 4.20) .008 
Blood tests requested 0.88 (0.34, 2.29) .798 0.75 (0.34, 1.68) .488 0.78 (0.38, 1.59) .496 
Dose changed 1.25 (0.64, 2.44) .518 1.14 (0.67, 1.99) .638 1.27 (0.79, 2.05) .327 
Referred to another 
HCP 
2.10 (0.78, 5.65) .141 1.58 (0.62, 3.99) .337 1.58 (0.70, 3.55) .268 
Kardex issue addressed 0.89 (0.25, 3.10) .848 0.75 (0.24, 2.41) .633 0.64 (0.23, 1.81) .402 
Medicines information 1.78 (0.68, 4.65) .239 0.92 (0.38, 2.24) .858 0.70 (0.30, 1.64) .408 
Other intervention 2.56 (0.54, 12.28) .235 2.40 (0.60, 9.71) .218 1.98 (0.51, 7.68) .326 
Fall  - - 1.22 (0.57, 2.59) .611 0.99 (0.49, 2.00) .973 
Essential primary 
hypertension 
- - 0.77 (0.41, 1.45) .417 0.77 (0.44, 1.33) .346 
Diverticular disease - - 0.54 (0.17, 1.67) .284 1.09 (0.49, 2.43) .839 
CKD - - 1.86 (0.91, 3.78) .088 1.48 (0.78, 2.79) .228 
Cognitive impairment - - 0.68 (0.39, 1.19) .171 0.97 (0.60, 1.58) .908 
Atrial 
fibrillation/flutter 
- - 1.23 (0.63, 2.37) .544 1.17 (0.65, 2.11) .592 
Osteoarthritis - - 0.41 (0.15, 1.07) .068 0.49 (0.22, 1.08) .076 
IHD - - 1.11 (0.54, 2.31) .775 0.88 (0.46, 1.69) .669 
Heart failure - - 1.33 (0.65, 2.76) .439 1.37 (0.73, 2.59) .331 
Hypercholesterolaemia - - 1.16 (0.50, 2.67) .736 1.31 (0.65, 2.65) .455 
Other COPD - - 2.00 (0.97, 4.13) .061 1.80 (0.95, 3.42) .072 
Acute MI - - 1.15 (0.49, 2.66) .750 0.92 (0.42, 2.02) .837 
Osteoporosis  - - 0.93 (0.43, 2.01) .855 1.08 (0.56, 2.09) .820 
Hypothyroidism - - 1.43 (0.71, 2.88) .319 1.47 (0.79, 2.71) .223 
Diabetes  - - 1.52 (0.84, 2.76) .166 1.71 (1.02, 2.86) .041 
HHD - - 0.69 (0.29, 1.64) .407 0.74 (0.36, 1.53) .413 
Renal failure - - 0.86 (0.34, 2.20) .760 1.26 (0.59, 2.73) .549 
Stroke - - 1.32 (0.76, 2.28) .331 1.51 (0.94, 2.42) .090 
Parkinson’s disease - - 0.23 (0.03, 1.77) .159 0.28 (0.06, 1.24) .093 
Senile cataract - - 0.54 (0.15, 1.99) .356 0.77 (0.27, 2.16) .614 
Gastric - - 1.25 (0.51, 3.06) .632 1.48 (0.70, 3.11) .305 
Angina pectoris - - 2.31 (1.02, 5.24) .045 1.67 (0.77, 3.63) .195 
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Depression - - 0.81 (0.40, 1.62) .547 0.77 (0.42, 1.42) .403 
Malignancy  - - 0.96 (0.44, 2.09) .925 1.26 (0.65, 2.43) .489 
Note. EMI = elderly mentally impaired; ACP = advanced care planning; IMM = integrated medicines management; 
CKD = chronic kidney disease; IHD= ischemic heart disease; COPD = chronic obstructive pulmonary disease; HHD = 
hypertensive heart disease; anaemia removed to allow for model identification; - = parameter removed to allow for 
model identification 
 
Time to readmission  
The survival distributions for time to first readmission (days) for CH participants can be 
observed in Figure 4-2. A log-rank test of differences indicated that the survival distributions 
for those who had experienced a change in total MAI score (Mdn = 42) and those who did not 
(Mdn = 34) were not statistically significantly different, Χ2 (1) = .247, p = .619.  
 
Figure 4-2: Kaplan-Meier survival plot for time to readmission for care home participants (N = 108) 
Length of stay on first readmission 
Change in participant total MAI score was significantly associated with a reduction in 
length of stay on the first unplanned readmission following pharmacist intervention (ß = -.265, 
p = .016). For each unit reduction in total MAI score a reduction in length of stay of 0.24 days 
was observed. Those who occupied a residential bed (ß = .224, p = .017) had a longer duration 
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of readmission in comparison with those who occupied a general nursing bed. Care home 
length of stays between 1-2 years and >2 years were also found to be significantly associated 
with longer readmissions than for those CH participants who had a length of stay of <6 
months. The number of previous hospital admissions had no significant relationship with the 
duration of unplanned hospital admission following pharmacist case management (ß = .089, p 
= .323).  
 
Table 4-9: Multivariate linear regression of predictors of length of stay (days) during first unplanned readmission for 








MAI score change -.243 -.265 .111 .016 
Age .150 .090 .088 .304 
Sex (ref: female)     
Male  .557 .023 .085 .786 
Bed type (ref: general nursing bed)     
Residential bed 7.223 .224 .094 .017 
EMI bed 4.408 .164 .090 .069 
Care home length of stay (ref:  <6 
months) 
    
6-12 months .551 .019 .088 .833 
1-2 years 11.156 .338 .123 .006 
>2 years 6.142 .256 .113 .023 
Baseline origin (ref: own home)     
Hospital .947 .040 .082 .629 
Received ACP  5.636 .193 .115 .094 
Received IMM  5.015 .208 .114 .068 
Direct access to GP computer system  5.082 .213 .123 .083 
Number of admissions in the previous 12 
months 
.764 .089 .090 .323 
Medication stopped 5.508 .200 .075 .007 
Medication initiated -1.984 -.066 .094 .486 
Blood tests requested 4.048 -.113 .108 .299 
Dose changed .361 .015 .075 .844 
Referred to another HCP 2.234 .058 .107 .591 
Kardex issue addressed 2.948 .053 .070 .447 
Medicines information -9.097 -.204 .110 .064 
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Other intervention -17.562 -.247 .096 .010 
Fall  -12.190 -.327 .121 .007 
Essential primary hypertension 2.203 .081 .100 .418 
Diverticular disease -.132 -.003 .106 .977 
CKD 6.543 .217 .104 .037 
Cognitive impairment 2.791 .117 .077 .130 
Atrial fibrillation/flutter -5.337 -.189 .100 .080 
Osteoarthritis 2.000 .045 .077 .563 
IHD .666 .020 .109 .857 
Heart failure -1.532 -.050 .098 .612 
Hypercholesterolaemia .119 .003 .112 .976 
Other COPD -3.753 -.122 .077 .115 
Acute MI .201 .005 .075 .947 
Osteoporosis  1.897 .058 .071 .420 
Hypothyroidism .987 .031 .097 .746 
Diabetes  .751 .030 .088 .737 
Hypertensive heart disease -1.635 -.051 .097 .599 
Renal failure -2.850 -.077 .090 .394 
Stroke 1.730 .071 .087 .418 
Parkinson’s disease 1.276 .015 .094 .875 
Senile cataract 15.186 .273 .182 .134 
Gastric -1.751 -.045 .078 .560 
Angina pectoris 4.651 .120 .120 .317 
Depression .428 .013 .068 .848 
Malignancy  -2.199 -.065 .083 .435 
 
Improvements in MAI total score was predictive of a decreased length of stay on first 
unplanned admission (ß = -.265, p = .016). Each unit reduction in MAI total score was 
associated with a reduction in admission duration of 0.24 days. Those CH participants who had 
at least one medication discontinued had a significantly longer duration of admission than 
those participants who did not have a medication stopped (ß = .200, p = .007). Having received 
a pharmacist intervention considered as ‘other’ was associated with a significantly shorter 
length of stay on readmission (ß = -.247, p = .010). Participants who had a previous medical 
history of a fall were also found to have a significantly shorter admission compared with those 
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CH participants who had no previous medical history of a fall (ß = -.327, p = .007). Those with 
chronic kidney disease had a longer duration of readmission (ß = .217, p =.037).  
Additional healthcare resource utilisation  
Information relating to additional healthcare resources was available for CH 
participants including GP call outs to the care home, out of hours GP call outs and ED 
presentations not leading to a hospital readmission was also recorded. Significant reductions in 
numbers of GP visits (t = 3.968, p < .001, n = 996), as well as out-of-hours GP visits (t = 4.126, p 
< .001, n = 1004) within 90 days of pharmacist intervention were observed. Significant 
reductions in ED visits in both periods were also observed.  
Table 4-10: Descriptive statistics, t values and associated significance values for pre- and post-intervention 
comparison of healthcare resource usage by care home residents 
Note. *= p < .05; ** p < .001 
Each additional unit reduction in MAI score was associated with a 1.02-fold increase in 
the number of GP call outs to the care home within 30 days of intervention (Table 4-11). 
However, this effect was not observed during the 90-day monitoring period. Integrated 
medicines management (IMM) resulted in significantly fewer care home GP call outs within 30-





GP call outs 30 days 1050 .26 (.56) .22 (.55) 1.631 .103 
GP call outs 90 days 996 .63 
(1.14) 
.47 (.84) 3.968 <.001** 
Out of hours GP call outs 30 days 1055 .14 (.45) .15 (.44) -.367 .714 
Out of hours GP call outs 90 days 1004 .41 (.86) .28 (.69) 4.126 <.001** 
ED presentation 30 days 1050 .07 (.32) .04 (.21) 2.141 .033* 
ED presentation 90 days 995 .16 (.52) .12 (.36) 2.342 .019* 
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days and 90-days of pharmacist intervention.  Baseline levels of healthcare utilisation 
significantly predicted the number of GP call outs within both time periods. Each GP call out in 
the 30 days before first contact with the case management pharmacist increased the number 
of subsequent GP call outs by 54%. Similarly, within the 90-day period it was observed that 
each GP call out in the 90 days prior to pharmacist intervention increased the number of GP 
call outs within 90 days by 18%.  
Table 4-11: Multivariate Poisson regression of predictors of number of GP call outs <30 and< 90 days for CH 
participants  
 N = 999 N = 947 
 <30 days <90 days 
Variables Odds ratio (95% CI) p Odds ratio (95% CI) P 
MAI difference 1.02 (1.01, 1.03) .002 1.01 (1.00, 1.02) .007 
Age 0.99 (0.97, 1.01) .250 1.00 (0.99, 1.02) .838 
Sex (ref: female)     
Male  1.36 (0.97, 1.91) .077 1.30 (1.01, 1.68) .046 
Bed type (ref: general nursing)     
Residential  1.57 (1.02, 2.44) .043 1.33 (0.93, 1.88) .115 
Elderly mentally impaired 0.80 (0.51, 1.26) .340 0.93 (0.67, 1.28) .643 
Care home length of stay (ref:  <6 
months) 
    
6-12 months 1.12 (0.63, 2.01) .697 0.96 (0.65, 1.41) .832 
1-2 years 0.80 (0.47, 1.37) .421 0.64 (0.44, 0.92) .017 
>2 years 0.89 (0.55, 1.44) .622 0.82 (0.59, 1.13) .213 
Baseline origin (ref: own home)     
Hospital  1.20 (0.86, 1.67) .295 1.02 (0.80, 1.30) .886 
Received ACP 1.51 (0.96, 2.73) .072 1.29 (0.90, 1.85) .162 
Received IMM  0.66 (0.44, 0.98) .041 0.74 (0.55, 0.98) .039 
Direct access to GP computer system  0.71 (0.49, 1.04) .077 0.77 (0.57, 1.05) .097 
Number of acute admissions in previous 
12 months 
1.14 (1.02, 1.27) .023 1.17 (1.08, 1.27) <.001 
Number of GP call outs (previous 30 
days) 
1.54 (1.28, 1.84) <.001 - - 
Number of GP call outs (previous 90 
days) 
- - 1.18 (1.12, 1.26) <.001 
Medication stopped 0.79 (0.51, 1.24) .309 0.99 (0.72, 1.35) .939 
Medication initiated 0.93 (0.55, 1.55) .767 1.11 (0.76, 1.62) .593 
Blood tests requested 0.60 (0.35, 1.02) .058 0.76 (0.53, 1.09) .134 
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Dose changed 1.00 (0.73, 1.26) .976 0.99 (0.78, 1.25) .931 
Referred to another HCP 1.36 (0.78, 2.36) .280 1.22 (0.82, 1.83) .328 
Kardex issue addressed 1.18 (0.70, 2.01) .537 0.94 (0.62, 1.43) .777 
Medicines information 1.03 (0.63, 1.69) .896 0.93 (0.64, 1.34) .682 
Other intervention 1.40 (0.60, 3.25) .434 1.31 (0.67, 2.55) .429 
Fracture - -   
Fall  1.56 (1.09, 2.25) .017 1.62 (1.25, 2.10) <.001 
Essential primary hypertension 0.92 (0.63, 1.35) .675 0.76 (0.56, 1.02) .065 
Diverticular disease 1.57 (0.97, 2.54) .064 1.46 (1.06, 2.02) .022 
CKD 1.79 (1.21, 2.63) .003 1.41 (1.03, 1.94) .034 
Cognitive impairment 0.92 (0.65, 1.30) .637 1.04 (0.80, 1.35) .776 
Atrial fibrillation/flutter 1.07 (0.73, 1.57) .721 1.04 (0.76, 1.42) .807 
Osteoarthritis 0.71 (0.45, 1.14) .159 0.91 (0.66, 1.27) .589 
IHD 1.20 (0.79, 1.83) .398 1.00 (0.72, 1.40) .997 
Heart failure 1.13 (0.73, 1.74) .594 1.06 (0.74, 1.51) .739 
Hypercholesterolaemia 0.70 (0.43, 1.14) .156 0.76 (0.52, 1.10) .140 
Other COPD 0.99 (0.65, 1.51) .948 1.08 (0.76, 1.53) .661 
Acute MI 0.96 (0.59, 1.57) .873 0.80 (0.54, 1.20) .276 
Osteoporosis  1.60 (1.08, 2.38) .020 1.40 (1.05, 1.87) .022 
Hypothyroidism 0.93 (0.62, 1.41) .742 1.11 (0.82, 1.50) .510 
Diabetes  0.94 (0.66, 1.32) .703 1.07 (0.82, 1.39) .613 
Hypertensive heart disease 0.84 (0.48, 1.47) .550 1.11 (0.73, 1.67) .632 
Renal failure 0.78 (0.45, 1.35) .371 0.82 (0.53, 1.28) .386 
Stroke 1.08 (0.78, 1.51) .639 1.07 (0.83, 1.39) .615 
Anaemia 0.58 (0.31, 1.08) .085 1.02 (0.69, 1.50) .921 
Parkinson’s disease 0.60 (0.34, 1.07) .086 0.74 (0.48, 1.14) .177 
Senile cataract 1.31 (0.78, 2.20) .301 1.07 (0.69, 1.67) .751 
Gastric 1.30 (0.70, 2.39) .410 0.87 (0.53, 1.42) .579 
Angina pectoris 1.19 (0.73, 1.96) .489 1.02 (0.70, 1.50) .917 
Depression 0.91 (0.60, 1.38) .672 0.95 (0.72, 1.26) .724 
Malignancy  0.67 (0.42, 1.07) .092 0.72 (0.51, 1.02) .062 
Note. Fracture omitted as redundant parameter (all individuals had a history of fracture) 
Each admission to acute care in the preceding 12 months was associated with a 14% 
and 17% increase in the number of GP call outs within 30 and 90 days, respectively. Those care 
home residents who occupied a residential bed experienced more GP call outs within 30 days, 
compared with those in a general nursing bed. Those with a care home length of stay between 
1-2 years had significantly fewer numbers of GP call outs within 90 days in comparison with 
those who had been resident within the care home for 6 months or less. A previous medical 
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history of a fall was associated with a 56% and 62% increase in the number of GP call outs 
within 30 days and 90 days, respectively. Similarly, chronic kidney disease and osteoporosis 
were both associated with greater numbers of GP call outs in both time periods. Diverticular 
disease was associated with an increased number of GP call outs within the 90-day period 
only.  
The magnitude of MAI score change was not a significant predictor of the number 
OOH GP visits by CH participants. Greater numbers of OOH GP call outs within 30 days were 
evident for those CH participants who occupied a residential bed in comparison with those 
who occupied a general nursing bed (Table 4-12). A care home length of stay of 1-2 years or >2 
years was associated with a reduced number of OOH GP call outs within 90 days of pharmacist 
intervention compared with a care home length of stay of <6 months. Blood tests ordered by 
the case management pharmacist was associated with a significant reduction in OOH call outs 
during both monitoring periods. The initiation of at least one medication and those who had 
been referred to another healthcare professional has significantly more OOH visits within 30 
days of pharmacist intervention. Baseline levels of healthcare resource utilisation variables 





Table 4-12: Poisson regression for number of Out of Hours (OOH) GP call outs to care home participants <30 and <90 
days of pharmacist intervention  
 N = 1004 N = 954 
 <30 days <90 days 
Variables Odds ratio (95% CI) p Odds ratio (95% 
CI) 
P 
MAI difference 1.02 (1.00, 1.03) .058 1.02 (1.00, 1.03) .020 
Age 1.00 (0.98, 1.03) .991 1.01 (0.99, 1.03) .483 
Sex (ref: female)     
Male  0.73 (0.46, 1.16) .181 1.09 (0.77, 1.53) .643 
Bed type (ref: general)     
Residential bed 1.75 (1.06, 2.86) .027 1.22 (0.82, 1.80) .334 
EMI bed 1.11 (0.69, 1.79) .669 1.22 (0.89, 1.68) .219 
Care home length of stay (ref: <6 
months) 
    
6-12 months 1.35 (0.76, 2.40) .305 0.88 (0.58, 1.35) .566 
1-2 years 0.63 (0.36, 1.10) .106 0.54 (0.36, 0.81) .003 
>2 years 0.75 (0.48, 1.18) .217 0.57 (0.40, 0.80) .001 
Baseline origin (ref: own home)     
Hospital 1.28 (0.88, 1.85) .200 1.16 (0.88, 1.52) .286 
Received ACP 0.64 (0.37, 1.11) .113 0.67 (0.45, 1.01) .053 
Received IMM  1.13 (0.70, 1.84) .619 1.01 (0.73, 1.41) .938 
Access to GP computer system  1.06 (0.64, 1.74) .833 1.13 (0.79, 1.61) .506 
Number of acute admissions in 
previous 12 months 
0.97 (0.80, 1.18) .971 1.10 (0.98, 1.22) .110 
Number of OOH call outs in previous 
30 days 
1.55 (1.24, 1.95) <.001 - - 
Number of OOH call outs in previous 
90 days 
- - 1.32 (1.21, 1.44) <.001 
Medication stopped 0.94 (0.55, 1.60) .814 1.02 (0.68, 1.53) .923 
Medication initiated 1.61 (1.03, 2.51) .037 1.20 (0.83, 1.74) .339 
Blood tests requested 0.34 (0.18, 0.63) .001 0.59 (0.39, 0.91) .016 
Dose changed 1.28 (0.85, 1.90) .235 1.05 (0.79, 1.40) .725 
Referred to another HCP 1.94 (1.15, 3.27) .013 1.27 (0.91, 2.07) .130 
Kardex issue addressed 0.85 (0.40, 1.81) .673 0.77 (0.43, 1.39) .391 
Medicines information 1.57 (0.89, 2.76) .117 1.08 (0.66, 1.28) .760 
Other intervention 0.96 (0.24, 3.86) .953 0.85 (0.30, 2.46) .766 
Fall  1.06 (0.65, 1.74) .821 0.71 (0.48, 1.06) .092 
Essential primary hypertension 0.86 (0.55, 1.34) .497 0.84 (0.59, 1.29) .316 
Diverticular disease 0.52 (0.23, 1.16) .110 0.98 (0.65, 1.48) .926 
CKD 1.99 (0.99, 2.56) .055 1.22 (0.83, 1.77) .313 
Cognitive impairment 1.21 (0.83, 1.77) .330 1.19 (0.88, 1.61) .270 
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Atrial fibrillation or flutter 1.21 (0.81, 1.81) .364 1.21 (0.86, 1.71) .270 
Osteoarthritis 1.03 (0.62, 1.70) .920 0.89 (0.56,1.42) .625 
Ischaemic heart disease 0.72 (0.43, 1.21) .212 0.88 (0.56, 1.40) .599 
Heart failure 0.99 (0.61, 1.60) .961 1.20 (0.80, 1.79) .376 
Hypercholesterolaemia 0.50 (0.27, 0.94) .030 0.59 (0.38, 0.92) .020 
Other COPD 1.25 (0.78, 2.00) .353 1.27 (0.84, 1.91) .264 
Acute MI 1.19 (0.60, 2.34) .616 0.88 (0.58, 1.35) .560 
Osteoporosis  1.99 (1.30, 3.04) .001 1.32 (0.95, 1.82) .097 
Hypothyroidism 1.30 (0.77, 2.19) .327 1.22 (0.83, 1.79) .321 
Diabetes  1.21 (0.74, 1.97) .441 1.17 (0.84, 1.61) .357 
Hypertensive heart disease 1.25 (0.72, 2.17) .425 0.73 (0.48, 1.12) .151 
Renal failure 1.19 (0.65, 2.16) .575 0.90 (0.58, 1.40) .648 
Stroke 1.22 (0.82, 1.82) .322 1.24 (0.94, 1.65) .134 
Anaemia  0.77 (0.39, 1.52) .458 1.36 (0.91, 2.03) .140 
Parkinson’s disease 0.85 (0.36, 1.99) .706 0.81 (0.45, 1.48) .500 
Senile cataract 0.45 (0.15, 1.38) .164 0.58 (0.28, 1.22) .153 
Gastritis, ulcer or GORD 1.48 (0.88, 2.51) .143 0.84 (0.54, 1.31) .446 
Angina pectoris 1.78 (0.91, 3.48) .092 1.64 (1.11, 2.42) .014 
Depression 0.60 (0.39, 0.93) .023 0.69 (0.46, 1.04) .075 
Malignancy  1.60 (1.00, 2.55) .048 1.62 (1.16 2.27) .005 
Note. Fracture omitted as redundant parameter 
Poisson regression models for ED visits which included the same predictors of interest 
as for GP and OOH GP call outs could not be identified within the data. The removal of 
previous medical history variables did not aid in model identification for either the <30 day or 
<90-day periods. A simplified model comprised of fewer demographic characteristics provided 
good fit to the sample data (Table 4-13). Those who occupied a residential bed had 
significantly greater numbers of ED visits within both periods, in comparison with those in a 





Table 4-13: Poisson regression for number of ED visits for CH participants <30 and < 90 days of pharmacist 
intervention  
 N = 1003 N = 951 
 <30 days <90 days 
Variables Odds ratio (95% CI) P Odds ratio (95% 
CI) 
P 
MAI difference 1.02 (0.99, 1.05) .251 0.99 (0.97, 1.01) .299 
Age 1.02 (0.98, 1.06) .352 1.00 (0.98, 1.03) .771 
Sex (ref: female)     
Male  1.46 (0.75, 2.84) .271 0.95 (0.60, 1.50) .835 
Bed type (ref: general)     
Residential bed 4.12 (2.01, 8.64) <.001 1.92 (1.13, 3.26) .016 
EMI bed 1.13 (0.48, 2.67) .773 0.94 (0.59, 1.50) .793 
Access to GP computer system  0.62 (0.32, 1.19) .150 0.73 (0.46, 1.14) .161 
Number of hospital admissions in 
previous 12 months 
1.27 (1.05, 1.53) .012 1.09 (0.96, 1.23) .180 
Number of ED visits in previous 30 
days 
1.25 (0.82, 1.89) .297 - - 
Number of ED visits in previous 90 
days 
- - 1.29 (1.07, 1.56) .007 
Medication stopped 0.78 (0.33, 1.83) .569 1.21 (0.71, 2.07) .483 
Medication initiated 1.41 (0.54, 3.71) .484 0.92 (0.46, 1.84) .815 
Blood tests requested 0.72 (0.24, 2.12) .545 0.78 (0.38, 1.62) .508 
Dose changed 1.42 (0.73, 2.75) .307 1.15 (0.74, 1.81) .535 
Referred to another HCP 1.04 (0.30, 3.65) .951 0.94 (0.33, 2.62) .898 
Kardex issue addressed 0.37 (0.06, 2.43) .303 0.32 (0.08, 1.28) .108 
Medicines information 1.69 (0.62, 4.56) .304 0.76 (0.36, 1.60) .471 




The degree of change in MAI total score was not significantly associated with 
likelihood of death for CH participants (Table 4-14). Similarly, none of the clinical intervention 
type variables had any significant predictive relationship with death. Those CH participants 
who had a previous medical history of a malignancy had an increased risk of death within 90 
days of pharmacist intervention (OR = 3.57, 95% CI 1.77, 7.19, p < .001). An increased risk of 
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death within 90 days was observed for those with a previous medical history of chronic kidney 
disease, atrial fibrillation or flutter, stroke, and depression.  
Table 4-14: Multivariate logistic regression for predictors of death for CH participants <90 days of pharmacist 
intervention (N = 1021) 
Variables Odds ratio (95% CI) P 
MAI difference 1.01 (0.98, 1.04) .557 
Age 1.03 (0.99, 1.08) .148 
Sex (ref: female)    
Male  1.98 (1.06, 3.72) .033 
Bed type (ref: general nursing bed)   
Residential bed 0.58 (0.19, 1.80) .349 
EMI bed 0.53 (0.24, 1.17) .115 
Care home length of stay (ref: <6 months)   
6-12 months 0.44 (0.15, 1.31) .141 
1-2 years 0.56 (0.21, 1.49) .242 
>2 years 0.82 (0.35, 1.94)  .654 
Baseline origin (ref: home)   
Hospital 1.25 (0.69, 2.27) .466 
Received ACP 2.29 (1.08, 4.83) .030 
Received IMM 1.07 (0.51, 2.22) .862 
Direct access to GP computer system  0.53 (0.22, 1.28) .159 
Number of acute admissions in previous 12 months 1.24 (0.95, 1.62) .118 
Medication stopped 0.62 (0.27, 1.40) .249 
Medication initiated 1.55 (0.64, 3.76) .331 
Blood tests requested 0.37 (0.12, 1.10)  .074 
Dose changed 1.28 (0.67, 2.46) .462 
Referred to another HCP 2.08 (0.69, 6.29) .196 
Kardex issue addressed 1.79 (0.63, 5.08) .276 
Medicines information 2.08 (0.85, 5.10) .111 
Other intervention - - 
Fall  0.17 (0.03, 0.84) .030 
Essential primary hypertension 0.84 (0.40, 1.65) .566 
Diverticular disease 0.59 (0.19, 1.84) .363 
Chronic kidney disease 2.30 (1.09, 4.85) .030 
Cognitive impairment 1.35 (0.73, 2.49) .334 
Atrial fibrillation or flutter 2.21 (1.12, 4.38) .023 
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Osteoarthritis 1.78 (0.85, 3.71) .125 
Ischaemic heart disease 0.84 (0.34, 2.07) .701 
Heart failure 1.10 (0.48, 2.49) .825 
Hypercholesterolaemia 0.58 (0.19, 1.84) .357 
Other COPD 0.85 (0.32, 2.28) .752 
Acute MI 0.21 (0.03, 1.62) .133 
Osteoporosis  0.61 (0.23, 1.62) .322 
Hypothyroidism 0.92 (0.39, 2.18) .847 
Diabetes  0.64 (0.31, 1.31) .220 
Hypertensive heart disease 1.19 (0.46, 3.05) .722 
Renal failure 0.90 (0.31, 2.66) .851 
Stroke 1.90 (1.05, 3.41) .033 
Parkinson’s disease 0.55 (0.12, 2.58) .450 
Senile cataract 0.64 (0.13, 3.11) .583 
Gastric 1.02 (0.37, 2.85) .698 
Angina pectoris 2.15 (0.82, 5.63) .117 
Depression 2.34 (1.18, 4.62) .014 
Malignancy  3.57 (1.77, 7.19) <.001 
Note. Other intervention not included to allow for model identification 
 
4.6 Discussion 
The present study sought to examine inappropriate prescribing within the Northern 
Irish care home context, to determine the effectiveness of pharmacist case management in 
reducing this inappropriate prescribing as well as an examination of the relationship these 
improvements had with subsequent healthcare usage within this cohort. Inappropriate 
prescribing was found to be highly prevalent (84%) within NHSCT and WHSCT care homes, 
when assessed using MAI, thereby extending the international literature that indicates care 
homes as a critical location to focus medicines optimisation efforts (Anrys et al., 2018; Cool et 
al., 2014; Elseviers et al., 2014; Heppenstall et al., 2016; Maguire et al., 2013; McKee et al., 
2016; Lau et al., 2004; Ryan et al., 2013). 
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When comparing the prevalence of inappropriate prescribing in care homes in the 
present study to published studies it is somewhat challenging to draw direct comparisons, 
given the wide variety of screening tools reported within the literature. Reported prevalence 
estimates are wide ranging, reporting values from 27-88% (Anrys et al., 2018; Cool et al., 2014; 
Elseviers et al., 2014; Heppenstall et al., 2016; Lau et al., 2004; Ryan et al., 2013). Furthermore, 
a recent systematic review has suggested that point prevalence estimates are higher in 
European contexts (49%) compared with North America (27%) (Morin et al., 2016). Morin and 
colleagues (2015) compared the performance of five different sets of criteria used to detect 
inappropriate prescribing among a sample of over 1.3 million Swedish people aged ≥ 65 years. 
Prevalence estimates ranged from 16-24 % dependent on the screening tool applied. Those 
who were resident in a nursing home were more likely to be exposed to inappropriate 
prescribing irrespective of which screening tool that was applied to the sample data. 
Nevertheless, despite the challenges in making direct comparisons across studies, it is 
apparent that the prevalence of inappropriate prescribing in Northern Irish care homes is 
towards the upper end of the scale.  
Several studies have examined inappropriate prescribing in care home settings using 
MAI. Crotty, Halbert, et al., (2004) reported that a case conferencing approach conducted in 
ten aged care facilities, involving a multidisciplinary team of health professionals including a 
pharmacist, resulted in a significant improvement in MAI score for the intervention group. 
Furthermore, a significant reduction in MAI score for benzodiazepines was also observed. 
Crotty, Rowett, et al., (2004) also found the inclusion of a pharmacist as a transition 
coordinator between hospital and long-term care prevented the worsening of inappropriate 
prescribing as measured using MAI and was also related to a reduction in emergency 
department visits and hospital readmissions. The present findings extend those of previous 
studies by reporting evidence that pharmacist case management also results in a significant 
reduction in MAI scores in Northern Irish care homes. 
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As observed in the IC chapter (Chapter 3) a significant moderate positive correlation 
was observed between the number of medications and baseline MAI score. Associations 
between number of medications and likelihood of inappropriate prescribing have been 
reported internationally for a variety of screening tools (Hudhra et al., 2016; Jiron et al., 2016; 
Morin et al., 2015). This association is evidenced in a variety of older people contexts including 
hospitalisation, post-discharge and among those residing in the community (Galvin et al., 2014; 
Hudhra et al., 2016; McMahon et al., 2014). Within the UK and Northern Irish contexts, 
polypharmacy (operationalised as ≥ 4 medications) has been found to be significantly 
associated with inappropriate prescribing, with a significant linear trend observed in NI 
(Bradley et al., 2012; Bradley et al., 2014). Polypharmacy has also been shown to be positively 
correlated with the number of prescribed medications within nursing home populations in the 
Republic of Ireland (Ryan et al., 2013), Belgium (Anrys et al., 2018) and Norway (Halvorsen, 
Selbӕk & Ruths, 2017). 
The only intervention to drive MAI score reduction in CH was medication cessation. In 
contrast, dosage changes and addressing of Kardex issues were also found to contribute to a 
reduced MAI score in IC settings (Chapter 3). Proponents of a holistic approach to 
deprescribing would perhaps infer that the context of patient care goals is somewhat different 
within care homes (Edey et al., 2018). Deprescribing for those who may be approaching end of 
life is thus likely to be different than that for a more robust older person (Todd, Jansen, Colvin 
& McLachlan, 2018). Spinewine, Schmader, et al., (2007) argues that prescribing is a function 
of the patient, prescriber, and the environment. Environmental influences, such as the 
demand for beds in acute care may mean that there is insufficient time to address clinical 
aspects during an acute inpatient stay. The clinician’s focus is often on the presenting acute 
illness with little time for follow up and collaboration between the different care interfaces 
(Edey et al., 2018). Thus, it is conceivable that IC participants, who transition into IC from acute 
care may require a broader range of interventions.   
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Deprescribing should be considered as an ongoing activity and not merely a 
reactionary response to an increased awareness of potential for medication related harm. It 
has been argued that deprescribing forms part of a good prescribing continuum, from 
medication initiation, dose adjustment, changes or additions to therapy and the cessation of 
medications (Scott et al., 2015). Thus, deprescribing should not be considered as a negative 
strategy aimed at denying effective medications (Scott et al., 2015), but rather as a positive 
continual improvement process, that remains dynamic to the changing patient context. The 
Scottish Government Polypharmacy Model of Care Group (2018) published guidance on the 
initiation and review of existing medications, with a holistic patient-centred approach to 
polypharmacy being advocated. Within this guidance document the emphasis is on considering 
‘what matters to the patient’. Deprescribing may occur as part of this but stopping 
medications is not necessarily the primary end point.  
Approximately five times as many participants in the IC sample (50%) had a medication 
started, compared with the CH sample (10%), suggesting that prescribing omissions were more 
frequent in the IC sample or that the potential benefit of medications were outweighed by the 
risks in a frailer CH population. Recent prescribing guidance caution that those residing in a 
care home are at greater risk of inappropriate polypharmacy (Scottish Government 
Polypharmacy Model of Care Group, 2018). Thus, a lower proportion of participants having a 
medication started may be reflective of this risk consideration. In contrast, a study conducted 
across seven nursing homes in the Munster region of Ireland found that 42% of residents 
experienced at least one prescribing omission as assessed using the START criteria (Ryan et al., 
2013). Thus, fewer medications being initiated may relate to the use of MAI as a medication 
review tool instead of the use of STOPP/START which likely prompts greater consideration of 
potential omissions.   
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It is imperative that medicines optimisation be viewed as a dynamic entity, and that 
opportunities for re-evaluation are considered going forward. For those in the care home 
setting who may experience substantive changes in functional status during their residency 
there is a continual need to re-evaluate therapy and not merely continue prescribing that 
occurred when community-dwelling. It has been argued that prescribing for care home 
residents is often a continuation of prescribing patterns within the community pre-admission 
as the resident’s GP remains the primary prescriber (Maguire et al., 2013). As such it is 
conceivable that dosages of medications may not have been reviewed for residents following 
their admission. Participants within the care home data were resident in their care home for a 
considerable period of time and were likely to have become frailer during this time. Dosages of 
medications may have been appropriate on admission but no longer remained so due to this 
declining functional status, reinforcing the need for continual review of pharmacotherapy in 
the care home context. The possibility of this is evidenced in the significant association 
between care home length of stay and baseline MAI score. Those who were resident in the 
care home > 2 years had higher baseline MAI total scores.  
The number of prescribed medications at baseline was the largest predictor of MAI 
score change for care home participants. The number of prescribed medications at patient 
‘wrap up’ was not recorded within the care homes dataset, thus a calculation of the change in 
numbers of medications between both time points could not be completed. Having 
experienced at least one medication discontinuation was also a significant predictor of MAI 
score change in the care home context. Interestingly none of the other intervention types was 
significantly associated with MAI score change in this context. Such a finding may be 
suggestive of additional frailty within the care home participants in comparison with those in 
intermediate care.  
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A significantly smaller reduction in MAI score was observed for those care home 
residents who occupied a residential bed, compared with those who occupied an elderly 
mentally impaired bed. This finding is of particular note as no differences in baseline MAI score 
category were observed for the three different care home bed types. Previous studies have 
shown that inappropriate prescribing is highly prevalent among those care home residents 
living with dementia (Renom-Giuteras et al., 2018). Such knowledge may inform the future 
approach of case management pharmacists with a focus on addressing inappropriate 
prescribing for those residents living with dementia.  
In comparison to those who were resident in their care home for more than two years, 
those who had been resident for less than six months, and those who were resident between 
six and 12 months both had significantly smaller reductions in MAI score following pharmacist 
intervention. A significant weak association was observed between care home length of stay 
and MAI total score category at baseline, with more residents in the > 2 years category 
observed to have MAI scores in the upper categories.  Such a finding reinforces the need for 
continual review of medications for care home residents as what may be appropriate at 
admission may not continue to be so throughout the duration of their residency.   
Care home residents who received IMM during their previous acute care admission 
experienced a smaller reduction in MAI score change, indicating that IMM may have already 
addressed any suboptimal prescribing. Burnett et al., (2009) previously reported evidence that 
IMM improved the appropriateness of prescribing when compared with standard 
pharmaceutical care. This finding supports IMM as a worthwhile initiative to support 
medicines optimisation across the primary-secondary care interface.  
In the care home model, the case management pharmacist conducted as many visits 
to the participant as necessary in order to resolve medication related issues. Approximately 
one-tenth of CH participants received follow up interventions in addition to those conducted 
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at baseline. The majority of these were graded as Eadon ≥ 4, signalling that, at a minimum, an 
improvement in the standard of patient care was delivered. These additional interventions 
mostly comprised of medication stopped, started and information given. These additional 
interventions, facilitated by this patient-specific component of the care home model, improved 
the standard of care for a considerable portion of care home residents. This supports the view 
that some care home residents require additional support with medication related issues and 
that a pharmacist case management model can support this.  
Within the care home context, direct access to the GP’s computer system by the case 
management pharmacist was a significant predictor of MAI score change, indicating its 
superiority to alternative methods of communicating medication related changes to 
prescribers. However, it must be acknowledged that baseline MAI scores were observed to be 
higher for those participants where direct access was available. Such a finding has important 
implications for future service delivery.  
Beginning in 2017 a number of Practice Based Pharmacists (PBPs) have been recruited 
into general practices in NI. Recruitment is ongoing with a future Department of Health 
Northern Ireland (DOHNI) goal to have a PBP in every GP practice in Northern Ireland (Miller, 
2018). It is further aimed that all PBPs will hold or begin the process of gaining the additional 
qualification of independent prescriber. This PBP role has been designed to alleviate pressures 
within primary care by supporting the GP to address medication-related issues (Avery, 2017; 
Torjesen, 2015). This new role is likely to deliver improvements in communication between 
primary and secondary care and is thus to be welcomed. As these new stakeholders take up 
their positions there is a real need to formalise communication between the case management 
pharmacists and these PBPs. Given that direct access to the GP’s computer system was found 
to be superior to alternative communication methods, such as letters and teleconferencing, it 
is vital that if this access is removed that it is replaced by a communication method that 
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maintains the benefits identified in the present study.  Going forward, any changes in 
communication style, and the introduction of a new stakeholder to the model needs to be 
assessed.  
In summary, a significant reduction in GP and ED visits was observed from pre- to post-
intervention. This supports the findings in earlier pilot work of the care home model of a trend 
towards reduced ED visits (McKee et al., 2016). The degree of MAI score change did not reduce 
healthcare utilisation, save for a reduction in hospital length of stay on first unplanned 
readmission. The significant reduction in MAI total score did not predict the likelihood of 
hospital admission and was not predictive of time to readmission.  
Within the care home context, a significant relationship was observed between MAI 
score change and length of stay on first unplanned readmission, with larger reductions in MAI 
score associated with shorter durations of hospital stay. Hospital admissions may not be 
entirely avoidable for older people, particularly among those residing in care homes who may 
be experiencing greater levels of frailty (Collard, Boter, Schoevers & Oude Voshaar, 2012; 
Kojima, Taniguchi, Ilifem Jivrak & Walters 2019). It is widely accepted that hospital admission is 
detrimental to the functional status of older people (Covinsky et al., 2003; Hirsch et al., 1990). 
In the present study, improvements in prescribing appropriateness, as indicated by reductions 
in MAI scores, was found to minimise the length of time spent in acute care for those care 
home residents who experienced an unplanned hospital admission. This reduction in length of 
stay may have further benefits for the older person but is beyond the scope of the present 
study.  
For care home residents the magnitude of MAI score reduction significantly predicted 
the number of GP call outs within the 30-day observation period, but not the 90-day period. 
For every unit reduction in MAI total score, from baseline to post-intervention, the number of 
GP call outs increased 1.02-fold. Thus, MAI score improvements, may be associated with an 
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initial increase in healthcare utilisation by care home residents, but this effect is not observed 
in the longer term. 
There is some evidence increases in healthcare utilisation may indicate better chronic 
disease management (Rosstad et al., 2017). An increase in GP visits during 12-month follow up 
for those older people in a post-acute care discharge intervention group has been interpreted 
as an increase in the active management of patients by GPs. Thus, it is possible that the small 
increase in GP visits within 30 days, but not 90 days, may be reflective of a refocusing of 
attention by GPs following pharmacist engagement. No significant association was observed 
between MAI score change and out of hours GP call outs, ED visits or hospital readmission, 
suggesting that improvements in prescribing appropriateness does not result in increased 
levels of escalated healthcare by care home residents.  
Medication discontinuation was associated with a longer duration of hospital 
readmission for those care home participants who had at least one medication discontinued, 
compared with those participants who did not. However, medication discontinuation was not 
associated with an increased likelihood of readmission. Thus, it is possible that medication 
discontinuation among the care home cohort may be related to the clinical status of the 
individual, with perhaps medications discontinued to prevent acute kidney injury or a move 
towards palliative care.   
Medication initiation was found to increase healthcare utilisation among CH 
participants. Those who received had at least one medication started had an increased 
likelihood of hospital readmission within 90 days and increased numbers of OOH call outs 
within 30 days of pharmacist intervention, compared with those who did not have a 
medication initiated. Similarly, the initiation of a new medication may infer a deterioration in 
the clinical status of the individual and may not necessarily indicate that such an intervention 
is detrimental to the individual.   
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A request for blood testing was associated with a decrease in the number of OOH visits 
in both monitoring periods. This decrease may have occurred because of several mechanisms. 
The outcome of blood testing may have changed the care strategy for the individual and 
prevented further deterioration in clinical status. Alternatively, additional aspects of clinical 
care may have been attended to during the initial visit for a blood draw, thereby capturing at 
an earlier stage possible declines in clinical status and preventing the need for an out of hours 
call.  
A referral to another healthcare professional was associated with significantly greater 
numbers of OOH call outs within 30 days, but not within 90 days of pharmacist intervention. 
No information was available as to whether these referrals had been actioned, but it is 
possible that care home residents had deteriorated whilst awaiting the input of another 
healthcare professional. Referrals to HCPs in IC are more readily facilitated as the individual is 
still placed within the HSCT at that time.  
Healthcare resource utilisation by CH participants was significantly associated with 
several medical diagnoses. Those with chronic kidney disease (CKD) had longer durations of 
acute care admissions and more GP call outs. Alexander et al., (2009) have previously reported 
that adults with late stage (Stage 3 and 4) CKD are more likely to have more physician visits 
(OR 1.81, 95% CI 1.46, 2.23) and hospital admissions (2.12, 95% CI 1.66, 2.71) than those with 
no CKD or early stage CKD. A diagnosis of diabetes was also found to increase the likelihood of 
hospital admission < 90 days for CH participants. A previous medical history of falls was also 
associated with a greater number of GP call outs in both time periods. Whilst it was not 
possible within the available data to ascertain the recency of falls for CH participants there is 
some evidence to suggest that such falls are more common within the care home setting. It 
has been estimated that care home residents are three times more likely to experience a fall 
compared with their community dwelling counterparts (DOH, 2009).  
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The present results provide some further evidence to support the utility of IMM in 
Northern Ireland, with an association with lower numbers of GP call outs for care home 
participants observed.  Such evidence supports the need for pharmacist involvement in the 
care of care home residents. Despite the proven effectiveness of IMM in reducing length of 
hospital stay (Scullin et al., 2007), the service is not delivered consistently across NI. The 
present study results highlight that the provision of this service can further complement the 
case management model of care for care home residents.  
Among the CH cohort, neither MAI score differences nor the pharmacist intervention 
types had any association with mortality. Those who had received advanced care planning, had 
a diagnosis of chronic kidney disease, stroke or atrial fibrillation or flutter were more likely to 
die within the 90-day post-intervention period. Such a finding highlights that pharmacist 
intervention is not detrimental to care home residents.  
Throughout the analyses presented here it was observed whereby previous healthcare 
resource utilisation was a significant predictor in a large proportion of the analyses. In Chapter 
3 it was observed that the number of hospital admissions in the 12-month period prior to the 
index IC admission was a consistent predictor of likelihood for readmission in all periods, and 
of numbers of readmissions and thus may serve as a marker of the relative clinical instability of 
some IC participants. Similarly, the number of hospital admissions within the preceding 12 
months was a significant predictor of likelihood for hospital admission for CH participants in all 
periods.  Furthermore, the number of previous GP call outs and OOH visits were significantly 
predicted by previous patterns of usage, suggesting that clinical need was a dominant factor in 
healthcare resource usage by care home residents following pharmacist case management.  
The results presented in this chapter must be interpreted within the context of several 
methodological limitations. Information was not available as to the recency of any previous 
medical history. Thus, any inferences regarding clinical instability of participants is speculative. 
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However, as a proportion of the total sample the level of hospital admission was relatively low 
and consistent with previous levels of healthcare resource usage. The absence of comparison 
to a control group prevent the assessment of model’s effectiveness in comparison with usual 
care. The development of randomised trials in older people approaching end of life requires 
considerable ethical consideration. Hutchinson, Parikh, Tacey, Harvy & Lim, (2015) propose the 
use of observational studies when randomisation is not appropriate. The high proportion of 
participants who experienced a change in total MAI score further limits the statistical power to 
detect differences in healthcare usage post-intervention.  
4.7 Conclusion 
In the present study, it has been shown that inappropriate prescribing is highly 
prevalent among care home residents aged ≥ 65 years in Northern Ireland. No differences in 
baseline severity of MAI score was observed for age or sex.  Regional differences in baseline 
severity of prescribing inappropriateness was observed, which may warrant further 
examination in future studies.  
The majority of interventions delivered by the case management pharmacists were 
clinically significant, resulting in improvements in the standard of care. The most common was 
medication discontinuation. The results lend support to earlier pilot work in the NHSCT and 
highlight the need for clinical pharmacist involvement in care home settings. The present study 
findings indicated that the successful delivery of the care model was maintained when 
delivered by case management pharmacists who were supported and mentored by a 
consultant pharmacist.  
The arrival of PBPs into general practice settings in Northern Ireland provides a new 
opportunity for both medicines optimisation models as it proffers a new channel for 
communication between primary and secondary care. Case management pharmacists 
operating within the care home model have found this new role to be beneficial to their case 
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management activities through the development of positive working relationships (Miller, 
2018). Improved communication and liaison between the MOOP pharmacists, PBPs and 
community pharmacists was central to the COVID-19 enhanced pharmacy response within 
care homes (Scott, Fleming & Martin, 2020). As both the PBPs and the care home model 
embed further across Northern Ireland there is a clear need to understand how this may 
influence MAI score change, given that direct access to the GP’s computer system explained 
variability in MAI score change for care home participants.  
The present study has also shown that improvement in prescribing appropriateness, as 
indicated by the degree of change in total MAI score, was not significantly associated with a 
reduction in healthcare resource usage, save for a reduction in length of hospital stay for CH 
participants who had been admitted to hospital. A small increase in the number of GP visits to 
CH participants in the 30-day monitoring period was observed. Several medical diagnoses 
showed significant relationships with increased healthcare resource usage including chronic 
kidney disease, angina pectoris and diabetes.  
Pharmacist impact is more granulated than can be captured using MAI. In the absence 
of the establishment of the care home model, inappropriate prescribing would go largely 
undetected, placing considerable demand on healthcare services. Previous levels of healthcare 
resource usage (pre-intervention) predicted healthcare utilisation in the post intervention 
period, remaining a dominant predictor in many analyses conducted. Such a finding points 
towards additional clinical need within the CH population. The clinical course of chronic 
conditions such as CKD, angina and diabetes are not directly modifiable by the clinical 
pharmacist, and thus lack of evidence of a significant association between MAI score change 
and healthcare resource usage must be cautiously interpreted. Multimorbidity and additional 
complexity inferred by increased levels of dependency may limit the degree of successful 
reduction in healthcare resource usage that can be achieved. No significant association with 
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likelihood of hospitalisation or death was associated with MAI score change, indicating that 
medicines can be discontinued with no detrimental effect for the older person in this context. 
Ultimately, the discontinuation of inappropriate medications is a laudable achievement, 
irrespective of any reduction in subsequent healthcare resource usage.  
Healthcare usage by older people is a highly complex and dynamic interaction that 
requires additional analysis. The chapters which follow seek to address this complexity in two 
ways: first, by examining healthcare utilisation at a medication level, and secondly through the 
longitudinal examination of a more heterogeneous sample of community-dwelling older 
adults. The inclusion of more psychosocial information allows for a greater analysis of 
potential relationships.   
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5 Healthcare utilisation following optimisation of medications 
prescribed inappropriately in Intermediate Care and Care 
Homes in Northern Ireland 
 
5.1 Chapter overview 
The purpose of this chapter is to examine the MOOP data pertaining to medication type in 
greater detail. Specifically, it aims to identify those medication subgroups most frequently 
found to be inappropriately prescribed at baseline in both intermediate care and care home 
settings. It further aims to identify which of these subgroups, when subsequently improved, 
are associated with reductions in healthcare resource usage.  
5.2 Introduction 
Prescribing rates in Northern Ireland are believed to be 12% higher per head of 
population compared with England or Scotland (Appelby, 2011). Furthermore, net ingredient 
costs per head of population have also risen by over 8%, resulting in 40% higher costs than in 
England (Appleby, 2011). With a projected increase in the proportion of older people living in 
Northern Ireland it is likely that levels of prescribing will continue to increase. The potential for 
medication-related harm serves not only to result in unwanted consequences for the older 
person but also to add additional pressure to the healthcare system. Thus, it is vital that 
preventable hospital admissions, such as those that are related to ADEs are avoided.  
Inappropriate prescribing was found to be highly prevalent in both IC and CH settings 
in Northern Ireland (refer to Chapters 3 and 4, respectively). The analysis presented thus far 
has considered the patient-level factors that explain variability in MAI score change and 
healthcare utilisation in both cohorts. However, an examination of the medication 
classifications has not been conducted. Whilst there is inherent value in understanding the 
quality of prescribing with respect to MAI scores, the nature of the inappropriate prescribing 
needs to be considered at an individual drug level also. Specifically, a more nuanced view of 
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the prescribing in terms of medication classifications provides valuable information regarding 
the prescribing culture for the respective cohorts. By doing so further refinements to the care 
models and opportunities for future intervention can be identified.  
Identification of the prescribing culture for IC patients is particularly beneficial, given 
the small amount of studies conducted in this care context. The work of Millar (2016) 
identified those STOPP/START indicators that were frequently endorsed within IC in Northern 
Ireland and can be considered to be an empirically driven approach, guided by the screening 
tool. However, as aforementioned in preceding chapters, explicit screening tools such as 
STOPP/START are subject to continual revision and do not necessarily put the individual older 
person at the centre of the review. The MAI on other hand encourages a more data-driven 
approach, where all medications are reviewed by the same criteria. Thus, the use of MAI to 
frame the review provides an opportunity to identify medication classifications that may be 
inappropriate for older IC patients, other than those indicators put forward on STOPP/START. 
Furthermore, this method provides for a more person-centred review and challenges the 
assumption that older adults are a homogenous group. Such an approach proffers additional 
opportunities to extend the limited knowledge base that exists regarding suboptimal 
prescribing in IC.  
Unsurprisingly, inappropriate prescribing was also found to be highly prevalent in 
Northern Irish care homes (refer to Chapter 4). The international literature is saturated with 
considerable evidence that suboptimal prescribing is pervasive in these care contexts (Anrys et 
al., 2018; Cool et al., 2014; Elseviers et al., 2013; Heppenstall et al., 2016; Lau et al., 2004; Ryan 
et al., 2013). The nature of inappropriate prescribing of psychoactive medications among the 
older adults is particularly concerning, especially among nursing home residents (Barry et al., 
2015; Patterson et al., 2007) and people with dementia (Renom-Giuteras et al., 2018). A high 
proportion of older patients (73.9%) receive at least one psychoactive medication; more than 
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half of these are considered to be prescribed inappropriately (Arnold et al., 2017). A 
comparison of cross-sectional data in Norway reported an increase in inappropriate 
prescribing from 1997 to 2011, with the most common increase in inappropriate prescribing 
found to occur for psychoactive medication (Halvorsen et al., 2017). 
Psychoactive medications are those which are capable of altering the mind, emotions, 
and behaviour of an individual. Psychoactive medications are often used to control the 
behavioural and psychological symptoms of dementia (BPSD) (Gustafsson, Sandman, Karlsson, 
Gustafson & Lövheim, 2013; Gustafsson, Karlsson & Lövheim, 2013; Mesquida et al., 2019) but 
can result in many unwanted sequelae such as falls, delirium, cerebrovascular events and 
death (Hill & Wee, 2012; Liperoti, Pedone & Corsonello, 2008; Mittal, Kurup, Williamson, 
Muralee & Tampi, 2011). Psychoactive medication use has been found to be higher among 
nursing home residents compared with those residing in the community, and to increase 
sharply following admission to such facilities (Maguire et al., 2013).  
Maguire et al., (2013) argue that a high prevalence of psychoactive prescribing in 
residential care and nursing homes has persisted despite numerous regulatory agencies issuing 
warnings regarding safe use. Whilst a reduction in prescribing of psychoactive medications 
following warnings from the Food and Drug Administration (FDA) in the US, and the Medicines 
and Healthcare Products Regulatory Agency (MHRA) in the UK has been observed, prescribing 
of such medications remains high (Guthrie, Clark, Reynish, McCowan & Morales, 2013; Kales et 
al., 2011). In the US approximately 30% of those newly admitted to nursing homes received an 
antipsychotic medication in 2006, despite the earlier 2005 FDA warning regarding excess 
mortality associated with the use of such medications (Chen et al., 2010). More concerning 
was the finding that 17% of residents with no clinical history of psychosis or dementia received 
an antipsychotic medication (Chen et al., 2010).  Thus, for many older people, the risk of 
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cerebrovascular events and sudden death associated with the use of antipsychotic medication 
to treat BPSD remains despite the best efforts of regulatory agencies to eliminate these risks.  
Chen and colleagues (2010) found that variation in antipsychotic prescribing within 
nursing home settings was related to the prescribing culture already in existence within the 
nursing home. Residents who were admitted to those nursing homes with the highest 
prescribing rates had a 34% increased risk of receiving an antipsychotic medication compared 
with those in nursing homes with the lowest prescribing rates (Chen et al., 2010). The use of 
antipsychotic medication among US nursing home residents must also be appreciated within 
the context of overall antipsychotic prescribing in the US. The use of second-generation 
antipsychotics nearly tripled from 1995 to 2008, resulting in more than 16 million prescription 
items (Alexander, Gallagher, Mascola, Moloney & Stafford, 2011). Between 1st January and 3rd 
June 2007, it was found that 14% of nursing home residents had Medicare claims for 
antipsychotic medication (Levinson, 2011). More concerning is the finding that 83% of these 
were for unlicensed indications and 88% were for residents diagnosed with conditions 
specified in the FDA warnings (Levinson, 2011).  
Westbury, Gee, Ling, Kitsos and Peterson (2018) found that almost two thirds of 
Australian care home residents were regularly prescribed a psychoactive medication, including 
antidepressants (41%), antipsychotics (22%), and benzodiazepines (22%). Benzodiazepines are 
often prescribed to alleviate anxiety, sleep disturbance an agitation in older adults. However, 
their use is problematic due to increased sensitivity to their sedating properties (Cook, 1986; 
EIDesoky, 2007; Shader & Greenblatt, 1981) and the increased risk of adverse outcomes such 
as falls, fractures, pneumonia and dementia (Díaz-Gutiérrez et al., 2017; Donnelly, Bracchi, 
Hewitt, Routledge & Carter, 2017; Glass, Lantôt, Herrman, Sproule & Busto, 2005; Islam et al., 
2006; Taipale, 2017; Seppala et al., 2018; Sun, Zhang, Zhang, Wu & Hu, 2019). Concerns have 
also been raised regarding the use of antidepressants in older people due to the increased risk 
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of falls, hyponatraemia, cerebrovascular events, seizures, and all-cause mortality (Coupland et 
al., 2011).  
Snowdon, Galanos and Vaswani (2011) contend that the rates of psychoactive 
prescribing in Australian nursing home are lower when compared to other countries. Repeated 
cross-sectional analyses of prescribing in nursing homes in Sydney between 1993 and 2009 
revealed an overall reduction in psychoactive prescribing during the period. However, 
reductions in benzodiazepine prescribing were coupled with a rebound return to previous 
levels of antipsychotic prescribing despite initial reductions (Snowdon et al., 2011). 
Furthermore, the prevalence of antidepressant prescribing increased from 15% in 1993 to 25% 
in 2009 (Snowdon et al., 2011).  Such findings highlight the need to consider type of 
psychoactive prescribing that occurs and not just the overall prevalence rates. Any reduction in 
risk associated with one medication classification may inadvertently be replaced with the 
initiation of alternative medications with considerable risk profiles. 
Increased attention is being drawn to the use of anticholinergic medications in older 
adults. The normal ageing process has been suggested to be associated with a deterioration of 
the central cholinergic system, and that this may contribute to the cognitive decline aspect of 
older age (Lechevallier-Michel, Molimard, Dartigues, Fabrigoule & Fourrier-Reglat, 2005). A 
recent case-control study in the United Kingdom identified an association between increasing 
medication anticholinergic burden over the preceding 4-20 years and incident dementia 
diagnosis (Richardson et al., 2018).  
Nevertheless, concerns regarding appropriateness of pharmacotherapy for older 
adults is not reserved solely for psychoactive medications. Non-steroidal anti-inflammatory 
drugs (NSAIDs) and antihistamines have also been found to be prescribed inappropriately 
(Lucchetti & Lucchetti, 2017). Particular concern has been raised regarding prolonged 
treatment with proton pump inhibitors (PPI) due to associations with an increased risk of 
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osteoporotic fractures, Clostridium difficile infection, dementia, and pneumonia (Maes, Fixen 
& Linnebur, 2017). Aggressive treatment of hypertension can increase the risk of orthostatic 
hypotension and thus the risk of falls. Thus, it is imperative that any assessment of 
inappropriate prescribing considers the possibility of all medication classifications as 
contributing to adverse events.  
5.3 Objectives 
• Identify and describe the prevalence of those medication subclassifications most 
frequently prescribed inappropriately at baseline within both intermediate care and 
care homes 
• Identify those medication subclassifications, prescribed inappropriately at baseline, 
which when improved by pharmacist intervention result in altered healthcare resource 
utilisation 
• Identify and describe the prevalence of psychoactive medication subclassifications 
prescribed inappropriately at baseline within both intermediate care and care homes 
5.4 Method 
5.4.1 Study population 
The present study involved secondary data analysis of the medication information 
collated by the MOOP pharmacists as described in further detail in Chapter 2 (Methodology).  
5.4.2 Design and variables 
Prescribed medicines were examined according to their subclassification within the 
BNF 70th Edition. The BNF classifies medications firstly by physiological system (refer to 
Chapter 2, Figure 2-3) before further subdivision according to mechanism of action.  Microsoft 
Excel was used to distinguish, for each recorded medication subgroup, cases where the 
baseline MAI score was zero and where it was greater than zero. These drug groups were 
consolidated to identify the medication subgroups which were most frequently identified as 
210 
 
inappropriately prescribed at baseline, as identified by counts. These counts were arranged in 
decreasing order of prevalence and analysis was conducted on the ten most prevalent 
medication subgroups in both cohorts.  
In the original datasets the medication subgroup prescribed was recorded across 
several variables (Med1 to Med24). Each BNF subcategory was coded between 1 and 352 
across each of these 24 variables. The accompanying MAI scores at baseline and post-
intervention were captured within two additional accompanying variables e.g. MAIpre1 and 
MAIpost1.  
 Variables were restructured and new variables created to indicate those drug 
subgroups which decreased in MAI and those where MAI score stayed the same or increased 
from baseline to post-intervention for each of the Med1-Med24 variables. For each of the drug 
subgroups most frequently prescribed inappropriately two count variables were created: one 
for the number of instances where the subgroup’s MAI score decreased and one for the 
number of instances where the MAI score stayed the same or increased. This was to account 
for the fact that some participants had duplicate prescribing within the same subgroup.   
Duplication of therapy meant that several different MAI score change trajectories 
were possible. For the participant who received multiple medications within the same BNF 
subgroup it was possible that some but not all medications were improved, ‘incomplete 
improvement, that ‘all medications within this class improved’, or that ‘MAI score stayed the 
same or worsened’ from baseline to post-intervention (Appendix F). Thus, the ‘incomplete 
improvement’ does not refer to those whose MAI score improved but did not return to zero 
but rather those who had one medication within that class be improved upon and another that 
did not. Due to small frequency values in the ‘incomplete improvement’ category it was 
collapsed with the ‘all medicines in this class improved’ to form a new ‘partial or complete 
improvement’ category. It must also be noted that those whose MAI score at baseline and 
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post-intervention were both zero would be categorised by the ‘MAI same or worsened’. These 
new categorical variables were operationalised as independent variables in the analyses.  
Binary outcome variables for the IC data included readmission (yes/no) and death 
(yes/no) for the periods of <30 days, 31-90 days and <90 days of discharge. Outcome variables 
for the CH data included unplanned hospital admission (yes/no) and death (yes/no) <30 days, 
31-90 days and <90 days of pharmacist intervention. Count outcome variables for CH 
participants included number of GP visits <30 and <90 days, number of ‘OOH GP visits <30 and 
<90 days, and number of ED visits <30 and <90 days.  
5.4.3 Data analyses 
Analyses were completed independently in both samples to reflect the distinct nature 
of the two cohorts.  Frequencies of endorsement across the drug group categories were 
tabulated and compared between cohorts using Microsoft Excel. Descriptive statistics were 
completed using IBM SPSS Statistics for Windows 24 (IBM Corp., 2016), and are expressed in 
terms of counts and frequencies. Chi-square tests for differences for binary categorical 
outcomes were conducted using IBM SPSS Statistics for Windows 24 (IBM Corp., 2016). Where 
sample sizes were small, and an expected cell count was less than five, Fisher’s exact tests are 
reported. Poisson regression analyses were completed for count outcome variables using the 
robust estimator of the ‘Generalized’ function within IBM SPSS Statistics for Windows 24 (IMB 
Corp., 2016). 
5.5 Results 
The reader is referred back to Chapter 2 (Figure 2-4) for a comparison of prescribing by 
BNF physiological chapter in both IC and CH cohorts. Within IC the most frequently endorsed 
chapter was the ‘Cardiovascular system’, with 464 (87.2%) participants prescribed at least one 
cardiovascular medication. In the CH cohort, the most frequently endorsed chapter was the 
‘Nervous system’, from which a total of 1067 (97.4%) participants were prescribed at least one 
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medication. Irrespective of the high prevalence of prescribing within these chapter 
classifications, an examination of the subclassifications (by mechanism of action) revealed that 
‘non-opioid analgesics and compound analgesics’ was the most frequently endorsed in IC (Fig. 
2-5). Within the CH setting the most frequently prescribed subclassification was for ‘osmotic 
laxatives’ (Fig 2-6). Thus, an examination at subgroup level provides a more nuanced view of 
the prescribing culture in both contexts and reveals that it is the combination of several drug 
subgroups that has contributed to the overall high count when examined at chapter level.  
5.5.1 Intermediate Care 
When inappropriate prescribing was considered among IC participants, the BNF 
subgroup found to be the most frequently prescribed inappropriately was the ‘opioid 
analgesics’ group (Figure 5-1). Approximately 60% of all instances of opioid prescribing were 
inappropriate at baseline, as defined by a MAI score > 0.  As a proportion of overall prescribing 
counts, ‘z-drugs’ had the highest proportion of inappropriate prescribing, with approximately 
65% of ‘z-drug’ prescribing found to be inappropriate to some degree at baseline.  
 
  
Figure 5-1: Counts for the top 10 most frequently endorsed BNF subgroups with baseline MAI > 0 and MAI=0 in IC (N 
= 532) 
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A review of duplicate prescribing of drug subgroups within the IC cohort for the Top 10 
most frequently inappropriately prescribed medications can be observed in Table 5-1. 
Duplication of therapy was observed for several drug subgroups including ‘opioid analgesics’, 
‘osmotic laxatives, ‘stimulant laxatives’, ‘benzodiazepines’, and ‘drugs used for megaloblastic 
anaemia’, which may have contributed to the overall prevalence of inappropriate prescribing 
within these drug subgroups.  
Table 5-1: Frequencies for duplication of prescribing for the BNF drug subgroups most frequently identified as 
prescribed inappropriately within the intermediate care sample (N = 532) 
 Number of medications 
BNF drug subgroup 0 1 2 3 
Opioid analgesics 294 176 54 8 
Osmotic laxatives 247 232 53 - 
Proton pump inhibitors 261 271 - - 
Benzodiazepines 442 81 9 - 
Stimulant laxatives 413 104 14 1 
Oral iron 401 131 - - 
Non-opioid analgesics 178 353 1 - 
Drugs used in megaloblastic anaemia 439 82 11 - 
Z-drugs 468 64 - - 
Calcium supplements 334 198 - - 
 
Frequencies for the MAI score change trajectories for the top ten BNF subgroups in IC 
can be observed in Table 5-2. The reader is referred to Appendix F for a more detailed view of 





Table 5-2: Frequencies for MAI score change type for the top ten BNF subgroups most frequently prescribed 
inappropriately within the IC sample (N=532) 







score at one 
time point 
Not on this 
medication  
Opioid analgesics 82 142 14 294 
Osmotic laxatives 135 130 20 247 
Proton pump inhibitors 161 92 18 261 
Benzodiazepines 40 43 7 442 
Stimulant laxatives 64 48 7 413 
Oral iron 78 46 7 401 
Non-opioid analgesics 284 46 24 178 
Drugs used in megaloblastic anaemia 46 39 8 439 
Z-drugs 23 37 4 468 
Calcium supplements 155 32 11 334 
 
The relationship between these categories of score change and readmission variables for IC 
participants can be observed in Table 5-3. A significant difference was observed for ‘proton 
pump inhibitors’ during both the 31-90-day and 0-90-day periods. A significant relationship 
between MAI score change category and death within 90 days of discharge from IC was also 
observed for ‘proton pump inhibitors (PPI)’ (Table 5-3).  
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Table 5-3: Chi-square tests for differences and Fisher’s exact tests for MAI score change, readmission, and death within IC sample 






Death < 90 days 
 N df Χ2 p Χ2 p Χ2 P Χ2 P 
Opioid analgesics 222 1 .012 .913 .016 .901 .000 .985 - .102b 
Osmotic laxatives 264 1 .001 .970 .026 .872 .060 .806 .261 .610 
Proton pump inhibitors 252 1 2.410 .121 5.511 .019 6.525 .011 - .028a 
Benzodiazepines 82 1 .639 .424 1.210 .271 .255 .614 .525a .469 
Stimulant laxatives 111 1 .288 .591 .924 .337 .006 .940 - 1.00b 
Oral iron 123 1 .446 .504 .284 .594 .022 .883 .126 .723 
Non-opioid analgesics 328 1 - .196a .981 .322 2.400 .121 - .703a 
Drugs used in megaloblastic anaemia 84 1 .965 .326 .072 .789 .236 .627 - .464b 
Z-drugs 59 1 - 1.00a - .510a .000 .992 .042 .837 
Calcium supplements 186 1 - .205a - .260a 2.051 .152 - 1.00b 




Fewer participants who experienced an improvement in MAI score for PPIs experienced a 
readmission in the longer term or died within three months of IC discharge, compared with 
those whose MAI score stayed the same or worsened (Table 5-4).  
Table 5-4: Crosstabulation of MAI score change trends for proton pump inhibitors and readmission to IC within 31-90 
days readmission <90 days and death <90 days of discharge (N = 252) 
  Readmission 31-90 daysa Readmission <90 daysb Death <90 daysc 




N 124 37 161 113 48 161 152 9 161 
% 49.2 14.7 63.9 44.8 19.0 63.9 60.3 3.6 63.9 
All medicines in 
this class 
improved 
N 81 10 91 77 14 91 91 0 91 
% 32.1 4.0 36.1 30.6 5.6 36.1 36.1 0 36.1 
Total N 205 47 252 190 62 252 243 9 252 
 % 81.3 18.7 100.0 75.4 24.6 100.0 96.4 3.6 100.0 
Note. aCramer’s V = .148, p = .019; b Cramer’s V = .161, p = .011; c Cramer’s V = .145, p = .022 
 
5.5.2 Care Homes 
The BNF subgroups most frequently found to be prescribed inappropriately for CH 
participants can be observed in Figure 5-2. As a proportion of total prescribing within the 
subgroup ‘drugs used to treat megaloblastic anaemia’ had the highest proportion, with 61.94% 
of instances considered to be inappropriate to some degree (MAI > 0). Approximately 54% of ‘z 
drugs’ prescribing was found to be inappropriate and 35% of ‘benzodiazepine’ prescribing was 




Figure 5-2: Counts for the top 10 most frequently endorsed BNF subgroups with baseline MAI >0 and MAI=0 in CH 
(N= 1095)  
 
‘Osmotic laxatives’ were the most frequently endorsed as having been prescribed 
inappropriately and may be related to the considerable levels of duplicate prescribing 
observed for this medication class (Table 5-5). A sizeable cohort of care home residents were 
prescribed two ‘osmotic laxatives’ (n=225), with smaller numbers in receipt of three or more 
‘osmotic laxatives’.  
Table 5-5: Frequencies for duplication of prescribing of the BNF drug subgroups most frequently identified as 
prescribed inappropriately within care home sample (N = 1095) 
 Number of medications 
BNF drug subgroup 0 1 2 3 4 
Osmotic laxatives 320 521 225 25 4 
Proton pump inhibitors 552 542 1 - - 
Non-opioid analgesics 278 771 45 1 - 
Benzodiazepines 708 317 68 2 - 
Opioid analgesics 744 301 45 5 - 
Oral iron 816 279 - - - 
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Z drugs 859 235 1 - - 
Megaloblastic anaemia 975 106 14 - - 
Bone metabolism 894 201 - - - 
Second-generation 
antipsychotics 
866 219 10 - - 
 
Duplication of therapy, in itself an indicator of inappropriate prescribing, was also 
evident for ‘non-opioid analgesics’, ‘benzodiazepines’ and ‘opioid analgesics’. Some duplication 
was also observed for ‘second generation antipsychotics’ and ‘drugs used to treat 
megaloblastic anaemias’.  Owed to this duplication of prescribing several possible trends for 
MAI score changes were possible for each drug subgroup. Possible change trends include all 
medications within this class had a MAI score that stayed the same or worsened, some 
medications within this class improved (incomplete improvement) and all medications within 
the class were improved upon.  Frequencies for the various type of score change trends for 
each of the BNF subgroups examined can be observed in Appendix G. The small cells of 
‘incomplete improvement’ and ‘all medicines within this class improved’ were collapsed into a 
new category ‘partial or complete improvement’ to facilitate further analyses (Table 5-6).  
Table 5-6: Frequencies for MAI score change type for the top 10 BNF subgroups most frequently prescribed 
inappropriately within CH (N = 1095)  






Missing MAI at 
one time point 
Not on this 
medication class 
Osmotic laxatives 503 265 7 320 
Proton pump 
inhibitors 
296 240 7 552 
Non-opioid analgesics 670 139 8 278 
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Benzodiazepines 293 90 4 708 
Opioid analgesics 213 131 7 744 
Oral iron 146 128 5 816 
Z drugs 174 61 1 859 
Megaloblastic 
anaemia 
34 81 5 975 
Bone metabolism 127 73 1 894 
2nd gen. 
antipsychotics 
189 37 3 866 
 
The relationship between these MAI score change trends and hospital readmission can 
be observed in Table 5-7. No significant differences in readmission were observed between 
those individuals who experienced a partial or complete improvement of MAI scores and those 
for which their MAI scores stayed the same or worsened. Significant differences were 
observed for drug groups ‘proton pump inhibitors’, ‘oral iron’ and death within 90 days of 




Table 5-7: Chi-square test of differences and Fisher’s exact tests for MAI score change, readmission, and death within CH sample 
BNF drug subgroup Readmission <30 days Readmission 31-90 days Readmission <90 days Death <90 days 
 N df Χ2 p N df Χ2 p N Df Χ2 p N df Χ2 p 
Osmotic laxatives 735 1 .998 .318 718 1 .005 .945 699 1 .732 .392 756 1 1.044 .307 
Proton pump inhibitors 512 1 .052 .819 501 1 1.137 .286 496 1 .493 .483 527 1 4.259 .039 
Non-opioid analgesics 775 1 .250 .617 759 1 .427 .513 747 1 .075 .784 796 1 .822 .365 
Benzodiazepines 360 1 - .771a 355 1 .034 .855 344 1 .986 .321 372 1 .227 .634 
Opioid analgesics 326 1 .647 .421 317 1 .047 .828 309 1 .192 .661 339 1 .439 .508 
Oral iron 263 1 1.406 .236 252 1 1.502 .220 246 1 3.423 .064 272 1 4.352 .037 
Z drugs 227 1 - .531a 223 1 3.022 .082 221 1 2.895 .089 234 1 - .564a 
Megaloblastic anaemia 108 1 - .692a 102 1 - .748a 102 1 - 1.00a 113 1 - .519a 
Bone metabolism 190 1 - .332a 189 1 .086 .769 188 1 .338 .561 198 1 1.211 .271 
2nd gen. antipsychotics 219 1 - .605a 217 1 - .482a 209 1 - .208a 222 1 - .387a 
Note. a25% cells have an expected count less than 5, thus the reported p value is for the Fisher’s exact test, two-tailed
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No incomplete improvement was observed for the ‘proton pump inhibitors’ and ‘oral 
iron’ subgroups (Appendix G). As such the crosstabulation of these drug subgroups and the 
death outcome variables (Tables 5-8 and 5-9) consider the MAI score change trends of ‘MAI 
stayed the same or worsened’ and ‘all medicines within this class improved’.  
Table 5-8: Crosstabulation of MAI score change trends for proton pump inhibitors and death <90 days of pharmacist 
intervention in CH (N = 527) 
  Death < 90 days 
  No Yes Total 
MAI worsened/stayed same N 263 25 288 
% 49.91% 4.74% 54.65% 
All medicines in this class improved N 229 10 239 
% 43.45% 1.90% 45.35% 
Total N 492 35 527 
 % 93.36% 6.64% 100% 
Note. Cramer’s V = .090, p = .039 
 
Fewer participants who experienced an improvement in their MAI score for ‘proton 
pump inhibitors’ died within 90 days of pharmacist intervention in comparison to those whose 
MAI score stayed the same or worsened. 
 
Table 5-9: Crosstabulation of MAI score change trends for oral iron and death <90 days of pharmacist intervention in 
CH (N = 527) 
  Death < 90 days 
  No Yes Total 
MAI worsened/stayed same N 127 19 146 
% 46.69% 6.99% 53.68% 
All medicines in this class improved N 119 7 126 
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% 43.75% 2.57% 46.32% 
Total N 246 26 272 
 % 90.44% 9.56% 100% 
Note. Cramer’s V = .126, p = .037 
 
Within the care home sample additional outcome variables included number of GP 
visits, number of OOH GP visits and ED visits, within both 30 and 90 days were examined. 
These variables were recorded as count variables and thus examined using Poisson regression, 
the results of which are summarised in Table 5-10. ‘Non-opioid analgesics’ had a significant 
effect on GP visits <90 days of pharmacist intervention. When compared to the reference 
group ‘partial or complete improvement of all medications within this class’ those whose ‘MAI 
score remained the same or worsened’ from pre- to post-intervention experienced reduced 
numbers of GP visits within the period (OR = 0.73, 95% CI 0.53, 0.99). Those care home 
residents on ‘drugs used to treat megaloblastic anaemia’ whose ‘MAI score remained the same 
or worsened’ were found to have more than twice the number of  OOH GP visits in comparison 
with those who experienced a ‘partial or complete improvement of all medications within this 
class’ (OR=  2.25, 95% CI 1.10, 4.60).   No significant differences in the numbers of GP, OOH or 
ED visits were observed for the other BNF subgroups most frequently identified as 
inappropriately prescribed at baseline. 
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Table 5-10: Poisson regressions for count outcomes of GP, OOH GP and ED visits in the care home sample  
BNF subgroup GP30 GP90 OOHGP30 OOHGP90 ED30 ED90 
Osmotic laxatives (N=694-742) 0.91 (0.63, 1.32) 0.82 (0.62, 1.08) 0.88 (0.58, 1.36) 0.82 (0.60, 1.14) 1.51 (0.67, 3.39) 1.38 (0.81, 2.34) 
Proton pump inhibitors (N=495-520) 0.83 (0.56, 1.23) 0.84 (0.63, 1.12) 0.98 (0.59, 1.62) 0.83 (0.57, 1.19) - 0.67 (0.39, 1.15) 
Non-opioid analgesics (N=743-783) 0.73 (0.47, 1.13) 0.73 (0.53, 0.99) 0.67 (0.43, 1.06) 0.84, (0.59, 1.20) 0.54 (0.35, 1.15) 1.17 (0.64, 2.14) 
Benzodiazepines (N=344-368) 0.99 (0.57, 1.75) - 1.09 (0.57, 2.08) 1.57 (0.94, 2.63) 1.15 (0,32, 4.14) 1.47 (0.62, 3.53) 
Opioid analgesics (N=310-332) 0.84 (0.55, 1.61) 1.10 (0.74, 1.64) 0.78 (0.45, 1.35) 0.91 (0.60, 1.39) - - 
Oral iron (N=241-264) 1.17 (0.68, 1.97) 1.35 (0.92. 1.99) 1.41 (0.76, 2.62) 1.20 (0.77, 1.86) 2.44 (0.80, 7.45) - 
Z drugs (N=220-228) 1.64 (0.77, 3.47) 1.12 (0.71, 1.77) 0.92 (0.40, 2.09) 0.71 (0.42, 1.21) 0.98 (0.31, 3.14) 0.97, (0.44, 2.14) 
Megaloblastic anaemia (N=101-110) 1.92 (0.83, 4.48) 1.55 (0.77, 3.12) - 2.25 (1.10, 4.60) 0.80 (0.08, 7.42) 1.74 (0.41, 7.42) 
Bone metabolism (N=188-194) 1.04 (0.56, 1.96) 0.96 (0.58, 1.59) 0.68 (0.33, 1.43) 0.92 (0.50, 1.69) 1.13 (0.29, 4.38) - 
Second-generation antipsychotics (N=206-221) 0.83 (0.30, 2.35) 0.72 (0.37, 1.42) 2.63 (0.64, 10.81) 0.75 (0.38, 1.46) 1.21 (0.14, 10.29) - 
Note. Significant odds ratios in bold. Reference group is ‘partial or complete improvement of medicines within this drug class’. GP30= number of GP visits within 30 
days; GP90= number of GP visits within 90 days; OOH30= number of out-of-hours GP visits within 30 days; OOH90= number of out-of-hours GP visits within 90 
days; ED30= number of Accident and Emergency visits within 30 days; ED90= number of Accident and Emergency visits within 90 days. 
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5.5.3 Psychoactive medications 
 
Several psychoactive medications were observed to be frequently prescribed 
inappropriately upon admission into IC, including ‘opioid analgesics’, ‘benzodiazepines’, ‘non-
opioid analgesics’, and ‘z-drugs’. The remainder of this results section will present results 
pertaining to other subgroups of the Central Nervous System BNF chapter not examined thus 
far. Several Central Nervous System BNF drug subgroups showed no or low levels of 
endorsement within the IC sample, preventing their examination in crosstabulation analyses. 
For reference these subgroups as listed in Appendix H.  
The Central Nervous System chapter subgroups most frequently found to be 
inappropriately prescribed upon admission into IC, in addition to those previously examined in 
Table 5-3 can be observed in Figure 5-3. Medications used in the ‘control of the epilepsies’ had 
the greatest level of endorsement. In total 46.25% of prescribing within this subgroup was 
found to exhibit some degree of inappropriateness. As a proportion of total prescribing within 
the subgroup ‘tricyclic antidepressants’ had the greatest proportion (66.6%), whereas ‘drugs 
used for dementia’ had the lowest proportion (12.12%).  
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Figure 5-3:  Counts for the frequently endorsed Central Nervous System chapter subgroups with baseline MAI > 0 and 
MAI=0 in IC (N = 532) 
An examination of duplication of therapy for subgroups identified in Figure 3 revealed that 
duplication of therapy occurred for all subgroups, save for ‘tricyclic antidepressants’ (TCAs) and 
‘selective serotonin reuptake inhibitors’ (SSRIs) (Table 5-11).  
Table 5-11: Frequencies for the duplication of prescribing of Central Nervous System BNF chapter subgroups most 
frequently identified as prescribed inappropriately within IC (N = 532) 
 Number of medications 
Central Nervous System subgroup 0 1 2 3 
Control of the epilepsies 456 72 4 - 
Antihistamines for nausea  479 50 3 - 
TCAs 496 36 - - 
SSRIs 400 132 - - 
Second-generation antipsychotics 201 28 3 - 
Dopaminergic drugs Parkinson’s 505 17 8 2 
Other antidepressant drugs 494 37 1 - 
Drugs for dementia 502 27 3 - 
 
 
Type of MAI score change for the psychoactive subgroups in the IC sample can be observed in 
Table 5-12. Only a small number of IC participants who were prescribed ‘antihistamines CNS 
nausea’, ‘dopaminergic drugs Parkinson’s’ or ‘other antidepressant drugs’ experienced a partial 




Table 5-12: Frequencies for MAI score change type for Central Nervous System chapter subgroups most frequently 
prescribed inappropriately in IC (N=532) 







score at one 
time point 
N/a 
Not on this 
medication  
Control of the epilepsies 40 31 5 456 
Antihistamines for nausea  17 30 6 479 
TCAs 14 19 3 496 
SSRIs 103 20 9 400 
Second-generation antipsychotics 21 7 3 501 
Dopaminergic drugs Parkinson’s 19 7 1 505 
Other antidepressant drugs 30 4 4 494 
Drugs for dementia 26 4 - 502 
 
An examination of the ‘Central Nervous System’ chapter subgroups and readmission outcome 
variables indicated that a significant difference was observed for ‘antihistamines for nausea’ 
and readmission <90 days (Table 5-13).  No significant differences were observed for any of the 
‘Central Nervous System’ chapter subgroups and readmission <30 days, readmission within 31-








Table 5-13: Chi-square tests of differences and Fisher’s exact tests for psychoactive drug subgroup MAI score change, readmission, and death within IC (N = 532) 
BNF drug subgroup   Readmission <30 days Readmission 31-90 
days 
Readmission <90 days Death < 90 days 
 N df Χ2 p Χ2 p Χ2 p N df p 
Control of the epilepsies  70 1 .087 .768 .023 .881 .100 .751 70 1 .580a 
Antihistamines for nausea  47 1 - .054b .- .653a - .041b 47 1 1.00a 
TCAs  33 1 - .698b - 1.00a - 1.00a 33 1 .628a 
SSRIs 122 1 .075 .785 - 1.00b .159 .690 122 1 1.00a 
Second-generation antipsychotics  28 1 - 1.00a - .075a - .364a 28 1 1.00a 
Dopaminergic drugs Parkinson’s  26 1 - .278a - 1.00a - .357a 26 1 - 
Other antidepressant drugs  34 1 - 1.00e - 1.00a - 1.00a 34 1 1.00e 
Drugs for dementia  30 1 - .360e - .360e - .454e 30 1 - 




Table 5-14: Crosstabulation of MAI score change trends for antihistamines for nausea and readmission <90 days of 
pharmacist intervention within IC (N = 47) 
  Readmission < 90 days 
  No Yes Total 
MAI worsened/stayed same N 9 8 17 
% 19.1% 17.1% 36.2% 
Partial/complete improvement for all 
medicines in this class 
N 25 5 30 
% 53.2% 10.6% 63.8% 
Total N 34 13 47 
 % 72.3% 23.7% 100% 
 
Several psychoactive medications were observed to be frequently identified as 
inappropriately prescribed at baseline for CH participants, including ‘benzodiazepines’, ‘opioid 
analgesics’, ‘z-drugs’ and ‘second-generation antipsychotics’. The remainder of this results 
section will present results pertaining to other subgroups of the Central Nervous System BNF 
chapter not examined thus far. Several of these subgroups showed either no endorsement or a 
low level of endorsement within the CH sample, preventing their examination in 
crosstabulation analyses. For reference these are listed in Appendix I.  
The most frequently endorsed psychoactive subgroups, in addition to those 
aforementioned in Figure 5-2 and Table 5-7, can be observed in Figure 5-4. An examination of 
the counts for each of these subgroups indicates that ‘SSRIs’, ‘antihistamines for nausea’ and 
‘first-generation antipsychotics’ were the most frequently identified as inappropriate at 
baseline. When considered as the total proportion of prescribing within their respective 
subgroup it was found that this amounted to approximately 17% of total ‘SSRI’ and 45% of 
both ‘antihistamines for nausea’ and ‘first-generation antipsychotic’ prescribing.  
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The subgroup with the highest proportion of inappropriate prescribing was 
‘betahistine’ with almost all prescribing (approximately 96%) found to be inappropriate. High 
prevalence of inappropriate prescribing was also found for ‘domperidone and 
metoclopramide’, with approximately 68% of prescribing of both of these medications found 
to be inappropriate. Approximately one half of ‘tricyclic antidepressant’ and ‘5HT3 antagonists’ 
were also found to be inappropriately prescribed.  
  
Figure 5-4: Counts for the most frequently endorsed Central Nervous System chapter subgroups with baseline MAI > 
0 and MAI=0 in CH (N = 1095) 
 
Duplication of therapy was also evident among CH participants for several subgroups 
including ‘drugs used for dementia’, ‘control of the epilepsies’ and ‘dopaminergic drugs used in 
Parkinson’s’, which may reflect the fact that monotherapy is often insufficient with these 
conditions (Table 5-15). Duplication of antidepressant therapy was identified for ‘SSRIs’ (n=2), 
‘tricyclic antidepressants (TCAs)’ (n=1) and ‘other’ (n=6).  
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Table 5-15: Frequencies for duplication of prescribing for the Central Nervous System BNF chapter subgroups most 
frequently identified as prescribed inappropriately within CH sample (N = 1095) 
 Number of medications 
Central Nervous System chapter subgroup 0 1 2 3 4 5 
SSRIs 753 340 2 - - - 
Antihistamines for nausea  979 113 3 - - - 
First-generation antipsychotics 1011 81 3 - - - 
TCAs 1023 71 1 - - - 
Betahistine 1068 27 - - - - 
Domperidone metoclopramide 1060 33 2 - - - 
Control of the epilepsies 940 132 17 5 - 1 
Other antidepressants 916 173 6 - - - 
Drugs used for dementia 723 298 74 - - - 
5HT3 antagonists 1080 15 - - - - 
Dopaminergic drugs Parkinson’s 1018 47 21 8 1 - 
Antimuscarinics Parkinson’s 1070 25 - - - - 
  
Types of MAI score changes from pre- to post-intervention can be observed in Table 5-
16. Most CH participants prescribed duplicate medications from the same subgroup and who 
experienced a change in MAI score did so for all instances of drugs within the respective 
subgroup. Some exceptions were noted including ‘first generation antipsychotics’, ‘tricyclic 
antidepressants’, ‘domperidone and metoclopramide’ and ‘other antidepressants’ where one 
individual for each drug group did not have all medicines within this class improved. Two 
individuals in both the ‘control of the epilepsies’ and ‘drugs used for dementia’ also had 




Table 5-16: Frequencies for MAI score change type for Central Nervous System BNF chapter subgroups for CH 
participants (N = 1095) 






at one time 
point 
Not on this 
medication 
class 
SSRIs 295 43 4 753 
Antihistamines for nausea  66 49 1 979 
First-generation antipsychotics 62 20 2 1011 
TCAs 50 20 2 1023 
Betahistine 2 25 - 1068 
Domperidone metoclopramide 12 22 1 1060 
Control of the epilepsies 139 16 - 940 
Other antidepressants 163 16 - 916 
Drugs used for dementia 360 10 2 723 
5HT3 antagonists 8 7 - 1080 
Dopaminergic drugs Parkinson’s 71 5 1 1018 
Antimuscarinics Parkinson’s 21 4 - 1070 
 
These MAI score change trends were cross tabulated with readmission and death 
outcome variables (Table 5-17). No significant differences in readmission rates were observed 
for either of the psychoactive drug groups examined, in either period. Furthermore, no 
differences in death within 90 days of pharmacist intervention were observed. Results for 
Poisson regressions conducted on count outcomes of GP, OOH GP and ED visits can be 
observed in Table 5-18. When compared to the reference group (partial or complete 
improvement of all medicines within this class), those residents whose ‘MAI score stayed the 
same or worsened’ for ‘dopaminergic drugs Parkinson’s’ experienced significantly fewer GP 
visits, both within and out-of-hours, within both timeframes.  
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Table 5-17: Fisher’s exact tests for psychoactive medication MAI score change, readmission and death for CH participants (N = 1095) 
Central Nervous System subgroup Readmission <30 days Readmission 31-90 days Readmission <90 days Death <90 days 
 N df p N df p N df p N df p 
SSRIs 322 1 .245a 317 1 1.00a 312 1 .434a 332 1 .248a 
Antihistamines for nausea  111 1 .381b 108 1 1.00b 109 1 .728a 113 1 .295a 
First-generation antipsychotics 79 1 .182a 77 1 .568b 77 1 .103a 80 1 328a 
TCAs 68 1 .294b 67 1 1.00b 66 1 .496b 69 1 1.00b 
Betahistine - - - 25 1 1.00c 25 1 1.00c 27 1 1.00c 
Domperidone and metoclopramide 32 1 1.00b - - - 31 1 1.00b 33 1 .104b 
Control of the epilepsies 146 1 1.00a 141 1 .217a 139 1 .465a 152 1 1.00a 
Other antidepressants 171 1 .504a 167 1 1.00a 163 1 .631a 176 1 .602a 
Drugs used for dementia 359 1 1.00a 351 1 1.00a 345 1 1.00a 365 1 1.00a 
5HT3 antagonists - - - - - - - - - 14 1 1.00b 
Dopaminergic drugs Parkinson’s 75 1 1.00c 74 1 1.00c 74 1 1.00c 76 1 1.00c 
Antimuscarinics Parkinson’s - - - 24 1 1.00c 21 1 1.00c 25 - - 
Note. a25% cells have an expected count less than 5; b50% cells have an expected count less than 5; c75% cells have an expected count less than 5, thus the 





Table 5-18: Poisson regressions for count outcomes of GP, OOH GP and ED visits 
Psychoactive Drug GP30 GP90 OOHGP30 OOHGP90 ED30 ED90 
SSRIs (N=315-330) 0.94 (0.52, 1.72) 1.19 (0.75, 1.91) 0.58 (0.30, 1.11) 1.26 (0.71, 2.23) 0.36 (0.11, 1.16) 1.48 (0.55, 3.95) 
Antihistamines for nausea (N=105-112) 0.88 (0.42, 1.83) 0.63 (0.33, 1.20) 1.09 (0.46, 2.59) 0.84 (0.41, 1.73) 0.78 (0.16, 3.69) 0.71 (0.26, 1.97) 
First generation antipsychotics (N=75-80) 0.75 (0.28, 2.03) 1.16 (0.55, 2.45) 2.67 (0.66, 10.83) 2.30 (0.73, 7.29) - - 
TCAs (N=65-68) 0.51 (0.17, 1.50) 0.58 (0.23, 1.51) 1.67 (0.20, 14.00) 0.88 (0.24, 3.16) 0.28 (0.04, 1.94) 0.30 (0.05, 1.86) 
Betahistine - - - - - - 
Domperidone and metoclopramide (N=31-33) - 0.76 (0.21, 2.78) 0.50 (0.06, 4.43) 0.79 (0.15, 4.16) - 3.15 (0.62, 15.97) 
Control of the epilepsies (N=138-149) 0.53 (0.25, 1.15) 0.64 (0.33, 1.24) 3.97 (0.57, 27.70) - - - 
Other antidepressants (N=163-174) 1.39 (0.48, 4.08) 1.90 (0.79, 4.56) 1.57 (0.38, 5.65) 1.75 (0.61, 5.07) - - 
Drugs used for dementia (N=344-363) 0.56 (0.09, 3.63) - 0.66 (0.19, 2.32) 1.04 (0.28, 3.92) 0.36 (0.05, 2.45) 1.08 (0.17, 7.01) 
5HT3 antagonists (N=13-14) 2.00 (0.23, 17.34) 1.17 (0.20, 6.75) - - - - 
Dopaminergic drugs Parkinson’s (N=73-76) 0.21 (0.06, 0.76) 0.25 (0.12, 0.54) 0.14 (0.05, 0.40) 0.30 (0.10, 0.92) 0.28 (0.04, 2.07) 0.88 (0.13, 5.89) 
Antimuscarinic Parkinson’s (N= 22-25) 0.25 (0.04, 1.72) 0.37 (005, 2.99) - - - - 
Note. Significant odds ratios in bold. Reference group is ‘partial or complete improvement of medicines within this drug class’. GP30= number of GP visits within 30 
days; GP90= number of GP visits within 90 days; OOH30= number of out-of-hours GP visits within 30 days; OOH90= number of out-of-hours GP visits within 90 




The results presented within this chapter build upon those within Chapters 3 and 4, by 
identifying medication classifications contributing to inappropriate prescribing within both 
contexts. Despite the fact that some similarities were identified in both contexts there is 
evidence to indicate that the prescribing culture in both settings is distinctive in nature. The 
disparity between both cohorts in terms of sample size limit the comparisons that can be 
made with respect to absolute prescribing counts. However, the order of frequency of these 
counts, and the proportion of overall prescribing within the subclassification lends itself to 
comparison.  
‘Opioid analgesics’ were the most frequently identified medication subclassification 
contributing to inappropriate prescribing within the IC cohort. Whilst opioids were also found 
to be inappropriately prescribed within the CH cohort, a greater proportion of IC participants 
received opioids inappropriately. Approximately 60% of opioid prescribing within IC (versus 
35% in CH) was found to be inappropriate at baseline review. This may be reflective of the 
rehabilitative nature of intermediate care, with participants having been discharged from 
acute care, and the higher likelihood that these participants may have experienced a fracture 
or surgery and thus required pain relief.  
Opioid analgesics are used in the management of both chronic and acute pain, both of 
which occur frequently among older people. They are usually reserved for moderate to severe 
pain due to the increased risk of adverse events with their use. Age-related changes in renal 
and hepatic clearance increase the susceptibility of older people to the sedating properties of 
opioid analgesics (Chau, Walker, Pai & Cho, 2008; Wilder-Smith, 2005). Thus, the risk of falls 
can be increased with the use of these agents. Reduced doses are recommended in older 
adults in order to limit the possibility of adverse effects. Furthermore, the potential for 





polypharmacy observed. Duplication of opioid prescribing was evidenced in both cohorts and 
may be warranted in order to provide adequate pain management. Modified release 
presentations which provide a continual release of opioids over a prolonged period, such as 12 
hours, are often used to provide a background level of analgesia, with additional immediate 
release preparations used to relieve any ‘breakthrough’ pain that occurs prior to the next 
dosing interval. Thus, some duplication of therapy may be considered clinically necessary. 
However, in a scenario where an individual no longer requires any opioid analgesia, the use of 
multiple preparations will result in a higher patient total MAI score following individual 
mediation MAI score summation. An examination of inappropriate prescribing and self-
reported adverse events in an older adult cohort in the US found that opioid analgesics was 
the most commonly duplicated medication group (Chrischilles, Van Gilder, Wright, Kelly & 
Wallace, 2009). 
Furthermore, common adverse effects of opioid analgesics, for example urinary 
retention and constipation, can lead to the development of a prescribing cascade as additional 
medications are prescribed in order to alleviate these common side effects. ‘Osmotic laxatives’ 
were identified as the most frequent inappropriately prescribed drug subgroup within the CH 
cohort, with the identified duplication of therapy likely contributing to this. Osmotic laxatives 
are considered first line therapy for the treatment of constipation in older adults and so the 
high prevalence of inappropriate prescribing of this subgroup is somewhat surprising and may 
be due to a prescribing cascade that developed from the maintenance of unnecessary opioid 
analgesia. Despite a greater proportion of CH participants being prescribed an osmotic laxative 
(71% vs. 53% in IC), a greater proportion of osmotic laxatives were found to be inappropriately 
prescribed within IC (51% vs. 44% in CH), which may be related to the overall higher 
prevalence of opioid prescribing within IC.  
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Similar to the findings of Peréz et al., (2018) and earlier Cool et al., (2014), it was found 
that ‘proton pump inhibitors’ (PPIs) were also frequently prescribed inappropriately for both IC 
and CH participants. The prolonged use of PPIs beyond the duration required for a therapeutic 
effect is a particular concern in older people due to associations with unwanted adverse 
effects such as the increased risk of osteoporotic fractures, Clostridium difficile infection, 
dementia, and pneumonia (Maes et al., 2017). Almost half (47%) of PPI prescribing within CH 
was found to be inappropriate with a smaller proportion of PPI prescribing found to be 
inappropriate upon admission to IC (35%).  
The high prevalence of inappropriate prescribing of PPIs within care homes may give 
credence to the argument that the prescribing culture for care home residents is often centred 
on the maintenance of medication that was prescribed pre-institutionalisation (Maguire et al., 
2013). Whilst no information was available as to the duration of treatment in either cohort, 
the identification of a high prevalence of inappropriate PPI prescribing points to a lack of 
regular medication review.  Such evidence would suggest that there is much to be gained from 
pharmacist intervention in care home settings, irrespective of the duration of residence.  
Huiskes et al., (2017) called for the cessation of widespread cross-sectional medication 
reviews as standard care, arguing that the absence of any effect on clinical outcomes such as 
hospital admissions, mortality or quality of life and inconclusive evidence as to the impact on 
economic outcomes undermined the effectiveness of such an approach. Rather, Huiskes and 
colleagues contend that medication review should take place longitudinally instead, with more 
of an integrated approach to pharmaceutical care whereby a review is conducted at initiation 
but also during specific ‘at risk’ moments for the patient.  However, as Avery and Bell (2019) 
argue, the absence of impact of deprescribing initiatives on clinical outcomes does not remove 
one from the ethical argument regarding patient autonomy. That the risks and benefits of 





a collaborative, shared decision-making process for deprescribing is encouraged. As such 
“deprescribing remains a worthwhile investment, however, and should be done in partnership 
with the patients and families who cope every day with burdensome polypharmacy” (Avery & 
Bell, 2019, p. I570). Accordingly, perhaps a pertinent question that we should ask ourselves is, 
by what metric do we consider an intervention to be effective?   
One can argue that the primary purpose of any medicines optimisation intervention is 
to do just that. The cessation or deprescribing of potentially harmful medication, the alteration 
of unsuitable dosages and the initiation of omitted medications that would provide a clinical 
benefit is the embodiment of the initiative in the first place. Secondary outcomes such as 
reductions in healthcare usage must be considered as an additional success. The absence of 
reductions in healthcare usage does not undermine the successful discontinuation of 
hazardous medications.  
The examination of interventions in purely economic terms does not always consider 
future cost savings that have been avoided through the prevention of adverse events and thus 
associated hospitalisations.  In this instance the work of Karnon and colleagues (2008) can be 
used to estimate the monetary cost of preventable adverse drug events (ADEs) and the value 
of health lost as a consequence of such ADEs. If the purpose of an intervention is aimed at 
improving patient care, then the individual should remain central to the evaluation and not be 
considered as secondary to the impact of overall service efficiency. Van Bussel et al., (2019) 
reported that patients trust their GP to make the right decision on their behalf with respect to 
medication decision making and that a “conspiracy of silence” (p. 6) prevents shared decision-
making from occurring. This is despite the fact that many older people wish to take an active 
part in their own care (Bastiaens, Van Royen, Pavlic, Raposo & Baker, 2007). The patient-
centred aspect of the MOOP care models respects the autonomy of the older person through 
active involvement in the generation of the pharmaceutical care plan.  
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Across both cohorts some differences in post-intervention healthcare resource usage 
was observed following improvements in MAI scores for some medication subgroups, 
indicating that medicines optimisation can be beneficial to the healthcare system as well as to 
the individual patient. Within IC, fewer readmissions between 31 and 90 days and within 90 
days of IC discharge were observed for those who had partial or complete improvement in 
their MAI scores for their PPIs, when compared with those who had no change or a worsening 
of MAI scores. Furthermore, in both settings, fewer participants who had partial or complete 
improvement in their MAI scores for PPIs died in the 90-day period. This finding further 
extends the literature regarding the safe use of PPIs among older adults. Prolonged treatment 
with PPIs has previously been shown to be associated with an increased risk of several 
negative outcomes for older adults, including osteoporotic fractures, Clostridium difficile 
infection, dementia, and pneumonia (Maes et al., 2017). Moriarty, Bennett, Cahir and Fahey 
(2016) previously identified a dramatic increase in long-term maximal dose use of PPIs among 
a cohort of community dwelling older Irish adults from 2007 to 2012. When compared to those 
who had partial or complete MAI score improvement for ‘drugs used in megaloblastic 
anaemia’, those who had no change in MAI score or a worsening of MAI scores for this drug 
subgroup had over twice the number of OOH visits <90 days of pharmacist intervention.  
Inappropriate prescribing of psychoactive medications was prevalent in both contexts 
with the prescribing of ‘benzodiazepines’ notable in both care settings. Considerable 
duplication of benzodiazepines was identified among CH participants and is a particularly 
concerning practice. Older adults have an increased susceptibility to the pharmacodynamic 
effects of benzodiazepines (EIDesoky, 2007) and thus experience an associated increased risk 
of falls (Bloch et al., 2011; Díaz-Guitérrez, et al., 2017; Hill & Wee, 2012; Landi et al., 2005). 
Falls can be a contributing factor in the return of a care home resident to an acute care setting, 





The cumulative sedative effects of duplicate benzodiazepine prescribing further the risk of falls 
and adverse consequences.  
Nevertheless, it would appear that a greater challenge of inappropriate prescribing of 
benzodiazepines is present within IC, where approximately 60% of benzodiazepine prescribing 
was inappropriate. In contrast, the proportion of inappropriate prescribing of benzodiazepines 
was lower in CH, accounting for approximately 35% of overall benzodiazepine prescribing. 
Such evidence builds on that identified within Chapter 3 such that pharmacist involvement 
within intermediate care is warranted. Those who were reviewed within IC were likely 
exhibiting pharmacotherapy issues that had not been addressed either within the community 
or during their acute care admission. Thus, if unaddressed during the IC admission, the 
continuation of suboptimal prescribing practices would fail to address the risk of adverse 
events for the older person. The assumption that medications had been optimised during the 
acute care admission would likely compound this risk.   
Furthermore, inappropriate use of the non-benzodiazepine sedative ‘z-drugs’ 
(zopiclone, zolpidem and zaleplon) was more often found to be inappropriate for IC 
participants, accounting for 65% of overall prescribing of this subclassification of psychoactive 
medications. Just over half of z-drug prescribing within CH was found to be inappropriate at 
baseline pharmacist review. Several interpretations may be drawn from this finding. 
Participants in IC may have experienced the onset of sleep disturbances during their acute care 
admission, leading to the initiation of a new medication which was then continued at 
discharge into IC. Alternatively, it may indicate that levels of inappropriate prescribing of ‘z-
drugs’ is prevalent within the community context and is not addressed during acute care 
admission and thus continues following discharge from acute care.  
A lower proportion of inappropriate z-drug prescribing in CH contexts may indicate an 
awareness on the part of the prescriber, usually a GP, of the concerns regarding the use of 
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such medications for older people. In this study a large proportion of CH participants were 
resident within the CH home setting for 2 years or more and may have had their 
pharmacotherapy reviewed at an earlier stage, given the increased concerns regarding 
psychoactive medication use in care homes. The sheer lack of studies examining inappropriate 
prescribing within IC may suggest an overall underestimation of the severity of inappropriate 
prescribing of psychoactive within settings outside of care homes.  
There was considerable variety in the psychoactive medication subgroups prescribed 
inappropriately for both cohorts, with some distinctions evident between both settings. With 
respect to antidepressant medications, approximately one fifth of ‘SSRI’ prescribing was 
identified as inappropriate in both contexts. As a proportion of overall prescribing within the 
subclassification, inappropriate prescribing of ‘TCAs’ was highly prevalent in both settings, with 
a greater proportion of IC participants prescribed a TCA inappropriately. Antidepressant use in 
older people increases the risk of falls, hyponatraemia, cerebrovascular events, seizures, and 
all-cause mortality (Coupland et al., 2011), thus antidepressant prescriptions among older 
adults should be reviewed to identify if they are still clinically necessary. 
Similarly, whilst ‘antihistamines for nausea’ were found to be suboptimal in both care 
contexts, a greater proportion of overall prescribing within the classification was identified as 
inappropriate among IC participants (59% versus 45% for CH participants). Previous research in 
intermediate care in Northern Ireland identified a low prevalence of prescribing for this 
subgroup with only just over 1% of participants prescribed a first-generation antihistamine 
(Millar, Hughes & Ryan, 2017).  
First-generation antihistamines are centrally active due to their ability to penetrate the 
blood brain barrier. Hence, adverse effects such as sedation, dizziness, impaired thinking and 
memory, agitation and hallucinations can result from their use (Tietze, 2012). Some older 





antihistamines can also produce adverse effects as a result of their anticholinergic effects. 
Consequently, blurred vision, dizziness, memory impairment, postural hypotension, 
constipation, and urinary retention may also occur in conjunction with their use (Tietze, 2012). 
Whilst the risks associated with the prescribing of antipsychotics, opioids, benzodiazepines, 
and other sedatives for older adults has received considerable attention, a refocus of attention 
on first-generation antihistamines may be required. The American Beer’s and European STOPP 
lists both advocate against the use of first-generation antihistamines in older adults, however 
the frequency of inappropriate prescription of such agents identified within both care settings 
could suggest that perhaps there is further room for clinical education with respect to this 
medication subgroup.  
Concerningly almost half of all prescribing of ‘first-generation antipsychotics’ for CH 
participants was found to be inappropriate at baseline review. Behavioural and psychological 
symptoms of dementia (BPSD) is a common cause for hospital admission among those living 
with dementia (Scottish Intercollegiate Guidelines Network, 2006). Antipsychotic medications 
are often prescribed to alleviate symptoms of BPSD, in spite of clear warnings regarding the 
increased risk of cerebrovascular accidents and cardiac death that have been issued by 
regulatory agencies (Chen et al., 2010; Guthrie, et al., 2013; Kales et al., 2011; Maguire et al., 
2013; Westbury et al., 2013). A lower prevalence of inappropriate prescribing was identified 
for ‘second-generation antipsychotics’ and was found to be similar in both settings 
(approx.25%). Patterson, Hughes, Crealey, Cardwell & Lapane (2010) previously reported that 
60% of antipsychotic prescribing in Northern Irish care homes was inappropriately at baseline. 
Recent data assessing prescribing in long term care homes in Canada estimates that 27.5% of 
antipsychotics are prescribed inappropriately (Kirkham et al., 2017).  
Within CH almost all ‘betahistine’ (96%) prescribing was found to be inappropriate and 
may reflect the continuation of medication when no longer clinically indicated and may 
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therefore point to the continuation of pre-admission medications within this care context in 
the absence of a thorough review. Furthermore, approximately two-thirds of prescribing of 
‘domperidone or metoclopramide’ was inappropriate within CH. It is impossible to determine 
which of these two medications that contributed to this. It could indicate the inappropriate 
use of metoclopramide in those with Parkinson’s Disease, given the risk of extrapyramidal side 
effects. Alternatively, it could indicate the failure to address domperidone prescribing in light 
of alerts relating to the risk of cardiac arrythmias and associated increased risk of death. In 
2014, the Coordination Group for Mutual Recognition and Decentralised Procedures – Human 
(CMDh) of the European Medicines Agency endorsed a recommendation to restrict the use of 
domperidone in terms of indication, dosage, and length of treatment, following a review of the 
risk of serious cardiac effects. Such an example indicates that the risk benefit ratio of a 
medication is a dynamic balance and can change considerably with increased data collection 
regarding its use. Prescribing within these two subclassifications points the clear need for 
continual review of medications for CH residents, irrespective of when they were admitted 
into the care home.  
From a healthcare utilisation perspective, the amelioration of psychoactive prescribing 
had little or no effect on healthcare outcomes for IC or CH participants. A difference in 
readmission within 90 days of IC discharge was observed for IC participants with respect to 
prescribing of ‘antihistamines for nausea’. Fewer readmissions within 90 days were recorded 
for those who had partial or complete improvement for MAI scores than those whose MAI 
scores stayed the same or worsened. Conversely, those CH participants who experienced ‘no 
change or a worsening in MAI score’ for their ‘dopaminergic drugs for Parkinson’s’ reported 
fewer GP and OOH GP visits within both 30 and 90 days, when compared with those who 





Several methodological limitations must be considered when considering the findings 
presented here. No assessment could be made as to whether any discontinued medications 
remained withdrawn during the follow up period. Thus, it is possible that some discontinued 
medications may have been resumed following pharmacist intervention and during the 
healthcare usage data collection period. A multidisciplinary intervention aimed at reducing 
psychoactive prescribing among nursing home residents living with dementia found that of the 
28% reduction in psychoactive prescribing achieved only 12% of discontinued medications 
were restarted at 6 months follow up (Mesquida et al., 2019).  
Furthermore, the analysis of medication subgroups was conducted independently to 
identify individual drug classifications that were of particular concern. Thus, it was not possible 
to identify whether combinations of optimised medications resulted in alterations in 
healthcare utilisation post-intervention. For example, the use of multiple psychoactive 
medication results in an additive sedative effect and so the cessation of multiple medications 
may have resulted in a reduction in the number of falls experienced by participants, evidenced 
as altered healthcare usage in the post-intervention period. Additionally, a considerable 
proportion of participants who would have been classified as ‘MAI score stayed the same or 
worsened’ would have been those whose medication MAI score was zero at both baseline and 
post-intervention. Thus, for some participants no improvement in MAI score would have been 
possible as medications had already been optimised.  
5.7 Conclusion 
Considerable variation in inappropriate prescribing occurs in both contexts with 
several medication subclassifications endorsed as having been prescribed inappropriately. 
These findings add nuance to the findings reported in Chapters 3 and 4 by providing insight 
into the culture of inappropriate prescribing evident in both locations. Inappropriate 
psychoactive prescribing was highly evident in both contexts, with the prescribing with some 
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psychoactive subclassifications more prevalent in IC than in CH. This could indicate that those 
responsible for prescribing for care home residents are attuned to the risks associated with 
psychoactive medications and that the prescribing culture has adapted to safety warnings. 
However, a considerable proportion of inappropriate prescribing was identified within the CH 
data also. Nevertheless, the findings extend the conclusions made in Chapter 3 that medicines 
optimisation interventions are warranted within intermediate care, and that particular 
attention should be paid to psychoactive prescribing within this context also. Addressing 
inappropriate prescribing of psychoactive medications at an earlier stage in the care journey 
may prevent negative outcomes such as falls and altered cognition, thereby delaying, or 
reducing the risk of institutionalisation. 
Overall, improvements in prescribing appropriateness at a medication subclassification 
level did not influence outcomes widely, save for some differences identified for ‘proton pump 
inhibitors’, ‘oral iron’, ‘non-opioid analgesics’, ‘drugs used in the treatment of megaloblastic 
anaemia’ and ‘antihistamines for nausea’. Nevertheless, the identification of those drug 
groups that are most frequently prescribed inappropriately can form the basis of future brief 
interventions, not only by the MOOP team pharmacists, but also by pharmacists across the 
entire healthcare journey. Furthermore, the absence of direct relationships between 
improvements within specific drug groups and healthcare utilisation and outcomes extends 
the discussion regarding deprescribing initiatives. It provides further weight to the narrative 
that the assessment of interventions for older people is challenging to disentangle into its 







6 Longitudinal patterns of healthcare usage among older adults: 
latent transition analysis of The Irish Longitudinal Study on 
Ageing (TILDA) 
 
6.1 Chapter overview 
The purpose of this chapter is to investigate temporal changes in healthcare utilisation among 
older people. In particular, the chapter seeks to determine whether distinguishable patterns of 
healthcare usage that remain stable over time can be elucidated. By doing so this chapter 
forms a foundation for subsequent analyses, which will provide a more detailed 
characterisation of healthcare utilisation by older people through the incorporation of those 
individual or person-centred characteristics that influence healthcare utilisation via the 
inclusion of relevant covariates.  
6.2 Introduction 
An ageing global population, living for longer with multimorbidity, is a considerable 
challenge to health systems globally. The idealistic healthcare model is one where healthcare is 
delivered in response to the needs of the population in a manner and form that is accessible to 
the recipient. Accessing healthcare involves a dynamic interplay of a broad range of factors, 
including those at an individual level, such as illness level and attitudes toward health, and 
those at a societal level, such as accessibility of services. Andersen and Newman (1973) 
proposed that the broad range of factors which influence healthcare utilisation could be 
categorised into three principal domains, predisposing, enabling and need factors. In doing so 
they sought to characterise the myriad of factors that influence the decision to access 
healthcare in a coherent and parsimonious manner, whilst retaining breadth and depth of 
these complexities.  
Predisposing factors are considered to be those that exist prior to the onset of the 
specific period of illness and are not considered to be a reason for seeking healthcare but 
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rather influence the likelihood of accessing services. (Andersen & Newman, 1973). These 
include demographic factors such as age, sex, and past illness. Social structural variables such 
as education and occupation are also considered to be predisposing variables, as they indicate 
the social environment within which the individual resides and may point towards the lifestyle 
of the individual (Andersen & Newman, 1973). Attitudinal variables such as health beliefs and 
attitudes towards health services are also deemed to be predisposing factors as they do not 
indicate a direct reason for healthcare services but may describe differential patterns of 
healthcare service use. Enabling factors are considered to be aspects that make healthcare 
services available to the individual (Andersen & Newman, 1973), including financial aspects 
such as family income or health insurance coverage, as well as accessibility of healthcare 
services. The availability of healthcare services in terms of personnel, facilities and location of 
these facilities are proposed to influence the individual in terms of their decision to access a 
service. Need factors include illness level, representing the most immediate cause of health 
service use (Andersen & Newman, 1973). This is further categorised by Andersen and Newman 
as perceived illness, such as self-reported general health status or self-reported symptoms, 
and evaluated illness, which may include a physical examination by a medical professional.  
Andersen and Newman (1973) in their theorising also considered the degree to which 
each of these factors can be altered to influence the distribution of health services, referring to 
this aspect as the mutability of the factors. Thus, demographic factors are deemed to have low 
mutability whereas enabling factors are considered to have higher mutability. In doing so, 
Andersen and Newman (1973) drew our attention to those factors which are potential targets 
for action when considering altering healthcare utilisation patterns. 
Chapters 3 and 4 examined two distinct populations of older people where concerns 
have been raised regarding the appropriateness of healthcare utilisation by these cohorts. 





burden on secondary care, indicating that this was not an appropriate location for older 
people’s care. Similarly, concerns have been raised internationally about the appropriate 
transfer of care home residents to emergency departments (Lemoyne et al., 2019).  
This raises the question as to what is the ‘ideal’ or optimum type of healthcare 
utilisation by the population, broadly speaking, and by older people, specifically? Findings from 
Chapters 3 and 4 highlighted that the evaluation of an intervention for older people in terms of 
secondary outcomes, such as healthcare usage, requires an appreciation of the pre-existing 
levels of healthcare usage pre-intervention. Analysis from these preceding chapters 
highlighted that older people who have high levels of healthcare usage are likely to continue 
with such usage patterns, irrespective of significant improvements in the appropriateness of 
their pharmacotherapy. Thus, an understanding of heterogeneity in terms of healthcare usage 
may prove an additional source of understanding of inter-individual differences in healthcare 
usage, over and above those characteristics identified in Chapters 3 and 4.  
However, it must be considered that whilst accessing healthcare involves a discrete visit, 
the person living with chronic multimorbidity may often find that multiple visits are required to 
ensure optimal management of their condition(s). Thus, we need to consider access of 
healthcare services over a longer period of time. As evidenced in Chapters 3 and 4, previous 
levels of healthcare attendances were significant predictors of healthcare resource usage 
within 90 days of pharmacist intervention. This evidence underscores the continual need that 
older people have for healthcare services, irrespective of the improvements made in their 
pharmacotherapy. Thus, this raises the question as to whether we have an in depth 
understanding of what governs healthcare usage by older people over a longer term.  
As much as we are aware that admission to secondary care can have detrimental effects 
for older people in terms of increasing frailty, decreasing cognition and increased risk of 
inappropriate prescribing, there is a need to identify the characteristics of older people who 
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present to secondary care in the first place. The identification of those characteristics that 
differentiate the frequent attenders from those with low levels of healthcare utilisation may 
offer greater insights into appropriate healthcare service design, over and above that of 
developing policy initiatives such as intermediate care and reductions in secondary care bed 
numbers. Furthermore, given the considerable heterogeneity that exists amongst older 
cohorts it is somewhat reductionist to assume that all older people exhibit the same high levels 
of healthcare utilisation. Rather, it is imperative that we identify those individuals who are at 
greatest risk of requiring high levels of healthcare usage. Kansagara et al., (2011) argue that 
most risk prediction studies have displayed poor predictive ability, indicating a better 
capability at predicting mortality rather than the risk of hospital readmission. Kansagara and 
colleagues call for the inclusion of broader factors such as wider social and environmental 
aspects when considering healthcare usage.  
Moreover, the identification of hospital admission risk, whilst highly important does 
little to inform of healthcare usage at primary care level. In many Western societies, GPs are 
considered to be the gatekeepers of access to secondary care, primarily via one of two 
pathways. The first is a referral to a specialist medical consultant for an outpatient 
consultation and is often considered to be the most appropriate means of initiating secondary-
level care. The second pathway that can be adopted is a referral to ED, whereby the patient 
may be admitted to secondary care for further investigation and treatment. This admission 
may facilitate the escalation of secondary-level care for the admitted inpatient as a means of 
encouraging a timely discharge and the vacation of an occupied hospital bed. Therefore, it is 
imperative that any profiling of healthcare usage among older people accounts for 
attendances at outpatient and ED departments, to serve as a proxy indicator for appropriate 





However, it is important to caution that referral to ED on the part of the GP is largely 
rooted in a valid concern for the declining health of the referred person and the exhaustion of 
options at a primary care level. In fact, such a referral pathway is largely indicative of a poorly 
functioning outpatient service that can often be characterised by long waiting lists, during 
which the condition of an older person is likely to diminish during this waiting time. Therefore, 
we can reframe the narrative such that the two referral mechanisms be considered as a 
functioning health service versus a malfunctioning service, rather than that of an appropriate 
versus an inappropriate referral.  
Our awareness of any concept is predicated upon the amount of information that we 
use to form our reasoning. The examination of healthcare usage as a single snapshot in time 
does little to inform of variation in healthcare utilisation longitudinally. Thus, an alternative 
approach is to examine the trajectories of healthcare usage that older members of our 
population follow over time. This also proffers an opportunity to consider the relative stability 
of these trajectories and the differential impact that they have. Through longitudinal 
assessments of healthcare usage, the ‘dynamic and recursive nature’ of health services use 
could be better understood (Andersen, 1995, p. 7).  
Longitudinal cohort studies that include healthcare usage questions within their study 
design offer an opportunity to examine healthcare utilisation over time within a wider context 
of sociodemographic and epidemiological information. Various longitudinal studies of ageing 
are currently in progress in England (ELSA), Ireland (TILDA) and Northern Ireland (NICOLA). 
Such studies gather information on a host of demographic, socioeconomic and psychosocial 
aspects of ageing in the study sample and have been designed to be representative of the 
population in question. The inclusion of broader contextual factors allows for a more thorough 
examination of the factors which influence healthcare utilisation. These studies are largely 
designed to be compatible with one another and thus also offer the opportunity of cross-
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country comparisons. Previous research conducted on healthcare utilisation in the TILDA 
sample has considered the Andersen Behavioural Model when selecting covariates for 
inclusion in the analysis (Hudson & Nolan, 2015; Mohan, Nolan & Lyons, 2019; Murphy, 
Whelan & Normand, 2014; Nolan, McCrory & Moore, 2019; Roe et al., 2017). However, these 
studies look at different types of healthcare utilisation e.g. GP visits, outpatient visits etc. as 
independent outcome variables and do not consider profiles of multiple healthcare usage. 
Furthermore, these studies largely consider healthcare usage cross-sectionally and do not 
examine changes in healthcare utilisation over time.  
A fundamental aspect must first be established prior to any understanding of the factors 
which influence healthcare service usage can be gleaned. The nature of healthcare usage over 
time by the population must be characterised. There are a whole host of analysis models that 
the researcher can adopt to examine longitudinal data, the selection of which is largely 
determined by the research question and the available data (Nylund, 2007). Latent variable 
modelling offers the opportunity to simplify a large amount of information into subpopulations 
that share commonality. Latent class analysis can be conducted to identify subpopulations who 
differ from one another in their response patterns to selected indicators. Such methodology 
provides a medium by which the considerable heterogeneity that exists among older people 
can be more easily manipulated within subsequent analyses. Latent variable modelling can 
also be applied within a longitudinal context to provide a simplified assessment of change over 
time, which remains true to the subtle nuances of each subpopulation. 
Latent transition analysis (LTA) can be considered to be a longitudinal extension of the 
latent class model. It incorporates two modelling traditions: latent class analysis (LCA) and 
autoregressive modeling (Nylund, 2007). LCA identifies unique subpopulations or groups at 
each point in the analysis and the autoregressive component identifies the transitions that 





each time point whilst also estimating the probability of transition from each class to another 
over time. In effect, LTA estimates the probability of latent class membership at time t+1, 
conditional upon membership at time t. Figure 6-1 outlines a simple LTA model consisting of 
two time points.  
 
Figure 6-1: Simple latent transition model (LTA) comprised of two time points 
 
Ryoo, Wang, Swearer, Hull and Shi (2018) propose that model building within LTA 
should follow a stepwise approach that is largely influenced by the researcher’s goals. By doing 
so, Ryoo and colleagues’ approach is an attempt to provide clarity to model building in LTA. 
According to Ryoo et al., (2018), the application of LTA within the literature has been the 
victim of much subjectivity, thereby resulting in confusion for applied researchers who seek to 
identify the optimal approach for LTA model building.    
Measurement invariance is a crucial step to the successful application of LTA, with the 
first step to assess the equivalence of the optimal number of classes at each time point. Where 
this has been satisfied the fit of two LTA models, one with freely estimated parameters and 
one with constrained parameters can be compared. The establishment of measurement 
invariance allows for greater confidence in the interpretation of transition parameters, and 
thus the model as a whole (Collins & Lanza, 2010). 
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LTA provides an opportunity to examine inter-individual and intra-individual 
heterogeneity of a construct. We can identify latent classes or statuses that are distinguishable 
from one another and thus address inter-individual patterns in healthcare utilisation, whilst 
also identifying changes in healthcare utilisation within the individual over time, intra-
individual heterogeneity. The selection of LTA as a technique accounts for the dynamic 
interplay of health and illness over time, as well as providing an opportunity to investigate 
those covariates which influence the transition from one state to another. Thus, in addition to 
identifying heterogeneity in healthcare utilisation within a sample it also provides an 
opportunity to characterise divergent healthcare trajectories.  
6.3 Objectives 
• To identify whether latent subpopulations characterised by different patterns of 
healthcare utilisation are present within a nationally representative data sample of 
older people, TILDA 
• To identify if these latent subpopulations are equivalent across three measurement 
occasions 
• To determine the probability of transitioning from one latent class to another over 
time  
6.4 Method 
6.4.1 Sampling and participants 
The present study utilised data from the Irish Longitudinal Study on Ageing (TILDA) as 
introduced in Chapter 2 (Methodology). Participants at Wave 1 were 8175 TILDA respondents 
who had completed the CAPI element of the survey and who were aged 50 years and over. 
Participant ages at Wave 1 ranged from 50 to 803 years (M = 63.53, SD = 9.16). The sample 
comprised of 54.2% females. Participant numbers at Wave 2 and Wave 3 were 6917 and 6128, 
 





respectively. Thus, resulting in attrition rates of 15.39% at Wave 2 and 25.04% at Wave 3, 
respectively. The sample size available for healthcare utilisation variables ranged from 8164 to 
8172 at Wave 1, 6903 to 6915 at Wave 2, and 6115 to 6124 at Wave 3. Further details on data 
collection sample and sample demographics can be observed Chapter 2 (Methodology).  
6.4.2 Design and variables 
Data collection during the TILDA study involved a Computer Assisted Personal 
Interview (CAPI), conducted on a two-yearly basis. To date, data pertaining to four waves of 
TILDA data collection are available. In the present study Latent Transition Analysis (LTA) was 
conducted using data from the first three study waves.  
6.4.3 Measures 
The derivation of latent classes was based upon four indicators available in each wave of 
the TILDA data capture. During the CAPI interview, respondents were asked the following 
questions:  
• HU005-In the last 12 months, about how often did you visit your GP? 
• HU007-In the last 12 months, how many times did you visit a hospital Emergency 
Department as a patient? 
• HU008-In the last 12 months, about how many visits did you make to a hospital as an 
outpatient? 
• HU010-In the last 12 months, on how many occasions were you admitted to hospital 
overnight? 
In the case of variable HU008, respondents were advised that outpatient visits included all 
types of consultations, tests, operations, procedures, or treatments (Kenny et al., 2010). These 
questions remained the same in subsequent data collection waves, irrespective of the fact that 
data collection was conducted on a biennial basis.  
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*Steps not included in analyses presented in the present chapter 
Respondents self-reported a total count value for each of these questions, which were 
reported as ordinal categories in the publicly available dataset from wave two onwards. 
Number of GP visits was reported in the following categories none, 1-4, 5-9, 10-14, and 15+ 
visits. For ED, outpatient and inpatient visits data was presented in the following categories 
none, single visit, and multiple visits (2+). Wave 1 data was available at a continuous level and 
was thus recoded to align with the aforementioned ordinal categories.   
6.4.4 Analytical plan 
Analysis was completed using Mplus version 8.1. Analysis was guided as per the 
methodology outlined by Ryoo and colleagues (2018), as illustrated in Figure 6-2.  
Figure 6-2: Summary of LTA model building procedure from Ryoo et al., (2018)
Preliminary analysis was conducted at a cross-sectional level, with latent class analysis 
conducted on Waves 1 to 3 separately. Measurement models ranging from 1-5 latent classes 
were specified for each of the three time points as a preliminary step to model building. 
Manifest indicators used at each wave included GP, ED visits, outpatient visits, and inpatient 
admissions. These indicators were coded as follows 
Step 0: Explore data at 
a cross-sectional level 
using Latent Class 
Analysis (LCA)
Step 1: Test 
measurement 
invariance using LTA
Step 2: Define the 
latent statuses
Step 3: Test latent 
statuses and transition 
probability invariance
Step 4: Include 
covariates*






• GP: none=0; 1-4 =1; 5-9 =2; 10-14 =3; 15+ =4 
• ED: none =0; single visit =1; and multiple visits (2+) =2 
• Outpatient: none =0; single visit =1; and multiple visits (2+) =2 
• Inpatient: none =0; single visit =1; and multiple visits (2+) =2  
 
Figure 6-3: Latent transition model examined using three waves of TILDA data 
Latent class analysis was conducted using the Maximum Likelihood estimator. With 
mixture models it is possible that multiple maxima of the likelihood often exist (Muthén & 
Muthén, 1998-2017). Thus, it is advised to use more than one set of starting values in order to 
find the global maximum. The highest loglikelihood value should be replicated in a minimum of 
two final stage solutions, in order to rule out a local solution having been reached (Muthén & 
Muthén, 1998-2017). If the loglikelihood has not been replicated as such interpretation of the 
model should not continue without further investigation. Thus, analysis was commenced using 
the default number of initial stage random sets of starting values of 20 and final stage 
optimisations of 4, increased where required to ensure convergence to a global maximum 
(Muthén & Muthén, 1998-2017).  
Following the fitting of a one class model, additional classes should be included on an 
incremental basis, one at a time, in order to identify which model provides the best fit to the 
data (van de Schoot Sijbrandij, Winter, Depaoli & Vermunt, 2016). Van de Schoot and 
colleagues (2016) argue that the inclusion of additional classes need not cease once model fit 
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stops improving, but rather that, at a minimum, one or two additional models should also be 
explored in order to ensure that all possible models has been investigated thoroughly.  
Selection of the optimum number of classes at each wave was based upon a review of 
the Akaike Information Criterion (AIC; Akaike 1981), Bayesian Information Criterion (BIC; 
Schwarz, 1978), the sample size adjusted BIC (ssBIC; Sclove, 1987) and entropy as well as a 
review of the substantive value of the classes observed. Lower AIC and BIC values indicate 
better model fit.  Entropy assess the accuracy of classification into the most likely class and can 
range from 0 to 1; higher scores represent greater classification accuracy. The Vuong- Lo-
Mendell Rubin (VLMR) likelihood ratio test and the Lo-Mendell Rubin (LMR) adjusted LRT were 
used to compare neighbouring class models (e.g. two vs. three class etc.) to determine 
whether the inclusion of an additional class led to an improvement in model fit. A non-
significant LMR p value favours the selection of the k-1 solution.  
Van de Schoot, Sijbrandij, Winter, Depaoli and Vermunt (2016) advocate that more 
than one model comparison tool should be used to select the final model. There is some 
consensus regarding the utility of BIC to evaluate model fit for LCA models (Nylund, 
Asparouhov & Muthen, 2007; van de Schoot et al., 2016). However, the evaluation of model fit 
and selection of the optimal number of classes should not solely be determined by statistical 
criteria; it has been argued that a judgement call on the part of the researcher will also be 
required (Chen, Curran, Bollen, Kirby & Paxton, 2008; Collins & Lanza, 2010; van de Schoot et 
al., 2016). Parsimony and interpretability of the latent classes should also play a role in model 
selection (Collins & Lanza, 2010). In a case where fit indices disagree with respect to the 
optimal number of classes, van de Schoot and colleagues (2016) argue that this finding should 
be acknowledged within the text. 
In the LTA model building, model fit was examined primarily by comparing differences 





2020). Raftery (1995) provides guidance such that a BIC difference of >10 provides very strong 
evidence for a better fitting model. The likelihood-ratio statistic (G2) is commonly used to 
assess absolute model fit, whereby a p value for G2 can be generated via comparison to the 
chi-square distribution that corresponds to the degrees of freedom in the model (Collins & 
Lanza, 2010). However, G2 can be impacted by the phenomenon of sparseness, which indicates 
the degree to which the average expected cell count is small (Collins & Lanza, 2010). 
Sparseness can be considered to be a function of the total sample size N and the size of the 
contingency table W, expressed as N/W (Collins & Lanza, 2010). Collins and Lanza (2010) argue 
that sparseness can occur quite readily, even in the presence of large sample sizes when the 
contingency table is large, such as that found in complex latent class models including LTA.  
In the analysis presented here the contingency table would follow a 5 x 3 x 3 x 3 
pattern resulting in 135 cells, with each cell representing a particular response pattern to the 
four questionnaire items (GP, ED, Outpatient, and Inpatient). Furthermore, Maydeu-Olivares 
and Cai (2006) express caution with the use of G2 as a measure of absolute model fit. In the 
case of comparisons where the least restrictive model has been misspecified, differences in G2 
are no longer appropriate, as in this instance the G2 statistic does not approximate the χ2 
distribution (Maydeu-Olivares & Cai, 2006). Owed to the possibility of sparseness becoming an 
issue, concerns regarding assurances that G2 meets the chi-square distribution and advice to 
Mplus users (Asparouhov, 2020) it was decided to examine model fit in LTA using BIC. 
Measurement invariance over time was conducted by comparing a model with freely 
estimated item-response probabilities with one in which these were constrained to be equal 
over time. Thus, measurement invariance assumes that any observed class differences in 
terms of latent class prevalence are purely quantitative in nature, with some classes larger 
than others and remaining so over time (Zammit et al., 2020).   
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6.5 Results  
Table 6-1 summarises healthcare utilisation in terms of GP, ED, outpatient, and 
inpatient visits at the three times points examined in LTA. Usage of secondary healthcare 
resources such as ED, outpatient and inpatient admissions was less common in comparison to 
usage of primary care resources of GP visits. Considerably fewer TILDA participants reported 
no GP visits in comparison with frequencies that endorsed no ED, outpatient, or inpatient 
visits.  
Table 6-1: Descriptive statistics for healthcare utilisation across three waves of TILDA data collection  










GP visits     
None  1022 (12.5) 700 (8.6) 485 (5.9) 442 (5.4) 
1-4 5033 (61.6) 4448 (54.4) 4079 (49.9) 3624 (44.3) 
5-9 1243 (15.2) 1127 (13.8) 986 (12.1) 933 (11.4) 
10-14 666 (8.1) 444 (5.4) 438 (5.4) 356 (4.4) 
15+ 200 (2.4) 184 (2.3) 127 (1.6) 91 (1.1) 
Missing     
Refused to answer 1 (0.0) - 2 (0.0) - 
Responded ‘do not know’ 10 (0.1) 14 (0.2) 11 (0.1) 11 (0.1) 
System missing - 1258 (15.4) 2047 (25.0) 2718 (33.2) 
     
ED visits     
None  6943 (84.9) 5808 (71.0) 5081 (62.2) 4527 (55.4) 
Single visit 901 (11.0) 834 (10.2) 798 (9.8) 729 (8.9) 
Multiple visits (2+) 323 (4.0) 273 (3.3) 241 (2.9) 199 (2.4) 
Missing     
Refused to answer 1 (0.0) 1 (0.0) 2 (0.0) - 
Responded ‘do not know’ 7 (0.1) 1 (0.0) 6 (0.1) 2 (0.0) 
System missing - 1258 (15.4) 2047 (25.0) 2718 (33.2) 
     





None  4824 (59.0) 3761 (46.0) 3439 (42.1) 3030 (37.1) 
Single visit 1315 (16.1) 1271 (15.5) 1125 (13.8) 1020 (12.5) 
Multiple visits (2+) 2029 (24.8) 1881 (23.0) 1553 (19.0) 1401 (17.1) 
Missing     
Refused to answer 1 (0.0) - 2 (0.0) - 
Responded ‘do not know’ 6 (0.1) 4 (0.0) 9 (0.1) 6 (0.1) 
System missing - 1258 (15.4) 2047 (25.0) 2718 (33.2) 
     
Inpatient admissions     
None  7115 (87.0) 5956 (72.9) 5255 (64.3) 4600 (56.3) 
Single admission  770 (9.4) 681 (8.3) 625 (7.6) 623 (7.6) 
Multiple admissions (2+) 287 (3.5) 278 (3.4) 244 (3.0) 230 (2.8) 
Missing     
Refused to answer - 1 (0.0) 2 (0.0) 1 (0.0) 
Responded ‘do not know’ 3 (0.0) 1 (0.0) 2 (0.0) 3 (0.0) 
System missing - 1258 (15.4) 2047 (25.0) 2718 (33.2) 
 
Step 0: Explore data at a cross-sectional level 
Prior to commencing LTA building, cross-sectional data was examined using LCA, as 
advocated by Ryoo and colleagues (2018). The goal of this preliminary examination was to 
identify the existence of distinct homogenous groups at each of the three time points and to 
determine if the same number of latent classes was observed at each of the three times 




Table 6-2: Results of LCA for healthcare utilisation indicators at each wave of TILDA data collection (Step 0) 
# 
classes 
Fit indices Likelihood ratio 
tests 
Entropy 
LL BIC ssBIC AIC VLMR 
p  
Adjusted 
LMR p  
 
Wave 1       
1 -25070.680 50231.447 50199.669 50161.360    
2 -23622.332 47433.647 47366.913 47286.464 <.0001 <.0001 .649 
3 -23426.318 47140.915 47039.225 46916.636 <.0001 <.0001 .591 
4 -23323.546 47034.467 46897.821 46733.092 <.0001 <.0001 .717 
5 -23283.704 47053.878 46882.277 46675.408 1.00 .1.00 .611 
6 -23273.510 47131.867 46925.309 46676.301 .5873 .5902 .627 
Wave 2       
1 -21506.693 43101.804 43070.026 43033.387    
2 -20215.639 40616.954 40500.221 40473.277 <.0001 <.0001 .675 
3 -20042.490 40367.915 40266.227 40148.979 <.0001 <.0001 .555 
4 -19959.411 40299.016 40162.372 40004.821 .0005 .0005 .661 
5 -19930.033 40337.520 40165.921 39968.066 .0004 .0005 .586 
Wave 3       
1  -18911.826 37910.856 37879.079 37843.653    
2  -17719.070 35261.267 35554.535 35480.141 <.0001 <.0001 .711 
3  -17571.965 35422.979 35321.292 35207.930 <.0001 <.0001 .609 
4  -17525.931 35426.836 35290.193 35137.863 .0466 .0486 .669 
5 -17498.980 35468.857 35297.260 35105.961 .9625 .9632 .618 
Note. LL= log likelihood; VLMR = Vuong-Lo-Mendell Rubin. The best solution for the 
corresponding fit index is indicated in bold. A six-class solution could not be identified at Wave 
2 or Wave 3.  
 
At Wave 1 BIC and entropy favoured a 4-class solution, whilst ssBIC and AIC suggested 
a five-class solution. The Lo-Mendell Rubin (LMR) tests favoured the selection of a four-class 
solution. An examination of the probability plots (Appendix K) suggested that the inclusion of a 
fourth class did not provide any additional meaningful interpretations. Furthermore, the 
inclusion of a fourth class resulted in the formation of two small classes both comprised of 7% 





Nylund et al., (2007) argue that if the LMR incorrectly identifies a model, it generally 
tends to overestimate the number of classes present., Nylund and colleagues (2007) further 
argue that if using LMR and one obtains a non-significant p value for LMR, one can have 
reasonable confidence that it indicates the maximum number of classes present, but also that 
there might actually be fewer classes. The authors further argue that overestimation of the 
number of classes is preferable to an underestimation, “as the true k class solution can still be 
extracted from the k+1 class solution” (Nylund et al., 2007, p. 562). It could be the case where 
one of the classes in the k+1 solution may be very small, and thus hard to identify or that one 
of the classes does not make substantive sense (Nylund et al., 2007). Thus, the researcher may 
be justified in selecting the k class solution despite the LMR identifying a k+1 solution.  
Meus, van de Schoot, Klimstra and Branje (2011) also contend that if the addition of 
another class results in the formation of a class which is a slight variation of one already in 
existence, then the more parsimonious solution should be accepted. Given that the selection 
of the optimal number of classes should not be conducted using statistical criteria alone (Chen 
et al., 2008, Collins & Lanza, 2010; van de Schoot et al., 2016) and that parsimony and 
interpretability of the classes are key considerations (Collins & Lanza, 2010), the more 
parsimonious three-class solution was selected as the optimal solution.  
For Wave 2 BIC, ssBIC and entropy favoured a four-class solution. The AIC suggested a 
five-class model as the optimal solution. The likelihood ratio tests could not be conducted as a 
six-class solution was not identified within the data irrespective of an increase to 2000 starts 
and 500 final stage optimisations. The inclusion of a fourth class resulted in the identification 
of two classes in the middle of the distribution that were not qualitatively different from one 
another. The inclusion of a fifth class resulted in a similar plot, with the three classes in the 
middle of the distribution showing some small distinctions. However, one of the classes at the 
extreme end of the distribution was very small (approx. 3%) and another class comprised of 
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only approximately 6% of the sample. When considering transitions between classes, the next 
step in the analysis, each class should represent at least 5% of the sample in order to facilitate 
such transitions (Meus et al., 2011). Thus, a three-class solution was selected on the grounds 
of parsimony and interpretability.  
At Wave 3 the BIC favoured a 3-class solution, the ssBIC favoured a 4-class solution, 
AIC favoured a 5-class solution and entropy favoured a 2-class solution. The likelihood ratio 
tests favoured a 4-class solution. A 6-class solution could not be identified within the data. The 
inclusion of a fourth class did not add any meaningful contribution despite having a more 
favourable ssBIC. The addition of a fifth class resulted in two classes with little discernible 
difference. Furthermore, two of the classes comprised of 6-8% of the sample. Again, a 3-class 
solution was identified as the most meaningful explanation of the data. 
Based upon the meaningful interpretation provided by the 3-class solution it was 
selected as the basis for further analysis using LTA.  Ryoo and colleagues (2018) previously 
found two classes at the centre of a four-class solution to merge when specified as a three-
class LTA, whereas the classes at either end of the distribution were found to remain relatively 
unchanged. Ryoo et al., (2018) argue that in a more diverse sample the distinction between 
these two classes may become more apparent.  
Step 1: Test measurement invariance using LTA 
Following the preliminary cross-sectional LCA analysis, an LTA model was specified, 
following which longitudinal measurement invariance was tested. Item thresholds were 
constrained to be equal over time. Results indicated that the measurement invariance held 
(Table 6-3), with the decrease in BIC of 221.742 in excess of Raftery’s (1995) recommendations 






Table 6-3: Results of longitudinal measurement invariance for three class LTA (Step 1) 
 Loglikelihood # free 
parameters 
BIC ssBIC AIC Entropy 
Non-
invariance 
-51137.812 104 103182.569 102852.085 102483.624 .733 
Invariance  -51288.560 44 102960.827 102821.007 102665.120 .735 
Step 2: Define the latent statuses 
Based upon the probabilities for each of the four indicators of healthcare utilisation 
the three latent statuses were defined as effective referral (LS1), multiple utilisation (LS2), and 
primary care only utilisation (LS3) (Table 6-4). The effective referral utilisation (LS1) status was 
characterised by higher probabilities of multiple GP visits and outpatient visits with a low 
probability of ED visits and inpatient admissions. This status was defined as an ‘effective 
referral’ as it was characterised by higher probability of GP and outpatient visits in 
combination with a low probability of ED visits or inpatient admissions.  The multiple utilisation 
status (LS2) showed moderate probabilities of endorsement of the various categories of GP 
visits, with thus, a low probability of endorsing the ‘no GP visit’ category.  
Table 6-4: Probabilities of item parameters of healthcare utilisation across three waves of TILDA data collection 
  Latent status 
 Response LS1 LS2 LS3 
GP visits None .002 .014 .188 
 1-4 .517 .417 .771 
 5-9 .313 .299 .039 
 10-14 .137 .178 .003 
 15+ .031 .093 .000 
ED visits None .925 .314 .947 
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 Single visit .075 .465 .048 
 Multiple (2+) .000 .222 .005 
Outpatient None .319 .217 .791 
 Single visit .252 .209 .139 
 Multiple (2+) .429 .574 .071 
Inpatient None .945 .324 .983 
 Single visit .055 .452 .015 
 Multiple (2+) .000 .224 .002 
Note. Bold indicates probability >.20. 
 
Furthermore, probabilities of endorsement of ED visits, outpatient visits and inpatient 
admissions were much higher for LS2 than either of the other latent statuses. The primary care 
only utilisation (LS3) status consisted of a high probability (.771) of endorsing 1-4 GP visits 
within the last year and low probabilities of endorsement of secondary healthcare such as ED, 
outpatient, or inpatient healthcare usage.   
 




































The latent status prevalence and transitions across the three waves can be observed in 
Table 6-5. The probabilities of being in the effective referral group were relatively high across 
the three time points: 0.28 at Wave 1, 0.30 at Wave 2 and 0.28 at Wave 3. The prevalence 
rates indicated that the multiple utilisation group were the lowest among the three statuses, 
0.14 at Wave 1, 0.14 at Wave 2 and 0.17 at Wave 3. Also, the prevalence rates indicated that 
the probabilities of being in the primary care only utilisation group were the highest across all 
three waves.  
Table 6-5: Latent status prevalence (δ) estimates and transition matrix (τ) estimates of healthcare utilisation over 
three time points 
 δ estimate   τa estimate  τb estimate 
Time LS1 LS2 LS3   LS1 LS2 LS3  LS1 LS2 LS3 
1 .2791 .1352 .5858  LS1 .774 .200 .026  .704 .225 .071 
2 .3011 .1436 .5553  LS2 .405 .369 .226  .414 .394 .192 
3 .2804 .1653 .5543  LS3 .043 .074 .884  .035 .080 .885 
Note. LS1 = effective referral utilisation; LS2 = multiple utilisation; LS3 = primary care only 
utilisation. a Transition matrix from Wave 1 (rows) to Wave 2 (columns). b Transition matrix 
from Wave 2 (rows) to Wave 3 (columns). Bold indicates probability >.20. 
 
The effective referral status (LS1) tended to stay within this status from Wave 1 to 
Wave 2 (.774) and also from Wave 2 to Wave 3 (.704). As discussed in Chapter 2 
(Methodology), data collection was conducted at approx. two-yearly intervals. Similarly, the 
primary care only utilisation (LS3) status tended to stay within the LS3 group from Wave 1 to 
Wave 2 (.884) and from Wave 2 to Wave 3 (.885). The multiple utilisation (LS2) status were 
more likely to transition into effective referral (LS1) (.405) from Wave 1 to Wave 2 rather than 
stay within LS2 (.369). The multiple utilisation group were also less likely to transition into the 
primary care only utilisation group (.226) in comparison to staying within LS2 from Wave 1 to 
Wave 2. When the transition from Wave 2 to Wave 3 was examined, the multiple utilisation 
group were more likely to transition into the effective referral status (.414) than remain within 
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LS2 (.394). However, that said more movement was evident for LS2 at both time transitions in 
comparison with either of the other two statuses.  
Step 3: Test transition probability invariance 
Transition probability invariance of the three-status model was tested and reported in 
Table 6-6. The results indicated that the invariant model had lower AIC and BIC values. 
Furthermore, Δ BIC= 45.881 provided evidence for a better fitting model (>10) when 
considered according to the recommendations of Raftery (1995).  
Table 6-6: Results of transition probability invariance for three latent status solution 
 Loglikelihood # free 
parameters 
BIC ssBIC AIC Entropy 
Non-
invariant 
-51288.560 44 102960.827 102821.007 102665.120 .735 
Invariant  -51291.781 38 102914.946 102794.192 102659.562 .733 
 
6.6 Discussion 
The present study used latent transition analysis to ascertain whether meaningful 
groups or latent statuses characterised by different types of healthcare utilisation by older 
adults could be identified across three different time points. Preliminary analysis using LCA 
identified three distinct classes of healthcare utilisation that were replicated across the three 
time points. Whilst comparative fit indices and likelihood ratio tests suggested the possibility 
of a 4-class or 5-class solution, a review of the probability plots indicated that no substantive 
additional interpretation was to be gleaned by the inclusion of additional and often small 
classes (Appendix K). Accordingly, LTA analysis proceeded using a 3-class solution. The three 
classes observed indicated a larger class of low healthcare utilisation restricted to primary 





referral healthcare utilisation), and a third smaller class with a higher probability of multiple 
types of healthcare usage across both primary and secondary care.  
Measurement invariance, a fundamental aspect of LTA model building was 
established, as indicated by the reduction in BIC signalling improved model fit. Thus, the class 
patterns identified were equivalent over time, indicating no differences in the latent statuses 
at each measurement occasion. Constraining the transition probabilities over time also 
resulted in a reduction in BIC, indicating an improvement in model fit.  
In general, over half of the cohort were found to display healthcare usage that 
consisted of GP visits only (LS3), and this proportion of the sample remained relatively stable 
over time. Similarly, just under a third of the sample was comprised of effective referral 
utilisation, displaying a high likelihood of endorsing GP visits as well as outpatient visits. Such a 
status is not surprising given that GPs largely act as the gatekeepers to other forms of 
healthcare usage, particularly in the form of referral to specialists. The co-occurrence of a high 
likelihood of outpatient visit endorsement suggests that this status can be defined as an 
appropriate step up to required care when necessary. All of the latent statuses identified in the 
present study were characterised by moderate to high probabilities of endorsing GP visits, 
reinforcing the view that GPs are central to healthcare for older people within Irish society 
(Barrett et al., 2011; Collins, O’Shea, Cunniffe & Finegan, 2018) and lending support to the 
contention that primary care must be adequately resourced in order to meet the healthcare 
demands of increasing complexity associated with multiple chronic conditions (HSE, 2017). The 
smallest status prevalence belonged to the multiple utilisation group (LS2) who exhibited a 
likelihood of endorsing all four of the healthcare utilisation indicators.  
With respect to probability of transitioning from one latent status to another over the 
three waves of TILDA data collection, the results indicated that movement between the 
statuses was more likely to occur for LS1 and LS2 statuses. Moving from LS2 into LS1 could be 
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seen to be an improvement in chronic disease management for the individual and can be 
observed to occur from Wave 1 to Wave 2, as well as from Wave 2 to Wave 3. The probability 
of transitioning from LS1 to LS2 was slightly higher from Wave 2 to Wave 3 and could be 
indicative of those participants who were in LS2 at Wave 1, had transitioned into LS1 at Wave 
2 and who were then transitioning back to LS2 by Wave 3. 
Transitions out of, as well as into the multiple utilisation (LS2) status may serve as 
potential targets for future study. This will be further explored in Chapter 8 through the 
incorporation of covariates into the model to explain what governs these transitions. The 
identification of both pathways (into LS2 and out from LS2) as a future study target not only 
provides an opportunity to deepen our understanding of healthcare usage within this cohort 
more broadly, but also aids in comparing the differential impact of those factors which have 
high mutability on health service usage.  
The results presented here indicated that healthcare utilisation by older people in the 
Republic of Ireland (ROI) is relatively stable across approximately six years, with the majority of 
participants remaining within their status during this time. Transitions that did occur were out 
of the multiple utilisation group either into the primary care only utilisation or effective referral 
utilisation groups. The majority of older adults were observed to adopt healthcare utilisation 
patterns that were stable over time, namely those in LS1 and LS3. Both of these latent statuses 
were characterised by moderate to high probabilities of endorsing GP visits and/or outpatient 
visits, with low probabilities of ED visits and inpatient admissions. Thus, usage of more 
expensive secondary care is perhaps less prevalent than would previously have been thought. 
The identification of heterogeneity in healthcare utilisation within the TILDA cohort 
provides clarity to the contention that all older people are frequent attenders to the different 
healthcare access points across the primary-secondary care interface. The multiple utilisation 





identified, indicating that multiple types of healthcare usage by older people may not be as 
prevalent as the general concern regarding adequate healthcare provision for this cohort 
would suggest.  
The analysis presented herein must be considered in light of several methodological 
limitations. The number of categories of GP visits was different from that of the other 
healthcare utilisation indictors. It is possible that the fewer category levels in the ED visits, 
outpatient visits and inpatient admission variables may absorb some of the heterogeneity in 
existence within the sample. The publicly available form of the TILDA dataset reports 
categorical information in such a way as to ensure the anonymity of respondents is 
maintained. Thus, in the present study, the lack of a more granulated assessment of secondary 
care healthcare usage could not be overcome. Future replications of the current analysis could 
be considered in collaboration with TILDA researchers on the original dataset through analysis 
conducted at the secure data location site.  
The present study utilises self-report healthcare utilisation data which is subject to 
recall bias on the part of the participant. Furthermore, the disparity between the interview 
questions regarding healthcare utilisation (in the last 12 months) versus other study questions 
(since the last time of interview approximately 24 months) also increases the risk of reporting 
error.  
Wallace et al., (2018) compared healthcare utilisation rates of a sub-sample of TILDA 
participants with a comparable cohort where such information was available in an electronic 
medical record. In multivariate analyses adjusted for cofounders such as age, gender, number 
of prescribed medications, education, social class, health insurance coverage there was no 
difference between the two cohorts in the number of GP visits and outpatient visits reported. 
However, TILDA respondents reported more ED visits. Wallace and colleagues (2018) propose 
that the possibility of underreporting of ED visits in the GP’s electronic medical record must be 
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also be considered, given that patients may not report all visits to the GP and issues can arise 
with respect to the receipt of electronic notifications for ED visits from secondary care. Thus, 
whilst the limitations of self-report healthcare utilisation data must be borne in mind, such 
reporting need not undermine the value of such information, which ordinarily may be more 
difficult to gather by other means.  
The data examined in the present study included all individuals who were aged 50 
years and over at the first Wave 1 interview and are thus a considerably younger cohort of 
individuals than those examined in earlier chapters. Whilst there is no consensus on a cut-off 
age by which one is considered to be an older person, the proportion of TILDA participants in 
the present study who were aged 65 years or older by Wave 3 was 55%. This was an increase 
compared with Wave 1, where 39% of the sample who provided data up until Wave 3 were 
aged 65 years or older. Given the considerable length of time between the 3 waves of TILDA 
data capture (approx. six years) it was considered prudent to include all participants who could 
have become aged 65 years by Wave 3. Thus, rather than to reduce the sample size available, 
an important consideration for longitudinal studies where attrition is an ongoing challenge, it 
was decided to include all TILDA participants who were aged 50 years and over at Wave 1 and 
exclude those aged below this threshold. Such a strategy would better facilitate comparisons 
with other studies conducted using the TILDA data, which have been largely conducted using 
participants aged 50 years and upwards.  
Furthermore, the examination of a cohort from the ROI limits the direct comparisons 
that can be made with the Northern Irish samples examined in Chapters 3 and 4, given 
considerable differences in the provision of universal healthcare between both jurisdictions. 
That said, within ROI those older adults over the age of 70 years qualify for universal 
healthcare, in addition to those whose income falls below the means-tested threshold. Future 





relevant to the NI population once sufficient waves of data collection have been conducted in 
the NICOLA study. The analysis presented here provides an adequate foundation for such 
future work.  
Notwithstanding the aforementioned limitations, the present study may serve to 
support better allocation of resources to support those older adults who access multiple 
healthcare services. It has been estimated that 30-60% of healthcare costs relate to the care of 
older adults (Hasan et al., 2017). The analysis presented here has identified that only 15% of 
community dwelling older adults in Ireland use multiple healthcare services at both primary 
and secondary care levels. A further 30% utilise GP and outpatient services. Notably, 
considerable movement between these two types of usage profiles occurs over time. 
Movement from effective referral utilisation to multiple utilisation indicates an increase in 
healthcare need that is not being met in a timely manner by existing service interactions. 
Prolonged waiting times for outpatient specialist appointments and procedures can lead to an 
escalation of care usage when the clinical status of the individual deteriorates further in the 
intervening period. Yet, despite this, a reduction in the number of acute care beds has been 
observed internationally (Appleby, 2013). Furthermore, an increase in the number of hospital 
admissions and readmissions for older adults has been observed (Godden et al., 2019). An 
ageing population, with increased levels of clinical complexity, is likely to exert additional 
demands upon health services for many years to come.  
It is increasingly being recognised that older adults may benefit more from integrated 
models of care provided within the communities within which they live (DOH, 2001; HSE, 
2017). Hospital admissions themselves can lead to declines in physical and cognitive 
functioning of older adults (Covinsky et al., 2003; Hirsch et al., 1990), stressing the need for a 
responsive model of care that provides the appropriate level of healthcare in the right setting 
for the individual.  Fundamental to the delivery of such a responsive model is the need to 
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prioritise care for those older adults who have greater healthcare needs. The identification of 
those characteristics that differentiate between latent populations of healthcare service usage 
may provide valuable opportunities where interventions can be targeted to prevent 
unnecessary escalation to multiple service use.  
6.7 Conclusion 
To date, there has been a lack of studies that have examined changes in healthcare 
utilisation by older people over time. The results indicated that three latent statuses of 
healthcare utilisation could be discerned within the sample population. Measurement 
invariance also indicated that these latent statuses remained stable over the three 
measurement occasions, which occurred at two-yearly intervals. The findings presented here 
support the view that the identification of latent sub-populations of healthcare utilisation 
provides a more nuanced view of healthcare usage by older people over and above the 
examination of individual indicators of healthcare usage. What was particularly interesting was 
that the greater levels of transitioning across statuses was for the LS2 cohort, as evidenced in 
their lower probability of remaining within this status from Wave 1 to Wave 2 and from Wave 
2 to Wave 3. Given that this status was defined as those with multiple types of healthcare 
usage it is necessary to ask the question as to what influences the transition from this status 
into that of others? Similarly, movement into LS2 from other latent statuses requires further 
characterisation. This evidence will be further built upon in the following two chapters through 
an examination of longitudinal change in a range of theoretically relevant covariates, in 
preparation for their inclusion to explain the transition between statuses observed here.  Of 
particular interest is to identify the characteristics that best describe those older people who 







7 A multidimensional model of healthcare utilisation: selection 
and examination of relevant covariates for further analysis 
7.1 Chapter overview 
The purpose of this chapter is to serve as a foundation to the analyses presented in 
Chapter 8. This chapter functions to identify and operationalise potential covariates which may 
explain differences in healthcare utilisation patterns, as identified in Chapter 6 (latent 
transition analysis). This chapter will identify, select, and prepare covariate variables for 
inclusion in the subsequent multivariate analyses presented in Chapter 8.  In order to retain 
the breadth of possible covariates for inclusion in Chapter 8, this chapter seeks to summarise 
the longitudinal change that occurs in these covariates themselves using data reduction 
techniques. 
7.2 Introduction 
The Andersen Behavioural Model (Andersen, 1968, 1995; Andersen & Newman, 1973) 
proposes that the decision to access healthcare services is influenced by a multitude of factors, 
which could be broadly characterised as either predisposing, enabling or need factors. This 
conceptual framework proposes the broader view that environmental and social 
characteristics influence healthcare usage in addition to individual health behaviours. Thus, 
according to this model, utilisation of health services must be considered within the context of 
aspects such as occupation, educational attainment, location of residence, and access to 
transport and not merely regard clinical diagnoses, symptoms, and disability level.  
Taking a broader view of what governs healthcare usage may prove advantageous for 
service planning and delivery. Within the context of a rapidly growing ageing population it is 
imperative that those factors that influence service usage are identified. The identification of 
demographic characteristics that show differential associations with patterns of healthcare 
usage can augment census information with respect to planning for future service provision. 
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Whilst many disease characteristics may not be modifiable, the identification of additional 
factors, with greater degrees of mutability, may also allow for the development of an adaptive 
service. 
The conceptual work of Andersen and colleagues (Andersen, 1968, 1995; Andersen & 
Newman, 1973) provide a systematic means of identifying potential covariates for examination 
without being prescriptive in what must be included. Rather, their work proposes categories 
for consideration. Therefore, the framework can be adapted to consider aspects that are more 
relevant to the population under examination. For older adults, an accumulation of factors 
over the life course may result in a considerable number to be considered. Table 7-1 outlines 
how such factors may be considered within the framework, with examples provided for each 
category.  
Table 7-1: Possible characteristics that influence health service utilisation (adapted from Andersen & Newman, 1973) 
Predisposing Enabling Illness/need 
Demographic Family Perceived 
e.g. age, sex, marital status e.g. income, health 
insurance, access to services 
e.g. symptoms, diagnoses, 
disability level 
Social structural  Community Evaluated 
e.g. education, occupation, 
family size 
e.g. urban/rural character, 
region of country, services 
available 
e.g. symptoms, diagnoses 
Beliefs   








Furthermore, Andersen (1995) considers that a relationship exists between healthcare 
service use itself and the triad of predisposing, enabling, and need factors. In other words, 
existing use of health services may influence future use of health services via these categories. 
For example, a healthcare visit that results in the initiation of a new sedative medication, could 
limit ability to drive and thus restrict access to future healthcare visits, if no other means of 
transport is accessible to the individual. Similarly, a hospital admission may alter a person’s 
attitudes towards health services thereby influencing future engagement with similar services. 
Thus, not only must we consider the breadth of factors that come to influence levels of health 
service usage, but also that which influence service utilisation going forward. The findings 
identified in Chapter 6 indicate that subpopulations of healthcare usage exist within the older 
Irish adult population, differentiated by intensity of service usage. Noticeable movement 
between these latent statuses was identified over three time points. The next logical step is to 
understand what governs movement from one status to another. In order to facilitate this step 
consideration must be given to potential covariates for inclusion.  
7.2.1 Multimorbidity 
Improvements in life expectancy, largely due to advances in public health including 
improved sanitation, air quality, housing, education, nutrition, antibiotics, vaccinations and 
chemotherapeutic advances, has resulted in the need for chronic disease management within 
the population, which is associated with higher levels of healthcare utilisation (Hutt et al., 
2004; Lehnert et al., 2011). An estimated one third of emergency admissions to NHS hospital 
beds among those aged 65 years and older are related to chronic conditions (Hutt et al., 2004). 
Multimorbidity, the presence of multiple chronic conditions, is also consistently shown to be 
more prevalent among older sections of the population (Violan et al., 2014). Among those 
aged ≥65 years prevalence estimates range from 55-83% in England, 65-82% in Scotland, 80-
87% in Spain (Barnett et al., 2012; Cassell et al., 2018; Violan et al., 2013). Among those 
Australians aged ≥75 years it is estimated that 83% have multimorbidity (Britt et al., 2008). An 
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examination of Medicare beneficiaries aged ≥65 years in the US revealed that 43% had ≥ 3 or 
more chronic conditions and 24% had ≥ 4 chronic conditions (Wolff et al., 2002). An analysis of 
the top 5% of highest cost patients treated within the US Veterans Affairs health system 
identified that 77% of them reported ≥3 chronic conditions and 41% reported ≥ five chronic 
conditions (Zulman et al., 2015). Hernandez, Reilly & Kenny (2019) report that the lifetime 
prevalence of multimorbidity to approximate 73% in the TILDA cohort.  
Management of multimorbidity places additional demands on health services and can 
be evidenced in the increased expenditure observed in the US, where healthcare spending on 
multimorbidity care increased from 78% in 1998 to 84% by 2010 (Anderson, 2010).  In the US, 
approximately 80% of Medicare expenditure relates to those with four or more chronic 
conditions (Wolff et al., 2002). Anderson (2010) postulates that healthcare spending for one 
chronic condition is approximately three times greater than that for someone with no chronic 
illness, and that it is approximately 17 times greater when someone has ≥5 long term 
conditions. Båhler et al., (2015) reported higher cost estimates from their analysis of insurance 
claims data among community-dwelling older people in Switzerland. Total healthcare costs 
were 5.5 times higher for multimorbid patients when compared with those with none or only 
one long term condition (Båhler et al., 2015). Each additional chronic condition was associated 
with a 33% increase in costs and 3.2 additional consultations (Båhler et al., 2015).  In addition 
to the degree of multimorbidity, the number of healthcare consultations in the previous year 
was also a significant predictor of healthcare utilisation, congruent with findings from Chapters 
3 and 4 (Båhler et al., 2015).  
Those with multimorbidity are more likely to be hospitalised, have longer hospital 
stays, receive more prescription medications, and have increased physician visits (Cassell et al., 
2018; Glynn et al., 2011; Marengoni et al., 2011; Palladino et al., 2016). It is estimated that 





2008). In a study examining a large cohort representative of the UK adult population, it was 
found that approximately 53% GP consultations, 79% of prescriptions and 56% of hospital 
admissions were accounted for by those with multimorbidity (Cassell et al., 2018). 
Furthermore, the costs and risk of avoidable hospital admissions increase dramatically with the 
number of comorbidities (Wolff et al., 2002).  Those with ≥ 4 chronic conditions were more 
than 90 times more likely to experience a hospitalisation that could have been prevented with 
more appropriate care at a primary care level and a hospital admission with preventable 
complications (Wolff et al., 2002).  
Boyd and Fortin (2010) claim that those with multimorbidity are less likely to have 
their needs met by modern healthcare systems, arguing that existing systems are fragmented, 
incomplete, and thus ineffective. There is considerable evidence that the distribution of 
multimorbidity, and thus associated healthcare needs, is influenced by other demographic 
factors in addition to age. Those who live alone are more likely to report multimorbidity and 
single disease morbidity than those living as a couple (Savva & McDaid., 2011). Associations 
have also been identified between a higher likelihood of multimorbidity and lower 
socioeconomic status (Barnett et al., 2012; Cassell et al., 2018; Savva & McDaid, 2011; Violan 
et al., 2014).  This risk has been shown to be more pronounced for those living in Northern 
Ireland than in the Republic of Ireland (Savva & McDaid, 2011). Furthermore, regional 
differences in levels of multimorbidity have been identified across Northern Ireland and the 
Republic of Ireland, with approximately a 2% variance in multimorbidity across ROI but a 4% 
variance observed across Northern Ireland (Savva & McDaid 2011).  
In light of such evidence it is unsurprising that Boyd and Fortin (2010) argue for an 
approach to care that is patient-centred and family-centred and away from a focus on single 
disease management. Thus, the adage ‘the whole is greater than the sum of its parts’ aptly 
captures the need for a broader perspective when considering healthcare service need, and 
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thus supply. The accumulation of many factors over the life course demands that any 
evaluation of healthcare utilisation by older people incorporate a comprehensive assessment.  
7.2.2 Frailty 
Increasing attention is being placed upon the functional status of older people as 
opposed to chronological age when examining medical need within this cohort. Frailty is a 
multidimensional state or condition of increased vulnerability characterised by an inability to 
maintain homeostasis in the presence of stressors, underpinned by an age-related decline in 
physiological reserve (Rockwood et al., 2005; Xue, 2011). It is typified by diminished strength, 
reduced physical functioning and exhaustion accompanied by unintentional weight loss and 
loss of muscle mass (Fried et al., 2001). More specifically, Fried and colleagues (2001) 
operationalised the frailty phenotype as a syndrome comprised of three or more criteria 
including unintentional weight loss (10 lbs in the past year), self-reported exhaustion, 
weakness (measured using grip strength), slow walking speed and low levels of physical 
activity. In this context, a relatively minor stressor, such as an infection or the addition of a 
new medication, leads to a dramatic and disproportionate change in the status of the 
individual, resulting in dramatic consequences (Clegg, Young, Iliffe, Rikkert & Rockwood, 2013). 
The older person may transition “from independent to dependent; mobile to immobile; 
postural stability to falling; lucid to delirious” (Clegg et al., 2013, p. 753).  
 Notably, frailty may possess some overlap with comorbidity and disability but is 
nevertheless a distinct state which poses independent risks for adverse events among older 
people including an increased risk of falls, increased disability, hospitalisation, 
institutionalisation, and death (Ensrud et al., 2008; Fried et al., 2001; Rockwood et al., 2004). 
An intermediate or pre-frail state is indicated by the presence of one or two of these criteria 
and is accompanied by an increased risk of becoming frail in the intervening three to four years 





Frailty has also been operationalised using a cumulative deficits approach whereby a 
risk index is calculated to represent the proportion of deficits that have been accumulated 
(Mitnitski, Mogilner & Rockwood, 2001). Indicators selected for assessment as deficits are 
varied but broadly speaking include symptoms, diseases, disability, and results of clinical 
investigations. Thus, a frailty index can be considered as a quantitative assessment of the 
frailty syndrome that seeks to assess aging at an individual level (Mitnitski et al., 2001). Hence, 
“the frailty index can be considered a state variable, in that it characterises the whole health of 
individuals and validly classifies risk across a wide range of people” (Rockwood & Mitnitski, 
2007, p. 725). In doing so, the frailty index provides a more sensitive measure to examine 
associations with outcomes, rather than the phenotypical approach which may be more 
beneficial in a clinical setting (Rockwood, Andrew & Mitnitski, 2007).   
Deficit accumulation frailty indices have been shown to predict mortality, disability, 
falls and institutionalisation (Rockwood et al., 2005; Rockwood & Mitnitski, 2007; Searle, 
Mitnitski, Gahbauer, Gill & Rockwood, 2008; Shi, McCarthy, Mitchell & Kim, 2020; Song, 
Mitnitski & Rockwood, 2010). Frailty has also been shown to be associated with increased 
levels of GP and practice nurse consultations, hospital admissions and hospital length of stay 
(Han et al., 2019). A retrospective longitudinal analysis of the Clinical Research Datalink in the 
UK identified that the rate of consultations and admissions increased with increasing severity 
of frailty, equating to a total annual cost to the NHS of £5.8 billion per annum (Han et al., 
2019).  
7.2.3 Polypharmacy 
Older adults who are pre-frail and frail are more likely to receive polypharmacy than 
those who are non-frail (Palmer et al., 2019; Saum et al., 2017). The significant association 
between polypharmacy and pre-frailty or frailty persists even following adjustment for 
comorbidity (Palmer et al., 2019). Furthermore, those who receive polypharmacy are at a 
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higher risk for incident frailty at 3 year follow up (Saum et al., 2017). However, the lack of 
longitudinal studies examining polypharmacy and frailty limits any inferences that can be made 
regarding the causal direction that drives this association (Palmer et al., 2019). Furthermore, 
the breadth in definitions of polypharmacy make it difficult to conduct meta-analyses 
(Masnoon et al., 2017). The coexistence of frailty and polypharmacy deserves particular 
attention as those with both are found to have longer hospital lengths of stay, more discharges 
to nursing homes and are more likely to be readmitted to hospital (Rosted et al., 2016).   
Previous examinations of polypharmacy defined as ≥5 medications, within the TILDA 
cohort identified an increase in point prevalence from 21% at Wave 1 to 26% at Wave 2 
(TILDA, 2014).  Using the same threshold definition for polypharmacy, an examination of 
prescription claims data for older Irish adults (≥65 years) living in the former Eastern Health 
Board region reported an increase in polypharmacy from 18% in 1997 to 60% in 2012 
(Moriarty, Hardy, et al., 2015). During the same period, inappropriate prescribing was found to 
increase from 32% to 37%. An updated examination of the year 2013 revealed that 64% of 
those aged 45 years and older were in receipt of polypharmacy (Tatum, Curry, Dunne, Walsh & 
Bennett, 2019). 
7.2.4 Falls 
Experiencing a fall is an additional healthcare concern among older adults. 
Approximately 28-35% of those aged ≥ 65 years fall each year, with an increased prevalence 
observed in those >70 years (WHO, 2007). Those older adults residing in long-term care have 
higher rates of falls and tend to experience falls with more serious complications such as 
fractures (Rubenstein, 2006). Functional impairment, cognitive impairment, altered gait, 
cardiovascular disorders, and the use of psychotropic medications are all recognised risk 
factors for falls (Gama & Gómez-Conesa, 2008; Rubenstein, 2006; Stenhagen, Ekström, Nordell 





In the UK, 30% of falls-related ED visits and 65% of falls-related hospital admissions 
occur in those aged ≥ 65 years (Scuffham, Legood, Wilson & Kennedy-Martin, 2002). The cost 
of falls is considerable, totalling £981 million in the UK for the year 1999, with 66% of costs 
attributable to fallers aged ≥ 75 years (Scuffham, Chaplin & Legood, 2003). ED attendances and 
hospital admissions were more prevalent among those aged ≥ 75 years, accounting for 66% of 
total attendances and 78% of admissions, respectively. Those aged ≥75 years were found to be 
four times more likely to be admitted following an unintentional fall compared with those 
aged 70-74 years, and 11 times more likely to be admitted when compared to those aged 60-
64 years (Scuffham et al., 2003). Older fallers were more likely to be admitted into long-term 
care following an unintentional fall; 8.6% of those aged 70-74 years were admitted into long-
term care and this rose to 27% for those aged ≥ 75 years (Scuffham et al., 2003).  
Common outcomes from falls include hip fractures, other fractures, and traumatic 
brain injuries. An examination of 1760 falls-related hospitalisations among those aged ≥ 65 
years in the Eastern region of ROI in 2002 found that 82% had sustained a fracture, with 
approximately half of these found to be hip fractures (Carey & Laffoy, 2005). Females were 
found to be more likely to experience a fracture whereas males were more likely to experience 
a head injury (Carey & Laffoy, 2005), congruent with findings from a Finnish study (Nurmi & 
Lüthje, 2002). It is worth noting that these falls-related hospital admissions accounted for 76% 
of all admissions in the ≥ 65 years age group (Carey & Laffoy, 2005). Those resident in long-
term care accounted for 6.5% of hospitalisations and 11% of hip fracture cases (Carey & Laffoy, 
2005).  
Hip fractures are associated with longer hospital stays, increased likelihood of 
institutionalisation and death (Carey & Laffoy, 2005; Judge et al., 2016; Nazrun, Tzar, Mokhtar 
& Mohamed, 2014). It is estimated that between 26-31% of those who experience a hip 
fracture die within a year (Judge et al., 2016). Falls among older people are also related to 
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psychological sequelae. Several falls-related psychological concerns (Moore & Ellis, 2008), 
including fear of falling (Tinetti & Speechley, 1989) and falls-related self-efficacy (Tinetti, 
Richman & Powell, 1990) have been examined within the literature (Hughes, Kneebone, Jones 
& Brady, 2015). Such concerns can pose additional harm for the older person leading to 
avoidance of activity, social withdrawal, and muscle deconditioning. Psychological constructs 
such as anxiety and depression have shown some associations with fear of falling and falls-
related self-efficacy, however methodological limitations question the strength and 
consistency of identified associations (Hughes et al., 2015).  
7.2.5 Cognitive impairment 
Cognitive impairment, which is increasingly prevalent among older adults, also 
increases the risk for hospitalisation. Behavioural problems, such as agitation and wandering, 
place people with dementia at an increased risk of being admitted to hospital (Toot et al., 
2013). Those living with dementia possess greater risk of an orthopaedic crisis, such as a fall or 
fracture, resulting in hospital admission in comparison with those without dementia (Malone 
et al., 2009; Natalwala et al., 2008; Nourhashemi et al., 2001; Tuppin et al., 2009). People with 
dementia have also been found to be at greater risk of experiencing a respiratory crisis 
resulting in hospitalisation compared with people without dementia (Natalwala et al., 2008; 
Sampson et al., 2009; Tuppin et al., 2009). Similarly, they are at greater risk of experiencing a 
urological crisis, such as a urinary tract infection, leading to hospital admission, compared with 
people without dementia (Carter & Porell, 2005; Natalwala et al., 2008; Sampson et al., 2009; 
Tuppin et al., 2009). Furthermore, those with cognitive impairment experience a significantly 
longer length of stay on admission and when discharged to their usual place of residence are 
more likely to experience hospital readmission within 28 days, compared with those without 
cognitive impairment (Tropea et al., 2018). Such evidence indicates that cognitive functioning 





Altered cognition is also known to occur within older people during periods of acute 
illness and hospitalisation. Delirium is characterised by rapid onset of confusion and impaired 
awareness and is independently associated with adverse outcomes (Clegg et al., 2013). It is 
estimated that delirium occurs in approximately one quarter of older persons admitted to 
hospital, with an estimated prevalence of 15% in long-term care settings (Inouye et al., 2014; 
Clegg et al., 2013). Thus, healthcare utilisation in and of itself can result in alterations in 
cognition for older people. Alterations in cognition can also increase the potential for adverse 
drug event related hospitalisation as impairments in cognitive functioning can increase the 
difficulty for the older person to manage their medicines in a safe manner.  
7.2.6 Depression and anxiety 
Variation in functional status and cognitive function of older people has been shown to 
be related to depression (Song et al., 2014). The relationship may extend bidirectionally with 
poorer cognitive function and reduced functional status related to greater depressive 
symptoms in older adults (Vankova et al., 2008).  Poorer cognitive function and impairments in 
activities of daily living (ADLs) were found to be predictive to depressive symptomology, even 
when controlling for antidepressant medication use (Vankova et al., 2008). However, the 
significant relationship between depression and functional dependency among older people 
appears to be weaker in older old age (≥ 85 years) (Tomita & Burns, 2013).  
Depression may exacerbate the relationship between chronic illness and healthcare 
utilisation. A review of 161 studies that examined the association between depression and 
healthcare utilisation among those with long term conditions found an overall 49% increase in 
odds for urgent healthcare utilisation (Dickens et al., 2012). However, studies which included 
multivariate analyses reported equivocal findings (Dickens et al., 2012). Among community-
dwelling older adults, healthcare service utilisation has been shown to be higher for those with 
depressive mood (Roelands, Van Oyen, Depoorter, Baro & Van Oost, 2003). 
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The prevalence of depression and anxiety is high in both COPD and chronic heart 
failure (Yohannes, Willgoss, Baldwin & Connolly, 2010). Furthermore, it is estimated that 
patients with COPD and comorbid depression or anxiety have greater levels of healthcare 
utilisation and costs (Gudmundsson et al., 2005; Laurin et al., 2009; Maurer et al., 2008; Xu et 
al., 2008). Similarly, those patients with chronic heart failure and comorbid depression have 
been shown to have increased medical costs, increased likelihood of hospital readmission and 
longer hospital stays (Albert et al., 2009; Jiang et al., 2001; Sullivan, Simon, Spertus & Russo, 
2002). Depressive symptoms have been shown to be associated with increased risk of 
cardiovascular mortality among older adults (Win et al. 2011). A review of 31 studies found 
that hospitalisation rates, outpatient visits, emergency department visits, medication costs and 
overall healthcare costs are higher for those with diabetes who have comorbid mental 
disorders, such as depression, when compared with those without such comorbidity (Hutter, 
Schnurr & Baumeister, 2010).  
7.2.7 Healthcare provision in the Republic of Ireland 
Within the Irish healthcare system, GPs adopt the role of gatekeeper, with referrals 
made to specialist consultants when required. The ROI has a mixed private and publicly funded 
health service. Those with an income below a certain threshold are given access to free 
medical care under the General Medical Services (GMS) Scheme through the issuance of a 
medical card. These individuals are registered to a single GP and receive primary care services 
free at the point of access, as well as free secondary care within the public hospital system. 
They also receive access to free prescription medications, subject to an item levy for each item 
dispensed, as well as a range of additional health services including dental, optical, and aural 
services. Individuals who are above the threshold for a medical card may qualify for a GP visit 
card, which has a higher income threshold. Under this scheme the individual is entitled to free 
access to a registered GP but must pay for prescriptions and hospital charges where required. 





entitled to free public hospital services but have to pay inpatient and outpatient hospital 
charges. They must also pay for services at a primary care level at the point of access.  
For older Irish adults, a GP visit card is available to everyone over the age of 70 years 
irrespective of means. Many older Irish adults also qualify for a medical card as the income 
threshold is considerably higher for those aged over 70 years compared with those younger 
than 70 years. Those medical card holders over the age of 70 years also pay a lower rate of 
prescription levies. Additional schemes are in existence that provide free medical care based 
on healthcare need, including the Long Term Illness (LTI) Scheme which provide free medicines 
and appliances to those with a diagnosis from a list of qualifying conditions, irrespective of age 
or income. The GMS and LTI schemes are not mutually exclusive and thus individuals may have 
coverage under both.  
Owed to the mixed public-private provision many Irish adults subscribe to health 
insurance, with a range of coverage options available, including day to day primary care 
expenses and inpatient treatment in a private hospital. The relative cost of insurance policies 
means that many people who qualify for GMS do not have private health insurance. However, 
those who have paid into health insurance during their working life may opt to continue their 
health insurance coverage whilst they become eligible for free GP care at the age of 70 years. 
Thus, several health cover permutations exist in ROI, including no cover/entitlement, medical/ 
GP visit card only, medical /GP visit card and private health insurance, and private health 
insurance only.  
Several policy changes have taken place during the course of TILDA data collection, 
resulting in altered healthcare entitlements/costs for TILDA participants including: the 
introduction of means testing for medical card entitlement for those aged 70 years and older 
in 2009; reductions in the financial threshold for a medical card during austerity Budgets; and 
the introduction of universal free GP for the over 70s in 2015 (TILDA, 2018). Thus, when 
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considering trends of healthcare utilisation, it is important to consider changes in healthcare 
coverage over time.  
With respect to healthcare utilisation by older adults, the literature discussed thus far 
suggests that broad range of factors may exert an important influence. In order to fully 
appreciate the ‘dynamic and recursive nature’ (Andersen, 1995, p. 7) of health service usage 
the temporal element must also be considered within the breadth of factors examined. In 
order to build upon the heterogeneity in healthcare usage by older people identified within 
Chapter 6, it is necessary to consider the role of these key factors in describing qualitative 
differences in health outcomes, and by doing so identify those mutable characteristics which 
may serve as targets for increasing capacity and improving efficiency within the health service. 
A fundamental step to achieve this aim is to summarise change in those elements which 
influence service usage in a manner that facilitates an interpretable model. Thus, this chapter 
serves to examine potential variables, identified within the preceding literature, and seeks to 
summarise those which are time varying in a manner conducive to further analysis.  
7.3 Objectives 
• Examine key variables available within the TILDA data using the Andersen Behavioural 
Model as a framework for variable identification 
• Operationalise those selected variables, describing key steps taken to transform or 
summarise any variables for inclusion in subsequent multivariate analyses 
7.4 Method 
7.4.1 Sampling and participants 
  The present study utilised data from TILDA as introduced in Chapter 2 (Methodology). 
Data pertaining to the first three waves of data collection were used, in line with analysis 
reported in Chapter 6. Further details on data collection and sample demographics can be 





7.4.2 Design and variables 
This study operationalises relevant covariates for further analysis in Chapter 8, where 
the influence of these variables on patterns of healthcare utilisation identified in Chapter 6 will 
be explored. Figure 7-1 outlines potential covariates that will be explored and operationalised 
in the present chapter. The purpose of this chapter is to capture longitudinal change within 
these variables in a concise manner, thereby supporting the retention of a breadth of 
covariates in the multivariate analyses presented in Chapter 8. Data reduction of longitudinal 
change in numeric covariates is conducted using Latent Growth Curve Models (LGCMs). As 
such, three waves of data collection are summarised through the estimation of a unique 
intercept and slope value for each participant for each of these covariates. These intercept and 
slope values are then examined as predictors of the healthcare utilisation patterns in the 
analyses presented in Chapter 8.
 
Figure 7-1: Potential covariates for inclusion in further analysis, as per the Andersen Behavioural Model 
 
Variables were coded as follows: 
• Age: Continuous variable obtained from Wave 1. Continuous data with top coding such 
that those participants aged over 80 years at were coded as 80 years of age.  






















• Marital status: Categorical variable captured at Wave 1, coded as 1= married, 2=never 
married, 3= separated/divorced and 4=widowed.  
• Widowed: Two binary variables collected at Waves 2 and 3 indicating whether the 
participant had become widowed (coded 0=No, 1=Yes).  
• Education: Categorical variable from Wave 1, coded such that 1=primary/none, 
2=secondary and 3=third level/higher.  
• Employment: Three categorical variables collected at Waves 1-3, coded such that 
1=employed, 2=retired and 3=other.  
• Health cover: Three categorical variables collected at Waves 1-3, coded such that 1= 
no cover, 2=medical or GP visit card only, 3= private health insurance only and 4= 
medical/GP visit card AND private health insurance (dual cover). 
• Urban/rural location: Categorical variable from Wave 1, coded such that 1=Dublin city 
or county, 2= another town or city and 3=a rural area.  
• Falls history: Three binary variables were available at each wave indicating whether 
the participant experienced a fall in the last 12 months (coded 0=No, 1=Yes).  
• Frailty: Several variables were available within the data that could be operationalised 
to describe frailty status (see next section, Measures). 
• Polypharmacy: Number of medications (excluding supplements) recorded at each 
wave, top-coded at 10.  
• Depression: Measured at each wave and captured as a continuous score, ranging from 
0-24, with higher scores indicating greater depressive symptomology. 
• Anxiety: Measured at each wave and recorded as a continuous score, ranging from 0-
21, with higher scores indicating greater anxiety symptoms. 
• Cognition: Measured at each wave and recorded as a continuous score, ranging from 






7.4.3.1 Frailty (Frailty Index) 
An adapted frailty index was created using 30 of 32 functional deficits created by Roe 
et al., (2017), using the methodology of Searle et al., (2008). The 30 indicators were obtained 
from the CAPI questionnaire and can be observed in Appendix D. Two questions were omitted, 
‘feeling lonely’ and ‘presence of knee pain’, on the basis that they were not available in the 
publicly available dataset across all data collection waves. Furthermore, no suitable proxy 
measures were available. The variable indicating ‘daytime sleepiness’ (variable bh201) was not 
available across all waves and was substituted with variable mh007 ‘everything is an effort’ as 
the most suitable alternative. Exhaustion is considered to be a key aspect of the frailty 
syndrome and thus it was decided to retain an item with conceptual overlap rather than 
omitting it in its entirety. The final 30 indicators had no more than 1% missing data across all 
data collection waves.  
Indicators were scored between 0 and 1 as follows. For binary indicators, the presence 
of a deficit e.g. ‘has difficulty walking 100m’ resulted in a score of 1. The absence of said deficit 
was scored as zero. Categorical indicators with multiple response categories were scored in 
accordance with increasing severity. For example, three response categories of no difficulty, 
some difficulty, or much difficulty were scored as 0, 0.5 and 1. Those with four response 
categories were scored 0, 0.33, 0.66, and 1. Indicators with five possible response categories 
were scored 0, 0.25, 0.5, 0.75, and 1. A total frailty score was computed for each participant by 
summating their scores for each individual item. This total frailty score was then divided by the 
number of indicators (30) to provide a frailty index score, ranging from 0 to 1. Frailty indices 
were calculated for each of the first three waves of data. Indicators relating to a diagnosis of 
various morbidities e.g. hypertension, angina etc. were only available at Wave 1 and thus the 
calculation of frailty indices for Waves 2 and 3 were calculated using the information provided 
for these indicators at Wave 1 given their invariant nature.  
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7.4.3.2 Depression (CESD-8) 
Depression was measured during the CAPI using the Center for Epidemiologic Studies 
Depression (CES-D: Radloff, 1977) questionnaire. The CES-D comprises of 20 items designed to 
measure how often the respondent has felt in line with item statements in the previous week, 
scored using a Likert response. Following factor analytic examination by O’Halloran, Kenny and 
King-Kallimanis (2014) a short form version of the CES-D comprised of eight items has been 
used by the TILDA research team was used from Wave 3 onwards in order to reduce the 
possibility of response fatigue. These items were scored on a four-point Likert scale (0-3), with 
two positively worded items reverse scored. A total scale score was computed by summating 
all responses resulting in a possible range of scores between 0 and 24, with higher scores 
indicating greater depressive symptomology.  
7.4.3.3 Anxiety (HADS-A) 
Anxiety was measured using the seven-item anxiety scale of the Hospital Anxiety and 
Depression Scale (Zigmond & Snaith, 1983). Participants were asked to report the frequency of 
which they experience feelings in line with items statements during the past week. Items were 
scored on a four-point Likert scale (0-3), with responses to two items reverse scored. Total 
scale scores are summated resulting in a possible range of scores between 0 and 21, with 
higher scores indicating greater levels of anxiety.  At Wave 1 the HADS-A questionnaire was 
included in the self-completion questionnaire but at subsequent waves was included in the 
CAPI.  
7.4.3.4 Cognition (MMSE) 
Cognitive status at each wave was measured using a variety of measures. The analysis 
presented herein refer to the Mini Mental State Examination (MMSE; Folstein, Folstein & 
McHugh, 1975) which comprises of 11 tasks aimed at providing a global assessment of 





attention and calculation, recall, and language. Examples of tasks include asking the date and 
location, completing the serial 7’s task and recall of words provided earlier in the assessment. 
Scores are calculated as per the MMSE scoring instructions such that a maximum that can be 
scored is 30, with higher scores indicating better cognitive performance. Further details on 
MMSE scoring can be obtained from the TILDA release guide (TILDA, 2020). At Wave 1 the 
MMSE assessment was conducted during the health assessment, whereas at subsequent 
waves it was included during the CAPI.  
7.4.4 Analytical plan 
A review of the Andsersen Behavioural Model and the available variables was first 
conducted to identify any variables that required computation. During this preliminary step it 
was identified that certain variables of interest such as illness or comorbidity level were not 
readily available within the data and would thus require the creation of new variables. 
Furthermore, several enabling factors such as health coverage and employment status were 
available at each wave but would require additional transformation in order to capture their 
relative stability. Thus, further categorical variables were created to describe the change in 
categorical variable as either change or no change. Several variables were available within the 
data that could be operationalised in order to describe frailty status. Thus, an adapted Frailty 
Index was created, following the previously reported methodology of Roe and colleagues 
(2017), established within the TILDA data (see Measures section and Appendix D).  
The change over time of those covariates which were numeric (frailty, anxiety, 
depression, polypharmacy, and cognition) were further summarised using latent growth curve 
models (LGCM). Growth models explore the development of individuals on an outcome over 
time, using random effects to describe individual differences in development (Muthén & 
Muthén 1998-2017). LGCM analysis allows for the examination of intraindividual change over 
time as well as the interindividual variability in this intraindiviudal change (Preacher, Wichman, 
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MacCallum & Briggs, 2008). Thus, growth models seek to estimate between-person differences 
in within-person change (Curran, Obeidat & Losardo, 2010). 
Individual trajectories are composed of fixed and random effects. The fixed effect 
represents the value within the population (e.g. population mean) and the random effect 
represents the random probability distribution around the fixed effect (population variance) 
(Curran et al., 2010). Thus, the fixed effect is the mean of the trajectory, incorporating all of 
the individual trajectories within the sample and the random effect is the variance in individual 
trajectories around this group mean (Curran et al., 2010). Crucially, random effects allow for 
the estimation and thus further exploration of individuals’ intercept and slopes.  
In LGCM, change is modelled as a function of time, represented through the 
specification of two latent growth factors, intercept, and slope, based upon individual 
trajectories (Felt, Depaoli & Tiemensma, 2017). The intercept represents the initial status 
whereas the slope describes the rate of change over time. These growth factors summarise the 
average trajectory and individual variation around the average trajectory (Felt et al., 2017). 
Thus, LGCM allows for the estimation of intraindividual growth trajectories, through the 
estimation of an intercept and slope, whilst also simultaneously allowing the estimation of 
interindividual differences in these two parameters (Wu, West & Taylor, 2009). Several growth 
trajectories are possible including flat (no change over time), linear (either increasing or 
decreasing) or non-linear change (Curran et al., 2010). In the case of a linear growth curve the 
mean intercept (initial status) and the mean slope (rate of change) jointly inform of the 
underlying mean trajectory within the sample (Curran et al., 2010).   
Growth curve models can be estimated within structural equation modelling (Duncan, 
Duncan & Stryker, 2006; McArdle & Epstein, 1987), where observed repeated measures serve 
as indicators of one or more latent factors used to characterise the unobserved growth 





both intra- and interindividual variability in a construct in the form of intercept and slope 
values for each participant emerged as an attractive means of data reduction, without loss of 
key information, in advance of subsequent multivariate analyses (presented in Chapter 8).   
Latent growth curve models were specified using three observed variables, 
representing three waves of data collection, for each of the covariates. Factor loadings for the 
intercept latent factor were fixed at 1, such that the mean represented the average score of 
the covariate at Wave 1. Factor loadings for the slope latent variable were fixed at 0, 1, and 2, 
in order to specify a linear change trajectory (Figure 7-2).  
 
Figure 7-2: Linear specification of a latent growth curve model with three time points 
 
The latent growth models were specified in Mplus 8.1 using the robust maximum 
likelihood estimator (MLR) to account for missing data. Following the specification of a linear 
model, the residual variances were then constrained to be equal over time, to assess if any 
improvement in model fit could be obtained. Following this, the second slope parameter was 
allowed to be freely estimated, to investigate the possibility of a non-linear model as 
representative of the change trajectory for the population.  
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Fit statistics determine how well or how poorly a model fits the data examined. 
Goodness of model fit was examined using a combination of fit statistics including the 
Comparative Fit Index (CFI; Bentler, 1990), Tucker-Lewis Index (TLI; Tucker & Lewis, 1973) and 
the root mean square error of approximation (RMSEA; Steiger, 1980) and associated 
confidence intervals. RMSEA, CFI and TLI are suitable for evaluating the fit of growth curve 
models (Wu, West & Taylor, 2009). Preacher and colleagues (2008) recommend the use of 
RMSEA when assessing growth curve fit as it provides an estimate of misfit within the 
population and not merely an estimate of misfit in the sample. Furthermore, the available 
confidence intervals for RMSEA provide an insight into the precision of the fit index also 
(Preacher et al., 2008).  
CFI and TLI values are bounded by an upper limit of 1.0, with values close to 1.0 
indicating a model that fits the data well. Yu (2002) reported that a cut off value for CFI of 0.96 
had higher power to reject misspecified models. A TLI value above 0.95 indicates a well-fitting 
model (Hu & Bentler, 1999). An RMSEA value of .05 or lower indicates a close-fitting model in 
relation to the degrees of freedom (Browne & Cudeck, 1992; Duncan, Ducan & Strycker, 2006). 
Furthermore, an examination of RMSEA confidence intervals to ensure that they do not exceed 
0.08 is also required (Browne & Cudeck, 1992). The use of several fit statistics to evaluate 
model fit is advisable owed to different tolerance for identification of model misspecification 
(Wu et al., 2009). Relative model fit is also assessed using the AIC (Akaike 1981), BIC (Schwarz, 
1978) as well as the ssBIC (Sclove, 1987). Such criteria can be used to compare competing 
models, where the model with the lowest value is considered to be the best model. Felt et al., 
(2017) advise that should a discrepancy arise between some indices indicating model fit and 
others suggesting poor fit, an examination of the substantive theory surrounding the model 





When estimating the growth curves for covariates consideration was given to the role 
of missing data. Missing data can be accounted for in the estimation of growth models in two 
manners. The first is to use Maximum Likelihood (ML) estimation, such that the model is 
estimated as a summation of individual contributions of each case, with those with a larger 
number of data points weighted more heavily than those with fewer data points (Curran et al., 
2010). An alternative approach is multiple imputation, where the growth curve is estimated in 
a two-step procedure. The first is to impute the missing data using information from the non-
missing data, the imputation of which is conducted multiple times (Curran et al., 2010). The 
second step involves the specification of the growth mode line in each of the imputed data 
sets separately, with the results aggregated to provide a final set of estimates (Curran et al., 
2010).  
Estimation of models with missing data can be conducted in Mplus using both 
frequentist and Bayesian approaches (Muthén & Muthén, 1998-2017). In the case of Bayesian 
analysis multiple imputation can be conducted for missing data with the generation of 
plausible values for latent variables (Muthén & Muthén, 1998-2017). Modelling missing data in 
Bayesian analysis gives asymptotically the same results as maximum-likelihood estimation 
under missing at random conditions (Muthén & Muthén, 1998-2017). Thus, the specification of 
growth curves in the present study was conducted whilst simultaneously imputing missing 
data. This was conducted in a two-step manner. The first step involved the identification of the 
true model, specified using the robust maximum likelihood estimator (MLR) following 
frequentist methods, and the estimation of factor scores for the intercept and slope 
(Asparouhov & Muthén, 2010). Once identified, this true model was then specified, as per the 
guidance of Muthén & Muthén (1998-2017) in User Guide Example 11.7, using a Bayesian 
estimator with simultaneous data imputation. Using this methodology, plausible values for the 
latent factors (Asparouhov & Muthén, 2010; Mislevy, Johnson & Muraki, 1992; von Davier, 
Gonzalez & Misleavy, 2009) were obtained for inclusion in subsequent analysis (presented in 
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Chapter 8).  A total of 10 imputed data sets were created from which a distribution of factor 
scores, plausible values for the intercept and slope factors, was generated for each participant. 
7.5 Results 
Descriptive statistics for the covariates examined as explanatory factors in healthcare 
utilisation patterns among the TILDA cohort can be observed in Table 7-2.  
Table 7-2: Descriptive statistics for covariates examined in healthcare utilisation analysis 
Covariate Wave 1 
N = 8715 
Wave 2 
N = 6917 
Wave 3 
N = 6128 
Age M (SD) 63.53 (9.16) - - 
Sex n (%)    
Male 3744 (45.8) - - 
Female 4431 (54.2) - - 
Marital n (%)     
Married/cohabiting with partner 5638 (69.0) - - 
Never married 791 (9.7) - - 
Separated/divorced 551 (6.7) - - 
Widowed 1195 (14.6) - - 
Widowed n (%)    
No - 5900 (72.2) 5184 (63.4) 
Yes - 1017 (12.4) 944 (11.5) 
Education n (%)    
Primary/none 2504 (30.6) - - 
Secondary 3263 (39.9) - - 
Third/higher level 2404 (29.4) - - 
Employment status n (%)    
Employed  2934 (35.9) 2296 (28.1) 1927 (23.6) 
Retired 3046 (37.3) 2880 (35.2) 2905 (35.5) 
Other 2195 (26.9) 1741 (21.3) 1285 (15.7) 
Location n (%)    
Dublin city/county 1936 (23.7) - - 





Rural location 3916 (47.9) - - 
Healthcare coverage n (%)    
No public or private cover 842 (10.3) 620 (7.6) 530 (6.5) 
Private health insurance only 3281 (40.1) 2663 (32.6) 2366 (28.9) 
Medical card or GP visit card only 2621 (32.1) 2267 (27.7) 2007 (24.6) 
Dual cover 1418 (17.3) 1334 (16.3) 1214 (14.9) 
Fall in previous 12 months n (%)    
No  6590 (80.6) 5369 (65.7) 4666 (57.1) 
Yes 1583 (19.4) 1541 (18.9) 1460 (17.9) 
Polypharmacy M (SD) 2.33 (2.45) 2.75 (2.61) 2.83 (2.67) 
Frailty Index M (SD) 0.16 (0.12) 0.17 (0.12) 0.17 (0.11) 
Depression M (SD) 2.99 (3.84) 2.84 (3.76) 3.27 (3.84) 
Anxiety M (SD) 5.39 (3.64) 3.40 (3.36) 3.52 (3.43) 
Cognition M (SD) 28.29 (2.16) 28.46 (2.16) 28.45 (2.08) 
Note. Dual cover= medical card/GP visit card and private health insurance.  
 
Prior to the operationalisation of change in employment status, the employment 
categorical variables at each wave were first collapsed into binary variables, representing 
‘employed’ or ‘retired or other’. The ‘other’ category was considered to be distinct from 
employment as it would include those who were in receipt of unemployment benefit, disability 
benefit and those who would have been categorised as a homemaker for national insurance 
purposes. As the goal was to identify those covariates that may explain change in healthcare 
usage over time, the change from one type of social welfare status to that of another would 
not be as distinctive the change from employment into either retirement or one of these other 
categories. This binary categorisation was deemed prudent in order to investigate the effect of 
employment. Following the creation of three binary employment variables for each wave, two 
binary variables were created to represent change from Wave 1 to Wave 2 (coded 0=No, 
1=Yes) and from Wave 2 to Wave 3 (coded 0=No, 1=Yes). A further binary variable was created 
to represent change in employment from Wave 1 to Wave 3 (coded 0=No, 1=Yes).  
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Similarly, the change in category of health coverage was also summarised through the 
creation of two new binary variables, representing change in health cover between Wave 1 
and Wave 2 and between Wave 2 and Wave 3 (coded 0=No, 1=Yes). A further binary variable, 
‘cover changer’ was created such that those who experienced any change in health coverage 
between Wave 1 and Wave 3 could be identified. This binary variable was coded such that 
0=no change in healthcare coverage and 1=change in healthcare coverage at some point 
between Wave 1 and Wave 3.  
Falls history across the three waves was also summarised through the creation of a 
new binary ‘faller’ variable, representing those participants who reported a fall at any wave 
(coded 0=No, 1=Yes). Comorbidity at baseline was examined using a count of long-term 
conditions reported across multiple binary variables at Wave 1. These counts were then 
categorised as follows: 0=none, 1= one condition, 2=two conditions, and 3=three or more 
comorbidities. New onset illness was captured by counting the number of new incident cases 
of new disease reported by WHO International Statistical Classification of Diseases and Related 
Health Problems 10th Revision (ICD-10) between Wave 1 and Wave 2 and between Wave 2 and 
Wave 3. These new incident cases had been recorded using binary variables representing 16 
classifications of disease types within ICD-10. Count variables were created for Waves 2 and 3 
as a count of new incident disease across these 16 disease categories. These counts were then 
categorised using the same coding as the comorbidity variable.  Descriptive statistic for these 
newly operationalised variables can be observed in Table 7-3.  
Table 7-3: Descriptive statistics for additional covariates created for examination in further analyses 
Covariate Wave 1 Wave 2 Wave 3 
Change in employment n (%)  W1→W2 W2→W3 
No  - 6094 (74.5) 5290 (64.7) 
Yes  - 823 (10.1) 624 (7.6) 





No  - - 4756 (58.2) 
Yes  - - 1259 (15.4) 
Faller n (%)    
No - - 3284 (40.2) 
Yes - - 3267 (40.0) 
Change in healthcare coverage n (%)  W1→W2 W2→W3 
No - 6035 (73.8) 5234 (64.0) 
Yes - 839 (10.3) 655 (8.0) 
Healthcare coverage change n (%)   W1→W3 
No - - 4694 (57.4) 
Yes - - 1308 (16.0) 
Comorbidity n (%)    
None 1210 (14.8) - - 
1 1720 (21.0) - - 
2 1699 (20.8) - - 
≥3 3546 (43.3) - - 
New incident disease n (%)    
None - 5109 (62.5) 5831 (71.3) 
1 - 2141 (26.2) 1726 (21.1) 
2 - 729 (8.9) 492 (6.0) 
≥3 - 196 (2.4) 126 (1.5) 
 
Fit statistics for latent growth curves can be observed in Table 7-4. An examination of 
the fit statistics, in particular RMSEA, and associated confidence intervals, CFI and TLI favoured 
the selection of linear growth models, with residuals constrained to be equal over time, for all 
covariate examined, except anxiety. For Anxiety, allowing the second slope parameter to be 
freely estimated resulted in an improved model fit. Parameter estimates for each of the 
LGCMs can be observed in Table 7-5, with plots for each LGCM shown in Figures 7-3 to 7-7. 
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Table 7-4: Fit statistics for growth curves for frailty, depression, polypharmacy, anxiety, and cognition 
 LL AIC BIC ssBIC RMSEA CFI TLI SRMR 
FRAILTY         
MLR, linear 22237.824 -44459.647 -44405.882 -44431.304 .051 (.032, .074) .997 .991 .007 
MLR, linear, residuals constrained 22237.396 -44462.791 -44422.468 -44441.534 .019 (.007, .033) .999 .999 .010 
DEPRESSION         
MLR, linear -48620.705 97257.411 97311.176 97285.754 .086 (.066, .108) .971 .913 .024 
MLR, linear, residuals constrained -48621.873 97255.747 97296.071 97277.004 .034 (.023, .048) .986 .986 .022 
POLYPHARMACY         
MLR, linear -36208.429 72432.858 72486.623 72461.201 .095 (.074, .116) .984 .952 .015 
MLR, linear, residuals constrained -36234.335 72480.670 72520.993 72501.927 .054 (.043, .067) .984 .984 .017 
ANXIETY         
MLR, linear‡  -44355.997 88727.994 88781.757 88759.336 .314 (.293, .335) .797 .392 .085 
MLR, linear, residuals constrained  -44375.644 88763.288 88803.611 88784.545 .161 (.149, .174) .839 .839 .075 
MLR, residuals constrained, time 2 freed -43936.878 87887.756 87934.799 87912.555 .030 (.016, .046) .996 .994 .016 
MMSE         
MLR, weightings, linear ‡  -34239.936 68495.871 68549.636 68524.214 .094 (.074, .116) .975 .924 .041 
MLR, linear, residuals constrained  -34250.778 68513.555 68553.879 68534.812 .041 (.029, .054) .986 .986 .154 





Table 7-5: Summary of parameter estimates (standard errors) for covariate growth curve models specified for subsequent analyses 
Parameter Frailty Depression Polypharmacy Anxiety MMSE 
Latent variable means      
Intercept mean .157 (.002) * 2.94 (.057) * 2.28 (.036) * 5.443 (.056) * 28.304 (.035) * 
Slope mean .009 (.001) * .158 (.030) * .327 (.013) * -.954 (.026) * .022 (.017) p = .195 
Slope loadings      
Wave 1 0 0 0 0 0 
Wave 2 1 1 1 2.070 1 
Wave 3 2 2 2 2 2 
Intercept-slope correlation .000 (.000) p = .908 -.731 (.212) p =.001 .046 (.046) p = .319 -.755 (.135) * .070 (.072) p = .328 
Variances      
Intercept variance .011 (.000) * 8.56 (.499) * 5.02 (.147) * 8.891 (.363) * 2.782 (.235) * 
Slope variance .000 (.000) * .728 (.147) * .287 (.031) * .351 (.079) * .075 (.052) p = .151 
Residual variances      
Wave 1 .002 (.000) * 6.702 (.231) * 1.040 (.040) * 4.617 (.144) * 1.640 (.072) * 
Wave 2 .002 (.000) * 6.702 (.231) * 1.040 (.040) * 4.617 (.144) * 1.640 (.072) * 
Wave 3 .002 (.000) * 6.702 (.231) * 1.040 (.040) * 4.617 (.144) * 1.640 (.072) * 



































Figure 7-5: Non-linear growth curve for anxiety, with residual variances constrained to be equal4 
 























































The present chapter sought to identify suitable covariates for inclusion in analyses to 
explain identified patterns of healthcare utilisation by older Irish adults. Using the Andersen 
Behavioural Model (Andersen, 1968, 1995; Andersen & Newman, 1973) as a guide for 
potential variable selection, several variables from each of the first three waves of TILDA data 
were first examined using descriptive statistics. Consideration was given to those variables 
which were time-varying by nature and how the dynamic change in these variables could best 
be captured, dependent on whether the variable was measured at a categorical or a 
continuous level.  
Several demographic variables, which could be considered as predisposing or enabling 
characteristics were reflected as categorical variables, some of which were not available at 
every wave of data collection. Marital status and location of residence were both available at 
baseline data collection but were not replicated in subsequent waves. In the case of marital 
status and additional variable representing widowhood as a binary variable was available at 
waves 2 and 3 and could thus be operationalised as a measure of a type of likely marital status 
change observed within an older cohort.  
Change in employment status was operationalised as new binary variables, reflective 
of whether an individual transition between employment and a retired/other category. It was 
theorised that a change into or out of employment would be the more prominent status 
change than perhaps a change between retirement and an ‘other’ category. By restructuring 
employment status as a binary measure at each wave new binary measures reflective of 
change between the waves could be created. Change in employment status could be 
hypothesised to influence healthcare usage in two ways. A greater availability of time for those 
who became retired may increase the likelihood of attending a GP during normal visiting 
hours, and/or decrease the likelihood of attending ED outside of hours. Alternatively, a 
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decrease in income may reduce the likelihood of healthcare service usage if costs were 
prohibitive. Based upon the binary recategorisation it was observed that 15% of the original 
sample reported a change in employment status from Wave 1 to Wave 3.  
An observance of change in healthcare coverage indicated that similar proportions of 
individuals possessed dual healthcare cover (public and private) throughout the three waves. 
Differences in the proportions of those who reported no healthcare cover were observed at 
the three data collection points. Given the existence of historical changes in healthcare 
entitlements it was decided to examine movement in healthcare cover type. It was not 
possible to isolate changes in healthcare cover that would result in increased coverage from 
those of decreased coverage. Specifically, no assessment could be made regarding the level of 
private insurance cover that an individual possessed, only the presence or absence of such 
cover. Therefore, it could not be ascertained whether those with dual cover had a greater 
degree of private health cover than those who reported having a private insurance policy only. 
It is entirely possible that those with dual cover (public and private insurance) may have had a 
more limited health insurance policy than those relying solely on private health insurance. 
Thus, new variables were created to represent any change in cover between the time points. 
Between Wave 1 and Wave 3 a total of 16% of the baseline sample reported some change in 
healthcare coverage.  
A similar proportion of older Irish adults reported a fall at each of the three waves of 
data collection, with approximately one fifth of the sample reporting a fall at each time point. 
When considered over the longer term, Wave 1 to Wave 3 approximately twice that number 
experienced a fall. Such findings suggest that there is variance in fall occurrence within the 
sample with some perhaps reporting only one fall over the three waves of data collection and 





In terms of examining those health need factors to be incorporated consideration was 
given to the manner in which comorbidity could be operationalised over time using 
information available within the dataset. At Wave 1 a number of binary indicators for chronic 
conditions were captured e.g. hypertension, diabetes mellitus, arthritis etc. These binary 
variables were used to categorise level of comorbidity using a count of conditions that was 
then categorised as none, one, two or three and above.  At each subsequent wave, new ICD-10 
indicators were reported providing information as to whether the individual had an incident 
case diagnosed according to the ICD-10 criteria which was recorded by body system e.g. 
disease of the eye, disease of the digestive system, certain infectious diseases etc. At Wave 2 
and Wave 3 a count was conducted across all of the ICD-10 variables and also categorised in 
the same manner as the comorbidity level. Between one fifth and one quarter of participants 
reported at least one new ICD-10 diagnoses, 6-8% two new diagnoses and 1-2% three or more 
new diagnoses, between the data collection waves.  
However, a fundamental limitation of the ICD-10 categorical variables was that they 
only indicated the body system which the diagnosis related to but gave no indication of the 
acute or chronic nature of these diagnoses. Thus, it was difficult to isolate those acute self-
limiting illnesses, such as an infective episode, from the development or diagnosis of a new 
chronic condition. The challenge in mapping these ICD diagnoses onto the original binary 
variables used to create the comorbidity categorisation created a limitation in how change in 
comorbidity burden over time could be accounted for.   
Furthermore, a concern regarding conceptual overlap with elements used to create 
the frailty index and the possibility of issues of multicollinearity arose during variable 
preparation. It is somewhat reasonable that frailty may possess more utility when examining 
older cohorts, as it considers not only the presence of a chronic illness but also provides an 
estimation of the functional capacity of the individual living with said chronic illness. Thus, it 
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perhaps can be argued that frailty provides a more nuanced view of the burden of chronic 
illness and thus may serve as a more sensitive indicator of health service need among older 
adults. Therefore, on the basis of eliminating potential multicollinearity and retaining 
information that would infer the functional status of the individual it was decided to omit the 
comorbidity variable from subsequent analysis and instead include frailty as a covariate.  
Frailty has been shown to be related to adverse events among older people including 
an increased risk of falls, increased disability, hospitalisation, institutionalisation, and death 
(Ensrud et al., 2008; Fried et al., 2001; Rockwood et al., 2004). Frailty indices have also been 
described as a means of characterising the “whole health of individuals” (Rockwood & 
Mitnitski, 2007, p. 725) and thus serves as a more holistic assessment than the inclusion of a 
count of chronic conditions instead. Furthermore, the significant association between pre-
frailty or frailty states and polypharmacy has been shown to persist even when one accounts 
for comorbidity (Palmer et al., 2019). Those who receive higher numbers of medications are 
also at higher risk for incident frailty at three year follow up (Saum et al., 2017).  
Latent growth curve analysis with data imputation was used to summarise change in 
several health need variables including frailty. LGCM allows for the incorporation of both 
nomothetic and idiographic aspects of change over time (Preacher et al., 2008), thereby 
situated, as argued by Curran and Willoughby (2003), at the “intersection between variable-
centred and person-centred analysis” (p. 603). This estimation identified a trend of increasing 
level of frailty over time as indicated by the significant positive slope value. The prevalence of 
frailty has been found to increase with age (Buchman, Wilson, Bienias & Bennett, 2009; Collard 
et al., 2012; Lohman, Mezuk & Dumenci, 2017) and when assessed longitudinally has also been 
found to increase at a faster rate than that reported in cross-sectional studies (Hoogendijk et 
al., 2018). Furthermore, frailty status may increase more rapidly in the last year of life. Stow, 





electronic frailty index, and identified a distinctive frailty trajectory for those at highest risk of 
death. This was characterised by a rapid rise in frailty from a low base and followed by a 
plateau.  
The initial frailty status of the cohort, as indicated by the intercept mean, indicated 
that on average participants were in a pre-frail state as per Roe and colleagues’ (2017) 
threshold cut off values. A study of community-dwelling older Chinese adults found that 
approximately 50% of the sample were pre-frail when frailty was assessed using the Fried 
phenotype (Lee, Auyeung, Leung, Kwok & Woo, 2014).  At two year follow up approximately 
one quarter of these who were pre-frail at baseline improved in terms of frailty status, with 
men found to be more likely to experience a decline in frailty than women (Lee et al., 2014). 
Prevalence of frailty within community samples has been reported to be broad ranging, from 
4-49% due to differences in how the syndrome is operationalised (Collard et al., 2012).  
Nevertheless, the importance of considering an intermediate state of pre-frailty when 
examining change in frailty over time is evidenced in the systematic review findings of Kojima 
et al., (2019). A review of 16 studies which examined frailty using a 5-item phenotype found 
that improvements in frailty over time related to the intermediary state of pre-frailty. Of those 
who were identified as frail at baseline, 55% remained frail, only 3% transitioned to robust but 
40% transitioned to pre-frail. For those who were pre-frail at baseline, 58% remained prefrail, 
23% transitioned to robust and only 15% transitioned into a frail status (Kojima et al., 2019). 
Pre-frailty has also been identified in much younger adults. Hanlon et al., (2018) examined a 
sample of adults aged 37-73 years from the UK Biobank using a phenotype approach and 
found that 38% were identified as pre-frail. Whilst transitions between frailty states can occur 
in both directions, transitions to states of increasing frailty are more common than to states of 
lesser frailty, and the probability to transition from frail to non-frailty has been reported to be 
very low (Gill, Gahbauer, Allore & Han, 2006).  
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The LGCM analysis indicated that many health need covariates observed a linear trend, 
with polypharmacy showing a trend of increased numbers of medications over time. An 
examination of prescription trends in the US from 1988 to 2010 previously revealed that the 
median number of medications for those aged ≥65 years doubled from two to four, and the 
proportion of those prescribed ≥ 5 medications tripled, from approximately 13% to 39% 
(Charlesworth, Smit, Lee, Alramadhan & Odden, 2015). Gao, Maidment, Matthews, Robinson 
& Brayne (2017) report similar dramatic increases in medication numbers among older adults 
living in England. An examination of two comparable studies conducted in 1991-1994 and 
2008-2011 found that the proportion of older adults prescribed five or more medications 
increased from 12 to 49%, representing a four-fold increase (Gao et al., 2017). Furthermore, 
the proportion of those not taking any prescribed medication was found to decrease from 
approximately 20% to approximately 8% (Gao et al., 2017).  
Given the preponderance for clinical best practice guidelines in chronic disease 
management it is not unusual to observe an increase in the number of medications prescribed 
for a given condition, irrespective of comorbidity. For example, over time an individual living 
with diabetes mellitus may require additional medication for optimum blood glucose control 
and may also receive additional medication as primary prevention for cardiac events, the risk 
of which increases with advancing age. Furthermore, improvements in life expectancy have 
largely been attributed to advances in medical treatments and as such many of us are living 
with more chronic conditions, necessitating the use of multiple medications. Thus, the focus 
has begun to shift away from considering the absolute number of medications to the relative 
appropriateness of each medication. In the present data it was not possible to assess 
appropriateness of pharmacotherapy. However, the estimation of an intercept and slope for 
polypharmacy serves as a useful indicator as to whether growth in medication burden is 





An increasing trend was also observed for depression (Figure 4). A LGCM with the 
second time point allowed to be freely estimated resulted in a worse model fit (not reported) 
and so whilst the plot indicates an observed decrease at Wave 2, the overall trend is one of 
increasing scores over time, albeit a small increase, when one observes the scale on the y-axis. 
Depression scores were measured on a scale of 0-24, with higher scores indicating greater 
depressive symptomology and so overall depression scores were observed to be low among 
the cohort.  
In contrast to depression, freeing the second time point for anxiety resulted in a better 
fitting curve (Figure 7-5). Anxiety scores were found to decrease by approximately two points 
on average, between Wave 1 and Wave 2 before then increasing slightly between Wave 2 and 
Wave 3. Given the magnitude of change in anxiety score between these time points it is 
evident that a non-linear growth curve would provide a better representation of the data. 
Several possible mechanisms may explain this non-linear change trajectory within the TILDA 
sample. At Wave 1 the anxiety questionnaire was included in the SCQ assessment, whereas 
subsequent data collection was conducted using the CAPI. Thus, whilst missing data was less 
evident at Wave 1, the reporting of lower scores at Waves 2 and 3 could represent a socially 
desirable type of response pattern.  
Interestingly, the growth parameters for both depression and anxiety were found to 
exhibit divergent trajectories. The average initial status for the cohort (intercept mean) 
indicated that participants began with a low score on the depression inventory and whilst this 
increased over time (positive significant slope), the increase was small, with depression score 
only increasing by .158 points at each wave. Given that the scale ranged from 0-24, overall 
depressive symptomology was considered to be low. De la Torre-Luque et al., (2019) 
previously reported that between two-thirds and three-quarters of older adults in UK followed 
a trajectory of minimal depressive symptoms with an increasing pattern over time, never 
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exceeding the clinical cut-off. In contrast, anxiety showed a non-linear trajectory, beginning 
with a higher mean intercept value, which decreased over time.  
Depression is purported to be common among older adults with prevalence estimated 
to range between 17% and 35% (Horackova et al., 2019). However, challenges in diagnosing 
late life depression may lead to an underestimate of the prevalence of depression among older 
adults (Mitchell, Rao & Vaze, 2010). It has been argued that for older adults, declines in 
physical functioning and the presence of multimorbidity can overwhelm the ability to cope, 
thereby creating a vulnerability for anxiety and depression (Nelson et al., 2009).  
However, the literature reports conflicting findings with respect to depression and 
aging. Depressive symptoms have been shown to remain stable for those older than 70 years 
of age (Nguyen & Zonderman, 2006), and to exhibit a stable trajectory over as many as five 
waves of data collection (Lohman et al., 2017). Thomas et al., (2016) examined a sample of 
1,546 adults ranging in age from 21 to 50 years and compared age cohorts using polynomial 
regression to examine trends in physical and cognitive functioning with age. A linear 
improvement in anxiety and depression scores was identified (Thomas et al., 2016). This in 
contrast to studies which have identified a U-shaped curve for psychological wellbeing 
(Blanchflower & Oswald, 2008; Stone, Schwartz, Broderick & Deaton, 2010). 
A review of studies examining anxiety, depression and distress across the lifespan 
concluded that no consistent pattern could be identified (Jorm, 2000).  Some evidence 
suggesting an initial increased prevalence of anxiety and depressive symptoms across age 
groups which was then followed by a drop. The inclusion of additional risk factors in 
multivariate analysis revealed a more consistent pattern characterised by a decrease in 
anxiety, depression, and distress emergence across the age groups, suggesting that ageing may 
be associated with a reduction in anxiety and depression (Jorm, 2000). Similarly, Scott et al., 





50 and 90, in the absence of comorbid physical or pain conditions. In those with comorbidity, 
mental disorders peaked in middle age and decreased in older age (Scott et al., 2008). 
However, no significant difference was found in the relationship between age and mental 
disorders as a function of comorbidity (Scott et al., 2008). Byers, Yaffe, Covinsky, Friedman & 
Bruce (2010) examined the prevalence of mood, anxiety and comorbidity of mood and anxiety 
disorders in a nationally representative sample of the US population. Likelihood of having any 
disorder was found to exhibit a general pattern of decline with increasing age.  
Overall, cognitive status was found to remain both high and stable over the course of 
the first three waves of TILDA data collection, when assessed using MMSE. At a cohort level, 
no significant change in cognition was observed over time as indicated by the non-significant 
slope value. Terrera, Matthews and Brayne (2008) examined cognitive change across four 
waves of the Cambridge City over 75 Cohort Study. Latent growth models were combined with 
logistic regression to account for missing data. A quadratic curve, characterised by an initial 
decrease followed by a deceleration in the rate of decline was observed (Terrera et al., 2008).  
Such a finding is in in contrast with the stable trajectory observed in the present study and 
may reflect differences in the age profile of the respective cohorts. Furthermore, the present 
study is limited as only three repeated measures of MMSE over time were examined, 
eliminating the investigation of a quadratic model within the sample.  
Johnson et al., (2012) examined longitudinal cognition trends among healthy controls 
and individuals with mild cognitive impairment using latent growth modelling. A decline in 
memory was observed for both groups; however, a faster rate of decline was observed in the 
mild cognitive impairment group. Further declines were observed in the MCI group for non-
memory cognitive factors, whereas the control group did not report any such declines 
(Johnson et al., 2012). Mortality appears to be higher among those who exhibit faster cognitive 
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decline, irrespective of cognition at baseline, especially for those with normal baseline levels of 
cognition (Lv et al., 2019).  
The present study’s findings of a trajectory characterised by high levels of cognition 
which remain stable over time is aligned with the findings of an American and Canadian study 
which examined cognitive and functional change over time, by combining a clinical sample 
with healthy controls prior for analysis. Hochstetler et al., (2016) used growth mixture 
modeling (GMM) to identify latent classes of participants that could be characterised 
according to their divergent trajectories of cognitive and functional change over time. The 
sample comprised of those with Alzheimer’s Disease (AD), early or late mild cognitive 
impairment (EMCI or LMCI) and healthy controls. Assessments were conducted at baseline, six, 
12 and 24 months in approximately 1200 participants. GMM was conducted on the total 
sample irrespective of the presence of AD, EMCI, LMCI or absence of any cognitive 
impairment. Three quadratic trajectories were identified for cognitive and functional 
impairment. A small class was identified (approx. 14%) characterised by high degree of 
impairment at baseline and the steepest worsening trajectory. A much larger class (approx. 
69%) characterised by low level of cognitive and functional impairment at baseline, with 
minimum change in both over time (Hochstetler et al., 2016). Whilst this group included some 
healthy controls (39%), it also included participants with EMCI or LMCI (59%).  Thus, the overall 
growth trajectory for the TILDA cohort mirrors the large subpopulation identified by 
Hochstetler and colleagues (2016).  
Previously Xie, Mayo & Koski, (2011) reported five trajectories of MMSE score change 
in a smaller sample of participants with either MCI or AD. The two groups with the least level 
of cognitive impairment were found to have a stable course over a period of approx. 3.5 years, 
providing further support for the overall growth trajectory identified here. Two classes of slow 





trajectories identified for two of these classes. A smaller study conducted in a sample of 
possible or probable AD over 13.5 years identified six different trajectories of MMSE score 
change (Wilkosz et al., 2010). Those who had higher baseline MMSE score tended to follow 
trajectories with slower decline and those with lower initial scores were found to decline more 
rapidly. All trajectories were found to decline to low levels of MMSE when examined over the 
longer study period (Wilkosz et al., 2010). The Cache County Dementia Progression Study 
(Leoutsakos et al., 2015) also identified a large class of AD patients which exhibited a slow 
progression of decline in MMSE scores over approx. a 12-year period. Three further smaller 
classes characterised with more rapidly declining cognition were also identified.  
The analysis presented here must be interpreted in light of several methodological 
limitations. All LGCMs were specified as unconditional models with no examination of any 
interrelationships in the growth processes of these covariates considered. Additionally, no 
time varying or time invariant covariates were included in the specification of the LGCMs. The 
purpose of the LGCMs was to summarise the covariates for subsequent analysis in Chapter 8.   
 
7.7 Conclusion 
The present chapter serves as a foundation for subsequent analysis presented in 
Chapter 8. Several new categorical variables representing change in covariates over time were 
created including change in healthcare cover, change in employment and the reporting of a fall 
during any of the waves. Several variables which were captured at a continuous level were 
summarised using latent growth curve models to generate an intercept and slope value for 
inclusion in further analysis, presented in the next chapter. All of the latent growth curve 
models specified indicated that an increase was observed over the course of the first three 
waves of TILDA data collection, save for anxiety which showed a decrease and cognition which 
remained stable. The analysis presented herein serve as a precursor to the analysis in the 
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subsequent chapter. Nevertheless, they serve to provide an insight into those variables which 
have shown some relationship with healthcare utilisation within the literature. The 
identification of many of these covariates as dynamic in nature themselves lends further 
support to a longitudinal examination of healthcare usage. What follows in Chapter 8 is the 








8 Biopsychosocial predictors of variation in longitudinal patterns 
of healthcare utilisation among community dwelling older Irish 
adults 
 
8.1 Chapter overview 
This chapter integrates the findings from Chapter 6 (latent transition analysis) and Chapter 7 
(covariate examination) to provide a more in-depth analysis of identified healthcare utilisation 
patterns. Explanatory differences between these patterns will be examined using multinomial 
logistic regression analyses, by incorporating covariates which have been identified and 
operationalised in Chapter 7.   
8.2 Introduction 
Health services research is considered to be a large field of enquiry that seeks to 
examine the breadth of factors which influence how care is organised, delivered, financed, and 
accessed (Lohr & Steinwachs, 2002). A particular driver for health services research is the 
increased demand that is being placed upon services by an ageing population that is living for 
longer with chronic disease and multimorbidity. The high proportion of expenditure on 
hospital inpatient beds has led to an increased scrutiny of the nature of inpatient bed use 
(Tucker, Hargreaves, Wilberforce, Brand & Challis, 2017). An increased focus on unnecessary or 
avoidable hospital admissions has led to the development of alternative models, such as 
intermediate care, particularly for the care of older adults within increased levels of clinical 
complexity (Melis et al., 2004; Smith et al., 2014; Steiner, 2001). Predicting future healthcare 
utilisation is an important aspect for providing adequate capacity and yet most risk prediction 
models for hospital readmission perform poorly (Billings, Dixon, Mijanovich & Wennberg, 
2006; Cooksley et al., 2016; Kansagara et al., 2011). Readmissions are complex and influenced 
by system, cultural and environmental factors as well as clinical need (Cooksley et al., 2016). 
Thus, an evaluation of health care usage needs to consider these broader contextual factors 
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and may serve to identify opportunities for intervention, where medical need is not 
modifiable.  
The analysis presented in Chapter 3 (IC analysis) identified that the number of hospital 
admissions in the 12-month period prior to the index admission into IC was a consistent 
predictor of the likelihood and number of readmissions in the post-intervention period. Each 
additional hospital admission in the 12-month period preceding IC admission increased the 
likelihood of unplanned hospital admission following intermediate care discharge by 37% in 
the <30 day and 31-90 day periods, and by 44% in the <90 day period (refer to Chapter 3, 
Tables 3-10 and 3-11). The increased odds ratios identified for the number of previous 
admissions is notable when one considers the multivariate nature of the analysis, adjusted for 
age, sex, demographic and intervention variables, and the presence or absence of the 25 most 
common medical diagnoses within the cohort. Similar findings were also obtained within the 
CH cohort (Chapter 4), where likelihood of unplanned hospital admission was increased by 27-
38% (across the three monitoring periods) for each previous hospital admission in the 12 
months preceding pharmacist intervention (refer to Chapter 4, Table 4-8). Thus, medical 
history alone does not predict likelihood of hospital admission and consideration should be 
given to the influence of healthcare utilisation itself.  
The analyses presented in Chapter 6 indicate that heterogeneity in healthcare 
utilisation patterns can be observed in a community-dwelling cohort of older adults and that 
considerable transition between these latent sub-populations also occurs. The analysis 
presented thus far makes the case for an examination of the factors which influence different 
types of healthcare utilisation, characterised by increasing severity, and the transition into and 
out of such healthcare utilisation patterns over time. At a time when global health systems are 
under pressure to cope with the demands of an ageing population living for longer with 





levels of healthcare usage. More specifically those factors which are considered to be mutable 
deserve particular attention. Such modifiable factors may serve as suitable points for 
intervention within a high-pressured health service and may provide an evidence base from 
which new models of care can be built upon.  
Theorists have long since advocated for the adoption of a wider viewpoint when 
assessing population healthcare usage (Andersen, 1968; Andersen, 1995; Andersen & 
Newman, 1973). In advocating a move away from the biomedical model, Engel (1980) 
proposed that clinicians should pay attention to the biological, psychological, and social 
aspects of illness. By doing so, Engel offered a counter argument to the biomedical model 
which could be interpreted as inherently reductionist and thus dehumanising (Borrell-Carrió, 
Suchman & Epstein, 2004). Behaviour does not occur within a vacuum but rather is shaped by 
the environment within which the individual is located (Bronfenbrenner, 1979; Grzywacz & 
Fuqua, 2000).  
Lehman, David and Gruber (2017) further propose that this biopsychosocial approach 
can be made more dynamic through the integration of Bronfenbrenner’s ecological approach, 
in order to emphasise the fact that influences on health interact with one another over time. 
Originally conceptualised as a theory of child development, Bronfenbrenner’s (1979) ecological 
systems framework provides an opportunity to account for the complexity of interactions 
between individual and environmental influences on behaviour. The ecological perspective is 
predicated on the notion that health and health behaviours are influenced at multiple levels, 
including at the personal, organisational, environmental and policy levels (Maus & Satariano, 
2018). Furthermore, the ecological perspective assumes that each of these levels of influence 
interact with one another and that reciprocal causation occurs among levels (McLaren & 
Hawe, 2005).  
322 
 
Richard, Gauvin and Raine (2011) posit that “ecological models offer an elegant 
conceptual contour of these levels of influence and guide the development of multilevel 
intervention models, which underscore the need for enacting various health education and 
promotion strategies to achieve population-level changes” (p. 309). Due to the 
comprehensiveness of this approach it is not surprising that ecological approaches to public 
health research and intervention have become increasingly popular in the last two to three 
decades (Grzywacz & Fuqua, 2000; Richard et al., 2011; Maus & Satariano, 2018).  
One of the greatest assets of an ecological framework is that it is comprehensive in 
nature. However, it may also perhaps be a considerable limitation (Grzywacz & Fuqua, 2000). 
Maintaining a balance between comprehensive assessments of influencing factors and the 
need for a parsimonious explanation in order to make testable predictions is a continual 
challenge. The concept of “leverage points” as proposed by Grzywacz and Fuqua (2000, p. 101) 
may provide an opportunity to reduce the comprehensive ecological perspective into factors 
which can be operationalised.   
Gryzwacz and Fuqua (2000) described several factors as ‘leverage points’ as they were 
multidimensional constructs with an influence on health and illness. Through this 
multidimensionality these factors could still represent the comprehensiveness of the social 
ecological perspective, whilst providing opportunities for intervention. For example, Grzywacz 
and Fuqua (2000) argue that socioeconomic status is often assessed using a unidimensional 
characteristic such as educational attainment, income, or occupational status, thereby 
restricting the identification of socioeconomic targets for intervention. According to Grzywacz 
and Fuqua (2000), multiple assessments of socioeconomic status are required to gain a deeper 
understanding of the phenomenon and how it links to individual and public health. Familial 
structure and employment are also considered to be key leverage points with respect to 





The work of Andersen and colleagues adopts an ecological perspective on healthcare 
service usage, when one considers the following definition: “a conceptual framework designed 
to draw attention to individual and environmental determinants of behaviour” (McLaren & 
Hawe, p. 9). In diagrammatical terms the Andersen Behavioural Model infers a linear process, 
however, in reality the Phase 4 version of the model does draw attention to the reciprocity 
between healthcare utilisation and enabling factors (Andersen, 1995). This particular iteration 
of the model sought to incorporate the recursive nature of health services use through the 
incorporation of feedback loops, whereby the outcome (service use) could in turn 
subsequently influence predisposing and enabling factors, as well as perceived need for health 
services (Andersen, 1995). A previous systematic review of 16 studies, conducted using 
Andersen’s Behavioural Model, identified a lack of consistency in findings relating to factors 
associated with healthcare usage (Babitsch et al., 2012). A criticism offered by the review 
authors, Babitsch and colleagues (2012), is that many studies that have evaluated factors have 
not used a multivariate approach and have not operationalised the complexity of health 
service use through the use of structural equation modelling techniques.  
Within aging research an increased focus of attention has been directed towards the 
frailty syndrome (Han et al., 2019; Sloane & Cesari, 2018). Whilst there is considerable merit in 
including frailty as an assessment of future healthcare utilisation, given its predictive 
associations with poorer outcomes, the many conceptualisations and measures of frailty do 
not consider wider contextual aspects that impinge upon hospital readmission. Hubbard and 
colleagues (2017) consider the limits in frailty measures and capture it quite succinctly by the 
following: "readmissions to the acute sector are notoriously difficult to predict but medical 
instability and socio-environmental vulnerability seem to be the key contributors, none of 
which is captured by current single-point frailty measures" (Hubbard et al., 2017, p805). 
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Thus, even the inclusion of a multidimensional construct such as frailty will fail to 
account for the “system, cultural and environmental factors exerting a significant influence” 
upon hospital admissions (Cooksley et al., 2016, p. 248). A wider viewpoint, such as that 
advocated by Andersen and colleagues, provides a suitable conceptual framework within 
which to place any examination of healthcare utilisation by older people, who are a cohort 
characterised by considerable complexity.  This behavioural model of healthcare utilisation 
incorporates the work of Bromfenbrenner (1979) and Engel (1980) in a manner that is specific 
to healthcare usage. Owing to the challenges posed by the findings of Babitsch and colleagues 
(2012) there is a real need to consider factors associated with healthcare usage in a 
multivariate manner.  
The findings of Chapter 6 identified three patterns of healthcare usage which 
remained stable over time. These findings added credence to the argument that combinations 
of healthcare usage, such as GP and outpatient consultant visits, should be examined rather 
than examining the various services used as isolated outcomes. Chapter 7 explored the 
dynamic stability of a range of covariates and identified considerable growth or change in 
many of these factors. Thus, there is a need to now integrate these two studies to identify 
which factors influence movement from one type of healthcare usage at a given point in time, 
to that of another. The identification of those factors which influence healthcare usage 
behaviour may serve as a basis for the development of strategies to preserve and promote 
public health.  
8.3 Objectives 
• Examine the role of predisposing, enabling and need factors in explaining differences 
in healthcare utilisation patterns of TILDA participants over three time points 
• Examine the influence of these factors in both bivariate and multivariate analyses, 






8.4.1 Sampling and participants 
 The present chapter utilised data from the first three waves of data collection from the 
TILDA study. The reader is referred to Chapter 2 (Methodology) for further detail on data 
collection and sample characteristics.  
8.4.2 Design and variables 
This study builds on the results of Chapter 6 by examining the patterns of healthcare 
utilisation identified within the latent transition analysis. Specifically, variables outlined in 
Figure 8-1 will be examined in relation to these patterns. Figure 8-1 outlines how the selected 
covariates map onto the theorising of Andersen and Newman (1973). Variables were coded as 
follows: 
• Age: Continuous variable obtained from Wave 1. Continuous data with ‘top coding’ 
such that those participants aged over 80 years at were coded as 80 years of age.  
• Sex: Binary covariate obtained from Wave 1, coded such that males = 1, females = 2. 
• Marital status: Categorical variable captured at Wave 1, reverse coded as 1= widowed, 
2=separated/divorced, 3= never married and 4=married.  
•  Widowed: Two binary variables collected at waves 2 and 3 indicating whether the 
participant had become widowed (0=no, 1=yes).  
• Education: Categorical variable from Wave 1, reverse coded such that 1=third 
level/higher, 2=secondary and 3=primary/none.  
• Baseline employment status: Binary variable coded such that 1=employed, 
2=retired/other.  
• Change in employment status W1→W2: Binary variable coded such that 0=no change, 
1=change in status from Wave 1 to Wave 2.  
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• Change in employment status W2→W3: Binary variable coded such that 0=no change, 
1=change in status from Wave 2 to Wave 3.  
• Change in employment status W1→W3: Binary variable coded such that 0=no change, 
1=change in status from Wave 1 to Wave 3.  
• Change in healthcare coverage W1→W2: Binary variable coded such that 0=no change, 
1=change in healthcare cover from Wave 1 to Wave 2.  
• Change in healthcare coverage W2→W3: Binary variable coded such that 0=no change, 
1=change in healthcare cover from Wave 2 to Wave 3. 
• Change in healthcare coverage W1→W3: Binary variable coded such that 0=no change, 
1=change in healthcare cover from Wave 1 to Wave 3. 
• Urban/rural location: Categorical variable from Wave 1, reverse coded such that 1=a 
rural area, 2= another town or city and 3=Dublin city or county.   
• Falls history: Two binary variables indicating whether a participant experienced a fall in 
the last 12 months (0=no, 1=yes), captured at Wave 2 and Wave 3, respectively.  
• Faller: binary variable indicating whether the participant reported a fall at any wave 
(0=no, 1=yes).  
• Frailty Index: Operationalised as the intercept and slope values obtained from latent 
growth curve model specified in Chapter 7.  Frailty intercepts were categorised 
according to the thresholds previously reported by Roe and colleagues (2017), 0 to 
0.09374 as robust (1); 0.09375 to 0.2499 as prefrail (2); and ≥0.25 as frail (3). Frailty 
slopes were summarised as two categorical variables, coded such that 0= zero or 
negative frailty slope value (stable or decreasing frailty) and 1= positive frailty slope 
value (increasing). 
• Polypharmacy: Operationalised as the intercept and slope values obtained from latent 





• Depression: Operationalised as the intercept and slope values obtained from latent 
growth curve model specified in Chapter 7. 
• Anxiety: Operationalised as the intercept and slope values obtained from latent 
growth curve model specified in Chapter 7. Owed to the non-linear change in anxiety 
over time, adjustments were made to the anxiety slope values to isolate the slope 
change from Wave 1 to Wave 2 from that of the slope change from Wave 2 to Wave 3, 
for those analyses which examined the time periods separately. Anxiety slope values 
were adjusted by the slope factor mean score for time 2 (2.070) and time 3 (2), via a 
multiplication by 2.070 and -0.070, respectively.   
• Cognition: Operationalised as the intercept and slope values obtained from latent 
growth curve model specified in Chapter 7. 
Due to conceptual overlap and the potential for multicollinearity, it was decided to omit 
comorbidity level and new incident disease as variables in the present analysis. The Frailty 
Index already accounts for several comorbidities and thus it would not be appropriate to retain 
both Frailty Index and comorbidity category within the analysis. Furthermore, the 
operationalisation of incident disease diagnosed at Waves 2 and 3 is somewhat crude, given 
that many such incident diagnoses could be time limited and therefore not count as an 
increase in chronic disease comorbidity e.g. an isolated infective episode. Frailty is a 
multidimensional construct that has previously been shown to be related to healthcare 
utilisation (Fried et al., 2001; Han et al., 2019; Roe et al., 2017). Thus, it serves as a more 
nuanced description of the inherent complexity of older people and proffers the opportunity 





Figure 8-1: Final selection of covariates for inclusion in Chapter 8 analyses, as per the Andersen Behavioural Model)  
 
8.4.3 Analytical plan 
Examination of movement from one healthcare utilisation pattern to another was 
conducted using multinomial logistic regression using Mplus 8.1 (Muthén & Muthén, 2018).  In 
order to operationalise categorical variables within Mplus those with more than two 
categories were dummy coded against a reference category. For example, baseline marital 
status was dummy coded such that marital1 (widowed), marital2 (separated/divorced) and 
marital3 (never married) were included in the analysis, in comparison to the omitted reference 
category of ‘married’. Similarly, education was dummy coded such that edu1 (third 
level/higher level) and edu2 (secondary level) were compared against the omitted reference 
category of ‘primary level/none ‘. Location was also dummy coded such that loc1 (rural) and 
loc2 (another town/city) were compared against the omitted reference category of ‘Dublin city 
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Three distinct latent statuses were identified in Chapter 6: effective referral utilisation 
(LS1), multiple utilisation (LS2) and primary care only utilisation (LS3). The identification of 
three latent statuses at three time points resulted in a total of 33 or 27 distinct patterns of 
healthcare utilisation. In order to summarise the large number of patterns identified it was 
decided to conduct the multinomial regression in three complementary steps: transition 
patterns from Wave 1 to Wave 2; from Wave 2 to Wave 3; and from Wave 1 to Wave 3.  
Table 8-1: Frequencies for healthcare utilisation patterns from Wave 1 to Wave 2 and Wave 2 to Wave 3 ( N = 6128) 
Healthcare utilisation 
pattern 
Wave 1 to Wave 2 
n (%) 
Wave 2 to Wave 3 
n (%) 
1→ 1 1325 (21.6) 1301 (21.2) 
1→ 2 311 (5.1) 401 (6.5) 
1→ 3 75 (1.2) 106 (1.7) 
2→ 1 322 (5.3) 333 (5.4) 
2→ 2 321 (5.2) 347 (5.7) 
2→ 3 188 (3.1) 225 (3.7) 
3→ 1 161 (2.6) 109 (1.8) 
3→ 2 273 (4.5) 251 (4.1) 
3→ 3 3152 (54.1) 3055 (49.9) 
Note. 1 = effective referral utilisation; 2 = multiple utilisation; 3 = primary care only utilisation  
In the case of transitions from Wave 1 to Wave 3 many of the groups identified within 
the 27 patterns were small in nature. Furthermore, Mplus limits the analysis of categorical 
outcome variables to 10 categories. Thus, it was further decided to amalgamate those 
groupings of latent status transition which possessed some conceptual overlap prior to 
analysis, rather than omit small sample size patterns which would have reduced the overall 
sample size. The combination of groups can be observed in Table 8-2. For each of the 
multinomial logistic regressions conducted, the reference group was those who remained in 




Table 8-2: Frequencies for combined healthcare utilisation patterns for multinomial regression from Wave 1 to Wave 
3 (N = 6128) 
Combined category Healthcare utilisation patterns n (%) 
Continued effective referral utilisation   111 990 (16.2) 
Continued multiple utilisation  222 140 (2.3) 
Late improver 221 + 223 181 (3.0) 
Improved and maintained 211 + 233 + 231 + 213 417 (6.8) 
Declined with no recovery 122 + 322 207 (3.4) 
Late decline  112 + 332 + 132 + 312 559 (9.1) 
Improvement but reverted 212 + 232 93 (1.5) 
Temporary decline 121 + 323 + 123 + 321 377 (6.2) 
No multiple utilisation 113 + 131 + 133 + 313 + 331 
+311 
324 (5.3) 
Continued primary care only utilisation‡  333 2840 (34.7) 
Note. ‡= reference category for multinomial regression; 1 = effective referral utilisation; 2 = 
multiple utilisation; 3 = primary care only utilisation 
 
8.5 Results 
8.5.1 Healthcare utilisation patterns from Wave 1 to Wave 2 
The transitions between the latent statuses identified in Chapter 6 from Wave 1 to 
Wave 2 can be observed in Table 8-3. Several covariates were found to increase the likelihood 
of remaining in the ‘multiple utilisation status’ when compared to the ‘primary care only’ 
status between Wave 1 and Wave 2. Whilst some associations were observed in unadjusted 
analyses for predisposing factors such as marital status or education, no such associations 
were observed in the fully adjusted model. Overall, no predisposing or enabling factors 
described the likelihood of remaining a user of multiple health services between Wave 1 and 
Wave 2. Rather, maintenance within this status was described by health need factors only. 
Having had a fall in the year before Wave 2 interview, higher depression intercept values, 





baseline were associated with an increased likelihood of remaining in the ‘multiple utilisation’ 
status between Wave 1 and Wave 2. 
Similarly, having had a fall in the previous 12 months, higher polypharmacy intercept 
and slope values, baseline frailty intercept of pre-frail or frail were more likely to move from 
‘effective referral’ at Wave 1 into ‘multiple utilisation’ by Wave 2. Those who had an increasing 
frailty slope between Wave 1 and Wave 2 were less likely to transition out of ‘multiple 
utilisation’ and into ‘effective referral utilisation’, when compared with those who remained 
primary care only service users between both time periods. Similarly, those who had an 
increasing frailty slope value were more likely to be in the primary care only→ multiple 
utilisation pattern than remain users of primary care only services. Having experienced a fall in 
the 12 months before the Wave 2 interview, higher depression slope values along with higher 
polypharmacy intercept and slope values were all associated with an increased likelihood of 
escalating from ‘primary care only utilisation’ to ‘multiple utilisation’ between Waves 1 and 2.  
Table 8-3: Multinomial logistic regression from Wave 1 to Wave 2  
 Unadjusted Adjusted 
Covariate OR (95%CI) OR (95% CI) 
Wave 1 effective referral→ W2 effective referral   
 
Age 1.05 (1.05, 1.06) 1.01 (0.99, 1.02) 
Sex 1.40 (1.22, 1.61) 1.14 (0.97, 1.34) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.92 (1.54, 2.38) 0.78 (0.39, 1.59) 
Marital status (separated/divorced) 1.42 (1.07, 1.87) 1.39 (1.02, 1.90) 
Marital status (never married) 1.01 (0.79, 1.30) 0.99 (0.75, 1.31) 
Widowed at W2 1.85 (1.51, 2.27) 1.22 (0.62, 2.40) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.44 (0.37, 0.54) 0.82 (0.66, 1.03) 
Education (third level/ higher level) 0.57 (0.48, 0.68) 0.88 (0.71, 1.07) 
Employment at W1 (retired/other) 2.82 (2.42, 3.29) 1.26 (1.04, 1.53) 
Change in employment status since last wave 0.80 (0.65, 1.00) 1.23 (0.97, 1.55) 
Change in health cover since last wave 1.11 (0.89, 1.37) 1.19 (0.94, 1.51) 
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Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.90 (0.75, 1.08) 0.92 (0.75, 1.13) 
Location (another town/city) 0.97 (0.79, 1.18) 0.85 (0.68, 1.06) 
Fallen in the last 12 months 1.61 (1.36, 1.91) 1.17 (0.96, 1.42) 
Anxiety intercept at W1 1.12 (1.09, 1.15) 1.06 (1.01, 1.11) 
Anxiety slope (from W1 to W2) 0.86 (0.77, 0.96) 1.06 (0.91, 1.24) 
Depression intercept 1.20 (1.16, 1.23) 1.04 (1.00, 1.09) 
Depression slope 1.18 (0.99, 1.41) 1.10 (0.90, 1.34) 
MMSE intercept 0.86 (0.81, 0.90) 1.04 (0.97, 1.11) 
MMSE slope 1.40 (0.51, 3.82) 1.02 (0.31, 3.38) 
Polypharmacy intercept 1.76 (1.69, 1.85) 1.46 (1.38, 1.55) 
Polypharmacy slope 4.36 (3.44, 5.51) 1.96 (1.53, 2.52) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 4.53 (3.74, 5.49) 2.20 (1.78, 2.73) 
Frailty intercept (frail) 19.75 (15.12, 25.80) 3.35 (2.37, 4.75) 
Increasing frailty slope 1.06 (0.88, 1.26) 1.03 (0.85, 1.26) 
Wave 1 effective referral→ W2 multiple utilisation   
Age 1.05 (1.04, 1.07) 0.99 (0.97, 1.01) 
Sex 1.14 (0.88, 1.49) 0.90 (0.66, 1.21) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.78 (1.21, 2.62) 0.60 (0.16, 2.35) 
Marital status (separated/divorced) 1.76 (1.08, 2.89) 1.52 (0.91, 2.54) 
Marital status (never married) 0.90 (0.56, 1.47) 0.81 (0.49, 1.34) 
Widowed at W2 1.78 (1.24, 2.56) 1.34 (0.37, 4.91) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.48 (0.34, 0.66) 1.11 (0.74, 1.67) 
Education (third level/ higher level) 0.56 (0.41, 0.77) 1.04 (0.73, 1.49) 
Employment at W1(retired/other) 3.05 (2.28, 4.09) 1.12 (0.78, 1.61) 
Change in employment status since last wave 0.76 (0.51, 1.15) 1.15 (0.74, 1.79) 
Change in health cover since last wave 0.76 (0.51, 1.14) 0.81 (0.52, 1.26) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.70 (0.51, 0.95) 0.65 (0.46, 0.91) 
Location (another town/city) 0.82 (0.58, 1.15) 0.65 (0.45, 0.93) 
Fallen in the last 12 months 2.65 (1.99, 3.53) 1.75 (1.27, 2.40) 
Anxiety intercept at W1 1.17 (1.12, 1.23) 1.04 (0.96, 1.12) 
Anxiety slope (from W1 to W2) 0.74 (0.60, 0.90) 0.92 (0.72, 1.19) 





Depression slope 1.48 (1.04, 2.10) 1.34 (0.98, 1.85) 
MMSE intercept 0.79 (0.74, 0.85) 0.91 (0.83, 1.00) 
MMSE slope 0.79 (0.74, 0.85) 0.05 (0.01, 0.33) 
Polypharmacy intercept 1.99 (1.87, 2.12) 1.57 (1.45, 1.71) 
Polypharmacy slope 6.98 (4.50, 10.82) 2.51 (1.64, 3.84) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 7.42 (4.50, 12.24) 3.21 (1.90, 5.43) 
Frailty intercept (frail) 53.08 (30.94, 91.04) 6.90 (3.50, 13.59) 
Increasing frailty slope 1.21 (0.86, 1.72) 1.23 (0.85, 1.78) 
Wave 1 effective referral→ W2 primary care only   
Age 1.03 (1.00, 1.06) 0.98 (0.94, 1.02) 
Sex 1.06 (0.59, 1.92) 0.93 (0.49, 1.74) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.94 (0.86, 4.39) 1.59 (0.26, 9.80) 
Marital status (separated/divorced) 0.36 (0.05, 2.65) 0.34 (0.05, 2.46) 
Marital status (never married) 2.13 (0.90, 5.06) 2.01 (0.86, 4.69) 
Widowed at W2 1.69 (0.77, 3.67) 0.99 (0.18, 5.41) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.32 (0.15, 0.70) 0.45 (0.17, 1.17) 
Education (third level/ higher level) 0.39 (0.20, 0.76) 0.46 (0.22, 0.95) 
Employment at W1(retired/other) 3.61 (1.89, 6.90) 3.05 (1.44, 6.49) 
Change in employment status since last wave 1.34 (0.63, 2.82) 2.08 (0.97, 4.50) 
Change in health cover since last wave 1.43 (0.63, 3.26) 1.45 (0.65, 3.23) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 1.23 (0.56, 2.71) 1.20 (0.52, 2.74) 
Location (another town/city) 1.44 (0.60, 3.43) 1.37 (0.60, 3.15) 
Fallen in the last 12 months 1.46 (0.71, 3.00) 1.32 (0.60, 2.89) 
Anxiety intercept at W1 1.13 (1.04, 1.24) 1.13 (0.98, 1.32) 
Anxiety slope (from W1 to W2) 0.66 (0.40, 1.11) 0.88 (0.51, 1.51) 
Depression intercept 1.12 (1.01, 1.26) 0.96 (0.81, 1.15) 
Depression slope 0.99 (0.47, 2.07) 1.06 (0.49, 2.30) 
MMSE intercept 0.82 (0.70, 0.96) 0.99 (0.83, 1.19) 
MMSE slope 4.88 (0.07, 328.54) 2.12 (0.04, 108.63) 
Polypharmacy intercept 1.41 (1.20, 1.65) 1.29 (1.11, 1.50) 
Polypharmacy slope 1.26 (0.53, 3.02) 0.80 (0.36, 1.80) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 2.25 (1.12, 4.54) 1.20 (0.54, 2.64) 
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Frailty intercept (frail) 3.54 (1.11, 11.3) 0.79 (0.22, 2.85) 
Increasing frailty slope 0.79 (0.39, 1.61) 0.79 (0.37, 1.66) 
Wave 1 multiple utilisation→ W2 effective referral   
Age 1.04 (1.03, 1.06) 0.99 (0.97, 1.01) 
Sex 1.33 (1.03, 1.72) 1.11 (0.84, 1.46) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.47 (0.99, 2.19) 0.48 (0.17, 1.39) 
Marital status (separated/divorced) 1.65 (1.04, 2.64) 1.53 (0.95, 2.49) 
Marital status (never married) 1.28 (0.84, 1.94) 1.28 (0.81, 2.01) 
Widowed at W2 1.44 (1.00, 2.09) 1.65 (0.58, 4.66) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.41 (0.30, 0.58) 0.77 (0.52, 1.13) 
Education (third level/ higher level) 0.56 (0.42, 0.76) 0.88 (0.63, 1.23) 
Employment at W1 (retired/other) 3.54 (2.64, 4.76) 1.74 (1.24, 2.45) 
Change in employment status since last wave 1.06 (0.73, 1.53) 1.85 (1.23, 2.77) 
Change in health cover since last wave 1.25 (0.87, 1.80) 1.32 (0.89, 1.97) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.94 (0.69, 1.30) 0.98 (0.69, 1.38) 
Location (another town/city) 0.98 (0.69, 1.39) 0.83 (0.57, 1.21) 
Fallen in the last 12 months 1.89 (1.41, 2.54) 1.33 (0.97, 1.83) 
Anxiety intercept at W1 1.16 (1.11, 1.22) 1.08 (0.99, 1.17) 
Anxiety slope (from W1 to W2) 0.80 (0.64, 0.99) 1.07 (0.82, 1.41) 
Depression intercept 1.25 (1.20, 1.31) 1.06 (0.98, 1.14) 
Depression slope 1.32 (0.92, 1.88) 1.27 (0.91, 1.77) 
MMSE intercept 0.85 (0.79, 0.91) 1.04 (0.95, 1.15) 
MMSE slope 3.68 (0.63, 21.43) 2.43 (0.33, 17.72) 
Polypharmacy intercept 1.97 (1.85, 2.10) 1.72 (1.59, 1.86) 
Polypharmacy slope 2.21 (1.34, 3.66) 1.03 (0.68, 1.56) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 5.06 (3.40, 7.54) 1.91 (1.25, 2.93) 
Frailty intercept (frail) 27.57 (17.6, 43.18) 2.60 (1.44, 4.70) 
Increasing frailty slope 0.67 (0.50, 0.91) 0.70 (0.51, 0.96) 
Wave 1 multiple utilisation→ W2 multiple utilisation   
Age 1.06 (1.05, 1.08) 1.00 (0.98, 1.02) 
Sex 1.29 (0.99, 1.68) 1.03 (0.76, 1.40) 
Marital status (married) 1.00 1.00 





Marital status (separated/divorced) 1.82 (1.12, 2.97) 1.68 (1.00, 2.81) 
Marital status (never married) 1.41 (0.92, 2.16) 1.33 (0.83, 2.11) 
Widowed at W2 1.80 (1.25, 2.58) 1.15 (0.35, 3.75) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.49 (0.35, 0.69) 1.18 (0.79, 1.79) 
Education (third level/ higher level) 0.59 (0.44, 0.81) 1.10 (0.77, 1.58) 
Employment at W1 (retired/other) 3.58 (2.62, 4.88) 1.11 (0.75, 1.64) 
Change in employment status since last wave 0.78 (0.50, 1.22) 1.35 (0.81, 2.23) 
Change in health cover since last wave 1.19 (0.81, 1.74) 1.31 (0.87, 1.97) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.94 (0.67, 1.30) 0.89 (0.63, 1.27) 
Location (another town/city) 1.13 (0.79, 1.62) 0.90 (0.61, 1.33) 
Fallen in the last 12 months 3.77 (2.86, 4.96) 2.52 (1.84, 3.43) 
Anxiety intercept at W1 1.16 (1.11, 1.21) 1.05 (0.97, 1.13) 
Anxiety slope (from W1 to W2) 0.87 (0.68, 1.10) 1.16 (0.87, 1.54) 
Depression intercept 1.28 (1.23, 1.34) 1.09 (1.01, 1.17) 
Depression slope 1.35 (0.95, 1.93) 1.28 (0.92, 1.77) 
MMSE intercept 0.79 (0.73, 0.85) 0.97 (0.87, 1.07) 
MMSE slope 2.63 (0.39, 17.57) 0.94 (0.12, 7.46) 
Polypharmacy intercept 2.20 (2.05, 2.35) 1.82 (1.67, 1.99) 
Polypharmacy slope 6.25 (4.11, 9.51) 2.14 (1.42, 3.22) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 11.59 (6.77, 19.84) 3.76 (2.12, 6.66) 
Frailty intercept (frail) 84.52 (48.01, 148.77) 5.13 (2.57, 10.24) 
Increasing frailty slope 0.92 (0.65, 1.28) 0.89 (0.62, 1.28) 
Wave 1 multiple utilisation→ W2 primary care only   
Age 1.03 (1.01, 1.05) 0.99 (0.96, 1.02) 
Sex 1.21 (0.86, 1.71) 1.22 (0.84, 1.77) 
Marital status (married) 1.00  
Marital status (widowed) 1.27 (0.70, 2.33) 0.52 (0.15, 1.73) 
Marital status (separated/divorced) 1.71 (0.93, 3.13) 1.60 (0.85, 3.00) 
Marital status (never married) 1.63 (0.97, 2.73) 1.44 (0.85, 2.44) 
Widowed at W2 1.19 (0.69, 2.05) 1.53 (0.50, 4.65) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.80 (0.53, 1.23) 1.23 (0.77, 1.97) 
Education (third level/ higher level) 0.60 (0.39, 0.93) 0.84 (0.52, 1.34) 
Employment at W1 (retired/other) 1.58 (1.12, 2.22) 1.02 (0.67, 1.55) 
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Change in employment status since last wave 0.93 (0.56, 1.54) 1.13 (0.66, 1.93) 
Change in health cover since last wave 0.89 (0.52, 1.54) 0.95 (0.55, 1.66) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 1.18 (0.73, 1.89) 1.18 (0.71, 1.94) 
Location (another town/city) 1.74 (1.06, 2.86) 1.62 (0.97, 2.69) 
Fallen in the last 12 months 1.25 (0.81, 1.92) 1.03 (0.68, 1.59) 
Anxiety intercept at W1 0.99 (0.92, 1.07) 1.00 (0.90, 1.11) 
Anxiety slope (from W1 to W2) 1.00 (0.74, 1.34) 1.04 (0.73, 1.48) 
Depression intercept 1.04 (0.94, 1.14) 0.94 (0.84, 1.06) 
Depression slope 0.88 (0.60, 1.29) 0.79 (0.51, 1.22) 
MMSE intercept 0.84 (0.75, 0.95) 0.91 (0.80, 1.03) 
MMSE slope 0.87 (0.05, 14.8) 0.41 (0.03, 6.04) 
Polypharmacy intercept 1.51 (1.37, 1.66) 1.41 (1.26, 1.58) 
Polypharmacy slope 0.88 (0.49, 1.56) 0.62 (0.36, 1.07) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 1.83 (1.25, 2.67) 1.31 (0.85, 2.01) 
Frailty intercept (frail) 5.75 (3.32, 9.97) 2.15 (1.10, 4.17) 
Increasing frailty slope 0.77 (0.51, 1.15) 0.84 (0.55, 1.27) 
Wave 1 primary care only→ W2 effective referral   
Age 1.06 (1.04, 1.08) 1.02 (0.99, 1.05) 
Sex 1.28 (0.87, 1.90) 1.10 (0.72, 1.70) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 2.24 (1.32, 3.82) 3.49 (0.37, 32.65) 
Marital status (separated/divorced) 1.55 (0.73, 3.28) 1.63 (0.76, 3.50) 
Marital status (never married) 0.75 (0.33, 1.74) 0.71 (0.31, 1.63) 
Widowed at W2 1.96 (1.17, 3.30) 0.33 (0.04, 3.08) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.48 (0.29, 0.80) 0.97 (0.54, 1.74) 
Education (third level/ higher level) 0.62 (0.39, 0.99) 1.01 (0.61, 1.68) 
Employment at W1 (retired/other) 2.68 (1.75, 4.12) 1.36 (0.77, 2.39) 
Change in employment status since last wave 0.47 (0.24, 0.92) 0.69 (0.34, 1.36) 
Change in health cover since last wave 0.74 (0.40, 1.36) 0.74 (0.40, 1.39) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.81 (0.50, 1.29) 0.76 (0.46, 1.26) 
Location (another town/city) 0.84 (0.49, 1.42) 0.75 (0.43, 1.29) 
Fallen in the last 12 months 1.06 (0.63, 1.79) 0.85 (0.48, 1.50) 





Anxiety slope (from W1 to W2) 0.79 (0.61, 1.01) 0.85 (0.60, 1.21) 
Depression intercept 1.14 (1.05, 1.23) 1.05 (0.94, 1.16) 
Depression slope 1.50 (0.95, 2.35) 1.41 (0.89, 2.25) 
MMSE intercept 0.82 (0.72, 0.93) 0.93 (0.79, 1.09) 
MMSE slope 0.57 (0.03, 11.05) 0.25 (0.01, 4.65) 
Polypharmacy intercept 1.42 (1.29, 1.56) 1.17 (1.03, 1.32) 
Polypharmacy slope 6.02 (3.50, 10.35) 3.50 (2.02, 6.08) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 3.39 (2.12, 5.42) 1.86 (1.12, 3.10) 
Frailty intercept (frail) 4.76 (2.15, 10.51) 1.21 (0.50, 2.97) 
Increasing frailty slope 1.69 (0.95, 3.01) 1.53 (0.83, 2.82) 
Wave 1 primary care only→ W2 multiple utilisation   
Age 1.03 (1.02, 1.05) 1.00 (0.97, 1.02) 
Sex 1.11 (0.84, 1.45) 1.06 (0.78, 1.44) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.08 (0.71, 1.65) 0.36 (0.14, 0.93) 
Marital status (separated/divorced) 1.20 (0.68, 2.13) 1.09 (0.60, 1.96) 
Marital status (never married) 1.00 (0.62, 1.62) 0.98 (0.60, 1.61) 
Widowed at W2 1.21 (0.82, 1.77) 1.77 (0.75, 4.21) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.52 (0.35, 0.75) 0.73 (0.47, 1.13) 
Education (third level/ higher level) 0.77 (0.55, 1.07) 1.03 (0.71, 1.51) 
Employment at W1 (retired/other) 1.79 (1.34, 2.38) 1.07 (0.75, 1.53) 
Change in employment status since last wave 0.91 (0.59, 1.40) 1.00 (0.63, 1.58) 
Change in health cover since last wave 1.06 (0.70, 1.61) 1.06 (0.69, 1.61) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 1.08 (0.76, 1.53) 0.97 (0.67, 1.39) 
Location (another town/city) 1.09 (0.74, 1.61) 0.93 (0.62, 1.39) 
Fallen in the last 12 months 2.28 (1.68, 3.09) 2.10 (1.54, 2.87) 
Anxiety intercept at W1 1.03 (0.97, 1.10) 0.98 (0.90, 1.06) 
Anxiety slope (from W1 to W2) 1.07 (0.86, 1.34) 1.10 (0.85, 1.42) 
Depression intercept 1.10 (1.02, 1.18) 1.06 (0.97, 1.16) 
Depression slope 1.52 (1.09, 2.12) 1.47 (1.04, 2.07) 
MMSE intercept 0.88 (0.81, 0.96) 0.98 (0.88, 1.09) 
MMSE slope 0.46 (0.06, 3.52) 0.30 (0.04, 2.40) 
Polypharmacy intercept 1.47 (1.37, 1.59) 1.32 (1.19, 1.46) 
Polypharmacy slope 6.82 (4.49, 10.35) 4.26 (2.76, 6.57) 
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Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 2.12 (1.57, 2.87) 1.24 (0.86, 1.79) 
Frailty intercept (frail) 3.91 (2.41, 6.33) 0.97 (0.51, 1.86) 
Increasing frailty slope 1.88 (1.24, 2.85) 1.62 (1.05, 2.51) 
Note. Reference group: W1 primary care only → W2 primary care only 
 
 
8.5.2 Healthcare utilisation patterns from Wave 2 to Wave 3 
Transitions between latent statuses of healthcare usage between Wave 2 and Wave 3 
can be observed in Table 8-4. The predisposing factors of age, female sex and marital status 
showed significant associations with healthcare utilisation patterns between Waves 2 and 3, 
even when adjusted for other covariates. Increasing age was associated with an increased 
likelihood of being in the effective referral→ primary care only pattern, as well as the primary 
care only→ effective referral pattern, when compared with the reference group. Females were 
less likely to escalate from ‘primary care only’ to ‘multiple utilisation’ and more likely than 
males to move from ‘effective referral’ to ‘primary care only’ utilisation.  
A recent fall, higher depression intercept and slope values, higher polypharmacy 
intercept and slope values and an increasing frailty slope, were all associated with an increased 
likelihood of remaining a user of multiple types of health services between Waves 2 and 3. 
Those who were separated or divorced were more likely than those who were married at 
baseline to move from ‘effective referral’ into ‘multiple utilisation’, or to remain in the 
‘multiple utilisation’ status between Waves 2 and 3. Transition into the ‘multiple utilisation’ 
transition was also less likely for those who lived in a rural area or another town or city, when 
compared to those who lived in Dublin.  
Again, between Wave 2 and Wave 3, health need factors were significant predictors of 
healthcare transition pattern membership. Movement into ‘multiple utilisation’ by Wave 3 
from either ’effective referral’ or ‘primary care only’ was also significantly predicted by a recent 





predicted movement into ‘multiple utilisation’ from the ‘effective referral’ latent status 
between Waves 2 and 3. Higher polypharmacy intercept and slope values predicted many 
transitions between Wave 2 and Wave 3, but polypharmacy intercept value was not associated 
with moving from ‘primary care only’ to ‘multiple utilisation’ between the two times. No 
association was observed between baseline cognitive status (MMSE intercept) nor 
improvement in cognition (MMSE slope) between Wave 2 and Wave 3.  
 
Table 8-4: Multinomial logistic regression from Wave 2 to Wave 3  
 Unadjusted Adjusted 
Covariate OR (95% CI) OR (95% CI) 
W2 effective referral →W3 effective referral   
 
Age 1.05 (1.04, 1.06) 1.01 (0.99, 1.02) 
Sex 1.32 (1.15, 1.52) 1.06 (0.90, 1.24) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.69 (1.35, 2.11) 1.09 (0.63, 1.88) 
Marital status (separated/divorced) 1.30 (0.97, 1.74) 1.29 (0.94, 1.76) 
Marital status (never married) 0.99 (0.77, 1.26) 0.96 (0.73, 1.27) 
Widowed at W3 1.65 (1.34, 2.04) 0.81 (0.49, 1.35) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.48 (0.40, 0.58) 0.84 (0.67, 1.05) 
Education (third level/ higher level) 0.63 (0.53, 0.75) 0.95 (0.78, 1.17) 
Employment at W1 (retired/other) 2.84 (2.43, 3.32) 1.33 (1.10, 1.62) 
Change in employment status since last wave 0.61 (0.48, 0.77) 0.93 (0.72, 1.20) 
Change in health cover since last wave 1.11 (0.89, 1.39) 1.26 (1.00, 1.60) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.95 (0.79, 1.14) 1.00 (0.81, 1.22) 
Location (another town/city) 0.97 (0.79, 1.19) 0.86 (0.69, 1.08) 
Fallen in the last 12 months 1.58 (1.33, 1.88) 1.23 (1.02, 1.48) 
Anxiety intercept at W2 1.15 (1.11, 1.18) 1.08 (1.03, 1.13) 
Anxiety slope (from W2 to W3) 100.08 (3.36, 2981.71) 0.69 (0.01, 35.85) 
Depression intercept 1.20 (1.16, 1.24) 1.05 (1.01, 1.10) 
Depression slope 1.21 (1.01, 1.45) 1.18 (0.96, 1.45) 
MMSE intercept 0.88 (0.84, 0.93) 1.06 (0.99, 1.13) 
MMSE slope 1.49 (0.56, 3.99) 1.36 (0.43, 4.36) 
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Polypharmacy intercept 1.70 (1.62, 1.78) 1.43 (1.35, 1.51) 
Polypharmacy slope 4.12 (3.20, 5.32) 2.20 (1.70, 2.83) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 4.56 (3.77, 5.52) 2.22 (1.79, 2.75) 
Frailty intercept (frail) 15.76 (12.05, 20.62) 2.76 (1.95, 3.91) 
Increasing frailty slope 0.99 (0.83, 1.18) 0.98 (0.81, 1.20) 
W2 effective referral →W3 multiple utilisation   
Age 1.07 (1.05, 1.08) 1.01 (0.99, 1.03) 
Sex 1.30 (1.03, 1.64) 1.05 (0.81, 1.36) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 2.36 (1.69, 3.28) 2.00 (0.76, 5.21) 
Marital status (separated/divorced) 1.93 (1.29, 2.88) 1.85 (1.19, 2.88) 
Marital status (never married) 1.01 (0.66, 1.53) 0.88 (0.57, 1.38) 
Widowed at W3 2.01 (1.47, 2.76) 0.45 (0.18, 1.11) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.35 (0.26, 0.48) 0.82 (0.57, 1.19) 
Education (third level/ higher level) 0.53 (0.40, 0.70) 0.97 (0.71, 1.34) 
Employment at W1 (retired/other) 3.06 (2.35, 4.00) 0.97 (0.70, 1.35) 
Change in employment status since last wave 0.53 (0.34, 0.83) 0.87 (0.54, 1.39) 
Change in health cover since last wave 0.90 (0.61, 1.32) 1.08 (0.72, 1.63) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.74 (0.56, 0.99) 0.72 (0.52, 0.99) 
Location (another town/city) 0.83 (0.61, 1.15) 0.68 (0.48, 0.96) 
Fallen in the last 12 months 1.89 (1.44, 2.48) 1.62 (1.23, 2.15) 
Anxiety intercept at W2 1.16 (1.11, 1.22) 0.99 (0.92, 1.06) 
Anxiety slope (from W2 to W3) 
2563.33 (11.07, 
5.9x105) 49.45 (0.10, 2.5x104) 
Depression intercept 1.27 (1.22, 1.33) 1.16 (1.08, 1.25) 
Depression slope 1.57 (1.16, 2.13) 1.66 (1.24, 2.20) 
MMSE intercept 0.80 (0.74, 0.85) 0.96 (0.87, 1.07) 
MMSE slope 1.94 (0.31, 12.31) 0.91 (0.13, 6.32) 
Polypharmacy intercept 1.91 (1.79, 2.03) 1.54 (1.42, 1.66) 
Polypharmacy slope 10.66 (7.41, 15.34) 4.70 (3.22, 6.86) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 4.68 (3.28, 6.69) 1.69 (1.14, 2.50) 
Frailty intercept (frail) 27.56 (18.39, 41.32) 2.40 (1.40, 4.12) 





W2 effective referral →W3 primary care only   
Age 1.08 (1.06, 1.11) 1.05 (1.01, 1.09) 
Sex 2.18 (1.28, 3.70) 1.83 (1.04, 3.22) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 2.63 (1.35, 5.12) 0.64 (0.21, 1.91) 
Marital status (separated/divorced) 1.52 (0.66, 3.50) 1.79 (0.76, 4.20) 
Marital status (never married) 0.46 (0.13, 1.65) 0.48 (0.14, 1.73) 
Widowed at W3 3.32 (1.84, 5.98) 1.64 (0.56, 4.81) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.33 (0.18, 0.61) 0.59 (0.30, 1.15) 
Education (third level/ higher level) 0.51 (0.28, 0.90) 0.75 (0.40, 1.40) 
Employment at W1 (retired/other) 3.13 (1.81, 5.41) 1.02 (0.53, 1.97) 
Change in employment status since last wave 0.22 (0.07, 0.71) 0.37 (0.11, 1.25) 
Change in health cover since last wave 0.94 (0.40, 2.24) 1.21 (0.51, 2.90) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.62 (0.34, 1.11) 0.63 (0.34, 1.17) 
Location (another town/city) 0.68 (0.35, 1.32) 0.59 (0.30, 1.17) 
Fallen in the last 12 months 1.71 (0.95, 3.08) 0.78 (0.40, 1.52) 
Anxiety intercept at W2 1.06 (0.95, 1.18) 1.08 (0.92, 1.26) 
Anxiety slope (from W2 to W3) 36.37 (0.01, 2.07x105) 7.08 (0, 1.06x105) 
Depression intercept 1.10 (1.01, 1.20) 0.97 (0.83, 1.15) 
Depression slope 1.15 (0.66, 2.01) 1.07 (0.58, 1.98) 
MMSE intercept 0.86 (0.75, 0.98) 1.07 (0.88, 1.29) 
MMSE slope 2.08 (0.06, 69.57) 2.03 (0.04, 98.63) 
Polypharmacy intercept 1.60 (1.45, 1.77) 1.35 (1.17, 1.55) 
Polypharmacy slope 1.45 (0.53, 3.97) 0.88 (0.41, 1.89) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 3.60 (1.94, 6.68) 1.67 (0.87, 3.20) 
Frailty intercept (frail) 9.69 (4.54, 20.68) 1.68 (0.55, 5.19) 
Increasing frailty slope 1.12 (0.62, 2.01) 1.15 (0.64, 2.09) 
W2 multiple utilisation →W3 effective referral   
Age 1.04 (1.03, 1.06) 0.98 (0.96, 1.01) 
Sex 1.20 (0.93, 1.54) 1.02 (0.77, 1.34) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.62 (1.10, 2.38) 0.82 (0.36, 1.88) 
Marital status (separated/divorced) 1.63 (1.03, 2.58) 1.51 (0.93, 2.45) 
Marital status (never married) 1.02 (0.67, 1.57) 0.97 (0.62, 1.53) 
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Widowed at W3 1.60 (1.12, 2.29) 1.08 (0.51, 2.26) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.53 (0.39, 0.73) 1.14 (0.78, 1.65) 
Education (third level/ higher level) 0.58 (0.43, 0.78) 1.02 (0.71, 1.44) 
Employment at W1 (retired/other) 2.93 (2.21, 3.87) 1.34 (0.95, 1.89) 
Change in employment status since last wave 0.79 (0.51, 1.21) 1.28 (0.81, 2.03) 
Change in health cover since last wave 1.10 (0.75, 1.64) 1.26 (0.83, 1.92) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.84 (0.62, 1.15) 0.82 (0.59, 1.14) 
Location (another town/city) 0.85 (0.60, 1.20) 0.69 (0.48, 1.00) 
Fallen in the last 12 months 2.29 (1.73, 3.04) 1.26 (0.92, 1.74) 
Anxiety intercept at W2 1.15 (1.09, 1.21) 1.01 (0.93, 1.09) 
Anxiety slope (from W2 to W3) 1253.95 (2.37, 6.6x105) 3.86 (0.01, 2206.92) 
Depression intercept 1.24 (1.18, 1.31) 1.11 (1.03, 1.19) 
Depression slope 1.23 (0.87, 1.75) 1.29 (0.94, 1.77) 
MMSE intercept 0.83 (0.77, 0.89) 0.95 (0.86, 1.04) 
MMSE slope 0.50 (0.08, 3.10) 0.25 (0.04, 1.61) 
Polypharmacy intercept 1.85 (1.74, 1.98) 1.56 (1.44, 1.69) 
Polypharmacy slope 9.11 (6.28, 13.22) 4.19 (2.88, 6.09) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 5.02 (3.45, 7.30) 2.10 (1.38, 3.17) 
Frailty intercept (frail) 22.27 (14.58, 34.02) 2.73 (1.54, 4.83) 
Increasing frailty slope 1.01 (0.73, 1.40) 0.96 (0.68, 1.35) 
W2 multiple utilisation →W3 multiple utilisation    
Age 1.07 (1.05, 1.08) 1.01 (0.99, 1.03) 
Sex 1.24 (0.96, 1.60) 0.94 (0.70, 1.26) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.99 (1.38, 2.86) 1.28 (0.51, 3.20) 
Marital status (separated/divorced) 1.99 (1.25, 3.16) 1.90 (1.17, 3.09) 
Marital status (never married) 1.22 (0.80, 1.86) 1.05 (0.66, 1.67) 
Widowed at W3 1.85 (1.32, 2.60) 0.57 (0.24, 1.34) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.43 (0.31, 0.60) 1.10 (0.74, 1.63) 
Education (third level/ higher level) 0.67 (0.50, 0.90) 1.33 (0.95, 1.86) 
Employment at W1 (retired/other) 3.42 (2.56, 4.58) 0.95 (0.66, 1.36) 
Change in employment status since last wave 0.46 (0.27, 0.77) 0.82 (0.48, 1.41) 





Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.82 (0.60, 1.12) 0.79 (0.56, 1.10) 
Location (another town/city) 1.02 (0.73, 1.44) 0.79 (0.55, 1.15) 
Fallen in the last 12 months 3.17 (2.42, 4.15) 2.16 (1.61, 2.90) 
Anxiety intercept at W2 1.21 (1.16, 1.27) 1.04 (0.97, 1.12) 
Anxiety slope (from W2 to W3) 105.86 (0.32, 3.48x104) 0.35 (0, 272.54) 
Depression intercept 1.31 (1.25, 1.37) 1.14 (1.06, 1.22) 
Depression slope 1.90 (1.37, 2.64) 1.65 (1.20, 2.27) 
MMSE intercept 0.79 (0.74, 0.84) 0.94 (0.86, 1.04) 
MMSE slope 0.94 (0.17, 5.30) 0.44 (0.07, 2.84) 
Polypharmacy intercept 2.06 (1.93, 2.21) 1.63 (1.49, 1.78) 
Polypharmacy slope 11.82 (7.62, 18.33) 4.44 (2.92, 6.74) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 9.97 (6.00, 16.57) 3.43 (1.98, 5.92) 
Frailty intercept (frail) 69.57 (40.57, 119.3) 5.47 (2.78, 10.76) 
Increasing frailty slope 1.70 (1.18, 2.45) 1.63 (1.10, 2.41) 
W2 multiple utilisation →W3 primary care only   
Age 1.05 (1.03, 1.06) 1.01 (0.99, 1.04) 
Sex 0.96 (0.71, 1.31) 0.87 (0.61, 1.26) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.21 (0.75, 1.95) 0.86 (0.33, 2.24) 
Marital status (separated/divorced) 0.91 (0.43, 1.90) 0.97 (0.46, 2.03) 
Marital status (never married) 0.75 (0.42, 1.32) 0.70 (0.40, 1.22) 
Widowed at W3 1.29 (0.83, 2.02) 0.74 (0.31, 1.74) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.53 (0.35, 0.81) 0.85 (0.52, 1.40) 
Education (third level/ higher level) 0.82 (0.57, 1.18) 1.22 (0.79, 1.90) 
Employment at W1 (retired/other) 1.67 (1.22, 2.28) 0.82 (0.56, 1.20) 
Change in employment status since last wave 0.64 (0.38, 1.08) 0.83 (0.49, 1.41) 
Change in health cover since last wave 1.14 (0.72, 1.81) 1.20 (0.75, 1.92) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.96 (0.66, 1.40) 0.87 (0.59, 1.29) 
Location (another town/city) 1.04 (0.68, 1.59) 0.89 (0.57, 1.37) 
Fallen in the last 12 months 3.83 (2.80, 5.26) 1.29 (0.88, 1.89) 
Anxiety intercept at W2 1.05 (0.98, 1.12) 1.03 (0.94, 1.12) 
Anxiety slope (from W2 to W3) 0.54 (0, 1246.33) 0.07 (0, 246.14) 
Depression intercept 1.08 (1.01, 1.16) 1.03 (0.94, 1.13) 
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Depression slope 1.42 (1.00, 2.02) 1.38 (0.95, 2.01) 
MMSE intercept 0.86 (0.79, 0.95) 0.94 (0.85, 1.05) 
MMSE slope 0.27 (0.03, 2.66) 0.18 (0.02, 1.69) 
Polypharmacy intercept 1.54 (1.43, 1.67) 1.40 (1.27, 1.55) 
Polypharmacy slope 3.86 (2.22, 6.72) 2.51 (1.50, 4.20) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 2.15 (1.51, 3.04) 1.20 (0.81, 1.80) 
Frailty intercept (frail) 5.56 (3.39, 9.13) 1.35 (0.68, 2.67) 
Increasing frailty slope 1.2 (0.79, 1.83) 1.11 (0.72, 1.73) 
W2 primary care only →W3 effective referral    
Age 1.05 (1.02, 1.08) 1.04 (1.01, 1.07) 
Sex 0.95 (0.61, 1.49) 0.89 (0.55, 1.46) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.74 (0.94, 3.21) 2.01 (0.55, 7.34) 
Marital status (separated/divorced) 0.89 (0.26, 3.04) 0.88 (0.28, 2.74) 
Marital status (never married) 1.09 (0.46, 2.54) 1.03 (0.43, 2.45) 
Widowed at W3 1.60 (0.89, 2.90) 0.53 (0.16, 1.75) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.63 (0.34, 1.16) 0.98 (0.53, 1.84) 
Education (third level/ higher level) 0.98 (0.56, 1.72) 1.39 (0.80, 2.41) 
Employment at W1 (retired/other) 2.09 (1.30, 3.36) 1.36 (0.85, 2.20) 
Change in employment status since last wave 1.28 (0.66, 2.49) 1.61 (0.85, 3.04) 
Change in health cover since last wave 1.72 (0.90, 3.28) 1.77 (0.95, 3.28) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.85 (0.48, 1.50) 0.77 (0.42, 1.41) 
Location (another town/city) 1.04 (0.55, 1.98) 0.93 (0.49, 1.77) 
Fallen in the last 12 months 1.30 (0.72, 2.35) 0.76 (0.42, 1.39) 
Anxiety intercept at W2 1.00 (0.93, 1.08) 0.92 (0.81, 1.05) 
Anxiety slope (from W2 to W3) 344.55 (0, 3.4x107)  2167.31 (0.02, 3.1x108)  
Depression intercept 1.11 (1.02, 1.20) 1.18 (1.02, 1.36) 
Depression slope 1.57 (0.85, 2.92) 1.91 (1.00, 3.66) 
MMSE intercept 0.89 (0.77, 1.04) 1.02 (0.86, 1.21) 
MMSE slope 3.87 (0.14, 107.77) 3.83 (0.14, 108.09) 
Polypharmacy intercept 1.30 (1.16, 1.47) 1.20 (1.06, 1.36) 
Polypharmacy slope 4.63 (2.28, 9.41) 3.45 (1.69, 7.05) 
Frailty intercept (robust) 1.00 1.00 





Frailty intercept (frail) 1.94 (0.78, 4.81) 0.48 (0.17, 1.42) 
Increasing frailty slope 1.54 (0.73, 3.23) 1.21 (0.57, 2.58) 
W2 primary care only →W3 multiple utilisation    
Age 1.03 (1.01, 1.05) 1.02 (1.00, 1.05) 
Sex 0.85 (0.64, 1.14) 0.71 (0.52, 0.98) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.13 (0.70, 1.84) 0.65 (0.28, 1.51) 
Marital status (separated/divorced) 1.07 (0.59, 1.94) 1.08 (0.58, 2.01) 
Marital status (never married) 0.51 (0.28, 0.95) 0.50 (0.27, 0.93) 
Widowed at W3 1.19 (0.75, 1.87) 1.24 (0.59, 2.60) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.68 (0.45, 1.01) 0.91 (0.59, 1.42) 
Education (third level/ higher level) 1.03 (0.72, 1.48) 1.30 (0.89, 1.89) 
Employment at W1 (retired/other) 1.24 (0.93, 1.66) 0.85 (0.58, 1.25) 
Change in employment status since last wave 0.94 (0.61, 1.44) 1.04 (0.66, 1.63) 
Change in health cover since last wave 1.65 (1.09, 2.49) 1.49 (0.98, 2.27) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.91 (0.63, 1.31) 0.97 (0.66, 1.44) 
Location (another town/city) 0.95 (0.63, 1.43) 0.94 (0.61, 1.44) 
Fallen in the last 12 months 1.49 (1.05, 2.12) 2.81 (2.06, 3.84) 
Anxiety intercept at W2 1.10 (1.03, 1.17) 1.09 (0.98, 1.20) 
Anxiety slope (from W2 to W3) 5.76 (0.01, 4960.93) 0.33 (0, 525.59) 
Depression intercept 1.08 (1.02, 1.15) 1.02 (0.93, 1.12) 
Depression slope 1.43 (1.03, 1.99) 1.33 (0.91, 1.96) 
MMSE intercept 0.93 (0.84, 1.02) 0.99 (0.89, 1.11) 
MMSE slope 1.07 (0.11, 10.66) 1.32 (0.13, 13.9) 
Polypharmacy intercept 1.22 (1.12, 1.33) 1.08 (0.96, 1.22) 
Polypharmacy slope 5.05 (3.19, 8.00) 4.46 (2.75, 7.24) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 1.80 (1.33, 2.45) 1.19 (0.82, 1.73) 
Frailty intercept (frail) 1.98 (1.13, 3.49) 0.83 (0.42, 1.66) 
Increasing frailty slope 1.19 (0.82, 1.74) 1.00 (0.67, 1.49) 
Note. Reference group: W2 primary care only → W3 primary care only. All intercepts related to 





8.5.3 Healthcare utilisation patterns from Wave 1 to Wave 3  
The transition patterns between Wave 1 and Wave 3 can be examined in Table 8-5. When 
maintenance in the ‘multiple utilisation’ status was examined it was mostly predicted by health 
need factors, including having experienced at least one fall since Wave 1, higher baseline 
anxiety and depressive symptoms as well as increased rate of depressive symptom growth. 
Those who were pre-frail or frail at Wave 1 were also more likely to be in this pattern of 
continued usage of multiple healthcare services. Similarly, the greater the number of 
medications at baseline and the greater the increase in the number of medications over time 
were both associated with an increased likelihood of membership of ‘continued multiple 
utilisation’ as opposed to ‘continued primary care only’ usage pattern.  
Several covariates showed no predictive relationship with membership of any 
transition when assessed over three points in time. Age, female sex, education level, change in 
employment status, change in healthcare cover, change in anxiety symptoms (anxiety slope), 
and cognitive status at baseline (MMSE intercept) were found not to be significant predictors 
of healthcare usage transition, when compared to a reference group of primary care only 
usage. Of the predisposing and enabling factors included within the model, those who were 
never married (at Wave 1) were less likely to be in a pattern characterised by ‘late decline’ 
across the three waves. Those who were widowed by Wave 3 were also less likely to be in the 
‘continued multiple utilisation’ pattern. Those who were not employed at Wave 1 (retired or 
other occupation status) were more likely to be in either the ‘continued effective referral’, 
‘improvement maintained’ or ‘no multiple utilisation’ patterns, when compared with the 
reference of ‘continued primary care only’ utilisation.  
Across the three waves health need factors were significant explanatory factors with 
respect to healthcare utilisation transition patterns. Having reported at least one fall between 
Wave 1 and Wave 3 predicted an increased likelihood of membership of all healthcare 





reference group. Higher odds ratios were identified for ‘continued multiple utilisation’ (OR = 
2.25), ‘late improver’ (OR = 2.29), ‘improved but reverted’ (OR = 3.89) and ‘decline with no 
recovery’ (OR = 2.19) patterns.  
Mental health factors such as anxiety, depression and cognitive function were all 
significant contributors also. Baseline anxiety levels predicted membership of several patterns, 
including ‘continued effective referral’, ‘continued multiple utilisation’ and ‘improvement 
maintained’ patterns. The rate of change in anxiety over time was not a significant predictor of 
healthcare usage across the three waves. Initial depressive status and increasing depressive 
symptomology over time predicted membership of several patterns, characterised by ‘multiple 
utilisation’ at a minimum of one wave. Increasing cognitive status over time was associated 
with a lower likelihood of being in the ‘decline with no recovery’ pattern, but no association 
was observed for baseline cognition for any of the transition patterns. 
 
Table 8-5: Multinomial logistic regression from Wave 1 to Wave 3  
 Unadjusted Adjusted 
Covariate OR (95% CI) OR (95% CI) 
Continued effective referral  
 
Age 1.06 (1.05, 1.07) 1.01 (0.99, 1.02) 
Sex 1.36 (1.17, 1.59) 1.06 (0.89, 1.27) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.89 (1.48, 2.41) 1.06 (0.59, 1.89) 
Marital status (separated/divorced) 1.29 (0.93, 1.78) 1.25 (0.88, 1.78) 
Marital status (never married) 1.00 (0.76, 1.32) 0.97 (0.71, 1.31) 
Widowed at W3 1.79 (1.43, 2.23) 0.86 (0.50, 1.47) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.46 (0.37, 0.56) 0.85 (0.66, 1.08) 
Education (third level/ higher level) 0.60 (0.49, 0.72) 0.94 (0.75, 1.17) 
Employment at W1 (retired/other) 2.94 (2.47, 3.50) 1.29 (1.04, 1.60) 
Change in employment status  0.66 (0.53, 0.81) 1.07 (0.85, 1.34) 
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Change in health cover  1.07 (0.88, 1.31) 1.18 (0.96, 1.45) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.94 (0.77, 1.16) 1.02 (0.82, 1.27) 
Location (another town/city) 1.00 (0.80, 1.26) 0.93 (0.73, 1.19) 
Reported a fall at minimum one wave 1.71 (1.46, 2.01) 1.30 (1.09, 1.55) 
Anxiety intercept 1.12 (1.09, 1.15) 1.06 (1.01, 1.12) 
Anxiety slope 0.77 (0.59, 0.99) 1.21 (0.86, 1.71) 
Depression intercept 1.20 (1.16, 1.24) 1.05 (1.00, 1.11) 
Depression slope 1.20 (0.98, 1.46) 1.16 (0.93, 1.45) 
MMSE intercept 0.87 (0.82, 0.92) 1.06 (0.99, 1.14) 
MMSE slope 1.35 (0.45, 4.08) 1.20 (0.34, 4.30) 
Polypharmacy intercept 1.78 (1.69, 1.87) 1.47 (1.38, 1.56) 
Polypharmacy slope 4.40 (3.38, 5.74) 2.13 (1.62, 2.81) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 4.82 (3.88, 5.99) 2.32 (1.82, 2.96) 
Frailty intercept (frail) 20.35 (15.05, 27.51) 3.33 (2.26, 4.91) 
Increasing frailty slope 1.07 (0.88, 1.31) 1.06 (0.86, 1.32) 
Continued multiple utilisation   
Age 1.08 (1.06, 1.11) 1.03 (1.00, 1.06) 
Sex 1.49 (1.00, 2.22) 1.11 (0.71, 1.74) 
Marital status (married) 1.00 1.00 
 Marital status (widowed) 2.82 (1.67, 4.75) 4.99 (0.99, 25.11) 
Marital status (separated/divorced) 1.83 (0.88, 3.81) 1.59 (0.78, 3.25) 
Marital status (never married) 1.65 (0.91, 2.98) 1.41 (0.72, 2.75) 
Widowed at W3 1.96 (1.19, 3.23) 0.16 (0.03, 0.81) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.44 (0.26, 0.72) 1.28 (0.72, 2.27) 
Education (third level/ higher level) 0.61 (0.39, 0.96) 1.31 (0.82, 2.09) 
Employment at W1 (retired/other) 4.02 (2.52, 6.41) 0.69 (0.39, 1.23) 
Change in employment status  0.50 (0.29, 0.87) 0.92 (0.50, 1.71) 
Change in health cover  1.04 (0.65, 1.66) 1.32 (0.83, 2.09) 





Location (rural) 0.83 (0.50, 1.36) 0.82 (0.48, 1.39) 
Location (another town/city) 1.28 (0.77, 2.12) 1.09 (0.64, 1.87) 
Reported a fall at minimum one wave 4.05 (2.64, 6.20) 2.25 (1.44, 3.50) 
Anxiety intercept 1.23 (1.16, 1.31) 1.13 (1.02, 1.25) 
Anxiety slope 0.85 (0.46, 1.57) 1.89 (0.87, 4.13) 
Depression intercept 1.35 (1.28, 1.42) 1.11 (1.01, 1.22) 
Depression slope 1.93 (1.16, 3.22) 1.59 (1.01, 2.51) 
MMSE intercept 0.76 (0.69, 0.84) 0.98 (0.84, 1.13) 
MMSE slope 23.41 (1.80, 304.12) 7.57 (0.48, 118.66) 
Polypharmacy intercept 2.48 (2.27, 2.71) 1.95 (1.71, 2.22) 
Polypharmacy slope 11.74 (6.5, 21.22) 3.80 (2.11, 6.82) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 11.60 (4.83, 27.86) 2.90 (1.13, 7.48) 
Frailty intercept (frail) 155.52 (64.67, 373.99) 5.58 (1.80, 17.29) 
Increasing frailty slope 1.47 (0.83, 2.59) 1.53 (0.85, 2.73) 
Late improver   
Age 1.05 (1.03, 1.07) 0.98 (0.96, 1.01) 
Sex 1.13 (0.81, 1.59) 0.93 (0.63, 1.36) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.63 (0.95, 2.79) 0.82 (0.28, 2.38) 
Marital status (separated/divorced) 1.86 (0.99, 3.47) 1.69 (0.89, 3.21) 
Marital status (never married) 1.15 (0.64, 2.08) 1.04 (0.57, 1.91) 
Widowed at W3 1.53 (0.96, 2.46) 0.88 (0.33, 2.32) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.51 (0.33, 0.78) 1.15 (0.69, 1.94) 
Education (third level/ higher level) 0.59 (0.39, 0.89) 1.10 (0.68, 1.78) 
Employment at W1 (retired/other) 3.49 (2.33, 5.23) 1.37 (0.82, 2.27) 
Change in employment status  0.64 (0.39, 1.05) 1.19 (0.69, 2.08) 
Change in health cover  1.04 (0.68, 1.60) 1.15 (0.74, 1.79) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 1.01 (0.66, 1.54) 1.04 (0.67, 1.61) 
Location (another town/city) 1.02 (0.63, 1.65) 0.87 (0.52, 1.46) 
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Reported a fall at minimum one wave 2.96 (2.07, 4.23) 2.29 (1.56, 3.36) 
Anxiety intercept 1.10 (1.04, 1.18) 0.95 (0.86, 1.06) 
Anxiety slope 0.67 (0.32, 1.39) 0.93 (0.42, 2.08) 
Depression intercept 1.25 (1.18, 1.32) 1.12 (1.02, 1.24) 
Depression slope 1.10 (0.69, 1.76) 1.25 (0.82, 1.91) 
MMSE intercept 0.80 (0.73, 0.87) 0.94 (0.83, 1.06) 
MMSE slope 0.48 (0.04, 6.52) 0.19 (0.01, 2.70) 
Polypharmacy intercept 2.07 (1.91, 2.25) 1.76 (1.59, 1.95) 
Polypharmacy slope 5.49 (3.17, 9.52) 2.28 (1.38, 3.78) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 12.44 (6.34, 24.40) 4.40 (2.18, 8.91) 
Frailty intercept (frail) 58.55 (28.38, 120.8) 4.49 (1.91, 10.56) 
Increasing frailty slope 0.71 (0.47, 1.07) 0.72 (0.46, 1.13) 
Improvement maintained   
Age 1.04 (1.02, 1.05) 0.99 (0.97, 1.01) 
Sex 1.27 (1.01, 1.60) 1.09 (0.85, 1.40) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.28 (0.86, 1.89) 0.58 (0.28, 1.19) 
Marital status (separated/divorced) 1.63 (1.06, 2.53) 1.49 (0.96, 2.30) 
Marital status (never married) 1.29 (0.90, 1.87) 1.20 (0.81, 1.79) 
Widowed at W3 1.31 (0.93, 1.84) 1.26 (0.65, 2.45) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.57 (0.42, 0.75) 0.95 (0.68, 1.32) 
Education (third level/ higher level) 0.59 (0.44, 0.78) 0.90 (0.65, 1.23) 
Employment at W1 (retired/other) 2.47 (1.93, 3.15) 1.38 (1.03, 1.86) 
Change in employment status  0.77 (0.58, 1.03) 1.21 (0.88, 1.65) 
Change in health cover  0.99 (0.75, 1.32) 1.08 (0.80, 1.45) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 1.00 (0.74, 1.35) 1.09 (0.79, 1.50) 
Location (another town/city) 1.27 (0.91, 1.75) 1.17 (0.83, 1.64) 
Reported a fall at minimum one wave 1.91 (1.51, 2.41) 1.57 (1.23, 2.01) 





Anxiety slope 0.78 (0.52, 1.18) 1.36 (0.83, 2.22) 
Depression intercept 1.17 (1.12, 1.23) 1.00 (0.93, 1.08) 
Depression slope 1.11 (0.82, 1.51) 1.07 (0.78, 1.47) 
MMSE intercept 0.84 (0.78, 0.91) 0.98 (0.90, 1.08) 
MMSE slope 3.84 (0.73, 20.18) 2.49 (0.42, 14.59) 
Polypharmacy intercept 1.78 (1.67, 1.89) 1.61 (1.49, 1.74) 
Polypharmacy slope 1.58 (0.99, 2.51) 0.96 (0.65, 1.43) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 3.27 (2.44, 4.38) 1.54 (1.12, 2.13) 
Frailty intercept (frail) 12.21 (8.27, 18.03) 1.82 (1.08, 3.08) 
Increasing frailty slope 0.71 (0.54, 0.93) 0.76 (0.57, 1.00) 
Decline with no recovery    
Age 1.06 (1.04, 1.08) 0.99 (0.97, 1.02) 
Sex 1.12 (0.82, 1.55) 0.88 (0.61, 1.26) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.6 (1.00, 2.57) 0.66 (0.25, 1.69) 
Marital status (separated/divorced) 2.18 (1.23, 3.87) 1.92 (1.08, 3.43) 
Marital status (never married) 1.04 (0.58, 1.85) 0.92 (0.50, 1.68) 
Widowed at W3 1.62 (1.06, 2.47) 0.97 (0.41, 2.26) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.41 (0.27, 0.63) 0.95 (0.58, 1.57) 
Education (third level/ higher level) 0.66 (0.46, 0.96) 1.27 (0.84, 1.93) 
Employment at W1 (retired/other) 3.32 (2.30, 4.78) 1.15 (0.73, 1.83) 
Change in employment status  0.59 (0.37, 0.95) 0.96 (0.58, 1.59) 
Change in health cover  1.04 (0.71, 1.54) 1.13 (0.75, 1.70) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.83 (0.56, 1.22) 0.80 (0.53, 1.20) 
Location (another town/city) 0.93 (0.60, 1.44) 0.75 (0.47, 1.18) 
Reported a fall at minimum one wave 2.94 (2.12, 4.06) 2.19 (1.56, 3.07) 
Anxiety intercept 1.15 (1.08, 1.22) 0.97 (0.89, 1.06) 
Anxiety slope 0.70 (0.41, 1.2) 0.92 (0.48, 1.78) 
Depression intercept 1.28 (1.21, 1.36) 1.15 (1.06, 1.25) 
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Depression slope 1.87 (1.23, 2.85) 1.78 (1.21, 2.62) 
MMSE intercept 0.79 (0.72, 0.85) 0.92 (0.82, 1.03) 
MMSE slope 0.10 (0.01, 0.87) 0.05 (0.01, 0.47) 
Polypharmacy intercept 1.97 (1.82, 2.13) 1.56 (1.40, 1.74) 
Polypharmacy slope 11.58 (6.71, 19.97) 4.39 (2.56, 7.54) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 9.89 (5.36, 18.26) 3.89 (2.03, 7.45) 
Frailty intercept (frail) 55.37 (28.47, 107.71) 5.88 (2.58, 13.39) 
Increasing frailty slope 1.85 (1.16, 2.94) 1.73 (1.06, 2.81) 
Late decline    
Age 1.05 (1.04, 1.06) 1.01 (1.00, 1.03) 
Sex 1.10 (0.90, 1.34) 0.91 (0.72, 1.13) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.82 (1.34, 2.47) 1.21 (0.59, 2.48) 
Marital status (separated/divorced) 1.56 (1.07, 2.27) 1.48 (0.99, 2.22) 
Marital status (never married) 0.72 (0.49, 1.06) 0.65 (0.44, 0.98) 
Widowed at W3 1.78 (1.35, 2.34) 0.75 (0.39, 1.45) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.45 (0.34, 0.59) 0.86 (0.63, 1.18) 
Education (third level/ higher level) 0.66 (0.52, 0.84) 1.06 (0.81, 1.40) 
Employment at W1 (retired/other) 2.02 (1.63, 2.50) 0.90 (0.67, 1.20) 
Change in employment status  0.76 (0.58, 0.98) 0.98 (0.73, 1.31) 
Change in health cover  1.11 (0.86, 1.42) 1.16 (0.89, 1.51) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.79 (0.61, 1.01) 0.80 (0.61, 1.05) 
Location (another town/city) 0.91 (0.69, 1.20) 0.82 (0.61, 1.11) 
Reported a fall at minimum one wave 1.96 (1.60, 2.41) 1.53 (1.23, 1.91) 
Anxiety intercept 1.12 (1.08, 1.17) 1.05 (0.98, 1.12) 
Anxiety slope 0.72 (0.51, 1.01) 1.00 (0.65, 1.54) 
Depression intercept 1.20 (1.15, 1.25) 1.09 (1.02, 1.16) 
Depression slope 1.49 (1.16, 1.92) 1.49 (1.14, 1.93) 





MMSE slope 2.16 (0.44, 10.75) 1.27 (0.24, 6.70) 
Polypharmacy intercept 1.66 (1.57, 1.76) 1.39 (1.28, 1.50) 
Polypharmacy slope 8.73 (6.35, 12.00) 4.77 (3.39, 6.70) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 2.88 (2.25, 3.68) 1.34 (1.00, 1.78) 
Frailty intercept (frail) 10.44 (7.43, 14.67) 1.63 (1.03, 2.58) 
Increasing frailty slope 1.27 (0.97, 1.66) 1.09 (0.82, 1.46) 
Improved but reverted    
Age 1.07 (1.04, 1.10) 1.00 (0.96, 1.05) 
Sex 1.29 (0.80, 2.09) 0.98 (0.60, 1.61) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 2.37 (1.21, 4.64) 1.71 (0.40, 7.40) 
Marital status (separated/divorced) 2.02 (0.96, 4.23) 1.71 (0.75, 3.91) 
Marital status (never married) 1.62 (0.75, 3.50) 1.33 (0.61, 2.87) 
Widowed at W3 1.78 (0.96, 3.30) 0.39 (0.09, 1.59) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.34 (0.17, 0.65) 0.72 (0.35, 1.51) 
Education (third level/ higher level) 0.54 (0.32, 0.94) 1.01 (0.57, 1.81) 
Employment at W1 (retired/other) 4.12 (2.34, 7.24) 1.28 (0.65, 2.53) 
Change in employment status  0.63 (0.33, 1.19) 1.34 (0.65, 2.77) 
Change in health cover  0.97 (0.51, 1.82) 1.14 (0.60, 2.19) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.98 (0.54, 1.79) 1.04 (0.56, 1.93) 
Location (another town/city) 0.91 (0.47, 1.76) 0.75 (0.38, 1.50) 
Reported a fall at minimum one wave 5.29 (3.11, 8.99) 3.89 (2.18, 6.92) 
Anxiety intercept 1.14 (1.04, 1.24) 0.89 (0.75, 1.04) 
Anxiety slope 0.52 (0.23, 1.20) 0.53 (0.18, 1.61) 
Depression intercept 1.33 (1.24, 1.42) 1.24 (1.11, 1.40) 
Depression slope 1.65 (0.94, 2.89) 1.97 (1.23, 3.16) 
MMSE intercept 0.81 (0.72, 0.90) 1.03 (0.89, 1.21) 
MMSE slope 0.23 (0.01, 10.21) 0.13 (0, 6.69) 
Polypharmacy intercept 2.21 (1.98, 2.47) 1.74 (1.53, 1.99) 
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Polypharmacy slope 4.94 (2.30, 10.62) 1.99 (1.01, 3.89) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 3.69 (1.66, 8.17) 1.17 (0.50, 2.72) 
Frailty intercept (frail) 47.21 (21.51, 103.62) 2.63 (0.97, 7.17) 
Increasing frailty slope 0.78 (0.44, 1.38) 0.76 (0.42, 1.37) 
Temporary decline   
Age 1.04 (1.03, 1.06) 1.00 (0.98, 1.02) 
Sex 1.11 (0.87, 1.40) 0.95 (0.73, 1.24) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 1.43 (0.99, 2.07) 0.70 (0.32, 1.52) 
Marital status (separated/divorced) 1.17 (0.71, 1.91) 1.08 (0.65, 1.80) 
Marital status (never married) 0.85 (0.56, 1.30) 0.78 (0.51, 1.21) 
Widowed at W3 1.55 (1.12, 2.15) 1.06 (0.53, 2.12) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.52 (0.38, 0.71) 0.94 (0.65, 1.36) 
Education (third level/ higher level) 0.65 (0.49, 0.87) 1.07 (0.76, 1.49) 
Employment at W1 (retired/other) 2.07 (1.62, 2.66) 1.06 (0.78, 1.44) 
Change in employment status  0.86 (0.64, 1.15) 1.18 (0.85, 1.62) 
Change in health cover  1.04 (0.78, 1.38) 1.07 (0.79, 1.44) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.85 (0.63, 1.13) 0.83 (0.61, 1.13) 
Location (another town/city) 0.92 (0.67, 1.28) 0.82 (0.58, 1.15) 
Reported a fall at minimum one wave 1.98 (1.56, 2.52) 1.64 (1.28, 2.12) 
Anxiety intercept 1.1 (1.05, 1.16) 1.03 (0.96, 1.11) 
Anxiety slope 0.78 (0.53, 1.13) 1.07 (0.68, 1.67) 
Depression intercept 1.17 (1.11, 1.23) 1.05 (0.98, 1.13) 
Depression slope 1.41 (1.04, 1.90) 1.36 (1.01, 1.83) 
MMSE intercept 0.84 (0.78, 0.90) 0.94 (0.86, 1.03) 
MMSE slope 0.37 (0.07, 2.07) 0.21 (0.04, 1.14) 
Polypharmacy intercept 1.70 (1.59, 1.81) 1.47 (1.35, 1.59) 
Polypharmacy slope 7.27 (5.00, 10.58) 3.86 (2.62, 5.68) 





Frailty intercept (prefrail) 2.46 (1.85, 3.27) 1.22 (0.88, 1.69) 
Frailty intercept (frail) 9.97 (6.82, 14.59) 1.75 (1.02, 3.00) 
Increasing frailty slope 1.35 (0.97, 1.87) 1.23 (0.87, 1.73) 
No multiple utilisation    
Age 1.05 (1.04, 1.07) 1.02 (1.00, 1.04) 
Sex 1.29 (0.98, 1.70) 1.10 (0.82, 1.48) 
Marital status (married) 1.00 1.00 
Marital status (widowed) 2.02 (1.36, 2.99) 1.33 (0.63, 2.80) 
Marital status (separated/divorced) 1.22 (0.68, 2.19) 1.29 (0.72, 2.31) 
Marital status (never married) 1.05 (0.63, 1.75) 1.02 (0.61, 1.71) 
Widowed at W3 1.90 (1.34, 2.71) 0.87 (0.44, 1.72) 
Education (primary/none) 1.00 1.00 
Education (secondary) 0.53 (0.37, 0.75) 0.86 (0.57, 1.29) 
Education (third level/ higher level) 0.70 (0.50, 0.97) 0.97 (0.68, 1.39) 
Employment at W1 (retired/other) 2.67 (1.99, 3.59) 1.73 (1.22, 2.44) 
Change in employment status  0.87 (0.62, 1.23) 1.34 (0.94, 1.89) 
Change in health cover  1.27 (0.90, 1.78) 1.31 (0.93, 1.86) 
Location (Dublin city or county) 1.00 1.00 
Location (rural) 0.93 (0.67, 1.31) 0.95 (0.67, 1.34) 
Location (another town/city) 0.99 (0.68, 1.45) 0.92 (0.63, 1.36) 
Reported a fall at minimum one wave 1.52 (1.16, 2.01) 1.30 (0.97, 1.75) 
Anxiety intercept 1.06 (1.01, 1.12) 1.03 (0.95, 1.12) 
Anxiety slope 0.67 (0.43, 1.03) 0.76 (0.45, 1.28) 
Depression intercept 1.11 (1.05, 1.17) 1.04 (0.96, 1.14) 
Depression slope 1.27 (0.92, 1.76) 1.33 (0.92, 1.91) 
MMSE intercept 0.87 (0.79, 0.96) 1.01 (0.91, 1.13) 
MMSE slope 0.90 (0.13, 6.22) 0.71 (0.09, 5.49) 
Polypharmacy intercept 1.41 (1.31, 1.52) 1.23 (1.13, 1.35) 
Polypharmacy slope 3.50 (2.26, 5.44) 2.28 (1.46, 3.56) 
Frailty intercept (robust) 1.00 1.00 
Frailty intercept (prefrail) 2.16 (1.58, 2.94) 1.15 (0.82, 1.63) 
Frailty intercept (frail) 3.64 (2.17, 6.11) 0.85 (0.44, 1.64) 
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Increasing frailty slope 1.21 (0.84, 1.73) 1.07 (0.73, 1.57) 
Note. Reference group: remained in primary care only W1 → W2 → W3  
 
The number of prescribed medications at baseline predicted membership of all 
healthcare transition patterns when compared with the reference group. Similarly, the 
increase in the number of medications over time predicted an increased likelihood of 
membership of all patterns except for the ‘improvement maintained’ pattern. Baseline frailty 
status was associated with almost all healthcare utilisation patterns between Wave 1 and 
Wave 3. No association was observed with the ‘improved but reverted’ and ‘no multiple 
utilisation’ patterns. Only those who were frail at Wave 1, compared with those who were 
robust, showed an increased likelihood of being in the ‘late decline’ pattern, characterised by 
movement into the ‘multiple utilisation’ status at Wave 3. Similarly, only those who were frail 
at Wave 1, and not those who were pre-frail, had an increased likelihood of being in the 
‘temporary decline’ pattern, when compared with the reference group of continued ‘primary 
care only’ service use.  
 
8.6 Discussion 
The present study sought to identify those factors which identify different longitudinal 
patterns of healthcare usage by older people, by comparing several different latent statuses 
against a reference trajectory typified by continual, stable, low level of primary care health 
usage. The inclusion of several demographic and health need factors allowed for an 
examination of those aspects which influence these different trajectories, and for the 
identification of possible intervention targets. Through a better understanding of what 
influences transition into and out of the ‘multiple utilisation’ status identified in Chapter 6, 
clinicians and service providers may be able to turn their attention to not only identifying 





delivery around healthcare need. For older adults these healthcare need factors extend 
beyond the mere presence of comorbidities to include frailty status, falls history, number of 
prescribed medications, anxiety and depressive symptomology. 
8.6.1 Predisposing factors  
Age showed significant associations with healthcare usage patterns when examined as 
a bivariate relationship. However, across the three analyses presented, most of these 
associations were no longer significant when included in the fully adjusted model. However, 
between Wave 2 and Wave 3 age was associated with an increased likelihood of escalating 
from ‘primary care only’ to ‘effective referral’, as well as an increased likelihood of de-
escalating from ‘effective referral’ to ‘primary care only’, in the fully adjusted model for Wave 2 
to Wave 3. Previous studies have shown that older adults have lower odds of consultations 
with specialists but increased odds of ≥ 4 GP visits (Nabalamba & Millar, 2007). 
In terms of other predisposing characteristics, some differences in longitudinal 
healthcare usage patterns were identified for females in unadjusted analyses, however, many 
of these became no longer significant when examined in the adjusted model. Associations did 
persist for an increased likelihood for females to be in the effective referral→ primary care only 
pattern and a decreased likelihood to be in the primary care only→ multiple utilisation pattern, 
between Wave 2 and Wave 3. Thus, it appears that females may be more likely to require 
primary care only services following a successful referral for outpatient services.  
Several studies that have identified sex differences with respect to healthcare 
utilisation. Among young and low-income adult samples, females were found to be more likely 
to consult with a doctor than males (Broyles, McAuley & Baird-Holmes, 1999; Dhingra, Zack, 
Strine, Pearson & Balluz, 2010; Parslow, Jorm, Christensen & Jacomb, 2002). Among older 
adults more specifically, females have been reported to experience more GP visits but fewer 
specialist visits than males, in a study conducted in Canada (Vegda et al., 2009). Within the 
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same cohort females reported more chronic conditions than males and were in receipt of 
more medications (Vegda et al., 2009). Conversely, a separate Canadian study reported older 
females to be no more likely than males to consult with their GP but were less likely to visit a 
specialist (Nambalamba & Millar, 2007). In Norway, older females were less likely to visit a 
specialist or be hospitalised compared with males (Suominen-Taipale, Martelin, Koskelin, 
Holmen & Johnsen, 2006). Those Norwegian females in the 65-69 years category were found 
to visit a GP more often than males, but this difference was not observed for older age 
categories (Suominen-Taipale et al., 2006).  In contrast, Finnish females were more likely to 
visit GPs and specialists more often than males (Suominen-Taipale et al., 2006). Cameron, 
Song, Manheim, and Dunlop (2010) found that after controlling for demographic, health need 
and economic access factors, females were 21% less likely to be hospitalised than males in an 
analysis of a national probability sample of community dwelling older American adults.  
Marital status did show some associations with various healthcare usage patterns over 
the different time periods examined when accounting for other relevant covariates. Those who 
were separated or divorced at Wave 1 were more likely to exhibit stability in healthcare usage 
from Wave 1 to Wave 2 or from Wave 2 to Wave 3, and for some to escalate to ‘multiple 
utilisation’ from ‘effective referral’ from Wave 2 to Wave 3. When examined across the three 
waves those who were never married were less likely to occupy the ‘late decline’ pattern. 
Those who were widowed at Wave 1 were less likely than those who were married to move 
from ‘primary care only’ to ‘multiple utilisation’ between Waves 1 and 2. When all three waves 
were examined, and baseline marital status was accounted for, widowhood was associated 
with a decreased likelihood of remaining in the ‘multiple utilisation’ status across all three 
waves.  
Several studies examining healthcare utilisation by older adults have shown significant 





cancer decedents in the last year of life found that married patients and those who were 
previously married utilised more GP and outpatient services, spent fewer days in short- or 
long-term institutions and spent more days at home than those who were never married 
(Bjørnelv, Edwin, Fretland, Deb & Aas, 2020). Whilst this analysis did include younger 
participants approx. 90% of those included were over the age of 60 years.  Being single in older 
adulthood has been shown to be associated with fewer GP and specialist visits as well as an 
increased risk of unplanned hospital admission within 28 days of hospital discharge compared 
with those who were married or cohabiting (Shebeshi, Dolja-Gore & Byles, 2020; Suominen-
Taipale, Koskinen, Martelin, Holmen & Johnsen, 2004). Older COPD patients who lived with a 
spouse or another adult have been reported to experience fewer emergency department visits 
than those who lived alone (Wakabayashi et al., 2011). Similarly, older American adults who 
live alone have been shown to be 60% more likely to visit an ED than those who lived with 
their spouse (Hastings et al., 2008).  As well as providing social support marriage may be 
associated with modified health risk behaviours. Schone and Weinick (1998) found that 
married men were more likely to engage in regular physical activity and to not smoke.  
An assessment of marital status or experience of widowhood only provides a small 
insight into the possible social structure within which the individual is placed. The wider social 
structure of the individual as well as the subjective experience of loneliness may be an 
important factor that was not considered in the present study. Previous research has 
suggested that loneliness is predictive of ED and physician visits (Andrén & Rosenqvist, 1987; 
Cheng, 1992; Ellaway, Wood & Macintyre, 1999; Geller, Janson, McGovern & Valdini, 1999). A 
recent systematic review by Valtorta, Moore, Barron, Stow & Hanratty (2018) found 
insufficient evidence to suggest that older people with low levels of social support place 
greater demands on ambulatory healthcare services, independent of health status. Molloy, 
McGee, O’Neill, and Conroy (2010) found that greater levels of loneliness among older Irish 
adults was correlated with increases in emergency hospital admissions but not planned 
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admissions. More recently, Shaw and colleagues (2017) found that objective isolation was 
associated with increased levels of Medicaid spending in the US, but that loneliness predicted 
reduced spending, inferring that loneliness may serve as a barrier to seeking healthcare. 
Future research examining the broad topic of objective and subjective measures of isolation, 
loneliness and the social network may reveal additional insights regarding healthcare 
utilisation by the TILDA cohort but was considered to be beyond the scope of this thesis.  
Those with a tertiary level of education were found to be less likely to move from 
‘effective referral’ to ‘primary care only’ between the first two waves of TILDA data collection. 
When the transitions between Wave 1 and Wave 3 were examined, education beyond primary 
school level was found to be associated with all healthcare usage patterns in unadjusted 
analyses only. However, when education was included as a covariate in the adjusted model for 
Wave 1 to Wave 3 no association was observed. Such a finding is consistent with several 
studies which failed to find any association between education and healthcare usage (Lin, Chu, 
Chen, Xiao & Wan, 2020; Picco et al., 2016). However, one Scandinavian study reported some 
associations between secondary and third level education and increased likelihood of 
healthcare service use (Suominen-Taipale et al., 2004).  
8.6.2 Enabling factors 
Being retired or in a status other than employed at Wave 1 was associated with 
continued ‘effective referral’, irrespective if examined from Wave 1→ Wave 2, from Wave 2→ 
Wave 3 or from Wave 1→ Wave 3. They were also observed to exhibit a de-escalation of 
healthcare usage between Waves 1 and 2, as indicated by increased likelihood of membership 
of effective referral→ primary care only and multiple utilisation→ effective referral patterns. 
Furthermore, between Wave 1 and Wave 3 those who were retired/other were more likely 
than those who were employed at Wave 1 to occupy the ‘improved and maintained’ and ‘no 





among those older adults who are in employment in later life. Alternatively, those who were 
not employed may indicate those who adopted early retirement and thus may infer a better 
socioeconomic advantage, which may have additional benefits with respect to health status.  
Picco et al., (2016) previously found that those who were retired had higher combined health 
and social care costs than those in employment. No evidence was obtained for change in 
employment across the three waves in influencing healthcare usage patterns.  
Our understanding of the role of health insurance and health care utilisation is largely 
shaped by research from countries such as the US, where it forms a large part of healthcare 
culture. Blackwell, Martinez, Gentleman, Sanmartin and Berthelot (2009) found that not 
having health insurance was associated with a decreased likelihood of attending a GP among a 
general population sample in the US. A systematic review of studies conducted by Babitsch et 
al., (2012) reported findings from seven studies that examined the Andersen Behavioural 
Model in the US and concluded that having healthcare insurance increased the likelihood of 
service use or decreased the delay in accessing services.  
The costs associated with medical treatment in the absence of public health cover or 
private health insurance in Ireland, particularly in relation to primary care resources, would not 
be as prohibitive as those in the US. Thus, it is perhaps not surprising that in the present study 
change in healthcare coverage across the three waves did not impact upon healthcare usage 
patterns. This could be related to the manner in which change in cover was operationalised. 
Increases and decreases in coverage could not be easily identified from the data and thus the 
change in cover variable represented both types of change. Furthermore, the mixed public and 
private healthcare system presents challenges for elucidating the nuance associated with 
change in coverage. With universal access to free GP care available to TILDA respondents once 
they became 70 years of age, a change in cover may also be reported by those who did not 
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renew their private health insurance policy at this time but these respondents would also not 
have experienced a decrease in access to a GP per se. 
The Andersen Behavioural Model posits that the rural-urban character wherein the 
individual resides may influence their ability to access healthcare services. In the present 
study, location was a significant predictor of healthcare usage patterns between Wave 1 and 
Wave 2 and between Wave 2 and Wave 3. However, no association for location of residence 
was observed when healthcare usage patterns were examined across three waves of data. 
Between Wave 1 and Wave 2, those living in a rural area were less likely to be in the effective 
referral→ multiple utilisation pattern, compared with those who lived in Dublin city or county. 
This effect was also observed between Wave 2 and Wave 3. Between Waves 2 and 3 those 
who lived in another town or city were also found to have a decreased likelihood of being in 
the effective referral→ multiple utilisation pattern when compared with those living in Dublin 
city or county. Taken together, these findings suggest that in the shorter term, those living 
outside Dublin city or county were less likely to transition to more intensive healthcare 
resource usage, which may suggest the need for improved services for older adults in 
population dense areas such as the greater Dublin area.  
8.6.3 Need factors 
Throughout the analyses presented here stronger, more consistent relationships were 
observed for those covariates that could be considered health need factors. Considerable 
relationships were observed for recent history of a fall across all three waves. In the adjusted 
model, having a history of a fall predicted membership of all healthcare transition patterns, 
save for the ‘no multiple utilisation’ pattern from Wave 1 to Wave 3. Thus, overall, falls were 
associated with an increased level of healthcare usage when compared with the reference 
group of ‘primary care only’ usage. Higher odds ratios were observed for those patterns which 





Such a finding is not surprising in the context of the many studies that have identified a 
strong relationship between falls and subsequent healthcare resource usage. In the UK, the 
cost of treating falls has been estimated to total £981 million for the year 1999; those fallers 
aged ≥ 75 years were responsible for two-thirds of these costs (Scuffham et al., 2003). Older 
fallers are more likely to be admitted to hospital than their younger counterparts (Scuffham et 
al., 2003). In a small study conducted in one region of Ireland, it was found that fall-related 
admissions accounted for approximately three quarters of all hospital admissions in the region 
(Carey & Laffoy, 2005). Falls often result in more complicated sequelae requiring intensive 
healthcare usage such as hip fractures, other fractures and traumatic brain injuries, which can 
increase the risk for a prolonged hospital stay, institutionalisation and death (Carey & Laffoy, 
2005; Judge et al., 2016; Nazrun et al., 2014; Scuffham et al., 2003).  
The findings observed here underscore the need for suitable falls prevention strategies 
and falls care pathways, given the persistent associations with escalated healthcare usage 
identified. Many falls are preventable, particularly when one considers the risks associated 
with the prescribing of medications that are established as increasing the risks of falls. The 
analysis of the intermediate care dataset presented in Chapter 5 highlighted that considerable 
prescribing of falls-risk medications occurs within older adults living in Northern Ireland. 
Previous research within the TILDA cohort has identified an association between medications 
with a high anticholinergic or sedative burden and an increased likelihood of falls (Byrne, 
Walsh, Cahir & Bennett, 2019). Approximately 42% of hospital admissions related to a hip 
fracture have been found to be related to a suspected medication-induced fall (Andersen et 
al., 2020).   
Thus, considerable scope exists for medicines optimisation pathways within the 
Republic of Ireland, which could be modelled on those developed in Northern Ireland. In 2017, 
the South Eastern HSCT commenced a targeted prevention approach for falls and fractures 
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within Intermediate Care (Madden & Miller, 2019). A fracture prevention review comprised of 
bone health assessment, dietary assessments and a structured medicines review was 
conducted for all patients admitted into intermediate care with a fall. Prescribing 
appropriateness, the falls risk and anticholinergic effect on cognition were also assessed for 
each medication. Adopting a patient-centred approach, tailored pharmaceutical care plans 
were developed in order to adjust relevant medications and make onward referrals to other 
services, where required. A significant reduction in inappropriate prescribing and in falls-risk 
medications was observed (Madden & Miller, 2019). Such a finding highlights the value that 
can be added by incorporating pharmacist input into an integrated care pathway and the value 
of intermediate care destinations for optimising the health of older adults prior to their return 
home.  
Internationally, falls prevention has become an increasing area of research, policy, and 
intervention (American Geriatrics Society (AGS), British Geriatrics Society (BGS) & American 
Academy of Orthopaedic Surgeons (AAOS) Panel on Falls Prevention, 2001; Close et al., 1999; 
Rubenstein, 2006; Rubenstein, Robbins, Josephson, Schulman & Osterweil, 1990).  
Programmes centred on risk prevention, environmental modifications, exercise, and education 
have been evaluated within the literature (Rubenstein, 2006). Clinical practice guidelines 
advocate the adoption of preventative strategies that incorporate a holistic risk assessment 
which is then related to targeted exercise interventions such as balance or strength training 
and with necessary environmental assessments and modifications, where necessary (AGS, BGS 
& AAOS, 2001). These guidelines have also been updated to reflect the need to consider a falls 
risk assessment in those older adults who report balance or gait issues, irrespective of falls 
history (Kenny et al., 2011). Several post-fall assessment interventions and fall prevention 
interventions have been shown to reduce falls and thus hospitalisations (Close et al., 1999; 
Rubenstein et al., 1990; Cooper et al., 2017). Several care pathways have been established 





2017; O’Keeffe et al., 2020). Furthermore, the HSE has established a national programme, 
AFFINITY National Falls and Bone Health Project, to coordinate the development of a falls and 
fracture prevention system through the integration of primary and secondary prevention and 
rehabilitation (HSE, 2019).  
Baseline anxiety levels were associated with remaining in the ‘effective referral’ status 
between Wave 1 and Wave 2, between Wave 2 and Wave 3 and between Wave 1 and Wave 3. 
Baseline anxiety levels were also found to predict maintenance in the ‘multiple utilisation’ 
status from Wave 1 to Wave 3. An increased likelihood of membership of the ‘improved and 
maintained’ pattern was also observed for increasing anxiety intercept level. Such findings are 
notable when one considers that an effect for anxiety and increased healthcare usage beyond 
primary care exists even when frailty status, falls and number of medications are accounted 
for. Such a finding is congruent with studies which have shown that anxiety is highly prevalent 
among COPD and CHF patients (Yohannes et al., 2010) and associated with increased numbers 
of GP and ED visits and an increased risk of hospital admission (Gudmundsson et al., 2005; Kim 
et al., 2000; Laurin et al., 2009). The non-linear change in anxiety levels across the three waves 
showed some relationships in unadjusted analyses, but no effect was observed in the fully 
adjusted model.  
However, caution must be exercised when interpreting the role of anxiety in predicting 
healthcare utilisation transitions due to differences in data collection between Wave 1 and 
subsequent waves. At Wave 1 the HADS-A questionnaire was administered during the SCQ, 
whereas for all subsequent waves it was conducted during the CAPI assessment. Thus, it is 
possible that higher initial levels of anxiety were underreported during subsequent data 
collections due to socially desirable responding during the face to face CAPI interview. Thus, 
the change in anxiety over time may constitute a method effect and so further examination of 
subsequent waves of data collection is warranted. Nevertheless, the identification of an 
366 
 
association between baseline anxiety levels and increased primary and secondary healthcare 
usage over time may serve as a new target for intervention in chronic disease management. 
For example, interventions such as pulmonary rehabilitation and cardiac rehabilitation have 
been shown to decrease anxiety and depression among COPD and CHF patients (Benzer et al., 
2007; Coventry & Hind, 2007).  
Depressive symptomology also showed significant associations with membership of 
different healthcare usage patterns. Initial baseline levels of depression were associated with 
several patterns in unadjusted and adjusted analyses. From Wave 1 to Wave 2 initial baseline 
levels of depression were associated with an increased likelihood of remaining in the ‘multiple 
utilisation’ status between both time points. This effect was also observed between Wave 2 
and Wave 3; thus, it was not surprising that baseline levels of depression were associated with 
an increased likelihood of ‘continued multiple utilisation’ across all three waves. Baseline 
depression was also found to predict a greater likelihood of being in the ‘late improver’, ‘late 
decline’, ‘improved and reverted’ and ‘declined with no recovery’ patterns also. Hence 
depression remains a key consideration when examining variability in healthcare utilisation 
among older adults. 
Longitudinal increases in self-reported depressive symptoms were also associated with 
increased likelihood of escalating from ‘primary care only’ healthcare usage to ‘multiple 
utilisation’ healthcare from Wave 1 to Wave 2, when compared with continued usage of 
primary care services. An increased likelihood of remaining in the ‘multiple utilisation’ status 
from Wave 2 to Wave 3 was also observed. When considered from Wave 1 to Wave 3, an 
increasing depression slope was also associated with an increased likelihood of being in the 
‘continued multiple utilisation’, ‘late improver’, ‘late decline’, ‘improved and reverted’ and 
‘declined with no recovery’ patterns. Thus, underscoring the association between increasing 





short period of time only. The literature evidence supports an increase in healthcare resource 
usage among those COPD, CHF and diabetic patients who also have comorbid depression 
(Hutter et al., 2010; Maurer et al., 2008; Xu et al., 2008).  
The persistence of an association between initial depressive status and the rate of 
growth in depressive symptoms when included in the fully adjusted model is notable when 
one considers the many other factors that were incorporated in the model, including frailty, 
falls and polypharmacy. Such a finding runs contrary to previous studies which assert that once 
disease severity, comorbidity and previous hospitalisations are accounted for, the bivariate 
associations between depression and increased likelihood of ED visits, hospitalisation or 
readmission among COPD patients disappears (Almagro et al., 2005; Fan et al., 2007).  
The presentation of depression in later life is distinct from the experience of 
depression at an earlier age. The different presenting clinical features suggest that late life 
depression is a different phenotype, owed to differences in social factors and different 
biological markers, such as altered vascular health and structural brain changes (Briggs, Kenny 
& Kennelly, 2016; Fiske, Wetherall & Gatz, 2009). Depression in older adults presents more as 
cognitive changes and somatic symptoms with a lower likelihood of affective symptoms (Fiske 
et al., 2009). Thus, the identification of depression separate form coexisting comorbidity or 
cognitive decline can lead to an underdiagnosis of the disorder. Given the evidence identified 
here that initial levels of depressive symptoms and increases in depressive symptoms are 
associated with fluctuations in healthcare usage beyond primary care level, and after 
controlling for other key aspects such as frailty, greater attention should be placed on the 
identification and management of depression among older adults. Screening for depression 
among those who are multiple users of healthcare or who attend outpatient clinics may 
identify those who have undiagnosed and untreated depression. Given the impact of hospital 
admission on functional status of older adults, appropriate treatment for depressive symptoms 
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could limit the risk of hospital admission and thus potentially associated declines in functional 
independence.  
Little evidence was found in the present sample to support an association between 
cognitive status and variation in healthcare utilisation. Some associations were observed 
between MMSE intercept and slope when examined in unadjusted analyses but for the most 
part these associations became non-significant when examined in the fully adjusted model. 
Increases in MMSE scores from Wave 1 to Wave 2, indicating better cognitive performance, 
was associated with a decreased likelihood of being in the effective referral→ multiple 
utilisation pattern. Over the course of the three waves of data collection, increases in cognitive 
performance were associated with a decreased likelihood of being in the ‘declined with no 
recovery’ pattern when compared with the ‘continued primary care only’ reference group.  
However, it must be acknowledged that the slope of the LGCM was non-significant for 
the sample overall, with on average high levels of cognitive performance observed across the 
three time points. Previous research has suggested that those with cognitive impairment 
experience a longer length of hospital admission and an increased likelihood of readmission 
within 28 days than those without cognitive impairment (Tropea et al., 2018). Furthermore, 
there is considerable evidence that those with dementia are at an increased risk of 
hospitalisation (Toot et al., 2013); reasons for hospital admission are wide ranging among 
those with dementia and include orthopaedic, respiratory, and urological crises (Carter & 
Porell, 2005; Malone et al., 2009; Natalwala et al., 2008; Nourhashemi et al., 2001; Sampson et 
al., 2009; Tuppin et al., 2009). The high levels of cognition observed in the present sample do 
not inform of longitudinal changes in healthcare transition of older Irish adults living with 
dementia in the community. In order to fully elucidate the relationship between cognitive 
status and changes in cognitive ability with healthcare resource usage purposive sampling of 





Higher medication burden was associated with variation in healthcare usage patterns 
across the three waves of data collection. Higher initial numbers of prescribed medications 
were associated with healthcare utilisation patterns beyond ‘primary care only’. This effect 
persisted when examined in the adjusted model such that from Wave 1 to Wave 3, 
polypharmacy intercept values predicted membership of all patterns other than the reference 
group of ‘continued primary care only’ usage. Such a finding is not surprising given that 
number of prescribed medications often serves as a proxy for medical need.  
Similarly, the increasing growth in the numbers of prescribed medications was 
associated with increased likelihood of being in several healthcare usage patterns from Wave 1 
to Wave 2; from Wave 2 to Wave 3; and overall, from Wave 1 to Wave 3. In fact, from Wave 1 
to Wave 3 a trend of higher odds ratio values for polypharmacy slope than for polypharmacy 
intercept were observed, indicating that the rate of growth in medication numbers had a 
greater effect on membership of the various healthcare usage patterns. 
Several possible mechanisms may be responsible for an increase in number of 
medications over time. Increases in medication numbers may indicate a declining health 
status, requiring additional medications for symptomatic control, and thus it could be 
expected that a greater need for more intensive healthcare services may emerge. 
Alternatively, increasing numbers of medications may suggest the development of a 
prescribing cascade, whereby a new medication leads to a side effect which is erroneously 
identified as a new symptom and not a side effect, leading to the initiation of further 
medications to alleviate these side effects.  
Prescribing cascades (Rochon & Gurwitz, 1995, 1997, 2017) can occur with great ease 
among older patients. Time and resource pressures, in conjunction with a fragmented system 
of care, can lead to the emergence of new symptoms in older adults to be too often attributed 
to old age and disease and not to the medications that may have actually caused them 
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(Aronson, 2019). Nguyen and Spinelli (2016) outline such an example case study of a 71-year-
old woman with a range of comorbidities admitted to ED post-fall. The cause of the fall was 
considered to be multi-factorial with medications playing a central role. In the months prior to 
the fall she was prescribed a new antihypertensive to control her blood pressure by her GP. 
This resulted in oedema of the lower limbs which was then interpreted as the development of 
heart failure and treated with two additional diuretic medications, prescribed by her 
cardiologist. This was soon to be followed by the initiation of an antimuscarinic medication by 
her urologist to treat her overactive bladder, likely aggravated by the two diuretics. This 
anticholinergic medication increased the risk of blurred vision, dry mouth, and postural 
hypotension. These four new medications, initiated by three prescribers were in addition to 
her already lengthy prescription for her multiple morbidities, leading to an increased 
anticholinergic burden and risks for postural hypotension and dizziness, Unsurprisingly, one 
month following its initiation she experienced a fall, multiple fractures and required a 
presentation to ED.   
This case was resolved by the deprescribing of the antihypertensive, the two diuretics 
and the antimuscarinic and the initiation of an alternative antihypertensive. The case resulted 
in a 14-day hospital admission until symptoms were resolved, indicating the significant burden 
that unidentified medication related harm misattributed as a sign of age-related declines in 
health can have on our healthcare systems. Each physician was seeking to attend to the needs 
of the woman but did not seek to identify alternative explanations for reported symptoms.  
Thus, in the absence of the patient having been made aware of possible side effects to be 
aware of and to report, and in the absence of a comprehensive review of the wider context of 
reported symptoms, the woman in question experienced a fall, multiple fractures and a 





Taken together, the significance of polypharmacy intercept and slope indicates that 
those with higher levels of medications and those with more rapid increases in numbers of 
prescribed medication are more likely to display significant variation in healthcare usage over 
time. These findings underscore the importance of prescribing in influencing healthcare usage. 
Increasing numbers of medications has previously been identified as being associated with an 
increased risk of ED visits among community dwelling older adults (Cahir, Bennett, et al., 
2014). The results presented here extend these previous findings by identifying that initial 
number of medications and rate of increase in medication numbers are both independent 
predictors of longitudinal profiles of healthcare usage across both primary and secondary care, 
even after accounting for other covariates including frailty status. Richardson et al., (2012) 
previously reported disproportionate healthcare resource usage among older TILDA 
participants with polypharmacy. Among those participants aged 50-64 years, those who 
reported polypharmacy (defined as ≥5 medications) constituted only 10% of the study sample 
and yet were responsible for 28% of hospital admissions, 30% of outpatient visits and 25% of 
GP visits reported by the sample. The effect was more pronounced for older TILDA 
respondents. For those aged 65 years and older, those reporting polypharmacy comprised 31% 
of the study sample but 51% of hospital admissions, 55% of outpatient visits and 41% of GP 
visits (Richardson et al., 2012).  
Throughout the analyses presented here both numbers of medications and frailty 
remained significant predictors of healthcare utilisation patterns in the fully adjusted model. In 
many instances the greatest magnitude odds ratios were identified for polypharmacy 
intercept, polypharmacy slope and/or frailty intercept category. Polypharmacy has previously 
been shown to be related to pre-frailty and frailty, even after accounting for comorbidity 
(Palmer et al., 2019). Those who receive ≥5 medications have been shown to be at risk of 
frailty three years later (Saum et al., 2017). Combined polypharmacy (≥5 medications) and 
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frailty has been shown to result in longer hospital admissions, more discharges to long-term 
care and an increased likelihood of hospital readmission (Rosted et al., 2016).  
Polypharmacy has also been shown to be a consistent predictor of inappropriate 
prescribing (Bradley et al., 2012; Bradley et al., 2014; Hudhra et al., 2016; McMahon, et al., 
2014). In turn, inappropriate prescribing has been shown to be associated with an increased 
risk of GP visits (Moriarty, Bennett, Cahir, Kenny & Fahey, 2016), ED visits (Cahir, Bennett, et 
al., 2014; Moriarty, Bennett, Cahir, Kenny & Fahey, 2016), hospitalisations (Cahir, Moriarty, et 
al., 2014; Fick et al., 2008; Fillenbaum et al., 2004; Hytinnen et al., 2016; Klarin et al., 2005; 
Moriarty et al., 2014). Moriarty, Bennett, et al., (2015) previously examined longitudinal 
change in inappropriate prescribing, assessed using STOPP/START, in a subpopulation of TILDA 
participants where linked prescription claims data was available. In the 12-month period 
preceding the Wave 1 interview inappropriate prescribing was present in 52.7% of the sample 
and was found to increase to 56.1% in the 12-month period prior to the Wave 2 interview 
(Moriarty, Bennett, et al., 2015).  
Given the consistent associations between polypharmacy slope and healthcare 
utilisation identified here, it is likely that some of the increase in polypharmacy observed in 
Chapter 7 is inappropriately prescribed. Therefore, there is a need to consider implementing 
interventions among the older Irish population living in the community to ensure that 
medications are optimised, and medication-related harm is avoided. The findings reported in 
Chapters 3 and 4 indicate the value that can be added through structured pharmacist 
intervention that is individualised to the needs and goals of the older person.  
The present study’s findings highlighted the consistent influence of frailty status on 
healthcare usage when examined longitudinally. Frailty intercept category was found to be 
associated with an increased likelihood of membership of most healthcare utilisation patterns 





values were found to decrease in the fully adjusted model, most associations that were 
identified persisted following adjustment for relevant covariates. Furthermore, larger OR 
values were generally observed for those who were frail in comparison to those who were pre-
frail, indicating that the greater the degree of frailty the greater the likelihood of membership 
of the particular healthcare usage pattern. 
When examined from Wave 1 to Wave 3, baseline frailty and pre-frailty were both 
found to be associated with almost all healthcare utilisation patterns except the ‘improved but 
reverted’ pattern, when compared with the reference group of ‘continued primary care only’ 
usage. Only those who were frail at Wave 1 were more likely to be in the ‘late decline’ and 
‘temporary decline’ patterns. Such findings underscore the important influence of frailty on 
healthcare usage that has been identified within the literature. Frailty has consistently been 
shown to increase the risk of falls, disability, GP and practice nurse consultations, 
hospitalisation, longer hospital admissions, institutionalisation, and death (Ensrud et al., 2008; 
Fried et al., 2001; Han et., al, 2019; Rockwood et al., 2004; Rockwood et al., 2005; Rockwood & 
Mitnitski, 2007; Searle et al, 2008; Shi et al., 2020; Song et al., 2010).  
Longitudinal increases in frailty were also associated with several healthcare utilisation 
patterns, when compared those who exhibited stable or decreasing levels of frailty. Between 
Wave 1 and Wave 2 an increasing frailty slope was found to predict an increased likelihood of 
membership of the primary care only→ multiple utilisation pattern, thereby extending the 
literature regarding the associations between frailty and healthcare resource usage through 
the identification of an increased level of usage with increasing frailty status.   
Furthermore, a lower likelihood of being in the multiple utilisation→ effective referral 
pattern was observed for increasing frailty slope, indicating that a decrease in healthcare 
usage was less likely. This is further supported by the increased likelihood of continued 
membership of the ‘multiple utilisation’ status between Waves 2 and 3. Thus, unsurprisingly 
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between Wave 1 and Wave 3 increases in frailty were found to be associated with an 
increased likelihood of the ‘declined with no recovery’ pattern. Thus, early identification of 
frailty and efforts to prevent further declines in functional status may serve to offset 
considerable increases in healthcare utilisation for older adults.  
Several care pathways have been suggested for implementation within Ireland 
including ambulatory care hubs, acute frailty pathways in ED, specialist frailty wards and 
integrated care teams within the community (HSE, 2017). These pathways are aimed to be 
directed towards those older adults who experience falls, exhibit mobility problems, have 
complex comorbidities, are prescribed multiple medications and perceived as vulnerable to 
medication-related harm, on the basis that literature evidence reports that improvements in 
frailty status can be achieved via comprehensive assessment, targeted multidisciplinary 
interventions and physical activity interventions (Cameron et al., 2013; Puts et al., 2017). The 
Systematic Approach to improving care for Frail Older patients (SAFE) study has recently been 
established to explore the process required to implement a model of excellence for patient-
centred integrated care for frail older people on acute admission to hospital (Ní Shé et al., 
2018). The findings presented here lend further support to the establishment of such care 
pathways by highlighting the longitudinal influence of frailty on healthcare usage.  
8.6.4 Limitations 
The findings presented here do much with respect to explaining longitudinal variation 
in healthcare resource usage by older adults, but their interpretation must be considered in 
light of several methodological limitations. The analyses did not account for comorbidity per 
se, but rather comorbidity as a component of overall frailty status. Therefore, a challenge 
persists for applied clinicians and policy makers in quickly identifying those older adults who 
may benefit most from any intervention. Rather a comprehensive assessment of frailty status, 





a more holistic view of the overall functional status of the individual and their resilience to 
potential stressors and given its consistent association with increased healthcare usage 
remains an important consideration for the clinician. Thus, the establishment of frailty 
pathways, improved frailty triage and assessment may complement existing primary care 
services, which are increasingly overburdened. 
Furthermore, no assessment of prescribing appropriateness could be considered such 
as in the manner explored in Chapters 3-5. Nevertheless, the significance of polypharmacy 
intercept and slope values in the fully adjusted model points to the importance of considering 
medication burden when examining healthcare utilisation. Future research and policy 
development would do well to consider the inclusion of pharmacists within integrated care 
programmes, particularly those frailty pathways that are being developed nationally. 
Polypharmacy and frailty have been shown to be closely related to one another and to be 
associated with increased healthcare resource usage when both are present (Palmer et al., 
2019; Rosted et al., 2016; Saum et al., 2017). The findings of Chapters 3 and 4 indicate that 
appropriateness of prescribing for older adults can be significantly improved using a medicines 
optimisation medicines case management approach.  
The data examined relates to self-reported healthcare resource usage and thus is 
vulnerable to memory bias. It has been suggested that underreporting of resource usage is 
more likely to increase as healthcare usage increases (Ritter et al., 2001). Nevertheless, 
Wallace and colleagues (2018), when comparing self-reported healthcare utilisation data with 
manual extraction of data from the GP electronic medical record, found no difference in the 
reported rates of GP or outpatient visits but did identify significantly higher self-reported visits 
to ED. The authors speculated that challenges with transfer of healthcare utilisation data 
between secondary and primary care and failure for ED visits to be notified to the GP as 
possible sources for the discrepancy (Wallace et al., 2018).   
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The analysis presented here examined self-reported symptoms of anxiety and 
depression and did not consider whether the respondents had a clinical diagnosis of either or 
were in receipt of treatment for same. Furthermore, caution must be exercised when 
examining the role of anxiety as data collection at Wave 1 was conducted during the SCQ, 
whereas for all subsequent waves anxiety data were collected using the CAPI. It is possible that 
lower levels of anxiety at Waves 2 and 3 are a consequence of a method effect, and so further 
examination of subsequent waves of data collection is warranted.   
The high level of cognition observed within the sample limits the inferences that can 
be drawn regarding the role of cognition and healthcare utilisation among all community 
dwelling older people. Future analysis comparing those with and without cognitive impairment 
are required in order to elucidate any relationship with healthcare usage for those older adults 
living in the community.  
The analysis in the present chapter is somewhat limited by the absence of additional 
covariates known to impact on healthcare utilisation, such as social support and loneliness. 
Recent analysis conducted within the TILDA cohort has found that loneliness was positively 
associated with the number of GP visits in both cross-sectional and longitudinal analyses 
(Burns, Leavey, Ward & O’ Sullivan, 2020). Associations with ED visits were found to be less 
consistent (Burns et al., 2020). A differential impact was also observed for gender. Older 
women who reported loneliness had an increased risk of an ED visit at Wave 1, and increased 
number of GP visits at both Wave 1 and Wave 2 (Burns et al., 2020).  
Such a finding also underscores the important influence of gender on healthcare 
utilisation. Some studies have shown females to be more likely to consult with a doctor than 
males (Broyles et al., 1999; Dhingra et al., 2010; Parslow et al., 2002) but less likely to attend a 
specialist doctor (Nambalamba & Miller, 2007; Vegda et al., 2009). The present study did not 





covariate in the fully adjusted model. Future research examining gender specific patterns of 
healthcare utilisation may identify an alternative latent structure of healthcare utilisation 
behaviour. For example, recent research conducted within the TILDA cohort and stratified by 
gender, examining symptoms of late life anxiety and depression, found that males and females 
diverged on some determinants of psychological disorders (Curran, Rosato, Ferry & Leavey, 
2020).  
Socio-demographic analyses were limited to education, occupational status and health 
insurance coverage to serve as indicators of relative income. The selection of these was 
governed by consistency of reporting of variables across the publicly available waves of data. 
When selecting variables for inclusion, emphasis was placed on examining the various health 
need factors in a multivariate manner in order to ascertain the independent associations 
between these factors and healthcare utilisation patterns. Future research, incorporating 
additional aspects such as social support, loneliness, health beliefs and income would enhance 
the findings presented here but was considered beyond the scope of the present thesis.  
The analyses presented here have not considered the directional influences of the 
factors examined. Additional longitudinal analysis is required in order to elucidate further 
these longitudinal relationships through the use of path analysis, cross-lagged panel analysis, 
and/or mediation analysis in order to “capture fully the causal web of determinants leading to 
health behaviours and outcomes” (Richard et al., 2011, p. 321). Furthermore, interaction 
between the factors themselves must also be considered. Briggs, Kennelly, and Kenny (2017) 
found that depression was associated with an increased risk of falls within the TILDA cohort. 
The relationship between depression, falls and subsequent healthcare usage is thus one 
pathway that merits examination. Given the relationships between orthostatic hypotension 
and depression (Briggs, Kenny & Kennelly, 2016, 2017), a further potential target for 
intervention could be identified.  
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Nevertheless, the findings presented here lend support to the adoption of a broader 
ecological perspective when examining healthcare utilisation. Capturing change in a number of 
pertinent variables using LGCM methods highlights the importance of accounting for dynamic 
change within the influencing factors of healthcare utilisation themselves in as much as 
examining temporal change in healthcare utilisation. Given the considerable variability in 
healthcare usage patterns that were predicted by both growth factors in the multivariate 
analysis, the findings presented extend the work of Andersen and colleagues within a 
longitudinal context.  
8.7 Conclusion 
Risk prediction algorithms aimed at improving case finding of patients at high risk for 
hospital admission are often limited by their sensitivity and specificity (Billings et al., 2006). 
Those algorithms that are predicated on electronic admissions data are particularly vulnerable 
to inaccurate coding and missing data (Billings et al., 2006). Yet, the need to identify those at 
increased risk remains for effective targeting of resources and interventions.  
The findings presented here have highlighted a number of factors associated with 
increased likelihood of membership of intensive resource usage over time. Whilst some 
predisposing and enabling factors do exert an influence on healthcare utilisation by older 
adults, many such associations become non-significant when one incorporates several health 
need factors prevalent within older cohorts. Significant relationships were identified including 
falls history, anxiety, depression, frailty, and number of prescribed medications. The 
identification of which proffers some opportunities for intervention to support older adults to 
age well.  
Investment in falls prevention and frailty prevention strategies in particular may serve 
to reduce healthcare resource usage over time. Of course, the goal is not to eliminate 





hospital admissions, as such admissions can have detrimental effects for the independent 
status of older adults. The establishment of integrated care pathways which provide 
healthcare solutions within the community may support older adults to remain well in their 
homes for longer.   
The identification of associations between anxiety and depression also serve to 
highlight the value of screening for psychological symptoms among older adults. The 
identification of late life depression is particularly challenging due to a different clinical 
presentation. Routine screening may not only help address underdiagnosis among older adults 
but may serve to reduce their risk of escalated healthcare usage which may have additional 
consequence for their functional and cognitive status.  
Escalations in healthcare usage by older adults may also be addressed through the 
development of improved pharmaceutical care services centred on medicines optimisation. 
Persistent associations were observed between initial numbers of prescribed medications and 
the longitudinal increase in medications with more intensive healthcare resource usage. Given 
the previous literature findings pointing toward high levels of inappropriate prescribing within 
the TILDA cohort, medicines optimisation may serve as a key intervention target.  
Longitudinal healthcare usage by older adults within the TILDA cohort is largely 
influenced by a variety of health need factors. By examining the different possible temporal 
patterns of healthcare usage, the findings provide a nuanced view of the complexity involved 
in healthcare usage by older adults, whilst also proffering insights that could serve as early 






9 General Discussion 
9.1 Introduction 
Health status is a consequence of the dynamic interaction between interpersonal, 
biological, psychological systems and contextual factors over the life span (Lehman et al., 
2017). Thus, the breadth of these factors must be considered during service design and 
implementation. It also follows that health services research should be a multifaceted enquiry. 
Health services research has been defined by the Association for Health Services Research 
(ASHR; 2000) as  
“the multidisciplinary field of scientific investigation that studies how social factors, 
financing systems, organizational structures and processes, health technologies, and 
personal behaviours affect access to health care, the quality and cost of health care, 
and ultimately our health and wellbeing. Its research domains are individuals, families, 
organizations, institutions, communities, and populations” (Lohr & Steinwachs, 2002, 
p. 16).  
Such a definition builds on the perspective put forward by the Institute of Medicine of the 
National Academy of Sciences in 1995, which emphasised the multidisciplinary nature of the 
field, encompassing a broad range of research, from basic to applied, with the aim of 
understanding the effects of health services on both individuals and populations (Lohr & 
Steinwachs, 2002).  
The work presented in this thesis aims to fulfil these expectations through the 
evaluation of a health service intervention in terms of individual and health system outcomes, 
in conjunction with an examination of individual variation in health usage behaviour in a non-
clinical dataset. This chapter will integrate the results obtained from the findings reported in 





9.2 Theoretical implications 
9.2.1 Understanding inappropriate prescribing in context 
The findings of Chapters 3, 4 and 5 do much to extend the literature surrounding 
inappropriate prescribing among older adults, particularly with respect to older adults in 
receipt of intermediate care following acute care discharge. Our understanding of the 
prevalence of inappropriate prescribing in this care context have been limited by the dearth of 
studies conducted in this area. Bakken et al., (2012) previously explored the prevalence of 
inappropriate prescribing among older adults admitted to IC in Norway (N = 157) and found it 
to be 24%. In contrast, Millar (2016) reported a prevalence of 72% on admission to IC (N = 74) 
in Northern Ireland. Both were prevalence studies, with no intervention delivered to address 
the inappropriate prescribing identified, and in both studies inappropriate prescribing was 
found to have increased by IC discharge.  
The present thesis extends our understanding of the problem of inappropriate 
prescribing within IC in Northern Ireland by using a much larger sample (N = 532) than that 
previously examined by Bakken et al., (2012) and Millar (2016). As reported in Chapter 3, the 
majority (90%) of IC participants had some degree of inappropriate prescribing upon admission 
into IC. However, this inappropriate prescribing was significantly improved upon following 
pharmacist intervention in this care setting. Neither Bakken et al., (2012) nor Millar (2016) 
used MAI in their studies, therefore it is challenging to draw comparisons between the studies.  
The high prevalence of inappropriate prescribing identified within care homes in NI 
(Chapter 4) is at the upper end of the scale in terms of prevalence estimates reported in 
international literature and greater than that previously reported in NI. Byrne and colleagues 
(2011) previously reported a prevalence of 67% among NI nursing homes and 73% among 
nursing homes in ROI. Within the international literature, differences in screening methods 
result in prevalence estimates ranging from 22-88%, making comparisons between studies 
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somewhat challenging (Anrys et al., 2018; Cool et al., 2014; Elseviers et al., 2014; Heppenstall 
et al., 2016; Lau et al., 2004; Ryan et al., 2013). Nevertheless, the findings of Byrne et al. (2011) 
are augmented by the present thesis, which investigates the phenomenon in a much larger 
sample (N = 1095 in the present thesis, compared with N = 315 examined by Byrne and 
colleagues). Furthermore, our understanding of how inappropriate prescribing can be 
successfully addressed within care homes is furthered by the examination of changes in MAI 
score from pre- to post- intervention.  
The findings of Chapters 3-5 provide a more nuanced perspective of what is 
contributing to inappropriate prescribing within both care contexts. To date, IC has been a 
setting which has been overlooked with respect to pharmaceutical care. The present thesis 
adds further weight to the evidence that many medication related problems persist beyond 
acute care discharge (Belleli et al., 2013; Sargent et al., 2007; Tong et al., 2017). A broad range 
of pharmacist interventions contributed to the significant reduction in MAI score achieved in 
this setting, including deprescribing, dosage changes and the addressing of Kardex issues. Care 
home participants were observed to have a greater medication burden than their IC 
counterparts. A greater proportion of CH participants were prescribed >10 medications and 
approximately three times as many CH participants were prescribed >20 medications when 
compared with IC participants. It has been estimated that frail older adults in nursing homes 
consume up to four times more medications than the average age-matched community-
dwelling non-frail older person (Verrue et al., 2009; Walley & Scott, 1995).  
The findings of Chapters 4 and 5 suggest that overprescribing contributes to 
inappropriate prescribing within NI care homes, as medication discontinuation was the only 
pharmacist intervention driver of MAI score reduction. Maguire and colleagues (2013) 
previously argued that pre-admission prescribing patterns often continue following care home 





5 may provide support for this contention. Those resident in their care homes >2 years had 
significantly greater baseline MAI scores, perhaps indicating a lack of regular medication 
review once admitted into CH. Furthermore, considerable duplication of prescribing within 
several medication classifications was identified for the CH cohort in Chapter 5. This could 
suggest that new medications were initiated without the existing ineffective medications being 
discontinued.  
9.2.2 Inappropriate psychoactive prescribing 
The findings of Chapters 4 and 5 infer that cognitive impairment may be a driver for 
inappropriate prescribing within the care homes context, particularly if medications are used 
to treat BPSD. Cognitive impairment diagnoses were more common within the CH cohort, 
which is not surprising given that cognitive impairment increases the risk of institutionalisation 
for older adults (Abrahamsen et al., 2014; Luppa et al., 2010). Almost half of first-generation 
antipsychotics and one quarter of second-generation antipsychotics were prescribed 
inappropriately within the CH cohort, despite the established risks of cerebrovascular 
accidents and cardiac death associated with their use. Patterson and colleagues (2010) 
previously reported that 60% of antipsychotic prescribing in NI care homes was inappropriate. 
Thus, perhaps warnings regarding the safety of antipsychotics in older adults have been 
heeded to a certain degree within Northern Ireland. Nevertheless, considerable use of 
psychoactive medications was observed within the CH cohort and could point to a shift in 
prescribing of alternative psychoactive medications. Previous research of prescribing trends 
following the issuance of risk communications for antipsychotic use in dementia have failed to 
identify persistent trends of compensatory prescribing of other psychoactive medicines 
(Guthrie et al., 2013; Kales et al., 2011).  
Irrespective of whether the prescribing of psychoactive medications was 
compensatory in nature, concerning findings regarding their use were identified within both 
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settings. Several falls-risk medication groups, including opioid analgesics, benzodiazepines and 
z-drug sedatives were found to be inappropriately prescribed in both IC and CH. Furthermore, 
a greater burden of inappropriate prescribing of benzodiazepines and other sedatives was 
observed within the IC cohort, which has traditionally received less attention within the 
literature. Given that older adults in NI are commonly admitted to IC following a falls-related 
acute care admission, it is somewhat concerning that falls-risk medications would be so 
commonly prescribed inappropriately within the IC cohort. Again, this extends the argument 
for expanding pharmaceutical care services to transitional care spaces such as IC.  
The duplication of benzodiazepine prescribing is also concerning with respect to the 
risk of falls; older adults have an increased susceptibility to the pharmacodynamic effects of 
benzodiazepines. Falls have been shown to be a contributory factor in the transfer of care 
homes residents to acute care, particularly if a fracture has been sustained (Quinn, 2011; NHS 
Scotland, 2016; Smith et al., 2015). Within Chapter 4 it was observed that those CH 
participants with a previous history of falls had more GP visits within both 30 and 90 days of 
pharmacist intervention. Whilst the temporal relationship of these historical falls with 
healthcare utilisation cannot be elucidated, it does suggest that a subset of older CH residents 
with a history of falls have greater healthcare utilisation. When examined within the context of 
the considerable inappropriate prescribing of psychoactive medication identified within 
Chapter 5 these falls may have been related to the use of falls-risk medicines. The amelioration 
of falls-risk medications continues to serve as a potential target for intervention as a previous 
history of falls was also shown to be associated with variation in healthcare utilisation patterns 
within the TILDA cohort (Chapter 8).  
Chapter 5 also highlights the importance of considering more than psychoactive 
medications as a source of inappropriate prescribing. Additional medications were identified 





frequently prescribed inappropriately in both IC and CH, supporting the existing literature 
regarding the high prevalence of inappropriate prescribing of this medication classification 
among older adults (Cool et al., 2014; Peréz et al., 2018). Chapter 5 furthers the literature 
surrounding inappropriate prescribing of PPIs by identifying an association between 
improvements in MAI scores for PPIs and fewer readmissions and lower mortality among IC 
and CH participants.  
9.2.3 Deprescribing or medicines optimisation? 
Overprescribing was found to be highly prevalent within both IC and CH, with almost 
three-quarters of participants having at least one medication stopped. Deprescribing initiatives 
have received considerable focus within the literature. The utility and cost-effectiveness of 
deprescribing initiatives have been questioned (Avery, 2019).  No effect on all-cause mortality 
and a limited effect on hospitalisation have been reported in meta-analytic studies of 
randomised trials (Johansson et al., 2016; Page, Clifford, Potter, Schwartz & Etherton-Beer, 
2016). Reductions in mortality have been shown in nonrandomised studies and in studies that 
applied patient-specific interventions compared with those which adopted generalised 
educational programmes (Page et al., 2016). The present thesis findings further extend the 
literature surrounding evaluation of deprescribing initiatives. Chapter 8 outlines the 
complexity of healthcare utilisation by older adults and the challenges that exist in isolating 
the impact of a pharmaceutical intervention on subsequent healthcare utilisation. Aspects 
such as falls, frailty, depression and anxiety were found to be independently associated with 
healthcare utilisation among a community dwelling cohort of older adults.  
Furthermore, the concept of deprescribing faces additional challenges; there is a lack 
of consensus on the definition, variation in how the process is operationalised and no clear 
consensus on what the goal of deprescribing should be (Reeve, Gnjidic, Long & Hilmer, 2015). 
It has been proposed that “deprescribing is the process of withdrawal of an inappropriate 
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medication, supervised by a healthcare professional with the goal of managing polypharmacy 
and improving outcomes” (Reeve et al., 2015, p. 1266). Whilst medication cessation formed a 
key component of pharmacist intervention in both IC (Chapter 3) and CH (Chapter 4) contexts, 
patient education and dosage changes were also shown to be related to reductions in 
healthcare utilisation post-intervention. Thus, evaluations of medication-focused interventions 
may benefit from merely considering the impact of deprescribing on outcomes. In addition, 
deprescribing does not consider prescribing omissions, which was found to be highly prevalent 
among IC participants. Thus, deprescribing alone cannot fully address inappropriate 
prescribing.  
Attempts have been made to extend deprescribing theory in a more comprehensive 
manner. Edey and colleagues (2018) define deprescribing as a “holistic and encompassing 
process that re-evaluates the risk-benefit ratio of medications in the context of individualized 
patient care goals, preferences and values” (p. 160). Furthermore, Todd and colleagues (2018) 
urge clinicians to consider the clinical, psychological, social, financial and physical determinants 
when deprescribing. Nevertheless, these approaches do not extend far enough with respect to 
considering additional medicines optimisation efforts. Deprescribing forms only one end of a 
good prescribing continuum, beginning with the initiation of medications and encompassing 
the adjustment of treatment regimens (Scott et al., 2015).  
Rather, emphasis should be place on medicines optimisation and the concept of ‘what 
matters to the patient’ (Scottish Government Polypharmacy Model of Care Group, 2018). 
Medicines optimisation has been defined as “a person-centred approach to safe and effective 
medicines use, to ensure people obtain the best possible outcomes from their medicines” 
(NICE, 2015, p. 6). Such a definition is congruent with Tinetti, Huang and Molnar’s (2017) 
description of the Geriatric 5Ms aide-memoire, which outlines the key components of geriatric 





matters most. By placing the individual at the centre of geriatric care, a focus is placed on 
ensuring that therapy goals are aligned with that of the individual and that their care 
preferences are respected. The MOOP models of care, developed prior to the NICE Medicines 
Optimisation Guideline (2015), have been considered by NICE to be an exemplar for shared 
learning (NICE, 2017).  
9.2.4 Review or intervention?  
The thesis findings also extend the debate surrounding the utility of medication 
reviews. Huiskes et al., (2017) questioned their impact on healthcare utilisation outcomes and 
called for their discontinuation. However, a high prevalence of inappropriate prescribing was 
identified within both IC and CH settings in NI. Thus, there is a clear need to conduct some 
element of medication review in order to identify suboptimal prescribing. The findings of 
Chapters 3 and 4 draw attention to the need to demarcate those interventions which are 
medication review only, often conducted at only one time point, from those which incorporate 
active adjustment and associated monitoring of pharmacotherapy. Active pharmacist 
intervention was associated with positive impacts on healthcare utilisation. Within IC, those 
who received at least one education intervention had a lower likelihood of hospital 
readmission and fewer numbers of readmission within 30 days of IC discharge. Those IC 
participants who had at least one medication dosage changed had fewer unplanned hospital 
readmissions within 31-90 days and spent five fewer days in acute care on readmission. In 
contrast, more passive intervention types, such as the provision of medicines information to 
the prescriber or a referral to another healthcare professional, were associated with increases 
in healthcare resource usage.  
9.2.5 Healthcare utilisation- the complexity  
Taken together, the thesis findings underscore the inherent complexity of healthcare 
utilisation by older adults. For example, within the CH cohort a comparison of pre- and post-
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intervention healthcare resource usage revealed a significant reduction in healthcare 
utilisation. Reductions in the number of GP visits and OOH GP visits within 90 days and a 
reduction in ED visits in both time periods was observed. Improvements in prescribing 
appropriateness, defined by a reduction in MAI score, was not associated with likelihood of 
hospital admission. However, each unit reduction in MAI score was found to be associated 
with a reduced length of stay on readmission of 0.24 days. With the average MAI score 
reduction for the cohort found to be 14 points, this suggests that a reduction in length of stay 
of 3 days could be achieved for CH residents following medicines optimisation by the MOOP 
pharmacist. Nevertheless, each unit reduction in MAI score achieved by CH participants was 
also associated with a small increase in GP visits within 30 days of intervention. Thus, such 
findings underpin the subtle and dynamic nature of health service usage and the challenges of 
evaluating interventions in terms of utilisation. 
Intervention may be associated with some form of increased healthcare utilisation in 
the short term. Rosstad and colleagues (2017) previously reported similar findings and 
interpreted an increase in GP visits as greater engagement by the GP in the care of the older 
person. Thus, evaluation of interventions for older adults must consider the outcomes which 
are to be used to evaluate success. Consideration must also be given to the broad range of 
other factors that have been shown within the literature, and within the present thesis, to 
influence healthcare utilisation. 
Within the MOOP intervention data, previous levels of healthcare utilisation that 
occurred in the pre-intervention period were consistently identified as independent predictors 
of healthcare utilisation in the post-intervention period. Andsersen (1995) had previously 
argued that previous encounters with healthcare services would impact upon future service 
usage. The findings reported in Chapter 8 indicated that a broad range of factors remained 





Sociodemographic aspects such as marital status and employment were found to predict 
membership of longitudinal healthcare utilisation even when accounting for health need 
aspects such as falls, frailty and psychological health. Chapter 8 also extends the literature 
surrounding healthcare utilisation by considering multiple factors as predictors of 
combinations of service use type, over a period of six years.  
9.2.6 Understanding healthcare utilisation in terms of individual needs 
Throughout the empirical work in the present thesis, it is evident that there is 
considerable heterogeneity within the healthcare service needs of older adults. As expected, 
the demographic profile differed between IC and CH, reinforcing the need for adaptive models 
of care to reflect individual needs. The intervention types required to address inappropriate 
prescribing and the impact of these interventions on healthcare service usage differed 
between the two cohorts. In addition, the health need factors associated with healthcare 
utilisation varied between both cohorts, again reinforcing the view that the influences on 
healthcare utilisation, even from a medical history standpoint are quite nuanced among older 
adults. Whilst both care models are broadly similar, the CH allows for additional visits by the 
case management pharmacist to review and monitor any emerging needs which may arise 
during intervention among a largely frailer population.  
Optimal healthcare utilisation cannot easily be identified. For many older adults 
increased service usage will be required in order to achieve clinical stability. The optimal 
service will vary with respect to the unique needs of the individual. Irrespective of needs, the 
optimal model is one which supports the individual to achieve their health-related goals and 
preferences in an accessible manner which does not cause any unintentional harm. Concerns 
have been raised within the literature with respect to the appropriateness of transferring care 
home residents to ED (Lemoyne et al., 2019). The decision to transfer a care home resident to 
ED can often result from a lack of sufficient medical input to the care home (Arendts et al., 
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2010). Given the detrimental impact hospitalisation can have in terms of cognitive and physical 
functioning of older adults, consideration must be given to services that can be developed to 
better meet the unique needs of older adults.  
Chapter 8 furthers the theory surrounding the health need factors of older adults. 
Rather than considering multimorbidity alone several health need factors were examined in 
multivariate analyses in order to understand the independent associations between these 
health needs and healthcare service utilisation. These findings also draw attention to those 
factors which are modifiable and may serve as future intervention targets. The goal of such 
intervention targets is not to deny services but rather to optimise care in those locations which 
are more beneficial to older adults, whilst minimising those situations which may have 
negative implications for their functional and cognitive status. 
The associations between factors such as number of prescribed medications, falls, 
frailty, depression and anxiety and healthcare service utilisation are extensively reported 
within the literature (Albert et al., 2009; Cahir, Bennett et al., 2014; Fried et al., 2001; 
Gudmundsson et al., 2005; Han et al., 2019; Hutter et al., 2010; Laurin et al., 2009; Maurer et 
al., 2008; Rosted et al., 2016; Scuffham et al., 2002; Scuffham et al., 2003; Sullivan et al., 2002). 
The findings of Chapter 8 extend this literature further, by considering the independent impact 
of these factors in multivariate models as well as considering longitudinal variation in health 
service utilisation patterns. Furthermore, the rate of change in health need factors over time 
was also examined. The methodology applied in Chapters 7 and 8 indicate that the breadth of 
factors which influence on healthcare utilisation can be accommodated within longitudinal 
analyses, through the application of LGCM as a means of data reduction.  
Within Chapter 8 higher medication burden was associated with healthcare utilisation 
patterns beyond ‘primary care only usage’ supporting the literature that increasing numbers of 





hospital admission and longer hospitalisations (Cahir, Bennett et al., 2014; Rosted, Schultz & 
Sanders, 2016). Interestingly, the rate of growth in numbers of prescribed medications had a 
greater effect on membership of the various longitudinal healthcare utilisation patterns. The 
influence of increasing numbers of medication over time was independent of changes other 
health need factors such as frailty. Studies which seek to examine the impact of medications 
on healthcare service usage should also consider dynamic trends within the numbers of 
medications as a factor independent of the number of medications at baseline.  
The impact of frailty on longitudinal health service use observed in Chapter 8 extends 
what we know about the relationship between frailty and healthcare utilisation. Frailty has 
been shown to increase the likelihood for GP and practice nurse visits, hospitalisation and 
longer hospital admission (Fried et al., 2001; Han et al., 2019).  Chapter 8 highlights that when 
the number of prescribed medications, often a proxy for level of multimorbidity, is accounted 
for, increasing levels of frailty at baseline and an increase in frailty over time predict the type 
of healthcare services an older individual uses over time.  
Irrespective of level of frailty or changes in frailty over time, an independent 
association between falls and increased healthcare utilisation was observed within the TILDA 
cohort. Those who had experienced a fall were more likely to occupy healthcare utilisations 
patterns characterised by escalation into the ‘multiple utilisation’ status or remaining within 
this status between two time points. The prevalence of inappropriate prescribing of falls risk 
medications in both IC and CH contexts suggests that further attention could be directed at 
ameliorating such prescribing practices as a point of intervention in reducing the burden on 
health services. This is particularly relevant when one considers evidence within the literature 
of persistent prescribing of sedative medications to older adults following a falls-related 




9.3 Research implications 
The adoption of an expanded definition of health services research at the turn of the 
century sought to emphasise the breadth of influence of individuals, organisations and 
communities on health service usage (Lohr & Steinwachs, 2002). The findings of Chapter 8 
validate the complexity of factors which influence service usage by older adults, illustrating the 
limitations of the biomedical model in explaining healthcare utilisation. Social factors such as 
family structure and occupational status, in addition to psychological factors such as anxiety 
and depressive symptoms were also found to be independently associated with longitudinal 
healthcare utilisation patterns. Furthermore, as evidenced in Chapter 8, the health need 
factors are more nuanced than can be captured by comorbidity alone. Additional factors such 
as frailty, falls, medication numbers, anxiety and depressive symptoms were all shown to 
independently contribute to variation in healthcare utilisation patterns. This raises challenges 
for parsimonious approaches to research.   
9.3.1 Intervention research 
9.3.1.1 Accounting for complexity 
The evaluation of healthcare interventions for older adults necessitates a design that 
accounts for the multiple factors shown in the present thesis to impact healthcare utilisation. 
Outcome selection and measurement are key considerations. Any assessment of a 
pharmaceutical care intervention to reduce inappropriate prescribing of fall-risk medications 
could reasonably select the number of falls experienced as a potential primary outcome, with 
number of ED visits and hospital admission as possible secondary outcomes. Nevertheless, 
medication related factors are not the sole contributory factor involved in the occurrence of 
falls. Environmental hazards, balance and mobility, sensory impairment, medication, footwear, 
and care equipment are key areas signposted by the Public Health Agency (PHA) in Northern 





medicines optimisation intervention may be lost in the confounding noise if other 
environmental factors are not addressed and the individual suffers a fall due to a trip hazard.  
9.3.1.2 Selection of appropriate outcomes 
Consideration must also be given to the outcomes that are relevant to the most 
important stakeholder, the individual themselves. It must be acknowledged that “older people 
have lived experience of the issues at stake, and we neglect their expertise at our peril” 
(Glasby et al., 2016, p. 4). For the older person in acute care, the more relational aspects of 
care supersede the technical aspects (Bridges, Flatley & Meyer, 2010). A systematic review of 
qualitative studies examining older patient’s and/or their relative’s experiences of acute care 
identified that an inpatient admission could instil feelings of fear, worthlessness and lack of 
autonomy among older adults (Bridges et al., 2010). Interpersonal connection, the ability to 
retain their identity and shared decision-making emerged as themes associated with more 
positive experiences of acute care (Bridges et al., 2010).  
Glasby and colleagues (2016) argue that solutions to care provision are often devised 
from the perspective of the health and social care system, policy makers or researchers, and 
do not sufficiently incorporate the perspective of older people and the staff on the front-line 
who care for them. A reduction in inappropriate hospital admissions and ED attendances are 
often used as a metric when evaluating clinical interventions. When considering the 
‘appropriateness’ of hospital admissions, Glasby and colleagues argue that the patient 
perspective must be considered. It is likely to differ from that of their GP, hospital clinicians or 
the bed manager (Glasby et al., 2016).  
The operationalisation of healthcare attendances also requires considerable attention. 
A reduction in hospital admissions is conceptualised as an absolute target, whereas hospital 
admissions are affected by a range of factors, including other system policies and initiatives 
(Kumpunen, Edwards, Georghiou and Hughes, 2019). Cooksley and colleagues (2015) argue 
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that readmission rates are predicated on the concept that they are the result of poor care and 
that they are preventable. Alternatively, they could be conceptualised as the application of 
sound clinical judgement by attempting to prevent a decline in health for a high-risk individual 
(Cooksley et al., 2015). Older adults with complex multimorbidity who survive to hospital 
discharge may be an indicator of the receipt of high-quality care, and future readmission may 
inevitably result from this complex multimorbidity (Cooksley et al., 2015).  
A systematic review of over 1500 interventions aimed at reducing avoidable hospital 
admissions found that most did not reduce hospital admissions (Purdy et al., 2012). Similarly, 
despite considerable innovation with respect to new service development, an almost 12% 
increase in emergency hospital admissions has been observed in England between 2004 and 
2009 (Blunt, Bardsley & Dixon, 2010). Similarly, a review of integrated and community-based 
interventions found that most models were not associated with reduction in hospital 
admissions (Bardsley, Stevenson, Smith & Dixon, 2013). The review authors did note that 
whilst no reductions in emergency admissions were observed in many studies, changes to 
outpatient and elective care were identified. Damery, Flanagan and Combes (2016) argue that 
the extent of achievable improvements in service usage is not likely to satisfy the high 
expectations of policymakers and their targets for reduced hospital activity.  Unrealistic 
expectations about outcomes, including a narrow focus on hospital utilisation, has been cited 
as a key reason why evaluations of integrated care models do not show positive impacts on 
health service utilisation (Kumpunen et al., 2019).  
Bardsley and colleagues (2013) argue that reducing the costs associated with 
avoidable hospitalisations attracts a high degree of policy attention, thereby resulting in the 
inclusion of reduced hospital admissions as an outcome, irrespective of the legitimacy of such 
an outcome to the model under evaluation. The availability of hospital data in comparison with 





(Bardsley et al., 2013). Furthermore, a system-wide priority to examine interventions “has set 
an unhelpful precedent to aim for impact on emergency admissions-even in cases where the 
programme should not logically have a significant impact on them” (Kumpunen et al., 2019, p. 
7). Bardsley et al., (2013) argue that hospital admissions and costs are not the only important 
measures of impact; understanding how a model of care is being implanted may be as 
important as what it has achieved (Bardsley et al., 2013). Kumpunen and colleagues (2019) 
argue that evaluators should look beyond aspects of the model that are easy to measure and 
consider those metrics that matter. The incorporation of patient-reported outcome measures 
serves as one means of incorporating the patient experience.  
9.3.1.3 Active public participation 
The co-design approach to health service development encourages a partnership 
between those working within the system and those who have lived experience of using the 
system (Ní Shé et al., 2018; O’Donnell et al., 2019). Such an approach is likely to identify 
additional outcomes which are more relevant to the older person.  A co-design study to 
improve care for frail older patients identified several patient-centred outcomes such as 
dignity, respectful communication, identity and independence as key outcomes for older 
adults (O’Donnell et al., 2019). Such outcomes are likely to pose challenges for evaluation but 
nevertheless cannot be discarded.  
9.3.2 Healthcare utilisation research 
 The present thesis has shown that longitudinal assessments of healthcare utilisation 
can be enhanced by using latent variable methodology. Not only can heterogeneity in 
utilisation patterns be identified but the dynamic change in health needs over time can also be 
summarised using growth models. By specifying a unique intercept and slope value for each 
individual on many health need variables a greater number of variables could be 
accommodated within the analysis. In doing so, a more holistic assessment of what influences 
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change in healthcare utilisation behaviour of older adults over time was achieved. As argued 
by Babitsch and colleagues (2012) many previous studies have failed to adopt multivariate 
approaches within their analyses, thereby not truly accounting for the complexity of factors 
which influence healthcare utilisation. Whilst the analysis of Chapter 8 did not include other 
aspects which influence healthcare utilisation, such as health beliefs, social support etc., it has 
provided a basis for including multidimensional aspects of the health needs of older adults. 
Thus, it may serve as a foundation for future research which examines additional relevant 
covariates not included in the present thesis.  
The examination of longitudinal patterns of healthcare utilisation using the TILDA 
cohort may also serve to influence future research themes within the NICOLA study in 
Northern Ireland. The identification of factors such as depression and anxiety as being 
independently associated with healthcare resource usage, may be stronger within a Northern 
Irish cohort which has experienced considerable conflict-related trauma. Analysis conducted in 
a representative sample of the NI population has estimated the lifetime prevalence of any 
mental health disorder to be 39% (Bunting, Murphy, O’Neill & Ferry, 2012). Within this sample 
a projected lifetime risk of any mental health disorder by age 75 years of 48% was identified 
(Bunting et al., 2012). Conflict-related trauma as well as economic adversity have previously 
been shown to be related to psychopathology among NI residents (McLafferty et al., 2015).   
9.3.3 Pharmaceutical care research 
9.3.3.1 Prescribing culture  
The present thesis extends the research regarding inappropriate prescribing among 
older adults in several manners. The findings of Chapters 3 and 4 serves to support the 
extensive body of literature concerning the prevalence of inappropriate prescribing among 
older adults. When examined across the entire medication regimen, using the MAI to quantify 





perhaps previously conceived. However, in the absence of a unified approach within the 
literature to detect and quantify inappropriate prescribing it will remain challenging to 
compare the extent of the phenomenon across different contexts. The prevalence of 
inappropriate prescribing in intermediate care is notable given the lack of research conducted 
in this setting and considerable attention should be diverted to further research in this care 
context. Further investigation is required in order to ascertain if any rebound prescribing of 
inappropriate medications occurs following optimisation by the case management pharmacist.  
Regional differences in baseline severity of inappropriate prescribing were observed 
for both care models, which may warrant further examination in future studies. IC participants 
in the NHSCT and CH participants in the WHSCT were observed to have higher MAI total scores 
at baseline, and thus experienced greater change in MAI score following pharmacist 
intervention. Geographical differences in inappropriate prescribing may reflect local 
prescribing practices which may warrant further examination, as these disparities may serve as 
additional points for intervention to reduce the prevalence of inappropriate prescribing for 
older adults. The size, location and accessibility of GP practices have been shown to explain 
variation in high-risk prescribing practices (Cahir, Fahey, Teljeur & Bennett, 2014; Guthrie et 
al., 2011).   
Alternatively, regional differences may occur as a result of inter-individual differences 
in MAI scoring by different pharmacists. Implicit tools such as MAI can be limited by the clinical 
experience of the user. MAI scores should be interpreted within their own context to account 
for differences in setting, medication numbers, types of patients and clinical experience 
(Castelino, Bajorek & Chen, 2010). Brenghøj and colleagues (2005) argue that those prescribed 
more medications may be more difficult to rate and may lead to lower agreement between 
evaluators. That said, reliability in MAI ratings is improved when assessments at two time 
points are carried out by the same individual, as was the case in the MOOP data. Furthermore, 
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Brenghøj and colleagues (2005) reported good intra-rater agreement for ratings conducted 
two years apart. Future delivery of both care models may be improved upon by a more in-
depth understanding of regional differences in baseline MAI scores. Future studies may seek to 
consider the influence of pharmacist experience on the calculation of MAI scores and the 
importance of consultant pharmacist mentorship of case management pharmacists in their 
professional development.  
9.3.3.2 Models of care and expanded pharmacy roles 
The MOOP models of care may also stimulate research themes currently under 
investigation in ROI. An intervention to examine the utility of GP practice pharmacists at 
improving prescribing appropriateness and outcomes is presently under investigation 
(Cardwell et al., 2018). This intervention will involve the management of repeat prescribing 
within the GP practice and the completion of medication reviews. However, in the absence of 
the extended prescribing rights accessible to pharmacists within Northern Ireland, following 
completion of the requisite training, it is challenging to appreciate how effective such an 
intervention may be. The provision of outreach pharmacy services to at-risk older adults such 
as those in community hospital and residential care settings could also be established as 
research themes.  Inappropriate prescribing has previously been examined among community 
dwelling older adults and nursing home residents in ROI (Byrne et al., 2011; Galvin et al., 2014; 
Moriarty, Bennett, et al., 2015; Moriarty, Bennett, Cahir, Kenny & Fahey, 2016; Moriarty et al., 
2017). Thus, the utility of the MOOP care models could be investigated as a strategy for similar 
populations outside Northern Ireland.  
The arrival of Practice Based Pharmacists (PBPs) into general practice in NI provides a 
new interface for both medicines optimisation care models, as it proffers a new channel for 
communication between primary and secondary care. Case management pharmacists 





found the PBP role to be beneficial to their case management activities (Miller, 2018). Moving 
forward, future research will be required to outline how these roles may complement one 
another to ensure coordination of activities and to prevent duplication of effort. Furthermore, 
the future of integration of pharmacy services within NI needs will necessitate further research 
as respective roles interface with one another. 
9.4 Policy and practice implications 
9.4.1 Service delivery implications 
9.4.1.1 Intermediate Care 
The findings of Chapter 3 advocate for the inclusion of pharmacy services within IC 
beyond a ‘supply only’ function. Not only was a high prevalence of inappropriate prescribing 
detected and successfully addressed by pharmacist intervention, but the nature of longer 
admissions which occur within IC provide an opportunity to make inroads in addressing 
suboptimal prescribing among older adults. Each additional day spent in IC was associated with 
further reductions in MAI score.  
The findings of Chapter 3 suggest that the needs of older adults are not being 
adequately served within the acute care system. The demand for inpatient beds and an 
increased focus on the presenting illness can result in insufficient time to address all the 
clinical needs of the patient during the hospital admission (Edey et al., 2018). A high level of 
prescribing omissions and Kardex issues to address indicates that medication-related issues 
were either not suitably addressed during the acute care stay or that inappropriate prescribing 
was initiated whilst in acute care. Peréz and colleagues (2018) previously found hospitalisation 
to be independently associated with inappropriate prescribing among a large sample (approx. 
n = 38,000) of community dwelling older Irish adults. Those who experienced a hospital 
admission were 72% more likely to receive inappropriate prescribing compared with before 
hospital admission (Peréz et al, 2018).  
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Almost three quarters (71%) of IC participants had previously been acute care 
inpatients. Thus, intermediate care is ideally placed as a setting to prevent the persistence of 
medication related issues beyond acute care discharge, further fulfilling its function as a bridge 
between hospital and home. Furthermore, the continual presence of a pharmacist within IC 
may explain why Kardex issues were more frequently addressed within the IC cohort in 
comparison with the CH cohort.  This continual presence may facilitate the ability to deliver a 
more robust and wide-ranging intervention. 
9.4.1.2 Care Homes 
Considerable challenges regarding the governance of care homes in NI have become 
evident in recent years and these are likely to have been further compounded by the challenge 
of the Covid-19 pandemic. The care standards for nursing homes in NI are not fit for purpose 
and need to be overhauled to include medicines optimisation as the benchmark. At present 
these care standards (DHSSPS, 2015) only address the process aspects of medicines 
management, including documentation and storage, and do not incorporate the patient-
centred approach of medicines optimisation as set out in the NICE (2015) guidance and as is 
delivered by the MOOP care home model. They do not assert a patient-centred approach for 
shared decision making and accounting for the individual’s needs, preferences and values. In 
order to support the care of our older adults in residential care there needs to be a shift away 
from the procedural aspects of medicines management and towards the patient-centred 
approach of medicines optimisation. Medicines optimisations services are likely to be easier to 
initiate in settings such as IC as it falls mostly under the governance of the HSCT. Nevertheless, 
there is a need to ensure that a medicines optimisation strategy for care homes is consistently 
delivered across the region, considering the poor prescribing practices identified within 





9.4.2 Promotion of positive ageing 
An ageing population with increasing levels of multimorbidity will serve to perpetuate 
the demand on healthcare systems. The Covid-19 pandemic has exposed gaps within 
healthcare systems across the globe, stimulating assessments and debate regarding how to 
ensure safe service delivery with minimal disruption. The pandemic has also forced timely 
innovation, challenged the approach of silo working and questioned how we care for the more 
medically vulnerable in our society.  
Arguably our older generation has suffered disproportionate effects from the Covid-19 
pandemic. Despite warnings about the need to plan for a pandemic and the challenges that 
congregated living settings such as care homes pose for infection control, greater levels of 
mortality have been identified among older adults aged ≥60 years and those in residential care 
(Burki, 2020; Centers for Disease Control, 2020; DOHNI 2020a, 2020b; Health Protection 
Surveillance Centre, 2020; Office for National Statistics, 2020; Powell, Bellin & Ehrlich, 2020). It 
has also cast a cold light on the disparaging lens within which older adults are often viewed. 
Enforcing a label of vulnerability upon older adults who have been living independently and 
contributing to society prior to the pandemic can have negative ramifications for those very 
older adults we have nobly sought to protect. Negative self-perceptions of health increase the 
odds for poorer functional status, with positive self-perceptions of aging protecting against a 
decline in functional status in later life (Levy, Slade & Kasl, 2002; Nogueira et al., 2010; 
Sargent-Cox, Anstey & Luszcz, 2012). 
Lak, Rashidghalam, Myint and Baradaran (2020) argue that in order to achieve a 
healthy life expectancy an emphasis must be placed on promoting the positive aspects of 
aging, with particular attention being paid to encouraging older adults to be active participants 
in their own health. The WHO (2002) consider active aging to be the optimisation of 
“opportunities for health, participation and security in order to enhance quality of life as 
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people age” (p. 12), as well as incorporating the rights, needs and preferences of older people 
(WHO, 2002). Yet, when one considers the topic of healthcare service delivery, we have some 
way to go to achieve an active participation in respecting the rights, needs and preferences of 
older people to support them to age well in place. Service design must consider how it alters 
the ecological landscape, thereby influencing behaviour and thus interaction with services 
themselves.  
This is not a suggestion that we move away from robust scientific practices and 
evidence-based medicine but rather that we consider that a scientific-only focus can also 
permeate the language we use around care. Aronson (2019) argues that this focus can relegate 
the importance of other aspects and can be inherently patient-blaming and often used to 
characterise certain patient groups such as older adults as ‘difficult’: “she is non-compliant, we 
said. Or, he failed the treatment” (p. 43). Going even further, older adults within the acute care 
system are often referred to as ‘bed blockers’ and have also been referred to as ‘GOMERs’, an 
acronym for ‘get out of my emergency room’, as described by Shem (1978) in his medical novel 
‘The House of God’. Aronson (2019) argues that whilst no physician would consider it 
acceptable to use racist, sexist, or homophobic language when discussing patients, there can 
be an acceptance of referring to older adults in such disparaging terms.  
A more positive, inclusive view of positive ageing may be achieved through active 
partnership with older adults. The inclusion of older adults in policy and service design and the 
selection of more appropriate outcome measures, including patient reported outcomes can do 
much to ensure that services are developed that meet the needs of older adults. Recognising 
the fifth M of Tinetti et al.’s (2017) 5Ms, what matters most to the individual, can serve as a 





9.4.3 Future of pharmacy services 
9.4.3.1 Brief interventions across the spectrum of services 
The thesis findings also have the capacity to shape future pharmacy service 
development. The identification of medications frequently prescribed inappropriately within 
Chapter 5 provide an opportunity to shape future brief interventions by pharmacists across the 
entire healthcare journey, and not solely within intermediate care and care home contexts. 
The identification of unsuitable prescribing practices may help the achievement of ‘quick wins’ 
by clinicians working across the entire healthcare landscape. Inappropriate prescribing of 
psychoactive medication requires a pathway with suitable opportunities for monitoring and 
follow up, given the additional challenges presented by their discontinuation or modification. 
The MOOP case management models are examples of suitable pathways.  
The present thesis findings underscore the importance of providing clinical pharmacy 
services to settings such as intermediate care and care homes. The high prevalence of 
unresolved medication related issues following acute care discharge, identified within the IC 
cohort, also raises awareness of the potential for medication related harm that exists among 
older adults living within the community. The persistent and independent associations 
identified for polypharmacy and frailty with healthcare utilisation identified in Chapter 8 
highlights the importance of considering both when examining future interventions or service 
delivery models. Palmer et al., (2018) contend that “any clinical evaluation of geriatric patients 
should include screening for frailty, as well as structured medication review that 
comprehensively evaluates prescribing and its appropriateness and clinical relevance” (p. 35).  
9.4.3.2 Advancing the profession  
The MOOP models evaluated in Chapters 3 and 4 benefit from the expanded legislative 
opportunities for pharmacists within the UK, where additional qualifications such as that of 
independent prescribers can be pursued. Prescribing rights are a particular asset to the MOOP 
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models and eliminate unnecessary delays in medicines optimisation whilst also reducing the 
burden upon existing members of the care team. Moving forward, any jurisdiction that seeks 
to pursue a viable and comprehensive healthcare strategy for older adults would do well to 
consider the aspects of the MOOP models of care which make them successful. Independent 
prescribing qualifications allow the case management pharmacist to make alterations to the 
medication regimen in a timelier manner, without the need to delay action via a referral 
process to the prescriber.  
Despite repeated calls to action for strategies and interventions to tackle 
polypharmacy and inappropriate polypharmacy, little has been established within the Republic 
of Ireland (ROI). The findings reported in Chapters 3 and 4 outline the possibility and 
opportunity that exists. Thus, consideration should be given to what differentiates the MOOP 
models of care from previous interventions which have shown no impact on healthcare 
utilisation. The care models are innovative by not only placing clinical pharmacists into a new 
frontier to deliver medicines optimisation through the implementation of a personalised 
pharmaceutical care plan, but also in that they operate via a caseload approach. In doing so, 
appropriate monitoring and follow up is conducted, additional interventions are delivered 
where required and medication related problems are resolved to completion. Such an 
approach also renders better communication with additional members of the care team, 
whilst ensuring that the experiences of the older person remain front and centre. The ability to 
follow up with older adults following IC discharge serves to create an additional opportunity 
for the patient voice to be heard and importantly to be responded to. Both models were 
entirely new concepts within pharmacy services in Northern Ireland and due to their successful 
implementation, they have been rolled out regionally (Miller, 2018).  
In contrast, the research themes in ROI are limited by the absence of independent 





optimise prescribing in primary care (Cardwell et al., 2018) could be further augmented were 
such roles to be granted prescribing rights. Within the ROI action is required to develop 
models of care that address inappropriate prescribing. Previous studies have estimated the 
prevalence of inappropriate prescribing to range from 28-42% and 20-53% among community 
dwelling older adults (Cahir, Moriarty, et al., 2014; Moriarty, Bennett, et al., 2015). 
International estimates suggest a higher prevalence to occur in in residential care settings, 
possibly related to the inappropriate use of psychoactive medications to manage BPSD 
(Renom-Giuteras et al., 2018).  Again, the development of a model of care such as the MOOP 
care home model will require an expanded role for pharmacists and thus the necessary 
training and legislative framework in order to make such a role as effective as possible.  
9.4.4 Policy and legislative changes 
For a cohesive pharmacy strategy to be developed in the ROI several policy and 
legislative changes will be required. A vision for pharmacy and the wide variety of new 
pharmacy roles that have been established in other jurisdictions is required. Despite 
considerable advances in clinical specialisation within hospital pharmacy, the sector continues 
to be limited by a career structure in existence since the 1970s. Furthermore, the absence of 
additional legislative powers with respect to prescribing has meant that the pharmacy 
profession is now many years behind that in operation in many other jurisdictions. Regulations 
to permit pharmacists to prescribe independently came into effect in the UK in 2006. These 
additional powers are extended to those pharmacists to complete the requisite training on an 
accredited course as well as learning in a practice environment under the mentorship of a 
medical practitioner (General Pharmaceutical Council, 2020).   
It has been said that independent prescribing by community pharmacists may pose a 
conflict of interest with respect to the dispensing of prescribed medication. Nevertheless, the 
Achieving Excellence in Pharmaceutical Care-A Strategy for Scotland sets out how community 
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pharmacist prescribing can be endorsed, supported and funded through policy drivers 
(Scottish Government Pharmacy and Medicines Division, 2017). Thus, scope exists for the safe 
continued prescribing of long-term medications provided access is granted to laboratory 
investigations and a shared care record. The ability of a patient to have their antihypertensive 
medications clinically reviewed and prescriptions renewed without having to consult their GP 
may serve to reduce the burden on GPs for chronic disease management. Alternatively, 
prescribing rights could be extended to pharmacists where no conflict of interest of dispensing 
exists, such as pharmacists working in general practice. The ageing population and increases in 
complex multimorbidity poses many challenges for primary care. A failure to consider 
alternative solutions to increasing capacity in primary care may only serve to increase the 
threat posed by an ageing population with increasing levels of multimorbidity.  
9.4.5 Integrated care 
9.4.5.1 The case for integrated care 
Overall, the thesis findings support the opportunity that integrated care presents for 
improving the health and wellbeing of older adults. The health need factors among older 
adults are multiple and will likely require multidisciplinary input to address them. Reducing the 
risk of falls will likely require the input of physicians, physiotherapists, occupational therapists, 
pharmacists and perhaps more. Addressing frailty will require similar inputs. Aspects such as 
fear of falling, which has been shown to be associated with an increased risk of falling (Briggs, 
Kennelly & Kenny, 2018), depressive and anxiety symptoms will require additional input from 
mental health practitioners. Thus, an integrated approach is no longer a notional objective but 
rather is mandated.  
Integrated care for older people switches the focus to that of the patient experience, 
outcomes and quality of care. The Institute for Healthcare Improvement enshrine the patient 





performance. It calls for a three-dimensional approach to service design that seeks to improve 
the patient experience of care, the health of populations and to reduce per capita healthcare 
costs (Institute for Healthcare Improvement, 2020). Integrated care involves a move away 
from acute, episodic care to a coordinated approach that reflects the complexity of care 
required to attend to multimorbidity (HSE, 2017). 
In ROI, the National Clinical Programme for Older People (NCPOP) Specialist Geriatric 
Services Acute Model of Care called for the establishment of a Specialist Geriatric Service to 
improve outcomes for frail older adults (HSE, 2012). This envisioned a complete patient 
journey from home, through primary care, acute care and to discharge home. Moving forward, 
the Integrated Care Programme for Older People (ICPOP; 2016) aims to amalgamate local 
health systems using a ten-step framework.  Key aspects of this framework are to establish the 
needs of the population, develop services and pathways that reflect new ways of working in 
order to deliver person-centred services (HSE, 2017). The development of a multidisciplinary 
team seeks to make the best use of the complementary skills within the team, with agreed 
systems for communication and interaction between members (HSE, 2017). Examples of new 
pathways proposed by ICPOP to meet the needs of frail older adults, identified in Chapter 8 as 
being at higher risk for multiple healthcare utilisation, include the establishment of frailty 
pathways in acute care that enable an immediate response within ED or the development of 
specialist frailty wards that are resourced by multidisciplinary teams.  
A frailty pathway has recently been piloted in the South Eastern HSCT in Northern 
Ireland.  This pathway also used a case management approach based upon the IC model of 
care, which was adapted to reflect a referral due to frailty and thus, the need to include 
additional assessments of other appropriate outcomes. Risk stratification occurs with those 
aged 85 years and older accepted into the pathway. Those aged 65 years and older with two or 
more frailty syndromes of falls, immobility, delirium or cognition issues, incontinence, 
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prescribed five or more medications and socially isolated are also accepted. In addition to 
assessments of prescribing appropriateness the anticholinergic burden of medications is also 
examined. This frailty pathway operates like the IC model, with case management continuing 
for 30 days post-discharge. Interim evaluation of this service has indicated that prescribing 
appropriateness, as well as the anticholinergic burden of medications, were successfully 
improved upon following intervention by the case management pharmacist (Saeed et al., 
2020). A total of 380 interventions were conducted in the sample of 72 patients; almost three-
quarters of these were assessed as significant and resulting in improved care standards 
according to the Eadon grading system (Saeed et al., 2020).  
In Northern Ireland, an Integrated Care Prototype has been developed in the Northern 
Trust to improve health outcomes through a collaborative approach between the Trust and 
GPs. To date GP services operate separately to the HSCTs in Northern Ireland. This prototype 
aims to bring the commissioning of services together (NHSCT, 2019). This approach seeks to 
embed a policy of ‘no more silos’ such that shared resources will provide a more efficient 
system of care. This new partnership seeks to rearrange the structure of health and social care, 
not only to integrate the work of primary care with that of the Trusts, but also to establish 
partnerships with the community and voluntary sector to focus on a shared goal of population 
health outcomes. Thus, significant change is occurring on the island with respect to integrated 
care. The importance of ensuring that medications are optimised throughout this process is 
supported by the findings of Chapters 3, 4, 5 and 8.  
9.4.5.2 The future for integrated care in Ireland  
The high prevalence of inappropriate prescribing reported in Chapters 3 and 4 
highlight the large room for improvement that exists with respect to safe and efficacious use 
of medicines for older adults. When one considers that Chapter 8 identified that frailty and 





frailty and polypharmacy have previously been found to be predictive of one another (Palmer 
et al., 2019; Saum et al., 2017), it is inconceivable to consider an integrated care strategy for 
older people that does not incorporate medicines optimisation across the entire patient 
journey. Nevertheless, both jurisdictions on the island of Ireland are faced with challenges with 
respect to delivering a comprehensive integrated care strategy which includes pharmacy 
services.  
Medicines optimisation by pharmacists needs to be embedded across the entire 
patient journey. Within the NHSCT Integrated Care Prototype, HSCT pharmacists and GP 
pharmacists are represented at the appropriate level through the joint working of HSCT 
directors and GP Federation leads. In NI, there are 17 GP Federations which work to support 
GP practices and whose boundaries align with the 17 Integrated Care Partnerships in existence 
(HSCBNI, 2020b). However, community pharmacy must also align with this new Integrated 
Care Prototype in order to achieve an equal level of commissioning and decision making going 
forward. At present, the Integrated Care Prototype does not allow for this.  
As the development of the Integrated Care Prototype advances, provision must be 
made for the inclusion of community pharmacy at the same level as that of HSCT pharmacists 
and GP pharmacists. This could be established by a structure akin to that represented by the 
Primary and Community Together (PACT) model. PACT seeks to deliver local patient-centred 
public health and medicine initiatives through the novel social enterprise of community 
pharmacists working in partnership with the community and voluntary sector (Mid and East 
Antrim Agewell Partnership: MEAAP, 2020; PACT, 2018). The IMPACT (Involving Many to 
Prescribe Alternative Care Together) Agewell initiative in the Mid and East Antrim area 
includes a PACT pharmacist to represent all community pharmacists within the local area. This 
approach is a move away from the traditional ‘silo’ model of community pharmacy provision 
and towards a more integrated care approach (MEAAP, 2020). These PACT pharmacists 
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provide support on pharmacy related issues and ensure that there are no gaps in the provision 
of commissioned community pharmacy services (MEAAP, 2020).  Interim evaluation of the 
IMPACT Agewell initiative identified that for every £1 spent on community pharmacists an 
invest to save return of £3.86 was achieved (MEEAP, 2020).  
The integrated care programme for older people currently established by the HSE in 
ROI does not provide for the type of care models examined in Chapters 3 and 4. Results from 
the MOOP care models indicate the value that can be added by expanding pharmacy services 
to older adults in care settings which traditionally do not have access to such services. The 
optimisation of medications in the post-discharge space of intermediate care can thus address 
potential medication related harm that persists beyond acute care discharge, whilst also 
providing a continuity of care for older adults as they transition from acute care back into the 
community. The HSE (2017) has already indicated that case management operating across care 
settings is a key aspect of care integration. Within the HSE’s 2017 guidance for local 
implementation of integrated care for older adults, case management is recognised as a 
proactive approach to address the medical, nursing, pharmaceutical and social care needs of 
older adults (HSE, 2017). Nevertheless, no provision for expanded pharmacy roles is 
considered. Furthermore, when considering pharmacy services there is no apparent 
acknowledgement of those pharmacists already providing clinical pharmacy services within 
acute care. Acknowledgement is made within the guidance document that emerging roles to 
support integrated care for older adults may be developed within community pharmacy. 
However, in the absence of a national strategic vision for pharmacy it is difficult to envision 







Rather than enshrine the care of older adults within our health and social care systems 
we have left it to the private sector and free market rules. Consequently, a disproportionate 
burden of morbidity and mortality associated with Covid-19 infection has been felt by those 
older adults that should be cherished within a system that aims to care for those citizens it 
serves. Shall we continue with the privatisation of the health and social care of our most 
valuable citizens? They have contributed to the development of our society, the services and 
resources that we take for granted, and without them we would not exist. As Aronson puts it 
so poignantly: “they are the future ‘us’, and we are the past ‘them’” (2019, p. 56).  
The findings presented in this work align with the 5Ms of ‘the geriatric salute’. Mind 
characteristics such as depression, anxiety and cognitive impairment have been identified as 
associated with healthcare utilisation in the MOOP and TILDA datasets. Mobility, examined in 
terms of initial frailty status and increasing levels of frailty over time, was found to be 
consistently associated with patterns of healthcare usage characterised by more intensive 
service usage. The role of medications has been examined through the evaluation of 
pharmacist services to improve medicines optimisation among at risk older adults and among 
community dwelling older adults. Furthermore, an appreciation of the multi-complexity of 
older adults has been achieved through the distinct features identified for intermediate care 
patients, care home residents and community dwelling older adults. By examining different 
cohorts of older adults, this thesis has served to highlight the considerable heterogeneity that 
exists amongst a section of the population that are often assumed to be homogenous. What 
matters most is perhaps where we go from here.  
What is the future goal of healthcare for our older adults? Encompassing the need for 
patient-centred care, Aronson (2019) argues that the goal for geriatric medicine is to “tailor 
care to the patient’s unique amalgam of health status, abilities, values, and care preferences, 
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no matter how healthy or sick they are” (p. 47). There is a clear need to move to a partnership 
with older adults and discourage the ‘conspiracy of silence’ that prevents shared decision-
making (Van Bussel et al., 2019, p. 6). The discontinuation of inappropriate medications must 
be prioritised. Care must move beyond a process approach and instead preserve a person-
centred approach. Within a healthcare system that is highly fractured, a move towards 
integrated care that supports the older person transitioning between care settings is required. 
Using an integrated approach can mean that care can be brought to the older person and 
unnecessary hospitalisations can be avoided. We also need to challenge ageist biases within 
the health and social care system. We cannot stop the ageing process, but nor should we 
inadvertently blame someone for succeeding in staying alive. Let us remove these biases as 
well as the accompanying denigrating language. Our elders are not bed blockers nor GOMERs 
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Appendix D: Adapted Frailty Index 
A frailty index, adapted from the work of Roe et al., (2017) was created using the following 30 variables 
from the CAPI questionnaire for each wave of TILDA data collection.  
   Wave 
Item Description Variable ID 1 2 3 
1 Difficulty walking 100m Fl001_01 ✓ ✓ ✓ 
2 Difficulty rising from a chair  Fl001_04 ✓ ✓ ✓ 
3 Difficulty climbing stairs Fl001_06 ✓ ✓ ✓ 
4 Difficulty stooping, kneeling, or crouching  Fl001_07 ✓ ✓ ✓ 
5 Difficulty reaching above shoulder height _08 ✓ ✓ ✓ 
6 Difficulty pushing/pulling large objects  _09 ✓ ✓ ✓ 
7 Difficulty lifting/carrying weights ≥10lb _10 ✓ ✓ ✓ 
8 Difficulty picking up a coin from a table _11 ✓ ✓ ✓ 
9 Poor self-rated physical health SR_health  ✓ ✓ ✓ 
10 Poor self-rated vision Disvision ✓ ✓ ✓ 
11 Poor self-rated hearing  Dishearing ✓ ✓ ✓ 
12 Poor self-rated memory Ph114 all waves ✓ ✓ ✓ 
13 Difficulty following a conversation Disconverse4 ✓ ✓ ✓ 
14 Everything an effort Mh007  ✓ ✓ ✓ 
15 Polypharmacy mdpoly_excl_supps ✓ ✓ ✓ 
16 Hypertension Ph201_1 ✓ ✓  
17 Angina Ph201_2 ✓   
18 Heart attack Ph201_3 ✓   
19 Diabetes Ph201_5 ✓   
20 Stroke and transient ischemic attack Ph201_6 or _7 ✓   
21 High cholesterol Ph201_8 ✓   
22 Irregular heart rhythm Ph201_10 ✓   
23 Other CVD Ph201_11 ✓   
24 Cataracts Ph105_1 ✓   
25 Glaucoma and age-related macular degeneration Ph105_2 or _3 ✓   
26 Arthritis Ph301_3 ✓   
27 Osteoporosis  Ph301_4 ✓   
28 Cancer Ph301_5 ✓   
29 Varicose ulcer Ph301_13 ✓   
30 Incontinence  Any_CHRincontinence ✓ ✓ ✓ 
 
Self-report questions MH014 ‘feeling lonely’ and ph503_03 ‘knee pain’ were omitted as they were not 
consistently available across the first three waves of TILDA data collection. Variable mh007 ‘everything 
was an effort’ was operationalised instead of bh201 ‘daytime sleepiness’ due to inconsistency in item 
availability across all waves of interest. The categorical cut-points created by Roe and colleagues (2017) 
were retained and as follows:  FI score <0.09374: Robust, FI score 0.09375-0.2499: Pre-frail and FI score 
≥0.25: Frail. Responses to items 16-29 were used in the formation of the adapted Frailty Index at waves 

















Appendix F: Intermediate Care MAI score change categories 
 
















Not on this 
medication  
Opioid analgesics 82 14 128 14 294 
Osmotic laxatives 135 11 119 20 247 
Proton pump inhibitors 161 - 92 18 261 
Benzodiazepines 40 3 40 7 442 
Stimulant laxatives 64 6 42 7 413 
Oral iron 78 - 46 7 401 
Non-opioid analgesics 284 1 45 24 178 
Drugs used in megaloblastic 
anaemia 
46 3 36 8 439 
Z-drugs 23 - 37 4 468 














in this class 
improved 
Missing 
MAI at one 
time point 
Not on this 
medication 
class 
Osmotic laxatives 503 79 186 7 320 
Proton pump 
inhibitors 
296 - 240 7 552 
Non-opioid 
analgesics 
670 9 130 8 278 
Benzodiazepines 293 22 68 4 708 
Opioid analgesics 213 12 119 7 744 
Oral iron 146 - 128 5 816 
Z drugs 174 1 60 1 859 
Megaloblastic 
anaemia 
34 13 68 5 975 
Drugs used in bone 
metabolism 
127 - 73 1 894 
Second generation 
antipsychotics 
189 2 35 3 866 
Note. Incomplete improvement refers to where the participants were on more than one 










Appendix H: Psychoactive medications with no or low 
endorsement in Intermediate Care data 
 
Several central nervous system BNF drug subgroups showed no endorsement within the 
intermediate care sample. Thus, these were not examined in Chapter 5. These included: 
‘hypnotics chloral hydrate’, ‘hypnotics chlomethiazole’, ‘sodium oxybate for narcolepsy’, 
‘meprobamate’, ‘barbituates’, ‘monoamine oxidase inhibitors’, ‘CNS stimulants and drugs used 
for ADHD’, ‘centrally acting appetite suppressants’, ‘neurokinin receptor antagonists CNS 
nausea and vomiting’, ‘nabilone CNS nausea and vomiting’, ‘hyoscine CNS nausea and 
vomiting’, ‘5HT1 receptor agonists’, ‘prophylaxis of migraine CNS’, ‘drugs used in status 
epilepticus’, ‘drugs used in alcohol dependence’ and ‘drugs used in opioid dependence’. 
Furthermore, a number of drug subgroups showed a low level of endorsement preventing 
their examination in crosstabulation analyses. These included: 
‘melatonin’, ‘buspirone’, ‘first generation antipsychotics’, ‘antipsychotic depot injections’, 
‘antimanic drugs’, ‘lithium’, ‘orlistat’, ‘phenothiazines and related drugs for nausea and 
vomiting’, ‘5HT3 receptor antagonists for nausea and vomiting’, ‘domperidone and 
metoclopramide’, ‘betahistine’, ‘tolfenamic acid’, ‘antimuscarinic drugs used in Parkinson’s 





Appendix I: Psychoactive medications with no or low 
endorsement in Care Homes data 
 
Several central nervous system BNF drug subgroups showed no endorsement within the care 
home sample. Thus, these were not examined in Chapter 5. These included: 
 ‘hypnotics chlomethiazole’, ‘sodium oxybate for narcolepsy’, ‘meprobamate’, ‘CNS stimulants 
and drugs used for ADHD’, ‘orlistat’, ‘centrally acting appetite suppressants’, ‘neurokinin 
receptor antagonists CNS nausea and vomiting’, ‘nabilone CNS nausea and vomiting’, 
‘tolfenamic acid’, ‘5HT1 receptor agonists’, ‘ergot alkaloids’, ‘prophylaxis of migraine CNS’, 
‘drugs used in alcohol dependence’ and ‘drugs used in opioid dependence’. 
Furthermore, a number of drug subgroups showed a low level of endorsement preventing 
their examination in crosstabulation analyses. These included: 
‘hypnotics chloral hydrate’, ‘melatonin’, ‘buspirone’, ‘barbiturates’, ‘antipsychotic depot 
injections’, ‘antimanic drugs’, ‘lithium’, ‘monoamine oxidase inhibitors’, ‘phenothiazines and 
related drugs for nausea and vomiting’, ‘hyoscine CNS nausea and vomiting’, ‘drugs used in 
status epilepticus’, ‘drugs used in essential tremor, chorea, tics and related disorders’ and 






Appendix J: Intermediate Care MAI score change categories for 
psychoactive medications 
 














Not on this 
medication  
Control of the 
epilepsies 
40 - 31 5 456 
Antihistamines CNS 
nausea  
17 2 28 6 479 
Tricyclic 
antidepressants 
14 - 19 3 496 
SSRIs 103 - 20 9 400 
Second generation 
antipsychotics 
21 - 7 3 501 
Dopaminergic drugs 
Parkinson’s 
19 4 3 1 505 
Other 
antidepressants  
30 1 3 4 494 







Appendix K: Probability plots for latent class analyses of 
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